<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>240</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">240</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nissen, Ricko Damberg</style></author><author><style face="normal" font="default" size="100%">Andersen, Aida Hougaard</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Addressing Religion in Secular Healthcare: Existential Communication and the Post-Secular Negotiation</style></title><secondary-title><style face="normal" font="default" size="100%">Religions</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Religions</style></full-title></periodical><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">1</style></number><section><style face="normal" font="default" size="100%">34</style></section><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">2077-1444</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/rel13010034</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>292</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">292</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Holmberg, T. T.</style></author><author><style face="normal" font="default" size="100%">Sainte-Marie, M.</style></author><author><style face="normal" font="default" size="100%">Jensen, E. K.</style></author><author><style face="normal" font="default" size="100%">Linnet, J.</style></author><author><style face="normal" font="default" size="100%">Runge, E.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Tarp, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit for Digital Psychiatry, Center for Digital Psychiatry, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Political Science, Danish Center for Studies in Research and Research Policy, Aarhus University, Aarhus, Denmark.&#xD;Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;Clinic on Gambling- and Binge Eating Disorder, Department of Occupational and Environmental Medicine, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">An analysis of patient motivation for seeking online treatment for binge eating disorder-A mixed methods study combining systematic text condensation with sentiment analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Front Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">969115</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20221104</style></edition><keywords><keyword><style face="normal" font="default" size="100%">binge eating disorder (BED)</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive behavioral therapy (CBT)</style></keyword><keyword><style face="normal" font="default" size="100%">internet based intervention</style></keyword><keyword><style face="normal" font="default" size="100%">mixed method approach</style></keyword><keyword><style face="normal" font="default" size="100%">self-determination theory (SDT)</style></keyword><keyword><style face="normal" font="default" size="100%">sentiment analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">1664-0640 (Print)&#xD;1664-0640 (Electronic)&#xD;1664-0640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36405908</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Online treatment for binge eating disorder (BED) is an easily available option for treatment compared to most standard treatment procedures. However, little is known about how motivation types characterize this population and how these impact treatment adherence and effect in an online setting. Therefore, we aimed to investigate a sample of written motivation statements from BED patients, to learn more about how treatment and online treatment in particular, presents in this population. METHODS: Using self-determination theory in a mixed methods context, we investigated which types of motivation were prevalent in our sample, how this was connected with patient sentiment, and how these constructs influence treatment and adherence. RESULTS: Contrary to what most current literature suggests, we found that in our sample (n = 148), motivation type was not connected with treatment outcome. We did find a strong association between sentiment scores and motivation types, indicating the model is apt at detecting effects. We found that when comparing an adult and young adult population, they did not differ in motivation type and the treatment was equally effective in young adults and adults. In the sentiment scores there was a difference between sentiment score and adherence in the young adult group, as the more positive the young adults were, the less likely they were to complete the program. DISCUSSION: Because motivation type does not influence online treatment to the same degree as it would in face-to-face treatment it indicates that the typical barriers to treatment may be less crucial in an online setting. This should be considered during intake; as less motivated patients may be able to adhere better to online treatment, because the latter imposes fewer barriers of the kind that only strong motivation can overcome. The fact that motivation type and sentiment score of the written texts are strongly associated, indicate a potential for automated models to detect motivation based on sentiment.</style></abstract><notes><style face="normal" font="default" size="100%">Holmberg, Trine Theresa&#xD;Sainte-Marie, Maxime&#xD;Jensen, Esben Kjems&#xD;Linnet, Jakob&#xD;Runge, Eik&#xD;Lichtenstein, Mia Beck&#xD;Tarp, Kristine&#xD;eng&#xD;Switzerland&#xD;2022/11/22&#xD;Front Psychiatry. 2022 Nov 4;13:969115. doi: 10.3389/fpsyt.2022.969115. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36405908</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9672086</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fpsyt.2022.969115</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>217</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">217</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sjogren, M.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Psychiatric Center Ballerup, 2750 Ballerup, Denmark.&#xD;Institute for Clinical Science, Umea University, 90185 Umea, Sweden.&#xD;Center for Eating Disorders, Odense University Hospital, Mental Health Services in the Region of Southern Denmark, 5000 Odense, Denmark.&#xD;Research Unit for Medical Endocrinology, Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anorexia Nervosa: Reduction in Depression during Inpatient Treatment Is Closely Related to Reduction in Eating Disorder Psychopathology</style></title><secondary-title><style face="normal" font="default" size="100%">J Pers Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Pers Med</style></full-title></periodical><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">20220426</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anorexia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">post-meal</style></keyword><keyword><style face="normal" font="default" size="100%">weight restoration treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2075-4426 (Print)&#xD;2075-4426 (Electronic)&#xD;2075-4426 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35629105</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Anorexia nervosa (AN) is a severe mental disorder frequently associated with high scores of depressiveness. We examined the short-term effects of inpatient treatment on depressiveness and eating disorder (ED) psychopathology using the self-rating Major Depression Inventory (MDI) and Eating Disorder Examination questionnaire (EDEq) for patients with AN. MATERIAL: Forty-nine patients with AN, all part of the PROspective Longitudinal all-comer inclusion study on EDs (PROLED), were observed over eight weeks with baseline psychometric measures, EDE-q at baseline and endpoint, and weekly MDI self-scoring. METHODS: Apart from the weekly Body Mass Index (BMI) measurements, patients were assessed at baseline using the Eating Disorder Inventory (EDI) and the Symptom Check List 92 (SCL-92). RESULTS: Inpatient treatment reduced MDI consistently over 8 weeks (Wilks Lambda = 0.59, F = 4.1, p &amp;lt; 0.01) and this reduction in MDI was positively correlated with a reduction in EDEq (r = 0.44; p &amp;lt; 0.01) during inpatient treatment. Baseline medication did not predict changes in MDI during the inpatient treatment. BMI increased from 14.9 (week 1) to 17.2 (week 8). CONCLUSIONS: Inpatient treatment of AN is associated with a reduction in depressiveness. This improvement in depressiveness scores correlates with an improvement in ED psychopathology but not with weight gain.</style></abstract><notes><style face="normal" font="default" size="100%">Sjogren, Magnus&#xD;Stoving, Rene Klinkby&#xD;eng&#xD;Switzerland&#xD;2022/05/29&#xD;J Pers Med. 2022 Apr 26;12(5):682. doi: 10.3390/jpm12050682.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35629105</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors of this paper declare no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9145215</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/jpm12050682</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>237</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">237</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Molenaar, N.</style></author><author><style face="normal" font="default" size="100%">Agerbo, E.</style></author><author><style face="normal" font="default" size="100%">Momen, N. C.</style></author><author><style face="normal" font="default" size="100%">Rommel, A. S.</style></author><author><style face="normal" font="default" size="100%">Lupattelli, A.</style></author><author><style face="normal" font="default" size="100%">Bergink, V.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.&#xD;iPSYCH-Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark.&#xD;CIRRAU-Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.&#xD;Department of Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antidepressant discontinuation before or during pregnancy and risk of psychiatric emergency in Denmark: A population-based propensity score-matched cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e1003895</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220131</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antidepressive Agents/*administration &amp; dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Disorders/diagnosis/*drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Population Surveillance</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Complications/diagnosis/*drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Propensity Score</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">*Withholding Treatment/trends</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1549-1676 (Electronic)&#xD;1549-1277 (Print)&#xD;1549-1277 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35100270</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Women prescribed antidepressants face the dilemma of whether or not to continue their treatment during pregnancy. Currently, limited evidence is available on the efficacy of continuing versus discontinuing antidepressant treatment during pregnancy to aid their decision. We aimed to estimate whether antidepressant discontinuation before or during pregnancy was associated with an increased risk of psychiatric emergency (ascertained by psychiatric admission or emergency room visit), a proxy measure of severe exacerbation of symptoms/mental health crisis. METHODS AND FINDINGS: We carried out a propensity score-matched cohort study of women who gave birth to live-born singletons between January 1, 1997 and June 30, 2016 in Denmark and who redeemed an antidepressant prescription in the 90 days before the pregnancy, identified by Anatomical Therapeutic Chemical (ATC) code N06A. We constructed 2 matched cohorts, matching each woman who discontinued antidepressants before pregnancy (N = 2,669) or during pregnancy (N = 5,467) to one who continued antidepressants based on propensity scores. Maternal characteristics and variables related to disease severity were used to generate the propensity scores in logistic regression models. We estimated hazard ratios (HRs) of psychiatric emergency in the perinatal period (pregnancy and 6 months postpartum) using stratified Cox regression. Psychiatric emergencies were observed in 76 women who discontinued antidepressants before pregnancy and 91 women who continued. There was no evidence of higher risk of psychiatric emergency among women who discontinued antidepressants before pregnancy (cumulative incidence: 2.9%, 95% confidence interval [CI]: 2.3% to 3.6% for discontinuation versus 3.4%, 95% CI: 2.8% to 4.2% for continuation; HR = 0.84, 95% CI: 0.61 to 1.16, p = 0.298). Overall, 202 women who discontinued antidepressants during pregnancy and 156 who continued had psychiatric emergencies (cumulative incidence: 5.0%, 95% CI: 4.2% to 5.9% versus 3.7%, 95% CI: 3.1% to 4.5%). Antidepressant discontinuation during pregnancy was associated with increased risk of psychiatric emergency (HR = 1.25, 95% CI: 1.00 to 1.55, p = 0.048). Study limitations include lack of information on indications for antidepressant treatment and reasons for discontinuing antidepressants. CONCLUSIONS: In this study, we found that discontinuing antidepressant medication during pregnancy (but not before) is associated with an apparent increased risk of psychiatric emergency compared to continuing treatment throughout pregnancy.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Xiaoqin&#xD;Molenaar, Nina&#xD;Agerbo, Esben&#xD;Momen, Natalie C&#xD;Rommel, Anna-Sophie&#xD;Lupattelli, Angela&#xD;Bergink, Veerle&#xD;Munk-Olsen, Trine&#xD;eng&#xD;R01 MH122869/MH/NIMH NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;2022/02/01&#xD;PLoS Med. 2022 Jan 31;19(1):e1003895. doi: 10.1371/journal.pmed.1003895. eCollection 2022 Jan.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35100270</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors have declared that no competing interests exist.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8843130</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pmed.1003895</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rommel, A. S.</style></author><author><style face="normal" font="default" size="100%">Momen, N. C.</style></author><author><style face="normal" font="default" size="100%">Molenaar, N. M.</style></author><author><style face="normal" font="default" size="100%">Agerbo, E.</style></author><author><style face="normal" font="default" size="100%">Bergink, V.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;NCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;CIRRAU - Centre for Integrated Register-Based Research at Aarhus University, Aarhus, Denmark.&#xD;iPSYCH-Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark.&#xD;Department of Psychiatry, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands.&#xD;Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York, USA.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antidepressant use during pregnancy and risk of adverse neonatal outcomes: A comprehensive investigation of previously identified associations</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Psychiatr Scand</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Psychiatr Scand</style></full-title></periodical><pages><style face="normal" font="default" size="100%">544-556</style></pages><volume><style face="normal" font="default" size="100%">145</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">20220218</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antidepressive Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Birth Weight</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Outcome/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Premature Birth/chemically induced/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressants</style></keyword><keyword><style face="normal" font="default" size="100%">low birthweight</style></keyword><keyword><style face="normal" font="default" size="100%">neonatal outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">perinatal depression</style></keyword><keyword><style face="normal" font="default" size="100%">preterm birth</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1600-0447 (Electronic)&#xD;0001-690X (Print)&#xD;0001-690X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35152413</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Prenatal antidepressant use is widespread. Observational studies have investigated the neonatal effects of prenatal antidepressant exposure with inconclusive results. We aimed to comprehensively investigate the associations between prenatal antidepressant exposure and the most commonly studied adverse neonatal outcomes: preterm birth, birthweight, poor neonatal adaptation, persistent pulmonary hypertension of the neonate (PPHN), neonatal admission and congenital malformations. METHODS: We included 45,590 singletons (born 1997-2015) whose mothers used antidepressants within one year before pregnancy. Children were categorised into two groups: continuation (antidepressant use before and during pregnancy) or discontinuation (antidepressant use before but not during pregnancy). We applied random-effects logistic and linear regressions, adjusting for covariates. RESULTS: After adjusting for confounders, prenatal antidepressant exposure was associated with a 2.3 day (95% CI -2.9; -2.0) decrease in gestational age and a 51 g (95% CI -62g; -41 g) decrease in birthweight. The continuation group was at increased risk for moderate-to-late preterm birth (32-37 weeks) (aOR = 1.43; 95%CI 1.33; 1.55), moderately low birthweight (1500-2499 g) (aOR = 1.28; 95%CI 1.17; 1.41), postnatal adaptation syndrome (aOR = 2.59; 95%CI 1.87; 3.59) and neonatal admission (aOR = 1.52; 95%CI 1.44; 1.60) compared to the discontinuation group. CONCLUSION: Prenatal antidepressant exposure was associated with small decreases in gestational age and birthweight, as well as higher risk for moderate-to-late preterm birth, moderately low birthweight, neonatal admission and postnatal adaptation syndrome. No differences in risk were found for PPHN, or congenital malformations. The causality of the observed associations cannot be established due to the potential for unmeasured residual confounding linked to the underlying disease.</style></abstract><notes><style face="normal" font="default" size="100%">Rommel, Anna-Sophie&#xD;Momen, Natalie C&#xD;Molenaar, Nina Maren&#xD;Agerbo, Esben&#xD;Bergink, Veerle&#xD;Munk-Olsen, Trine&#xD;Liu, Xiaoqin&#xD;eng&#xD;R01 MH122869/MH/NIMH NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/02/14&#xD;Acta Psychiatr Scand. 2022 Jun;145(6):544-556. doi: 10.1111/acps.13409. Epub 2022 Feb 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35152413</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflict of Interest: All authors declare: support for the submitted work as described below; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9117424</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/acps.13409</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buus, N.</style></author><author><style face="normal" font="default" size="100%">Nygaard, L.</style></author><author><style face="normal" font="default" size="100%">Berring, L. L.</style></author><author><style face="normal" font="default" size="100%">Hybholt, L.</style></author><author><style face="normal" font="default" size="100%">Kamionka, S. L.</style></author><author><style face="normal" font="default" size="100%">Rossen, C. B.</style></author><author><style face="normal" font="default" size="100%">Sondergaard, R.</style></author><author><style face="normal" font="default" size="100%">Juel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Nursing and Health Sciences, Monash Nursing and Midwifery, Monash University, Melbourne, Victoria, Australia.&#xD;Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.&#xD;Research Unit for Gynaecology and Obstetrics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Gynaecology and Obstetrics, Odense University Hospital, Odense, Denmark.&#xD;Psychiatric Research Unit, Mental Health Region Zealand, Denmark, Slagelse, Denmark.&#xD;Center for Relationships and De-escalation, Mental Health Region Zealand, Slagelse, Denmark.&#xD;Mental Health Services East, Mental Health Region Zealand, Roskilde, Denmark.&#xD;Research Unit, Child and Adolescent Mental Health, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Elective Surgery Center, Silkeborg Regional Hospital, Silkeborg, Denmark.&#xD;Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Arksey and O&apos;Malley&apos;s consultation exercise in scoping reviews: A critical review</style></title><secondary-title><style face="normal" font="default" size="100%">J Adv Nurs</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">2304-2312</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">20220422</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Consensus</style></keyword><keyword><style face="normal" font="default" size="100%">*Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Research Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">community participation</style></keyword><keyword><style face="normal" font="default" size="100%">health services research</style></keyword><keyword><style face="normal" font="default" size="100%">methods</style></keyword><keyword><style face="normal" font="default" size="100%">nursing</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1365-2648 (Electronic)&#xD;0309-2402 (Print)&#xD;0309-2402 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35451517</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: To explore how consultation exercises were described in a convenience sample of recent scoping reviews. DESIGN: Critical literature review. DATA SOURCES: We searched PsycINFO, Embase, CINAHL and PubMed in July 2020. Our inclusion criterion was a peer-reviewed journal article reporting a scoping review in Danish, English, Norwegian or Swedish. REVIEW METHODS: We identified a convenience sample of articles (n = 66) reporting a consultation exercise as part of a scoping review. The descriptions of the consultation were charted, summarized and critically discussed. RESULTS: The current analysis showed no widely accepted consensus on how to approach and report a consultation exercise in the sample of scoping reviews. The reports of stakeholder consultation processes were often brief and general, and often there were no reports of the effects of the stakeholder consultation processes. Further, there was no discussion of the principal theoretical problems mixing stakeholder voices and review findings. CONCLUSION: The finding that conventional research ethics and research methods often were suspended could indicate that the stakeholder consultants were in a precarious position because of power imbalances between researchers and stakeholder consultants. We suggest that a consultation exercise should only be included when it genuinely invites participation and reports on the effect of alternative voices. IMPACT: Scoping reviews are common across a range of disciplines, but they often lack definitional and methodological clarity. In their influential approach to scoping studies, Arksey and O&apos;Malley introduced an optional &apos;consultation exercise&apos;, which has been heralded as a valuable tool that can be used to strengthen the process and outcome of a scoping study and to support the dissemination of the study&apos;s findings and its implications. However, there is no clear outline on about how to operationalize consultations of stakeholders in scoping studies/reviews. This article includes recommendations for consultation exercises, including encouraging an aspirational move from &apos;consultation&apos; to &apos;participation&apos;.</style></abstract><notes><style face="normal" font="default" size="100%">Buus, Niels&#xD;Nygaard, Lene&#xD;Berring, Lene Lauge&#xD;Hybholt, Lisbeth&#xD;Kamionka, Stine Lundstrom&#xD;Rossen, Camilla Blach&#xD;Sondergaard, Rikke&#xD;Juel, Anette&#xD;eng&#xD;Review&#xD;England&#xD;2022/04/23&#xD;J Adv Nurs. 2022 Aug;78(8):2304-2312. doi: 10.1111/jan.15265. Epub 2022 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35451517</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors report no conflicts of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9545832</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jan.15265</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>238</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">238</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bauer, M.</style></author><author><style face="normal" font="default" size="100%">Glenn, T.</style></author><author><style face="normal" font="default" size="100%">Achtyes, E. D.</style></author><author><style face="normal" font="default" size="100%">Alda, M.</style></author><author><style face="normal" font="default" size="100%">Agaoglu, E.</style></author><author><style face="normal" font="default" size="100%">Altinbas, K.</style></author><author><style face="normal" font="default" size="100%">Andreassen, O. A.</style></author><author><style face="normal" font="default" size="100%">Angelopoulos, E.</style></author><author><style face="normal" font="default" size="100%">Ardau, R.</style></author><author><style face="normal" font="default" size="100%">Aydin, M.</style></author><author><style face="normal" font="default" size="100%">Ayhan, Y.</style></author><author><style face="normal" font="default" size="100%">Baethge, C.</style></author><author><style face="normal" font="default" size="100%">Bauer, R.</style></author><author><style face="normal" font="default" size="100%">Baune, B. T.</style></author><author><style face="normal" font="default" size="100%">Balaban, C.</style></author><author><style face="normal" font="default" size="100%">Becerra-Palars, C.</style></author><author><style face="normal" font="default" size="100%">Behere, A. P.</style></author><author><style face="normal" font="default" size="100%">Behere, P. B.</style></author><author><style face="normal" font="default" size="100%">Belete, H.</style></author><author><style face="normal" font="default" size="100%">Belete, T.</style></author><author><style face="normal" font="default" size="100%">Belizario, G. O.</style></author><author><style face="normal" font="default" size="100%">Bellivier, F.</style></author><author><style face="normal" font="default" size="100%">Belmaker, R. H.</style></author><author><style face="normal" font="default" size="100%">Benedetti, F.</style></author><author><style face="normal" font="default" size="100%">Berk, M.</style></author><author><style face="normal" font="default" size="100%">Bersudsky, Y.</style></author><author><style face="normal" font="default" size="100%">Bicakci, S.</style></author><author><style face="normal" font="default" size="100%">Birabwa-Oketcho, H.</style></author><author><style face="normal" font="default" size="100%">Bjella, T. D.</style></author><author><style face="normal" font="default" size="100%">Brady, C.</style></author><author><style face="normal" font="default" size="100%">Cabrera, J.</style></author><author><style face="normal" font="default" size="100%">Cappucciati, M.</style></author><author><style face="normal" font="default" size="100%">Castro, A. M. P.</style></author><author><style face="normal" font="default" size="100%">Chen, W. L.</style></author><author><style face="normal" font="default" size="100%">Cheung, E. Y. W.</style></author><author><style face="normal" font="default" size="100%">Chiesa, S.</style></author><author><style face="normal" font="default" size="100%">Crowe, M.</style></author><author><style face="normal" font="default" size="100%">Cuomo, A.</style></author><author><style face="normal" font="default" size="100%">Dallaspezia, S.</style></author><author><style face="normal" font="default" size="100%">Del Zompo, M.</style></author><author><style face="normal" font="default" size="100%">Desai, P.</style></author><author><style face="normal" font="default" size="100%">Dodd, S.</style></author><author><style face="normal" font="default" size="100%">Etain, B.</style></author><author><style face="normal" font="default" size="100%">Fagiolini, A.</style></author><author><style face="normal" font="default" size="100%">Fellendorf, F. T.</style></author><author><style face="normal" font="default" size="100%">Ferensztajn-Rochowiak, E.</style></author><author><style face="normal" font="default" size="100%">Fiedorowicz, J. G.</style></author><author><style face="normal" font="default" size="100%">Fountoulakis, K. N.</style></author><author><style face="normal" font="default" size="100%">Frye, M. A.</style></author><author><style face="normal" font="default" size="100%">Geoffroy, P. A.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Pinto, A.</style></author><author><style face="normal" font="default" size="100%">Gottlieb, J. F.</style></author><author><style face="normal" font="default" size="100%">Grof, P.</style></author><author><style face="normal" font="default" size="100%">Haarman, B. C. M.</style></author><author><style face="normal" font="default" size="100%">Harima, H.</style></author><author><style face="normal" font="default" size="100%">Hasse-Sousa, M.</style></author><author><style face="normal" font="default" size="100%">Henry, C.</style></author><author><style face="normal" font="default" size="100%">Hoffding, L.</style></author><author><style face="normal" font="default" size="100%">Houenou, J.</style></author><author><style face="normal" font="default" size="100%">Imbesi, M.</style></author><author><style face="normal" font="default" size="100%">Isometsa, E. T.</style></author><author><style face="normal" font="default" size="100%">Ivkovic, M.</style></author><author><style face="normal" font="default" size="100%">Janno, S.</style></author><author><style face="normal" font="default" size="100%">Johnsen, S.</style></author><author><style face="normal" font="default" size="100%">Kapczinski, F.</style></author><author><style face="normal" font="default" size="100%">Karakatsoulis, G. N.</style></author><author><style face="normal" font="default" size="100%">Kardell, M.</style></author><author><style face="normal" font="default" size="100%">Kessing, L. V.</style></author><author><style face="normal" font="default" size="100%">Kim, S. J.</style></author><author><style face="normal" font="default" size="100%">Konig, B.</style></author><author><style face="normal" font="default" size="100%">Kot, T. L.</style></author><author><style face="normal" font="default" size="100%">Koval, M.</style></author><author><style face="normal" font="default" size="100%">Kunz, M.</style></author><author><style face="normal" font="default" size="100%">Lafer, B.</style></author><author><style face="normal" font="default" size="100%">Landen, M.</style></author><author><style face="normal" font="default" size="100%">Larsen, E. R.</style></author><author><style face="normal" font="default" size="100%">Lenger, M.</style></author><author><style face="normal" font="default" size="100%">Lewitzka, U.</style></author><author><style face="normal" font="default" size="100%">Licht, R. W.</style></author><author><style face="normal" font="default" size="100%">Lopez-Jaramillo, C.</style></author><author><style face="normal" font="default" size="100%">MacKenzie, A.</style></author><author><style face="normal" font="default" size="100%">Madsen, H. O.</style></author><author><style face="normal" font="default" size="100%">Madsen, Saka</style></author><author><style face="normal" font="default" size="100%">Mahadevan, J.</style></author><author><style face="normal" font="default" size="100%">Mahardika, A.</style></author><author><style face="normal" font="default" size="100%">Manchia, M.</style></author><author><style face="normal" font="default" size="100%">Marsh, W.</style></author><author><style face="normal" font="default" size="100%">Martinez-Cengotitabengoa, M.</style></author><author><style face="normal" font="default" size="100%">Martiny, K.</style></author><author><style face="normal" font="default" size="100%">Mashima, Y.</style></author><author><style face="normal" font="default" size="100%">McLoughlin, D. M.</style></author><author><style face="normal" font="default" size="100%">Meesters, Y.</style></author><author><style face="normal" font="default" size="100%">Melle, I.</style></author><author><style face="normal" font="default" size="100%">Meza-Urzua, F.</style></author><author><style face="normal" font="default" size="100%">Mok, Y. M.</style></author><author><style face="normal" font="default" size="100%">Monteith, S.</style></author><author><style face="normal" font="default" size="100%">Moorthy, M.</style></author><author><style face="normal" font="default" size="100%">Morken, G.</style></author><author><style face="normal" font="default" size="100%">Mosca, E.</style></author><author><style face="normal" font="default" size="100%">Mozzhegorov, A. A.</style></author><author><style face="normal" font="default" size="100%">Munoz, R.</style></author><author><style face="normal" font="default" size="100%">Mythri, S. V.</style></author><author><style face="normal" font="default" size="100%">Nacef, F.</style></author><author><style face="normal" font="default" size="100%">Nadella, R. K.</style></author><author><style face="normal" font="default" size="100%">Nakanotani, T.</style></author><author><style face="normal" font="default" size="100%">Nielsen, R. E.</style></author><author><style face="normal" font="default" size="100%">O&apos;Donovan, C.</style></author><author><style face="normal" font="default" size="100%">Omrani, A.</style></author><author><style face="normal" font="default" size="100%">Osher, Y.</style></author><author><style face="normal" font="default" size="100%">Ouali, U.</style></author><author><style face="normal" font="default" size="100%">Pantovic-Stefanovic, M.</style></author><author><style face="normal" font="default" size="100%">Pariwatcharakul, P.</style></author><author><style face="normal" font="default" size="100%">Petite, J.</style></author><author><style face="normal" font="default" size="100%">Pfennig, A.</style></author><author><style face="normal" font="default" size="100%">Ruiz, Y. P.</style></author><author><style face="normal" font="default" size="100%">Pinna, M.</style></author><author><style face="normal" font="default" size="100%">Pompili, M.</style></author><author><style face="normal" font="default" size="100%">Porter, R.</style></author><author><style face="normal" font="default" size="100%">Quiroz, D.</style></author><author><style face="normal" font="default" size="100%">Rabelo-da-Ponte, F. D.</style></author><author><style face="normal" font="default" size="100%">Ramesar, R.</style></author><author><style face="normal" font="default" size="100%">Rasgon, N.</style></author><author><style face="normal" font="default" size="100%">Ratta-Apha, W.</style></author><author><style face="normal" font="default" size="100%">Ratzenhofer, M.</style></author><author><style face="normal" font="default" size="100%">Redahan, M.</style></author><author><style face="normal" font="default" size="100%">Reddy, M. S.</style></author><author><style face="normal" font="default" size="100%">Reif, A.</style></author><author><style face="normal" font="default" size="100%">Reininghaus, E. Z.</style></author><author><style face="normal" font="default" size="100%">Richards, J. G.</style></author><author><style face="normal" font="default" size="100%">Ritter, P.</style></author><author><style face="normal" font="default" size="100%">Rybakowski, J. K.</style></author><author><style face="normal" font="default" size="100%">Sathyaputri, L.</style></author><author><style face="normal" font="default" size="100%">Scippa, A. M.</style></author><author><style face="normal" font="default" size="100%">Simhandl, C.</style></author><author><style face="normal" font="default" size="100%">Smith, D.</style></author><author><style face="normal" font="default" size="100%">Smith, J.</style></author><author><style face="normal" font="default" size="100%">Stackhouse, P. W., Jr.</style></author><author><style face="normal" font="default" size="100%">Stein, D. J.</style></author><author><style face="normal" font="default" size="100%">Stilwell, K.</style></author><author><style face="normal" font="default" size="100%">Strejilevich, S.</style></author><author><style face="normal" font="default" size="100%">Su, K. P.</style></author><author><style face="normal" font="default" size="100%">Subramaniam, M.</style></author><author><style face="normal" font="default" size="100%">Sulaiman, A. H.</style></author><author><style face="normal" font="default" size="100%">Suominen, K.</style></author><author><style face="normal" font="default" size="100%">Tanra, A. J.</style></author><author><style face="normal" font="default" size="100%">Tatebayashi, Y.</style></author><author><style face="normal" font="default" size="100%">Teh, W. L.</style></author><author><style face="normal" font="default" size="100%">Tondo, L.</style></author><author><style face="normal" font="default" size="100%">Torrent, C.</style></author><author><style face="normal" font="default" size="100%">Tuinstra, D.</style></author><author><style face="normal" font="default" size="100%">Uchida, T.</style></author><author><style face="normal" font="default" size="100%">Vaaler, A. E.</style></author><author><style face="normal" font="default" size="100%">Vieta, E.</style></author><author><style face="normal" font="default" size="100%">Viswanath, B.</style></author><author><style face="normal" font="default" size="100%">Yoldi-Negrete, M.</style></author><author><style face="normal" font="default" size="100%">Yalcinkaya, O. K.</style></author><author><style face="normal" font="default" size="100%">Young, A. H.</style></author><author><style face="normal" font="default" size="100%">Zgueb, Y.</style></author><author><style face="normal" font="default" size="100%">Whybrow, P. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Faculty of Medicine, Technische Universitat Dresden, Dresden, Germany. Electronic address: michael.bauer@ukdd.de.&#xD;ChronoRecord Association, Fullerton, CA, USA.&#xD;Michigan State University College of Human Medicine, Division of Psychiatry &amp; Behavioral Medicine, Grand Rapids, MI, USA; Pine Rest Christian Mental Health Services, Grand Rapids, MI, USA.&#xD;Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.&#xD;Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara, Turkey.&#xD;Department of Psychiatry, Selcuk University Faculty of Medicine, Mazhar Osman Mood Center, Konya, Turkey.&#xD;NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital &amp; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.&#xD;Department of Psychiatry, National and Capodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece.&#xD;Section of Neurosciences and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Sardinia, Italy.&#xD;Department of Psychiatry, Selcuk University Faculty of Medicine, Konya, Turkey.&#xD;Department of Psychiatry and Psychotherapy, University of Cologne Medical School, Cologne, Germany.&#xD;Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Faculty of Medicine, Technische Universitat Dresden, Dresden, Germany.&#xD;Department of Psychiatry, University of Munster, Munster, Germany; Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia; The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.&#xD;Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Johann Wolfgang Goethe-Universitat Frankfurt am Main, Frankfurt am Main, Germany.&#xD;National Institute of Psychiatry &apos;&quot;Ramon de la Fuente Muniz&quot;, Mexico City, Mexico.&#xD;Department of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI, USA.&#xD;Department of Psychiatry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed University), Wardha, India.&#xD;Department of Psychiatry, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.&#xD;Bipolar Disorder Research Program, Department of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil.&#xD;Departement de Psychiatrie et de Medecine Addictologique, Assistance Publique - Hopitaux de Paris, INSERM UMR-S1144, Universite de Paris, FondaMental Foundation, Paris, France.&#xD;Professor Emeritus of Psychiatry, Ben Gurion University of the Negev, Beer Sheva, Israel.&#xD;University Vita-Salute San Raffaele, Milan, Italy; Psychiatry &amp; Clinical Psychobiology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.&#xD;Deakin University, IMPACT - the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia; Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia.&#xD;Department of Psychiatry, Faculty of Health Sciences, Beer Sheva Mental Health Center, Ben Gurion University of the Negev, Beer Sheva, Israel.&#xD;Department of Psychiatry, Hacettepe University Faculty of Medicine, Ankara, Turkey; Department of Psychiatry, Baskent University Faculty of Medicine, Ankara, Turkey.&#xD;Butabika Hospital, Kampala, Uganda.&#xD;Department of Psychiatry, Trinity College Dublin, St Patrick&apos;s University Hospital, Dublin, Ireland.&#xD;Mood Disorders Clinic, Dr. Jose Horwitz Psychiatric Institute, Santiago de Chile, Chile.&#xD;Department of Mental Health and Substance Abuse, Piacenza, Italy.&#xD;Deakin University, IMPACT - the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.&#xD;Department of Psychiatry, Chiayi Branch, Taichung Veterans General Hospital, Chiayi, Taiwan.&#xD;Private practice, Central, Hong Kong.&#xD;Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.&#xD;Department of Molecular Medicine, University of Siena School of Medicine, Siena, Italy.&#xD;Psychiatry &amp; Clinical Psychobiology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.&#xD;Pine Rest Christian Mental Health Services, Grand Rapids, MI, USA.&#xD;Deakin University, IMPACT - the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia; Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia.&#xD;Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria.&#xD;Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland.&#xD;Department of Psychiatry, School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.&#xD;3rd Department of Psychiatry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.&#xD;Department of Psychiatry &amp; Psychology, Mayo Clinic Depression Center, Mayo Clinic, Rochester, MN, USA.&#xD;Departement de psychiatrie et d&apos;addictologie, AP-HP, GHU Paris Nord, DMU Neurosciences, Hopital Bichat - Claude Bernard, F-75018 Paris, France; GHU Paris - Psychiatry &amp; Neurosciences, 1 rue Cabanis, 75014 Paris, France; Universite de Paris, NeuroDiderot, Inserm, FHU I2-D2, F-75019 Paris, France.&#xD;BIOARABA. Department of Psychiatry, University Hospital of Alava, University of the Basque Country, CIBERSAM, Vitoria, Spain.&#xD;Department of Psychiatry, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.&#xD;Mood Disorders Center of Ottawa and the Department of Psychiatry, University of Toronto, Canada.&#xD;Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.&#xD;Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya, Tokyo, Japan.&#xD;Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.&#xD;Department of Psychiatry, GHU Paris Psychiatrie &amp; Neurosciences, F-75014, Paris France, Universite de Paris, F-75006 Paris, France.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Universite Paris Est Creteil, INSERM, IMRB, Translational Neuropsychiatry, APHP, Mondor Univ Hospitals, Fondation FondaMental, F-94010 Creteil, France; Universite Paris Saclay, CEA, Neurospin, F-91191 Gif-sur-Yvette, France.&#xD;Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; National Institute for Health and Welfare, Helsinki, Finland.&#xD;University Clinical Center of Serbia, Clinic for Psychiatry, Belgrade, Serbia.&#xD;Department of Psychiatry, University of Tartu, Tartu, Estonia.&#xD;Unit for Psychiatric Research, Aalborg University Hospital, Aalborg, Denmark.&#xD;Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen, Denmark.&#xD;Department of Psychiatry, Chosun University School of Medicine, Gwangju, Republic of Korea.&#xD;BIPOLAR Zentrum Wiener Neustadt, Wiener Neustadt, Austria.&#xD;Khanty-Mansiysk Clinical Psychoneurological Hospital, Khanty-Mansiysk, Russia.&#xD;Department of Neuroscience, Michigan State University, East Lansing, MI, USA.&#xD;Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.&#xD;Mental Health Department Odense, University Clinic and Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark.&#xD;Psychiatry - Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.&#xD;Mood Disorders Program, Hospital Universitario San Vicente Fundacion, Research Group in Psychiatry, Department of Psychiatry, Faculty of Medicine, Universidad de Antioquia, Medellin, Colombia.&#xD;Forensic Psychiatry, University of Glasgow, NHS Greater Glasgow and Clyde, Glasgow, UK.&#xD;Copenhagen University Hospitals, Psychiatric Centre Copenhagen, Copenhagen, Denmark.&#xD;Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, India.&#xD;Department of Psychiatry, Faculty of Medicine, Mataram University, Mataram, Indonesia.&#xD;Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada; Section of Psychiatry, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy.&#xD;Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA.&#xD;Osakidetza, Basque Health Service, BioAraba Health Research Institute, University of the Basque Country, Spain; The Psychology Clinic of East Anglia, Norwich, United Kingdom.&#xD;Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.&#xD;Dept of Psychiatry &amp; Trinity College Institute of Neuroscience, Trinity College Dublin, St Patrick&apos;s University Hospital, Dublin, Ireland.&#xD;Department of Child and Adolescent Psychiatry und Psychotherapy, SHG Klinikum, Idar-Oberstein, Germany.&#xD;Department of Mood and Anxiety disorders, Institute of Mental Health, Singapore City, Singapore.&#xD;Michigan State University College of Human Medicine, Traverse City Campus, Traverse City, MI, USA.&#xD;Department of Mental Health, Norwegian University of Science and Technology - NTNU, Trondheim, Norway; Department of Psychiatry, St Olavs&apos; University Hospital, Trondheim, Norway.&#xD;Soviet Psychoneurological Hospital, Urai, Russia.&#xD;Department of Psychiatry, University of California San Diego, San Diego, CA, USA.&#xD;Makunda Christian Leprosy and General Hospital, Bazaricherra, Assam 788727, India.&#xD;Razi Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia.&#xD;Affective Disorders Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, Japan.&#xD;Tunisian Bipolar Forum, Erable Medical Cabinet 324, Lac 2, Tunis, Tunisia.&#xD;Department of Psychiatry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.&#xD;Hospital &quot;Angeles del Pedregal&quot;, Mexico City, Mexico.&#xD;Section of Psychiatry, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy; Lucio Bini Mood Disorder Center, Cagliari, Italy.&#xD;Department of Neurosciences, Mental Health and Sensory Organs, Sant&apos;Andrea Hospital, Sapienza University of Rome, Rome, Italy.&#xD;Deparment of Psychiatry, Diego Portales University, Santiago de Chile, Chile.&#xD;University of Central Lancashire, School of Pharmacy and Biomedical Sciences, Preston, Lancashire, United Kingdom.&#xD;SA MRC Genomic and Precision Medicine Research Unit, Division of Human Genetics, Department of Pathology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa.&#xD;Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, Palo Alto, CA, USA.&#xD;Asha Bipolar Clinic, Asha Hospital, Hyderabad, Telangana, India.&#xD;Departments of Psychiatry, Epidemiology, and Internal Medicine, Iowa Neuroscience Institute, The University of Iowa, Iowa City, IA, USA.&#xD;Department of Neuroscience and Mental Health, Federal University of Bahia, Salvador, Brazil.&#xD;Bipolar Zentrum Wiener Neustadt, Sigmund Freud Privat Universitat, Vienna, Austria.&#xD;Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.&#xD;AREA, Assistance and Research in Affective Disorders, Buenos Aires, Argentina.&#xD;Science Directorate/Climate Science Branch, NASA Langley Research Center, Hampton, VA, USA.&#xD;Department of Psychiatry, MRC Unit on Risk &amp; Resilience in Mental Disorders, University of Cape Town, Cape Town, South Africa.&#xD;College of Medicine, China Medical University (CMU), Taichung, Taiwan; An-Nan Hospital, China Medical University, Tainan, Taiwan.&#xD;Research Division, Institute of Mental Health, Singapore.&#xD;Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.&#xD;Department of Social Services and Health Care, Psychiatry, City of Helsinki, Helsinki, Finland.&#xD;Department of Psychiatry, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.&#xD;McLean Hospital-Harvard Medical School, Boston, MA, USA; Mood Disorder Lucio Bini Centers, Cagliari e Roma, Italy.&#xD;Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.&#xD;Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Melbourne, Australia.&#xD;Subdireccion de Investigaciones Clinicas. Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz, Mexico City, Mexico.&#xD;Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK.&#xD;Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association between polarity of first episode and solar insolation in bipolar I disorder</style></title><secondary-title><style face="normal" font="default" size="100%">J Psychosom Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Psychosom Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">110982</style></pages><volume><style face="normal" font="default" size="100%">160</style></volume><edition><style face="normal" font="default" size="100%">20220625</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Bipolar Disorder/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Circadian Rhythm</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Seasons</style></keyword><keyword><style face="normal" font="default" size="100%">Sunlight</style></keyword><keyword><style face="normal" font="default" size="100%">Bipolar disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Depression</style></keyword><keyword><style face="normal" font="default" size="100%">Polarity</style></keyword><keyword><style face="normal" font="default" size="100%">Solar insolation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-1360 (Electronic)&#xD;0022-3999 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35932492</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Circadian rhythm disruption is commonly observed in bipolar disorder (BD). Daylight is the most powerful signal to entrain the human circadian clock system. This exploratory study investigated if solar insolation at the onset location was associated with the polarity of the first episode of BD I. Solar insolation is the amount of electromagnetic energy from the Sun striking a surface area of the Earth. METHODS: Data from 7488 patients with BD I were collected at 75 sites in 42 countries. The first episode occurred at 591 onset locations in 67 countries at a wide range of latitudes in both hemispheres. Solar insolation values were obtained for every onset location, and the ratio of the minimum mean monthly insolation to the maximum mean monthly insolation was calculated. This ratio is largest near the equator (with little change in solar insolation over the year), and smallest near the poles (where winter insolation is very small compared to summer insolation). This ratio also applies to tropical locations which may have a cloudy wet and clear dry season, rather than winter and summer. RESULTS: The larger the change in solar insolation throughout the year (smaller the ratio between the minimum monthly and maximum monthly values), the greater the likelihood the first episode polarity was depression. Other associated variables were being female and increasing percentage of gross domestic product spent on country health expenditures. (All coefficients: P&lt;/=0.001). CONCLUSION: Increased awareness and research into circadian dysfunction throughout the course of BD is warranted.</style></abstract><notes><style face="normal" font="default" size="100%">Bauer, Michael&#xD;Glenn, Tasha&#xD;Achtyes, Eric D&#xD;Alda, Martin&#xD;Agaoglu, Esen&#xD;Altinbas, Kursat&#xD;Andreassen, Ole A&#xD;Angelopoulos, Elias&#xD;Ardau, Raffaella&#xD;Aydin, Memduha&#xD;Ayhan, Yavuz&#xD;Baethge, Christopher&#xD;Bauer, Rita&#xD;Baune, Bernhard T&#xD;Balaban, Ceylan&#xD;Becerra-Palars, Claudia&#xD;Behere, Aniruddh P&#xD;Behere, Prakash B&#xD;Belete, Habte&#xD;Belete, Tilahun&#xD;Belizario, Gabriel Okawa&#xD;Bellivier, Frank&#xD;Belmaker, Robert H&#xD;Benedetti, Francesco&#xD;Berk, Michael&#xD;Bersudsky, Yuly&#xD;Bicakci, Sule&#xD;Birabwa-Oketcho, Harriet&#xD;Bjella, Thomas D&#xD;Brady, Conan&#xD;Cabrera, Jorge&#xD;Cappucciati, Marco&#xD;Castro, Angela Marianne Paredes&#xD;Chen, Wei-Ling&#xD;Cheung, Eric Y W&#xD;Chiesa, Silvia&#xD;Crowe, Marie&#xD;Cuomo, Alessandro&#xD;Dallaspezia, Sara&#xD;Del Zompo, Maria&#xD;Desai, Pratikkumar&#xD;Dodd, Seetal&#xD;Etain, Bruno&#xD;Fagiolini, Andrea&#xD;Fellendorf, Frederike T&#xD;Ferensztajn-Rochowiak, Ewa&#xD;Fiedorowicz, Jess G&#xD;Fountoulakis, Kostas N&#xD;Frye, Mark A&#xD;Geoffroy, Pierre A&#xD;Gonzalez-Pinto, Ana&#xD;Gottlieb, John F&#xD;Grof, Paul&#xD;Haarman, Bartholomeus C M&#xD;Harima, Hirohiko&#xD;Hasse-Sousa, Mathias&#xD;Henry, Chantal&#xD;Hoffding, Lone&#xD;Houenou, Josselin&#xD;Imbesi, Massimiliano&#xD;Isometsa, Erkki T&#xD;Ivkovic, Maja&#xD;Janno, Sven&#xD;Johnsen, Simon&#xD;Kapczinski, Flavio&#xD;Karakatsoulis, Gregory N&#xD;Kardell, Mathias&#xD;Kessing, Lars Vedel&#xD;Kim, Seong Jae&#xD;Konig, Barbara&#xD;Kot, Timur L&#xD;Koval, Michael&#xD;Kunz, Mauricio&#xD;Lafer, Beny&#xD;Landen, Mikael&#xD;Larsen, Erik R&#xD;Lenger, Melanie&#xD;Lewitzka, Ute&#xD;Licht, Rasmus W&#xD;Lopez-Jaramillo, Carlos&#xD;MacKenzie, Alan&#xD;Madsen, Helle Ostergaard&#xD;Madsen, Simone Alberte Kongstad A&#xD;Mahadevan, Jayant&#xD;Mahardika, Agustine&#xD;Manchia, Mirko&#xD;Marsh, Wendy&#xD;Martinez-Cengotitabengoa, Monica&#xD;Martiny, Klaus&#xD;Mashima, Yuki&#xD;McLoughlin, Declan M&#xD;Meesters, Ybe&#xD;Melle, Ingrid&#xD;Meza-Urzua, Fatima&#xD;Mok, Yee Ming&#xD;Monteith, Scott&#xD;Moorthy, Muthukumaran&#xD;Morken, Gunnar&#xD;Mosca, Enrica&#xD;Mozzhegorov, Anton A&#xD;Munoz, Rodrigo&#xD;Mythri, Starlin V&#xD;Nacef, Fethi&#xD;Nadella, Ravi K&#xD;Nakanotani, Takako&#xD;Nielsen, Rene Ernst&#xD;O&apos;Donovan, Claire&#xD;Omrani, Adel&#xD;Osher, Yamima&#xD;Ouali, Uta&#xD;Pantovic-Stefanovic, Maja&#xD;Pariwatcharakul, Pornjira&#xD;Petite, Joanne&#xD;Pfennig, Andrea&#xD;Ruiz, Yolanda Pica&#xD;Pinna, Marco&#xD;Pompili, Maurizio&#xD;Porter, Richard&#xD;Quiroz, Danilo&#xD;Rabelo-da-Ponte, Francisco Diego&#xD;Ramesar, Raj&#xD;Rasgon, Natalie&#xD;Ratta-Apha, Woraphat&#xD;Ratzenhofer, Michaela&#xD;Redahan, Maria&#xD;Reddy, M S&#xD;Reif, Andreas&#xD;Reininghaus, Eva Z&#xD;Richards, Jenny Gringer&#xD;Ritter, Philipp&#xD;Rybakowski, Janusz K&#xD;Sathyaputri, Leela&#xD;Scippa, Angela M&#xD;Simhandl, Christian&#xD;Smith, Daniel&#xD;Smith, Jose&#xD;Stackhouse, Paul W Jr&#xD;Stein, Dan J&#xD;Stilwell, Kellen&#xD;Strejilevich, Sergio&#xD;Su, Kuan-Pin&#xD;Subramaniam, Mythily&#xD;Sulaiman, Ahmad Hatim&#xD;Suominen, Kirsi&#xD;Tanra, Andi J&#xD;Tatebayashi, Yoshitaka&#xD;Teh, Wen Lin&#xD;Tondo, Leonardo&#xD;Torrent, Carla&#xD;Tuinstra, Daniel&#xD;Uchida, Takahito&#xD;Vaaler, Arne E&#xD;Vieta, Eduard&#xD;Viswanath, Biju&#xD;Yoldi-Negrete, Maria&#xD;Yalcinkaya, Oguz Kaan&#xD;Young, Allan H&#xD;Zgueb, Yosra&#xD;Whybrow, Peter C&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/08/07&#xD;J Psychosom Res. 2022 Sep;160:110982. doi: 10.1016/j.jpsychores.2022.110982. Epub 2022 Jun 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35932492</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jpsychores.2022.110982</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Trabjerg, B. B.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author><author><style face="normal" font="default" size="100%">Christensen, J.</style></author><author><style face="normal" font="default" size="100%">Dreier, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Association of Maternal Antipsychotic Prescription During Pregnancy With Standardized Test Scores of Schoolchildren in Denmark</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Intern Med</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1035-1043</style></pages><volume><style face="normal" font="default" size="100%">182</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Clopenthixol</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Flupenthixol</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Methotrimeprazine</style></keyword><keyword><style face="normal" font="default" size="100%">Olanzapine</style></keyword><keyword><style face="normal" font="default" size="100%">Perphenazine</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Prescriptions</style></keyword><keyword><style face="normal" font="default" size="100%">Quetiapine Fumarate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 1</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">American Medical Association (AMA)</style></publisher><isbn><style face="normal" font="default" size="100%">2168-6114 (Electronic)&#xD;2168-6106 (Print)&#xD;2168-6106 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35969410</style></accession-num><abstract><style face="normal" font="default" size="100%">IMPORTANCE: An increasing number of individuals fill antipsychotic prescriptions during pregnancy, and concerns have been raised about prenatal antipsychotic exposure on neurodevelopmental outcomes. OBJECTIVE: To examine whether maternal prescription fill for antipsychotics during pregnancy was associated with performance in standardized tests among schoolchildren. DESIGN, SETTING, AND PARTICIPANTS: This register-based cohort study included 667517 children born in Denmark from January 1, 1997, to December 31, 2009, and who were attending public primary and lower secondary school. All children had completed at least 1 language (Danish) or mathematics test as part of the Danish National School Test Program between 2010 and 2018. Data were analyzed from November 1, 2021, to March 31, 2022. EXPOSURES: Antipsychotic prescriptions filled by pregnant individuals were obtained from the Danish National Prescription Register. MAIN OUTCOMES AND MEASURES: Differences in standardized test scores (range, 1-100; higher scores indicate better test results) in language and mathematics between children of mothers with and without antipsychotic prescription fills during pregnancy were estimated using linear regression models. Seven sensitivity analyses, including a sibling-controlled analysis, were performed. RESULTS: Of the 667517 children included (51.2% males), 1442 (0.2%) children were born to mothers filling an antipsychotic prescription during pregnancy. The mean (SD) age of children at the time of testing spanned from 8.9 (0.4) years in grade 2 to 14.9 (0.4) years in grade 8. Maternal prescription fill for antipsychotics was not associated with performance in language (crude mean test score: 50.0 [95% CI, 49.1-50.9] for the exposed children vs 55.4 [95% CI, 55.4-55.5] for the unexposed children; adjusted difference, 0.5 [95% CI, -0.8 to 1.7]) or in mathematics (crude mean test score: 48.1 [95% CI, 47.0-49.3] for the exposed children vs 56.1 [95% CI, 56.1-56.2] for the unexposed children; adjusted difference, 0.4 [95% CI, -1.0 to 1.8]). There was no evidence that results were modified by the timing of filling prescriptions, classes (first-generation and second-generation) of antipsychotics, or the most commonly prescribed antipsychotic monotherapies, including chlorprotixene, flupentixol, olanzapine, zuclopenthixol, quetiapine, perphenazine, and methotrimeprazine. The results remained robust across sensitivity analyses, including sibling-controlled analyses, negative control exposures analyses, and probabilistic bias analyses. CONCLUSIONS AND RELEVANCE: In this register-based cohort study, maternal prescription fill for antipsychotics during pregnancy did not appear to be associated with standardized test scores in the offspring. The findings provide further reassuring data on offspring neurodevelopmental outcomes associated with antipsychotic treatment during pregnancy.</style></abstract><notes><style face="normal" font="default" size="100%">Liu, Xiaoqin&#xD;Trabjerg, Betina Bitsch&#xD;Munk-Olsen, Trine&#xD;Christensen, Jakob&#xD;Dreier, Julie Werenberg&#xD;eng&#xD;2022/08/16&#xD;JAMA Intern Med. 2022 Oct 1;182(10):1035-1043. doi: 10.1001/jamainternmed.2022.3388.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35969410</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflict of Interest Disclosures: Dr Christensen reported personal fees from UCB Nordic and Eisai AB, and grants from the Novo Nordisk Foundation (NNF22OC0075033) during the conduct of the study. No other disclosures were reported.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9379822</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jamainternmed.2022.3388</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hjorth, P.</style></author><author><style face="normal" font="default" size="100%">Juel, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Syddansk Universitet, Odense, Denmark.&#xD;Vejle County, Vejle, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Auditory vocal hallucination group treatment of patients with schizophrenia experiencing severe sleep problems and obesity</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Soc Psychiatry</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">224-226</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20210130</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Hallucinations/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity/complications/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/complications/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Sleep Wake Disorders/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Voice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">SAGE Publications</style></publisher><isbn><style face="normal" font="default" size="100%">1741-2854 (Electronic)&#xD;0020-7640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33522366</style></accession-num><notes><style face="normal" font="default" size="100%">Hjorth, Peter&#xD;Juel, Henriette&#xD;eng&#xD;Letter&#xD;England&#xD;2021/02/02&#xD;Int J Soc Psychiatry. 2022 Feb;68(1):224-226. doi: 10.1177/0020764021991580. Epub 2021 Jan 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33522366</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/0020764021991580</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>296</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">296</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Johansen, K. K.</style></author><author><style face="normal" font="default" size="100%">Runge, E.</style></author><author><style face="normal" font="default" size="100%">Hansen, M. B.</style></author><author><style face="normal" font="default" size="100%">Holmberg, T. T.</style></author><author><style face="normal" font="default" size="100%">Tarp, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research, Syddansk Universitet Det Samfundsvidenskabelige Fakultet, Odense, Denmark.&#xD;Research Unit for Digital Psychiatry, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Psychology, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Behind the athletic body: a clinical interview study of identification of eating disorder symptoms and diagnoses in elite athletes</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open Sport Exerc Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Open Sport Exerc Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e001265</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20220620</style></edition><keywords><keyword><style face="normal" font="default" size="100%">body image</style></keyword><keyword><style face="normal" font="default" size="100%">diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">eating disorders</style></keyword><keyword><style face="normal" font="default" size="100%">exercise</style></keyword><keyword><style face="normal" font="default" size="100%">validation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">2055-7647 (Print)&#xD;2055-7647 (Electronic)&#xD;2055-7647 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35813128</style></accession-num><abstract><style face="normal" font="default" size="100%">Eating disorders are more prevalent in athletes than in the general population and may have severe consequences for sports performance and health. Identifying symptoms can be difficult in athletes because restrictive eating and slim body images are often idealised in a sports setting. The Eating Disorders Examination Questionnaire (EDE-Q) and the SCOFF (Sick, Control, One stone, Fat and Food) questionnaire (SCOFF) are widely used generic instruments to identify symptoms of eating disorders. This study aimed to investigate the instruments&apos; validity and explore eating disorder symptoms in a sample of athletes. A sample of 28 athletes (25 females) competing at a national level was interviewed based on the diagnostic criteria for eating disorders. We interviewed 18 athletes with a high score on EDE-Q and 10 with a low score. All interviews were transcribed and analysed from a general inductive approach. We identified 20 athletes with an eating disorder diagnosis, while 8 had no diagnosis. EDE-Q found 90% of the cases, while SCOFF found 94%. EDE-Q found no false-positive cases, while SCOFF found one. The qualitative results showed that most athletes reported eating concerns, restrictive eating, eating control (counting calories), weight concerns, body dissatisfaction (feeling fat and non-athletic), excessive exercise and health problems (eg, pain, fatigue). In conclusion, EDE-Q and SCOFF seem valid instruments to screen athletes&apos; samples but may fail to find 6%-10% cases with eating disorders. Despite athletic bodies and normal body mass index, many athletes report severe eating problems and dissatisfaction with weight and body appearance. Implementation of regular screening may identify these symptoms at an early stage.</style></abstract><notes><style face="normal" font="default" size="100%">Lichtenstein, Mia Beck&#xD;Johansen, Karen Krogh&#xD;Runge, Eik&#xD;Hansen, Marina Bohn&#xD;Holmberg, Trine Theresa&#xD;Tarp, Kristine&#xD;eng&#xD;England&#xD;2022/07/12&#xD;BMJ Open Sport Exerc Med. 2022 Jun 20;8(2):e001265. doi: 10.1136/bmjsem-2021-001265. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35813128</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Competing interests: None declared.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9214368</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmjsem-2021-001265</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Basu, M. N.</style></author><author><style face="normal" font="default" size="100%">Mortz, C. G.</style></author><author><style face="normal" font="default" size="100%">Jensen, T. K.</style></author><author><style face="normal" font="default" size="100%">Barington, T.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Halken, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;Open Patient Data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.&#xD;Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.&#xD;Department of Pharmacology, Clinical Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Neurology, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biomarkers in asthma in the context of atopic dermatitis in young children</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatr Allergy Immunol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e13823</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Allergens</style></keyword><keyword><style face="normal" font="default" size="100%">*Asthma/complications/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Dermatitis, Atopic/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Food Hypersensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoglobulin E</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Ccl18</style></keyword><keyword><style face="normal" font="default" size="100%">Nmf</style></keyword><keyword><style face="normal" font="default" size="100%">Tslp</style></keyword><keyword><style face="normal" font="default" size="100%">asthma</style></keyword><keyword><style face="normal" font="default" size="100%">atopic dermatitis</style></keyword><keyword><style face="normal" font="default" size="100%">sensitization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1399-3038 (Electronic)&#xD;0905-6157 (Print)&#xD;0905-6157 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35871461</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Diverse pathways stemming from a history of atopic dermatitis (AD) might modulate different biomarkers associated with the development of asthma. Biomarkers associated with AD and asthma separately have been investigated, but none have characterized a combined AD+asthma phenotype. We investigated the clinical and molecular characteristics associated with an AD+asthma phenotype compared with AD, asthma and controls. METHODS: From a prospective birth cohort and the outpatient allergy clinic, we included four groups of 6-12-year-old children: (1) healthy controls (2) previous, current, or present AD without asthma, (3) previous, current, or present AD and current asthma and (4) current asthma without AD. We performed clinical examinations and interviews and measured serum IgE, natural moisturizing factors (NMF), and plasma cytokine levels. RESULTS: We found an increased number of IgE sensitizations in AD+asthma, prominent after stratifying for food allergens (p &lt; .05). Pro-Th(2) cytokines CCL18, TSLP, and Eotaxin-3 were elevated in AD+asthma, though not significantly higher than asthma, and elevated in asthma compared with controls. NMF levels were decreased in AD compared with asthma and control groups (p = .019, p &lt; .001, respectively). NMF levels correlated negatively to sensitization (p = .026), though nonsignificant with only the patient groups. CONCLUSION: Our results indicate that Th(2) cytokines and increased number of sensitizations are associated with AD + asthma phenotypes compared with AD alone and that skin barrier impairment as well as decreased airway epithelial integrity may play a role in sensitization and immune modulation. Our findings suggest candidate biomarkers that should be further explored for their functional roles and prognostic potential.</style></abstract><notes><style face="normal" font="default" size="100%">Basu, Millie Nguyen&#xD;Mortz, Charlotte G&#xD;Jensen, Tina Kold&#xD;Barington, Torben&#xD;Lambertsen, Kate Lykke&#xD;Halken, Susanne&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/07/25&#xD;Pediatr Allergy Immunol. 2022 Jul;33(7):e13823. doi: 10.1111/pai.13823.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35871461</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors have no conflicts of interest to declare.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9544684</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/pai.13823</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tarp, K.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, J.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author><author><style face="normal" font="default" size="100%">Folker, M. P.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Telepsychiatry, Mental Health Services, Region of Southern Denmark, Odense, Denmark.&#xD;Research Unit for Telepsychiatry and E-mental Health, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Steno Diabetes Centre Odense, Odense, Denmark.&#xD;Unit of Clinical Alcohol Research, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;OPEN Odense Patient data Explorative Network, Odense, Denmark.&#xD;Department of Psychiatry, Mental Health Services, Region of Southern Denmark, Odense, Denmark.&#xD;BRIDGE, Brain Research - Inter-Disciplinary Guided Excellence, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blended Treatment for Alcohol Use Disorder (Blend-A): Explorative Mixed Methods Pilot and Feasibility Study</style></title><secondary-title><style face="normal" font="default" size="100%">JMIR Form Res</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">e17761</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220425</style></edition><keywords><keyword><style face="normal" font="default" size="100%">alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">blended treatment</style></keyword><keyword><style face="normal" font="default" size="100%">mobile phone</style></keyword><keyword><style face="normal" font="default" size="100%">patient perceptions</style></keyword><keyword><style face="normal" font="default" size="100%">therapist perspectives</style></keyword><keyword><style face="normal" font="default" size="100%">usability</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 25</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">JMIR Publications Inc.</style></publisher><isbn><style face="normal" font="default" size="100%">2561-326X (Electronic)&#xD;2561-326X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35468082</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: In Denmark, approximately 150,000 people have alcohol use disorder (AUD). However, only approximately 10% seek AUD treatment, preferably outside conventional health care settings and opening hours. The AUD treatment area experiences low adherence to treatment, as well as high numbers of no-show and premature dropouts. OBJECTIVE: The purpose of the Blend-A (Blended Treatment for Alcohol Use Disorder) feasibility and pilot study was to describe the process of translating and adapting the Dutch treatment protocol into Danish and Danish culture with a high amount of user involvement and to report how patients and therapists perceived the adapted version, when trying it out. METHODS: The settings were 3 Danish public municipal outpatient alcohol clinics. Study participants were patients and therapists from the 3 settings. Data consisted of survey data from the System Usability Scale, individual patient interviews, and therapist group interviews. Statistical analyses were conducted using the Stata software and Excel. Qualitative analysis was conducted using a theoretical thematic analysis. RESULTS: The usability of the treatment platform was rated above average. The patients chose to use the blended treatment format because it ensured anonymity and had a flexible design. Platform use formed the basis of face-to-face sessions. The use of the self-determined platform resulted in a more thorough process. Patient involvement qualified development of a feasible system. Managerial support for time use was essential. Guidance from an experienced peer was useful. CONCLUSIONS: This study indicates that, during the processes of translating, adapting, and implementing blended, guided, internet-based, and face-to-face AUD treatment, it is relevant to focus on patient involvement, managerial support, and guidance from experienced peers. Owing to the discrete and flexible design of the blended offer, it appears that it may reach patient groups who would not otherwise have sought treatment. Therefore, blended treatment may increase access to treatment and contribute to reaching people affected by excessive alcohol use, who would not otherwise have sought treatment. In addition, it seems that the blended offer may enhance the participants&apos; perceived satisfaction and the effect of the treatment course. Thus, it appears that Blend-A may be able to contribute to existing treatment offers. Such findings highlight the need to determine the actual effect of the Blend-A offer; therefore, an effectiveness study with a controlled design is warranted.</style></abstract><notes><style face="normal" font="default" size="100%">Tarp, Kristine&#xD;Rasmussen, Johan&#xD;Mejldal, Anna&#xD;Folker, Marie Paldam&#xD;Nielsen, Anette Sogaard&#xD;eng&#xD;Canada&#xD;2022/04/26&#xD;JMIR Form Res. 2022 Apr 25;6(4):e17761. doi: 10.2196/17761.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35468082</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflicts of Interest: None declared.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9086873</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2196/17761</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tonges, L.</style></author><author><style face="normal" font="default" size="100%">Buhmann, C.</style></author><author><style face="normal" font="default" size="100%">Klebe, S.</style></author><author><style face="normal" font="default" size="100%">Klucken, J.</style></author><author><style face="normal" font="default" size="100%">Kwon, E. H.</style></author><author><style face="normal" font="default" size="100%">Muller, T.</style></author><author><style face="normal" font="default" size="100%">Pedrosa, D. J.</style></author><author><style face="normal" font="default" size="100%">Schroter, N.</style></author><author><style face="normal" font="default" size="100%">Riederer, P.</style></author><author><style face="normal" font="default" size="100%">Lingor, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Ruhr-University Bochum, St. Josef Hospital, Gudrunstr. 56, 44791, Bochum, Germany. lars.toenges@ruhr-uni-bochum.de.&#xD;Center for Protein Diagnostics (ProDi), Ruhr University Bochum, 44801, Bochum, Nordrhein-Westfalen, Germany. lars.toenges@ruhr-uni-bochum.de.&#xD;Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.&#xD;Department of Neurology, University Hospital Essen, 45147, Essen, Germany.&#xD;Department of Digital Medicine, University Luxembourg, LCSB, L-4367, Belval, Luxembourg.&#xD;Digital Medicine Research Group, Luxembourg Institute of Health, L-1445, Strassen, Luxembourg.&#xD;Centre Hospitalier de Luxembourg, Digital Medicine Research Clinic, L-1210, Luxembourg, Luxembourg.&#xD;Department of Neurology, Ruhr-University Bochum, St. Josef Hospital, Gudrunstr. 56, 44791, Bochum, Germany.&#xD;Department of Neurology, St. Joseph Hospital Berlin-Weissensee, 13088, Berlin, Germany.&#xD;Department of Neurology, Universitatsklinikum Giessen and Marburg, Marburg Site, 35043, Marburg, Germany.&#xD;Center of Mind, Brain and Behaviour (CMBB), Philipps-Universitat Marburg, 35043, Marburg, Germany.&#xD;Department of Neurology and Clinical Neuroscience, University of Freiburg, 79106, Freiburg, Germany.&#xD;Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Clinic and Policlinic for Psychiatry, 97080, Wuerzburg, Germany.&#xD;University of Southern Denmark Odense, 5000, Odense, Denmark.&#xD;School of Medicine, Klinikum Rechts Der Isar, Department of Neurology, Technical University of Munich, 81675, Munchen, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Blood-based biomarker in Parkinson&apos;s disease: potential for future applications in clinical research and practice</style></title><secondary-title><style face="normal" font="default" size="100%">J Neural Transm (Vienna)</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1201-1217</style></pages><volume><style face="normal" font="default" size="100%">129</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">20220415</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis, Differential</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Parkinson Disease/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-Synuclein</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinsonian syndromes</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson&apos;s disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1435-1463 (Electronic)&#xD;0300-9564 (Print)&#xD;0300-9564 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35428925</style></accession-num><abstract><style face="normal" font="default" size="100%">The clinical presentation of Parkinson&apos;s disease (PD) is both complex and heterogeneous, and its precise classification often requires an intensive work-up. The differential diagnosis, assessment of disease progression, evaluation of therapeutic responses, or identification of PD subtypes frequently remains uncertain from a clinical point of view. Various tissue- and fluid-based biomarkers are currently being investigated to improve the description of PD. From a clinician&apos;s perspective, signatures from blood that are relatively easy to obtain would have great potential for use in clinical practice if they fulfill the necessary requirements as PD biomarker. In this review article, we summarize the knowledge on blood-based PD biomarkers and present both a researcher&apos;s and a clinician&apos;s perspective on recent developments and potential future applications.</style></abstract><notes><style face="normal" font="default" size="100%">Tonges, Lars&#xD;Buhmann, Carsten&#xD;Klebe, Stephan&#xD;Klucken, Jochen&#xD;Kwon, Eun Hae&#xD;Muller, Thomas&#xD;Pedrosa, David J&#xD;Schroter, Nils&#xD;Riederer, Peter&#xD;Lingor, Paul&#xD;eng&#xD;Review&#xD;Austria&#xD;2022/04/17&#xD;J Neural Transm (Vienna). 2022 Sep;129(9):1201-1217. doi: 10.1007/s00702-022-02498-1. Epub 2022 Apr 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35428925</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">All authors declare that they have no conflicts of interest in regard to this work.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9463345</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00702-022-02498-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>267</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">267</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Christiansen, R.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Cultural Science, Faculty of Humanities, Philosophy, University of Southern Denmark, Odense, Denmark.&#xD;The Faculty of Health Sciences, The Unit of Clinical Alcohol Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bring me my alcohol!-On the continuum of pleasure and pain</style></title><secondary-title><style face="normal" font="default" size="100%">Nurs Philos</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nurs Philos</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e12403</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220731</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Pleasure</style></keyword><keyword><style face="normal" font="default" size="100%">*Pain</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol</style></keyword><keyword><style face="normal" font="default" size="100%">conflicts</style></keyword><keyword><style face="normal" font="default" size="100%">older adults</style></keyword><keyword><style face="normal" font="default" size="100%">values</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1466-769X (Electronic)&#xD;1466-7681 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35909307</style></accession-num><abstract><style face="normal" font="default" size="100%">Alcohol use has been recognized as a challenge in eldercare and social care, and some anticipate that problems related to alcohol use will increase in the future as the current adult generation has high alcohol consumption rates. Accordingly, it is suggested that care workers are at risk of becoming passive bystanders to the destructive lifestyles of vulnerable older adults and even facilitating these lifestyles. In the present paper, we suggest that alcohol exacerbates and underscores inherent difficulties in eldercare, such as finding an appropriate balance between the personal freedom of the older adult and the responsibility of the care worker to provide care. The specific focus in the paper regard the communication and interaction involving values between people in eldercare in cases of problematic alcohol-related situations to uncover the difficulties. We found it noteworthy that the objectives and perspectives of older adults, care workers, managers and relatives have implications regarding their interactions and communications because their varying experiences involve values that are not necessarily aligned. Sometimes, care workers have no choice but to act against what, in the public sphere and to the other care workers, is ruled out by virtue of their professional ethics. It is suggested that care workers describe and judge situations where alcohol is present paradoxically by virtue of their professional ethics, yet regulate their care to preserve the dignity of older adults, even when they find the situation to be an apparent dilemma.</style></abstract><notes><style face="normal" font="default" size="100%">Christiansen, Regina&#xD;Nielsen, Anette S&#xD;eng&#xD;00018143/Velux Fonden/&#xD;England&#xD;2022/08/02&#xD;Nurs Philos. 2023 Jan;24(1):e12403. doi: 10.1111/nup.12403. Epub 2022 Jul 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35909307</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/nup.12403</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>297</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">297</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mathiasen, K.</style></author><author><style face="normal" font="default" size="100%">Andersen, T. E.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Ehlers, L. H.</style></author><author><style face="normal" font="default" size="100%">Riper, H.</style></author><author><style face="normal" font="default" size="100%">Kleiboer, A.</style></author><author><style face="normal" font="default" size="100%">Roessler, K. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit for Telepsychiatry and E-Mental Health, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychology, University of Southern Denmark, Odense, Denmark.&#xD;Danish Center for Healthcare Improvements, Aalborg University, Aalborg, Denmark.&#xD;Nordic Institute of Health Economics, Aarhus, Denmark.&#xD;Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Clinical Effectiveness of Blended Cognitive Behavioral Therapy Compared With Face-to-Face Cognitive Behavioral Therapy for Adult Depression: Randomized Controlled Noninferiority Trial</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Internet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Internet Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e36577</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">20220907</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Cognitive Behavioral Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Depression</style></keyword><keyword><style face="normal" font="default" size="100%">*Depressive Disorder, Major/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cbt</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">blended care</style></keyword><keyword><style face="normal" font="default" size="100%">blended cognitive behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive therapy</style></keyword><keyword><style face="normal" font="default" size="100%">depressive disorder, major</style></keyword><keyword><style face="normal" font="default" size="100%">effectiveness</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 7</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1438-8871 (Electronic)&#xD;1439-4456 (Print)&#xD;1438-8871 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36069798</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Internet-based cognitive behavioral therapy (iCBT) has been demonstrated to be cost- and clinically effective. There is a need, however, for increased therapist contact for some patient groups. Combining iCBT with traditional face-to-face (FtF) consultations in a blended format may produce a new treatment format (B-CBT) with multiple benefits from both traditional CBT and iCBT, such as individual adaptation, lower costs than traditional therapy, wide geographical and temporal availability, and possibly lower threshold to implementation. OBJECTIVE: The primary aim of this study is to compare directly the clinical effectiveness of B-CBT with FtF-CBT for adult major depressive disorder. METHODS: A 2-arm randomized controlled noninferiority trial compared B-CBT for adult depression with treatment as usual (TAU). The trial was researcher blinded (unblinded for participants and clinicians). B-CBT comprised 6 sessions of FtF-CBT alternated with 6-8 web-based CBT self-help modules. TAU comprised 12 sessions of FtF-CBT. All participants were aged 18 or older and met the diagnostic criteria for major depressive disorder and were recruited via a national iCBT clinic. The primary outcome was change in depression severity on the 9-item Patient Health Questionnaire (PHQ-9). Secondary analyses included client satisfaction (8-item Client Satisfaction Questionnaire [CSQ-8]), patient expectancy (Credibility and Expectancy Questionnaire [CEQ]), and working (Working Alliance Inventory [WAI] and Technical Alliance Inventory [TAI]). The primary outcome was analyzed by a mixed effects model including all available data from baseline, weekly measures, 3-, 6, and 12-month follow-up. RESULTS: A total of 76 individuals were randomized, with 38 allocated to each treatment group. Age ranged from 18 to 71 years (SD 13.96) with 56 (74%) females. Attrition rate was 20% (n=15), which was less in the FtF-CBT group (n=6, 16%) than in the B-CBT group (n=9, 24%). As many as 53 (70%) completed 9 or more sessions almost equally distributed between the groups (nFtF-CBT=27, 71%; nB-CBT=26, 68%). PHQ-9 reduced 11.38 points in the FtF-CBT group and 8.10 in the B-CBT group. At 6 months, the mean difference was a mere 0.17 points. The primary analyses confirmed large and significant within-group reductions in both groups (FtF-CBT: beta=-.03; standard error [SE] 0.00; P&lt;.001 and B-CBT: beta=-.02; SE 0.00; P&lt;.001). A small but significant interaction effect was observed between groups (beta=.01; SE 0.00; P=.03). Employment status influenced the outcome differently between groups, where the B-CBT group was seen to profit more from not being full-time employed than the FtF group. CONCLUSIONS: With large within-group effects in both treatment arms, the study demonstrated feasibility of B-CBT in Denmark. At 6 months&apos; follow-up, there appeared to be no difference between the 2 treatment formats, with a small but nonsignificant difference at 12 months. The study seems to demonstrate that B-CBT is capable of producing treatment effects that are close to FtF-CBT and that completion rates and satisfaction rates were comparable between groups. However, the study was limited by small sample size and should be interpreted with caution. TRIAL REGISTRATION: ClinicalTrials.gov NCT02796573; https://clinicaltrials.gov/ct2/show/NCT02796573. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.1186/s12888-016-1140-y.</style></abstract><notes><style face="normal" font="default" size="100%">Mathiasen, Kim&#xD;Andersen, Tonny E&#xD;Lichtenstein, Mia Beck&#xD;Ehlers, Lars Holger&#xD;Riper, Heleen&#xD;Kleiboer, Annet&#xD;Roessler, Kirsten K&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Canada&#xD;2022/09/08&#xD;J Med Internet Res. 2022 Sep 7;24(9):e36577. doi: 10.2196/36577.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36069798</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflicts of Interest: The software NoDep was developed jointly by the Region of Southern Denmark and the private partner Context Consulting. KM participated in the development process as representative of the public partner Region of Southern Denmark. KM has no affiliations to any of the private vendors involved in the project including Context Consulting and gains no economic income from sales of licenses. The other authors declare that they have no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9543221</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2196/36577</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hassiotis, A.</style></author><author><style face="normal" font="default" size="100%">Almvik, R.</style></author><author><style face="normal" font="default" size="100%">Fluttert, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Psychiatry, University College London, London W1T 7BN, UK; Camden and Islington NHS Foundation Trust, London, UK. Electronic address: a.hassiotis@ucl.ac.uk.&#xD;St Olavs University Hospital, Centre for Research and Education in Forensic Psychiatry, Trondheim, Norway; Department of Mental Health, Norwegian University of Science and Technology, Trondheim, Norway.&#xD;Molde University College, Centre for Research and Education in Forensic Psychiatry, Oslo University Hospital, Oslo, Norway; Van Mesdagkliniek Hospital, Groningen, Netherlands; University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Coercion as a response to violence in mental health-care settings</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6-8</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Behavior Control</style></keyword><keyword><style face="normal" font="default" size="100%">*Coercion</style></keyword><keyword><style face="normal" font="default" size="100%">Europe</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">*Mentally Ill Persons</style></keyword><keyword><style face="normal" font="default" size="100%">*Persons with Mental Disabilities</style></keyword><keyword><style face="normal" font="default" size="100%">*Violence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">2215-0374 (Electronic)&#xD;2215-0366 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34921797</style></accession-num><notes><style face="normal" font="default" size="100%">Hassiotis, Angela&#xD;Almvik, Roger&#xD;Fluttert, Frans&#xD;eng&#xD;England&#xD;2021/12/19&#xD;Lancet Psychiatry. 2022 Jan;9(1):6-8. doi: 10.1016/S2215-0366(21)00476-4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34921797</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">We declare no competing interests.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S2215-0366(21)00476-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>224</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">224</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dyrberg, H.</style></author><author><style face="normal" font="default" size="100%">Bjorvatn, B.</style></author><author><style face="normal" font="default" size="100%">Larsen, E. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for Affective Disorders, Aarhus University Hospital, Central Denmark Region, 8000 Aarhus, Denmark.&#xD;Department of Global Public Health and Primary Care, University of Bergen, Norway and Norwegian Competence Centre for Sleep Disorders, Haukeland University Hospital, 5009 Bergen, Norway.&#xD;Mental Health Department Odense, University Clinic, Mental Health Service, J. B. Winslows Vej 18, 5000 Odense, Denmark.&#xD;Institute of Regional Health Research, University of Southern Denmark, 6700 Esbjerg, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cognitive Behavioral Therapy for Chronic Insomnia in Outpatients with Major Depression-A Randomised Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Med</style></full-title></periodical><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">19</style></number><edition><style face="normal" font="default" size="100%">20221001</style></edition><keywords><keyword><style face="normal" font="default" size="100%">dysfunctional beliefs and attitudes about sleep</style></keyword><keyword><style face="normal" font="default" size="100%">insomnia severity index</style></keyword><keyword><style face="normal" font="default" size="100%">mood disorder</style></keyword><keyword><style face="normal" font="default" size="100%">nonpharmacological treatment</style></keyword><keyword><style face="normal" font="default" size="100%">sleep disorder</style></keyword><keyword><style face="normal" font="default" size="100%">sleep medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2077-0383 (Print)&#xD;2077-0383 (Electronic)&#xD;2077-0383 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36233712</style></accession-num><abstract><style face="normal" font="default" size="100%">The aim of this randomised controlled assessor-blinded trial was to examine the effect of cognitive behavioural therapy for insomnia on sleep variables and depressive symptomatology in outpatients with comorbid insomnia and moderate to severe depression. Forty-seven participants were randomized to receive one weekly session in 6 weeks of cognitive behavioural therapy for insomnia or treatment as usual. The intervention was a hybrid between individual and group treatment. Sleep scheduling could be especially challenging in a group format as patients with depression may need more support to adhere to the treatment recommendations. The primary outcome measure was the Insomnia Severity Index. Secondary measures were sleep diary data, the Dysfunctional Beliefs and Attitudes about Sleep Questionnaire, the Hamilton Depression Rating Scale, and the World Health Organization Questionnaire for Quality of Life and polysomnography. Compared to treatment as usual, cognitive behavioural therapy significantly reduced the insomnia severity index (mean ISI 20.6 to 12.1, p = 0.001) and wake after sleep onset (mean 54.7 min to 19.0 min, p = 0.003) and increased sleep efficiency (mean SE 71.6 to 83.4, p = 0.006). Total sleep time and sleep onset latency were not significantly changed. The results were supported by analyses of the other rating scales and symptom dimensions. In conclusion, cognitive behavioural therapy for insomnia as add-on to treatment as usual was effective for treating insomnia and depressive symptoms in a small sample of outpatients with insomnia and major depression. ClinicalTrials.gov Identifier: NCT02678702.</style></abstract><notes><style face="normal" font="default" size="100%">Dyrberg, Henny&#xD;Bjorvatn, Bjorn&#xD;Larsen, Erik Roj&#xD;eng&#xD;ID109566/TrygFonden/&#xD;Switzerland&#xD;2022/10/15&#xD;J Clin Med. 2022 Oct 1;11(19):5845. doi: 10.3390/jcm11195845.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36233712</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest. The results are reported honestly and without inappropriate data manipulation.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9570822</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/jcm11195845</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>294</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">294</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orskov, P. T.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Ernst, M. T.</style></author><author><style face="normal" font="default" size="100%">Fasterholdt, I.</style></author><author><style face="normal" font="default" size="100%">Matthiesen, A. F.</style></author><author><style face="normal" font="default" size="100%">Scirea, M.</style></author><author><style face="normal" font="default" size="100%">Bouchard, S.</style></author><author><style face="normal" font="default" size="100%">Andersen, T. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit for Digital Psychiatry, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Centre for Innovative Medical Technology, Odense University Hospital, Odense, Denmark.&#xD;Maersk Mc-Kinney Moller Institute, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychoeducation and Psychology, University du Quebec en Outaouais, Gatineau, QC, Canada.&#xD;Department of Psychology, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cognitive behavioral therapy with adaptive virtual reality exposure vs. cognitive behavioral therapy with in vivo exposure in the treatment of social anxiety disorder: A study protocol for a randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Front Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">991755</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20221010</style></edition><keywords><keyword><style face="normal" font="default" size="100%">cognitive behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">electrodermal activity</style></keyword><keyword><style face="normal" font="default" size="100%">exposure</style></keyword><keyword><style face="normal" font="default" size="100%">heart rate</style></keyword><keyword><style face="normal" font="default" size="100%">machine learning</style></keyword><keyword><style face="normal" font="default" size="100%">psychophysiological measurements</style></keyword><keyword><style face="normal" font="default" size="100%">social anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">virtual reality</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">1664-0640 (Print)&#xD;1664-0640 (Electronic)&#xD;1664-0640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36299540</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Social anxiety disorder (SAD) has a high prevalence and an early onset with recovery taking decades to occur. Current evidence supports the efficacy of cognitive behavioral therapy (CBT) with virtual reality (VR) exposure. However, the evidence is based on a sparse number of studies with predominantly small sample sizes. There is a need for more trials investigating the optimal way of applying VR based exposure for SAD. In this trial, we will test the efficacy of CBT with adaptive VR exposure allowing adjustment of the exposure based on real-time monitoring of the participants&apos;s anxiety level. METHODS: The trial is a randomized controlled, assessor-blinded, parallel-group superiority trail. The study has two arms: (1) CBT including exposure in vivo (CBT-Exp), (2) CBT including exposure therapy using individually tailored VR-content and a system to track anxiety levels (CBT-ExpVR). Treatment is individual, manual-based and consists of 10 weekly sessions with a duration of 60 min. The study includes 90 participants diagnosed with SAD. Assessments are carried out pre-treatment, mid-treatment and at follow-up (6 and 12 months). The primary outcome is the mean score on the Social Interaction Anxiety Scale (SIAS) with the primary endpoint being post-treatment. DISCUSSION: The study adds to the existing knowledge by assessing the efficacy of CBT with adaptive VR exposure. The study has high methodological rigor using a randomized controlled trial with a large sample size that includes follow-up data and validated measures for social anxiety outcomes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT05302518.</style></abstract><notes><style face="normal" font="default" size="100%">Orskov, Per Trads&#xD;Lichtenstein, Mia Beck&#xD;Ernst, Mathias Torp&#xD;Fasterholdt, Iben&#xD;Matthiesen, Asge Frederik&#xD;Scirea, Marco&#xD;Bouchard, Stephane&#xD;Andersen, Tonny Elmose&#xD;eng&#xD;Switzerland&#xD;2022/10/28&#xD;Front Psychiatry. 2022 Oct 10;13:991755. doi: 10.3389/fpsyt.2022.991755. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36299540</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">SB is the president and owns equity in Cliniques et Development in Virtuo, which develops virtual environments, and conflicts of interest are managed according to Universite du Quebec en Outaouais conflict of interest policy. Cliniques et Development in Virtuo did not create the virtual environments use in this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9589352</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fpsyt.2022.991755</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>193</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">193</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">von Linstow, C. U.</style></author><author><style face="normal" font="default" size="100%">Waider, J.</style></author><author><style face="normal" font="default" size="100%">Bergh, M. S.</style></author><author><style face="normal" font="default" size="100%">Anzalone, M.</style></author><author><style face="normal" font="default" size="100%">Madsen, C.</style></author><author><style face="normal" font="default" size="100%">Nicolau, A. B.</style></author><author><style face="normal" font="default" size="100%">Wirenfeldt, M.</style></author><author><style face="normal" font="default" size="100%">Lesch, K. P.</style></author><author><style face="normal" font="default" size="100%">Finsen, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense C, Denmark.&#xD;Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.&#xD;Division of Molecular Psychiatry, Center of Mental Health, University of Wuerzburg, Wurzburg, Germany.&#xD;Section for Drug Abuse Research, Department of Forensic Sciences, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway.&#xD;BRIDGE - Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.&#xD;Department of Pathology, Institute of Clinical Science, Odense University Hospital, Denmark.&#xD;Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Department of Neuropsychology and Psychiatry, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Combined Effects of Amyloidosis and Serotonin Deficiency by Tryptophan Hydroxylase-2 Knockout Impacts Viability of the APP/PS1 Mouse Model of Alzheimer&apos;s Disease</style></title><secondary-title><style face="normal" font="default" size="100%">J Alzheimers Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Alzheimers Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1283-1300</style></pages><volume><style face="normal" font="default" size="100%">85</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alzheimer Disease/*pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid beta-Peptides/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid beta-Protein Precursor/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloidosis/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Hippocampus/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Knockout</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin/*deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Tryptophan Hydroxylase/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">5-ht</style></keyword><keyword><style face="normal" font="default" size="100%">App/ps1</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">AbetaPP processing</style></keyword><keyword><style face="normal" font="default" size="100%">cerebral amyloidosis</style></keyword><keyword><style face="normal" font="default" size="100%">cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">neuroinflammation</style></keyword><keyword><style face="normal" font="default" size="100%">tryptophan hydroxylase 2</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">IOS Press</style></publisher><isbn><style face="normal" font="default" size="100%">1875-8908 (Electronic)&#xD;1387-2877 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34924373</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A decline of brain serotonin (5-HT) is held responsible for the changes in mood that can be observed in Alzheimer&apos;s disease (AD). However, 5-HT&apos;ergic signaling is also suggested to reduce the production of pathogenic amyloid-beta (Abeta). OBJECTIVE: To investigate the effect of targeted inactivation of tryptophan hydroxylase-2 (Tph2), which is essential for neuronal 5-HT synthesis, on amyloidosis in amyloid precursor protein (APP)swe/presenilin 1 (PS1) DeltaE9 transgenic mice. METHODS: Triple-transgenic (3xTg) APP/PS1 mice with partial (+/-) or complete Tph2 knockout (-/-) were allowed to survive until 6 months old with APP/PS1, Tph2-/-, and wildtype mice. Survival and weight were recorded. Levels of Abeta42/40/38, soluble APPalpha (sAbetaPPalpha) and sAbetaPPbeta, and cytokines were analyzed by mesoscale, neurotransmitters by mass spectrometry, and gene expression by quantitative PCR. Tph2, microglia, and Abeta were visualized histologically. RESULTS: Tph2 inactivation in APP/PS1 mice significantly reduced viability, without impacting soluble and insoluble Abeta42 and Abeta40 in neocortex and hippocampus, and with only mild changes of soluble Abeta42/Abeta40. However, sAbetaPPalpha and sAbetaPPbeta in hippocampus and Abeta38 and Abeta40 in cerebrospinal fluid were reduced. 3xTg-/-mice were devoid of Tph2 immunopositive fibers and 5-HT. Cytokines were unaffected by genotype, as were neocortical TNF, HTR2a and HTR2b mRNA levels in Tph2-/- mice. Microglia clustered around Abeta plaques regardless of genotype. CONCLUSION: The results suggest that Tph2 inactivation influences AbetaPP processing, at least in the hippocampus, although levels of Abeta are unchanged. The reduced viability of 3xTg-/-mice could indicate that 5-HT protects against the seizures that can impact the viability of APP/PS1 mice.</style></abstract><notes><style face="normal" font="default" size="100%">von Linstow, Christian Ulrich&#xD;Waider, Jonas&#xD;Bergh, Marianne Skov-Skov&#xD;Anzalone, Marco&#xD;Madsen, Cecilie&#xD;Nicolau, Aina Battle&#xD;Wirenfeldt, Martin&#xD;Lesch, Klaus-Peter&#xD;Finsen, Bente&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;2021/12/21&#xD;J Alzheimers Dis. 2022;85(3):1283-1300. doi: 10.3233/JAD-210581.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34924373</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3233/JAD-210581</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>221</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">221</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nielsen, D. G.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Nielsen, F.</style></author><author><style face="normal" font="default" size="100%">Behrendt, S.</style></author><author><style face="normal" font="default" size="100%">Bilberg, R.</style></author><author><style face="normal" font="default" size="100%">Bogenschutz, M.</style></author><author><style face="normal" font="default" size="100%">Buhringer, G.</style></author><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit for Clinical Alcohol Research, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;BRIDGE, Brain Research, Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Open, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark.&#xD;Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Institute for Psychology, University of Southern Denmark, Odense, Denmark.&#xD;NYU Grossman School of Medicine, New York City, New York, USA.&#xD;Health Sciences Center, University of New Mexico, Albuquerque, New Mexico, USA.&#xD;Institute of Clinical Psychology and Psychotherapy, Technische Universitat Dresden, Dresden, Germany.&#xD;IFT Institut fur Therapieforschung, Munich, Germany.&#xD;Tele-Psychiatric Center, Region of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparison of self-reported alcohol consumption and ethyl glucuronide in hair in a sample of 60+ year -olds treated for DSM-5 alcohol use disorder</style></title><secondary-title><style face="normal" font="default" size="100%">Addict Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Addict Biol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e13231</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol Drinking</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcoholism</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Hair</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Self Report</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">outcome assessment</style></keyword><keyword><style face="normal" font="default" size="100%">self-report</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1369-1600 (Electronic)&#xD;1355-6215 (Print)&#xD;1355-6215 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36301220</style></accession-num><abstract><style face="normal" font="default" size="100%">There is a lack of evidence for the consistency between self-reported alcohol consumption (SRAC) and concentrations of ethyl glucuronide in hair (hEtG) among elderly patients treated exclusively for alcohol use disorder (AUD). Hence, this study assessed the consistency between these two measures in these patients. A total of 190 patients with AUD were assessed for SRAC using Form 90 and hEtG, 14 or 22 weeks after treatment conclusion. Patients were grouped according to SRAC (g/day) and corresponding hEtG concentrations (pg/mg): 0 and &lt;5 (abstinence), 0.1-14.3 and 5.0-9.9 (low consumption), 14.4-21.4 and 10.0-15.9 (moderate consumption), 21.5-59.9 and 16.0-30 (high consumption) and &gt;/=60 and &gt;30 (excessive consumption). The extent of underreporting and overreporting was examined by crosstabulations, and inter-rater reliability was reported by kappa correlations. Associations and effect modification were examined by conditional logistic regression. Due to multitesting, p-values &lt;/=0.01 were considered significant. Underreporting was found in 96 patients (50.5%) and overreporting in 41 patients (21.6%). The kappa coefficients varied between 0.19 and 0.34. HEtG was more likely to detect low, moderate and high alcohol consumption compared with SRAC (ORs between 5.1 and 12.6, all p-values &lt;0.01), but SRAC and hEtG did not differ significantly with respect to identification of abstinence (OR = 1.9, p = 0.05). Inconsistency between the outcome measures was found in a considerable number of the patients. More studies examining the consistency between SRAC and specific direct biomarkers of alcohol in this population seem warranted.</style></abstract><notes><style face="normal" font="default" size="100%">Nielsen, Dorthe Gruner&#xD;Andersen, Kjeld&#xD;Nielsen, Anette Sogaard&#xD;Nielsen, Flemming&#xD;Behrendt, Silke&#xD;Bilberg, Randi&#xD;Bogenschutz, Michael&#xD;Buhringer, Gerhard&#xD;Mellentin, Angelina Isabella&#xD;eng&#xD;Comparative Study&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/10/28&#xD;Addict Biol. 2022 Nov;27(6):e13231. doi: 10.1111/adb.13231.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36301220</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">No competing interests to declare.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9786874</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/adb.13231</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>227</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">227</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wieben, E.</style></author><author><style face="normal" font="default" size="100%">Kjeldsen, M. J.</style></author><author><style face="normal" font="default" size="100%">Sorensen, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Odense University Hospital, Department of Psychiatry, Odense, Denmark.&#xD;Odense University Hospital, Department of Neurology, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Convulsive Status Epilepticus Induced by Electroconvulsive Therapy in a Patient with Major Depression</style></title><secondary-title><style face="normal" font="default" size="100%">Case Rep Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Case Rep Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">8545991</style></pages><volume><style face="normal" font="default" size="100%">2022</style></volume><edition><style face="normal" font="default" size="100%">20220317</style></edition><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">2090-682X (Print)&#xD;2090-6838 (Electronic)&#xD;2090-6838 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35342656</style></accession-num><abstract><style face="normal" font="default" size="100%">Electroconvulsive therapy (ECT) is a well-known, safe, and efficient treatment for a variety of psychiatric diseases. We present here an unusual case of a 34-year-old patient with major depression, who developed convulsive status epilepticus persistent for eight days in connection to her first ECT-a very uncommon but serious complication. The patient was, prior to ECT treatment, treated with lithium carbonate and clomipramine for her depression. Six years prior to the ECT, the patient had experienced a convulsive syncope resulting in traumatic subarachnoid haemorrhage. This case emphasizes the importance of medical recording to detect possible risk factors when considering ECT treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Wieben, Emilie&#xD;Kjeldsen, Marianne Juel&#xD;Sorensen, Claus H&#xD;eng&#xD;Case Reports&#xD;2022/03/29&#xD;Case Rep Psychiatry. 2022 Mar 17;2022:8545991. doi: 10.1155/2022/8545991. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35342656</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no conflicts of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8947920</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2022/8545991</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hemmingsen, S. D.</style></author><author><style face="normal" font="default" size="100%">Jensen, N. A.</style></author><author><style face="normal" font="default" size="100%">Larsen, P. V.</style></author><author><style face="normal" font="default" size="100%">Sjogren, J. M.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Eating Disorders, Odense University Hospital, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Research Unit for Medical Endocrinology, Department of Clinical Research, Open Patient Data Explorative Network (OPEN), University of Southern Denmark, Odense, Denmark.&#xD;Mental Health Services in the Region of Southern Denmark, Vejle, Denmark.&#xD;Psychiatric Center Ballerup, Copenhagen, Denmark.&#xD;Department of Clinical Sciences, Umea University, Umea, Sweden.&#xD;Centre for Telepsychiatry, Region of Southern Denmark, Vejle, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cortisol, Depression, and Anxiety Levels Before and After Short-Term Intensive Nutritional Stabilization in Patients With Severe Anorexia Nervosa</style></title><secondary-title><style face="normal" font="default" size="100%">Front Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">939225</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20220712</style></edition><keywords><keyword><style face="normal" font="default" size="100%">HPA axis</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">cortisol</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">eating disorder</style></keyword><keyword><style face="normal" font="default" size="100%">re-nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">weight gain</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/7/12</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Frontiers Media SA</style></publisher><isbn><style face="normal" font="default" size="100%">1664-0640 (Print)&#xD;1664-0640 (Electronic)&#xD;1664-0640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35903636</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Depression and anxiety are well-known comorbid conditions in patients with anorexia nervosa (AN). Hypercortisolemia in patients with AN may be pathogenic and contribute to depression and anxiety symptomatology. OBJECTIVE: The aim of this study was to investigate short-term changes in cortisol levels and depression and anxiety symptomatology following intensive re-nutrition in patients with severe AN and hospitalized in a specialized unit. Furthermore, we investigated the potential association between cortisol levels and psychometric parameters. METHODS: A total of 36 patients with AN were enrolled in the study. Nine dropped out before follow-up. Patients underwent paraclinical and psychometric examinations at admission and discharge. Measurements included plasma cortisol, cortisol binding globulin (CBG), 24-h urine cortisol, and self-report questionnaires regarding eating disorder, depression, anxiety, and stress symptoms. Patients were hospitalized in the unit for somatic stabilization and intensive re-nutrition. Mean admission length was 41 days. The study was registered at ClinicalTrials.gov (NCT02502617). RESULTS: Cortisol levels in blood and urine did not change from admission to discharge in patients with severe AN. Symptoms of depression, anxiety, stress, and eating disorder remained elevated at discharge. There were no associations between changes in cortisol levels and changes in psychometrics. DISCUSSION: Our results suggest that short-term intensive re-nutrition did not alter hypothalamic-pituitary-adrenal axis activity or mental health in patients with severe AN. Long-term stabilization and longer follow-up after hospital discharge may be needed to detect changes in cortisol levels and whether these changes are associated with depression and anxiety symptomatology. Greater knowledge about cortisol levels and mental health in patients with severe AN may help in the development of new treatment choices for the chronically ill patients. Future studies could investigate whether cortisol-lowering drugs have a therapeutic effect on mental health in AN.</style></abstract><notes><style face="normal" font="default" size="100%">Hemmingsen, Simone Daugaard&#xD;Jensen, Nikolai Arndal&#xD;Larsen, Pia Veldt&#xD;Sjogren, Jan Magnus&#xD;Lichtenstein, Mia Beck&#xD;Stoving, Rene Klinkby&#xD;eng&#xD;Switzerland&#xD;2022/07/30&#xD;Front Psychiatry. 2022 Jul 12;13:939225. doi: 10.3389/fpsyt.2022.939225. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35903636</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9314772</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fpsyt.2022.939225</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wolf, R. T.</style></author><author><style face="normal" font="default" size="100%">Jeppesen, P.</style></author><author><style face="normal" font="default" size="100%">Pedersen, M. M. A.</style></author><author><style face="normal" font="default" size="100%">Puggaard, L. B.</style></author><author><style face="normal" font="default" size="100%">Thastum, M.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Thomsen, P. H.</style></author><author><style face="normal" font="default" size="100%">Silverman, W. K.</style></author><author><style face="normal" font="default" size="100%">Plessen, K. J.</style></author><author><style face="normal" font="default" size="100%">Neumer, S. P.</style></author><author><style face="normal" font="default" size="100%">Correll, C. U.</style></author><author><style face="normal" font="default" size="100%">Pagsberg, A. K.</style></author><author><style face="normal" font="default" size="100%">Gyrd-Hansen, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Child and Adolescent Mental Health Center, Mental Health Services - Capital Region of Denmark, Copenhagen, Denmark. rasmus.trap.wolf@regionh.dk.&#xD;Danish Centre for Health Economics, Department of Public Health, University of Southern Denmark, Odense, Denmark. rasmus.trap.wolf@regionh.dk.&#xD;Child and Adolescent Mental Health Center, Mental Health Services - Capital Region of Denmark, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Child and Adolescent Psychiatry, Copenhagen University Hospital - Psychiatry Region Zealand, Smedegade 16, 4000, Roskilde, Denmark.&#xD;Centre for the Psychological Treatment of Children and Adolescents, Department of Psychology and Behavioural Sciences, Aarhus BSS, Aarhus University, Aarhus, Denmark.&#xD;Department for Child and Adolescent Psychiatry, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Institute of Clinical Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Research Center at the Department for Child- and Adolescent Psychiatry, Aarhus University Hospital, Skejby, Denmark.&#xD;Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Anxiety and Mood Disorders Program, Yale Child Study Center, Yale School of Medicine, New Haven, CT, USA.&#xD;Division of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital CHUV, Lausanne, Switzerland.&#xD;Centre for Child and Adolescent Mental Health, Oslo, Norway.&#xD;The Arctic University of Norway, Centre for Child and Youth Mental Health and Child Welfare, North Norway (RKBU North), Tromso, Norway.&#xD;Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.&#xD;Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA.&#xD;Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA.&#xD;Department of Child and Adolescent Psychiatry, Charite Universitatsmedizin, Berlin, Germany.&#xD;Danish Centre for Health Economics, Department of Public Health, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cost-effectiveness of a transdiagnostic psychotherapy program for youth with common mental health problems</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Health Serv Res</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">819</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220624</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Health</style></keyword><keyword><style face="normal" font="default" size="100%">Parents</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Quality-Adjusted Life Years</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescents</style></keyword><keyword><style face="normal" font="default" size="100%">Anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">Behavioral problems</style></keyword><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive behavioral intervention</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-effectiveness</style></keyword><keyword><style face="normal" font="default" size="100%">Depression</style></keyword><keyword><style face="normal" font="default" size="100%">Informant</style></keyword><keyword><style face="normal" font="default" size="100%">Preference weights</style></keyword><keyword><style face="normal" font="default" size="100%">Transdiagnostic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 24</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1472-6963 (Electronic)&#xD;1472-6963 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35739556</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Our objective was to evaluate the cost-effectiveness of the transdiagnostic psychotherapy program Mind My Mind (MMM) for youth with common mental health problems using a cost-utility analysis (CUA) framework and data from a randomized controlled trial. Furthermore, we analyzed the impact of the choice of informant for both quality-of-life reporting and preference weights on the Incremental Cost-Effectiveness Ratio (ICER). METHODS: A total of 396 school-aged (6-16 years) youth took part in the 6-month trial carried out in Denmark. CUAs were carried out for the trial period and four one-year extrapolation scenarios. Costs were based on a combination of budget and self-reported costs. Youths and parents were asked to report on the youth&apos;s quality-of-life three times during the trial using the Child Health Utility 9D (CHU9D). Parental-reported CHU9D was used in the base case together with preference weights of a youth population. Analyses using self-reported CHU9D and preference weights of an adult population were also carried out. RESULTS: The analysis of the trial period resulted in an ICER of euro170,465. The analyses of the one-year scenarios resulted in ICERs between euro23,653 and euro50,480. The ICER increased by 24% and 71% compared to the base case when using self-reported CHU9D and adult preference weights, respectively. CONCLUSION: The MMM intervention has the potential to be cost-effective, but the ICER is dependent on the duration of the treatment effects. Results varied significantly with the choice of informant and the choice of preference weights indicating that both factors should be considered when assessing CUA involving youth.</style></abstract><notes><style face="normal" font="default" size="100%">Wolf, Rasmus Trap&#xD;Jeppesen, Pia&#xD;Pedersen, Mette Maria Agner&#xD;Puggaard, Louise Berg&#xD;Thastum, Mikael&#xD;Bilenberg, Niels&#xD;Thomsen, Per Hove&#xD;Silverman, Wendy K&#xD;Plessen, Kerstin Jessica&#xD;Neumer, Simon-Peter&#xD;Correll, Christoph U&#xD;Pagsberg, Anne Katrine&#xD;Gyrd-Hansen, Dorte&#xD;eng&#xD;Randomized Controlled Trial&#xD;England&#xD;2022/06/24&#xD;BMC Health Serv Res. 2022 Jun 24;22(1):819. doi: 10.1186/s12913-022-08187-9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35739556</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">RTW, LBP, MMAP, AKP, WKS, KJP, SPN, DGH, MT, NB, PHT and PJ declare that they have no conflict of interest. CUC has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&amp;J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9229821</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12913-022-08187-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>281</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">281</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carrozzino, D.</style></author><author><style face="normal" font="default" size="100%">Christensen, K. S.</style></author><author><style face="normal" font="default" size="100%">Patierno, C.</style></author><author><style face="normal" font="default" size="100%">Wozniewicz, A.</style></author><author><style face="normal" font="default" size="100%">Moller, S. B.</style></author><author><style face="normal" font="default" size="100%">Arendt, I. T. P.</style></author><author><style face="normal" font="default" size="100%">Zhang, Y.</style></author><author><style face="normal" font="default" size="100%">Yuan, Y.</style></author><author><style face="normal" font="default" size="100%">Sasaki, N.</style></author><author><style face="normal" font="default" size="100%">Nishi, D.</style></author><author><style face="normal" font="default" size="100%">Berrocal Montiel, C.</style></author><author><style face="normal" font="default" size="100%">Ceccatelli, S.</style></author><author><style face="normal" font="default" size="100%">Mansueto, G.</style></author><author><style face="normal" font="default" size="100%">Cosci, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychology &quot;Renzo Canestrari&quot;, Alma Mater Studiorum University of Bologna, Bologna, Italy.&#xD;Research Unit for General Practice and Section for General Medical Practice, Department of Public Health, Aarhus University, Aarhus, Denmark.&#xD;Department of Geriatrics, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.&#xD;Department of Psychology, University of Southern Denmark, Denmark.&#xD;School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China; Department of Psychosomatics and Psychiatry, Zhongda Hospital, Southeast University, Nanjing, China.&#xD;Department of Psychosomatics and Psychiatry, Zhongda Hospital, Southeast University, Nanjing, China.&#xD;Department of Mental Health, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.&#xD;Department of Surgical, Medical and Molecular Pathology, and Critical Care Medicine, University of Pisa, Pisa, Italy.&#xD;Department of Health Sciences, University of Florence, via di San Salvi 12, 50135 Florence, Italy.&#xD;Department of Health Sciences, University of Florence, via di San Salvi 12, 50135 Florence, Italy; Department of Psychology, Sigmund Freud University, Ripa di Porta Ticinese, 77, 20143 Milan, Italy.&#xD;Department of Health Sciences, University of Florence, via di San Salvi 12, 50135 Florence, Italy; Department of Psychiatry &amp; Neuropsychology, Maastricht University, PO Box 616, Maastricht, the Netherlands. Electronic address: fiammetta.cosci@unifi.it.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cross-cultural validity of the WHO-5 Well-Being Index and Euthymia Scale: A clinimetric analysis</style></title><secondary-title><style face="normal" font="default" size="100%">J Affect Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Affect Disord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">276-283</style></pages><volume><style face="normal" font="default" size="100%">311</style></volume><edition><style face="normal" font="default" size="100%">20220521</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Cross-Cultural Comparison</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Psychometrics</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">World Health Organization</style></keyword><keyword><style face="normal" font="default" size="100%">Clinimetrics</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-cultural</style></keyword><keyword><style face="normal" font="default" size="100%">Euthymia</style></keyword><keyword><style face="normal" font="default" size="100%">Psychological well-being</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity</style></keyword><keyword><style face="normal" font="default" size="100%">Validity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-2517 (Electronic)&#xD;0165-0327 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35609763</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The assessment of psychological well-being and euthymia represents an emerging issue in clinical psychology and psychiatry. Rating scales and indices such as the 5-item version of the World Health Organization Well-Being Index (WHO-5) and the Euthymia Scale (ES) were developed but insufficient attention has been devoted to the evaluation of their cross-cultural validity. This is the first study using Clinimetric Patient-Reported Outcome Measures (CLIPROM) criteria to assess cross-cultural validity and sensitivity of five different versions of the WHO-5 and ES. METHODS: A multicenter cross-sectional study involving a total of 3762 adult participants from different European (i.e., Italy, Poland, Denmark) and non-European (i.e., China, Japan) countries was conducted. Item Response Theory models (Mokken and Rasch analyses) were applied. RESULTS: Mokken coefficients of scalability were found to range from 0.42 to 0.84. The majority of the versions of the WHO-5 fitted the Rasch model expectations. Paired t-tests revealed that the Italian and Danish WHO-5 versions were unidimensional. Person Separation Reliability indices showed that the Polish, Danish, and Japanese ES versions could reliably discriminate between subjects with different levels of euthymia. LIMITATIONS: A convenience sampling was used, thus limiting the generalizability of study findings. In addition, no measures of negative mental health were administered. CONCLUSIONS: WHO-5 can be used in international studies for cross-cultural comparisons since it covers transcultural components of subjective well-being. Findings also suggest that the ES can be used as a cross-cultural screening tool since it entailed the clinimetric property of sensitivity.</style></abstract><notes><style face="normal" font="default" size="100%">Carrozzino, Danilo&#xD;Christensen, Kaj Sparle&#xD;Patierno, Chiara&#xD;Wozniewicz, Agnieszka&#xD;Moller, Stine Bjerrum&#xD;Arendt, Ida-Marie T P&#xD;Zhang, Yuqun&#xD;Yuan, Yonggui&#xD;Sasaki, Natsu&#xD;Nishi, Daisuke&#xD;Berrocal Montiel, Carmen&#xD;Ceccatelli, Sara&#xD;Mansueto, Giovanni&#xD;Cosci, Fiammetta&#xD;eng&#xD;Multicenter Study&#xD;Netherlands&#xD;2022/05/25&#xD;J Affect Disord. 2022 Aug 15;311:276-283. doi: 10.1016/j.jad.2022.05.111. Epub 2022 May 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35609763</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jad.2022.05.111</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>194</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">194</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jensen, T. S. R.</style></author><author><style face="normal" font="default" size="100%">Andersen-Ranberg, N.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author><author><style face="normal" font="default" size="100%">Bergholt, B.</style></author><author><style face="normal" font="default" size="100%">Hundsholt, T.</style></author><author><style face="normal" font="default" size="100%">Fugleholm, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark. Electronic address: tjens07@gmail.com.&#xD;Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark.&#xD;Department of Neurosurgery, Odense University Hospital, Odense, Denmark; Clinical Institute and BRIDGE (Brain Research-Interdisciplinary Guided Excellence), University of Southern Denmark, Odense, Denmark.&#xD;Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark.&#xD;Department of Neurosurgery, Aalborg University Hospital, Aalborg, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Danish Chronic Subdural Hematoma Study-Risk Factors for Second Recurrence</style></title><secondary-title><style face="normal" font="default" size="100%">World Neurosurg</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">e178-e186</style></pages><volume><style face="normal" font="default" size="100%">168</style></volume><edition><style face="normal" font="default" size="100%">20220921</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Hematoma, Subdural, Chronic/diagnostic imaging/surgery/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Drainage/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic subdural hematoma</style></keyword><keyword><style face="normal" font="default" size="100%">Multiple recurrences</style></keyword><keyword><style face="normal" font="default" size="100%">Second recurrence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1878-8769 (Electronic)&#xD;1878-8750 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36152937</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Treatment of multiple recurrent chronic subdural hematomas (CSDH) is challenging. Identification of specific risk factors for multiple recurrences may allow a higher degree of personalized treatment, including closer postoperative follow-up, detailed prognostication, and a more aggressive initial surgical strategy, such as craniotomy, adjuvant embolization of the middle meningeal artery, or adjuvant medical treatment, such as steroids. The aim of this study was to identify pretreatment risk factors for a second recurrence of CSDH (re-re-CSDH) and risk factors for developing re-re-CSDH once operated for the first recurrence. METHODS: Clinical and demographic data on all Danish patients admitted to a neurosurgical department with CSDH between 2010 and 2012 were retrospectively recorded. Data were retrieved before the evacuation of a primary CSDH, a first recurrent CSDH (re-CSDH), and a re-re-CSDH. We compared patients undergoing first, second, and third CSDH evacuation to identify risk factors for re-CSDH and re-re-CSDH. RESULTS: The cohort comprised 1052 patients, with 172 patients with re-CSDH and 29 patients with re-re-CSDH. Risk factors for re-re-CSDH included radiological subtype, midline shift, and hematoma volume, while postoperative drainage lowered the risk of re-re-CSDH. These risk factors were not specific for re-re-CSDH. CONCLUSIONS: We found similar independent risk factors for re-CSDH and re-re-CSDH, and for re-re-CSDH once treated for re-CSDH. Hence, it was not possible to identify specific risk factors for patients at risk of re-re-CSDH at the time of the primary diagnosis.</style></abstract><notes><style face="normal" font="default" size="100%">Jensen, Thorbjorn Soren Ronn&#xD;Andersen-Ranberg, Nina&#xD;Poulsen, Frantz Rom&#xD;Bergholt, Bo&#xD;Hundsholt, Torben&#xD;Fugleholm, Kare&#xD;eng&#xD;2022/09/25&#xD;World Neurosurg. 2022 Dec;168:e178-e186. doi: 10.1016/j.wneu.2022.09.072. Epub 2022 Sep 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36152937</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.wneu.2022.09.072</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>250</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pedersen, Martin Locht</style></author><author><style face="normal" font="default" size="100%">Gildberg, Frederik Alkier</style></author><author><style face="normal" font="default" size="100%">Birkeland, Sren</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Danish Court Case Database: a data source in forensic mental health?</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Forensic Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Forensic Science</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-5</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">1</style></number><section><style face="normal" font="default" size="100%">1</style></section><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">2353-0707</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2478/sjfs-2022-0011</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scholer, P. N.</style></author><author><style face="normal" font="default" size="100%">Sondergaard, J.</style></author><author><style face="normal" font="default" size="100%">Barfod, S.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Unit for Clinical Alcohol Research, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. pscholer@health.sdu.dk.&#xD;The Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark. pscholer@health.sdu.dk.&#xD;The Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Retired general practitioner, former researcher in alcohol topics in primary health care, Frederiksvaerk, Denmark.&#xD;The Unit for Clinical Alcohol Research, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Danish feasibility study of a new innovation for treating alcohol disorders in primary care: the 15-method</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Prim Care</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">34</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220228</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alcoholism/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*General Practitioners</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Primary Health Care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2731-4553 (Electronic)&#xD;2731-4553 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35227207</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The 15-method: a new brief intervention tool for alcohol problems in primary care has shown promising results in Sweden for mild to moderate alcohol use disorders. The present study evaluated the 15-method&apos;s usability, organizational integration, and overall implementation feasibility in Danish general practice in preparation for a large-scale evaluation of the method&apos;s effectiveness in identifying and treating alcohol problems in general practice. METHODS: Five general practices in the Central and Southern Region of Denmark participated: seven general practitioners (GPs), eight nurses. Participants received a half day of training in the 15-method. Testing of implementation strategies and overall applicability ran for 2 months. A focus group interview and two individual interviews with participating GPs along with five individual patient interviews concluded the study period. RESULTS: Results indicate that implementation of the 15-method is feasible in Danish general practice. The healthcare professionals and patients were positive about the method and its possibilities. The method was considered a new patient centered treatment offer and provided structure to a challenging topic. An interdisciplinary approach was much welcomed. Results indicate that the method is ready for large scale evaluation. CONCLUSIONS: Implementation of the 15-method is considered feasible in Danish general practice and large-scale evaluation is currently being planned.</style></abstract><notes><style face="normal" font="default" size="100%">Scholer, Peter Naesborg&#xD;Sondergaard, Jens&#xD;Barfod, Sverre&#xD;Nielsen, Anette Sogaard&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/03/02&#xD;BMC Prim Care. 2022 Feb 28;23(1):34. doi: 10.1186/s12875-022-01639-5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35227207</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8884098</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12875-022-01639-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>195</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">195</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wallhed Finn, S.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author><author><style face="normal" font="default" size="100%">Baskaran, R.</style></author><author><style face="normal" font="default" size="100%">Sogaard Nielsen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Clinical Alcohol Research, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.&#xD;SDU Health Informatics and Technology, The Maersk Mc-Kinney Moller Institute, The Faculty of Engineering, University of Southern Denmark, Odense, Denmark.&#xD;Psychiatric Hospital, University Function, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Danish RESPEKT Campaign: Impact of a National Mass Media Campaign Aiming to Increase Treatment Seeking for Alcohol Use Disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Subst Use Misuse</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1082-1096</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">20220415</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcoholism/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Health Knowledge, Attitudes, Practice</style></keyword><keyword><style face="normal" font="default" size="100%">Health Promotion</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mass Media</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol use disorders</style></keyword><keyword><style face="normal" font="default" size="100%">mass media</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword><keyword><style face="normal" font="default" size="100%">treatment seeking</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/4/15</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1532-2491 (Electronic)&#xD;1082-6084 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35422189</style></accession-num><abstract><style face="normal" font="default" size="100%">Background: A minority of all with alcohol use disorders seek treatment. In Denmark, a media campaign, &quot;RESPEKT,&quot; has been broadcast nationwide since 2015. The campaign is unique from an international perspective and aims to increase treatment-seeking. Similar interventions have, up until now, not been scientifically evaluated.Aim: To investigate campaign awareness, understanding, attitudes, and information-seeking pre- and post the campaign period. Also, associations to demographic factors and year of campaign will be investigated.Method: Study design: Repeated cross-sectional studyParticipants: Adults aged 30-70 years, in total n = 9169.Data: Pre- and post the campaign period between 2017 and 2020, an online questionnaire was administered by a market research company. The questionnaire covered demographic data, campaign awareness, understanding, attitudes, and information-seeking about treatment for alcohol use disorders. In addition, complete-case logistic regression was performed to model dichotomous outcomes, and odds ratios were calculated.Results: Campaign awareness varied between 8 and 40% over the different years. Understanding of the main message was high and received higher endorsements over the study period. A majority expressed positive attitudes toward the campaign and support for the main message regarding free treatment. However, very few self-reported seeking information about AUD treatment. Female sex was associated with higher awareness of the campaign, higher understanding and more positive attitudes toward the campaign.Conclusion: The campaign evoked positive attitudes and had an impact on increasing knowledge and changing attitudes. However, no effect on self-reported information seeking about treatment was found.</style></abstract><notes><style face="normal" font="default" size="100%">Wallhed Finn, Sara&#xD;Mejldal, Anna&#xD;Baskaran, Ruben&#xD;Sogaard Nielsen, Anette&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/04/16&#xD;Subst Use Misuse. 2022;57(7):1082-1096. doi: 10.1080/10826084.2022.2063897. Epub 2022 Apr 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35422189</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/10826084.2022.2063897</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>305</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">305</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Linnet, J.</style></author><author><style face="normal" font="default" size="100%">Hertz, S. P. T.</style></author><author><style face="normal" font="default" size="100%">Jensen, E. S.</style></author><author><style face="normal" font="default" size="100%">Runge, E.</style></author><author><style face="normal" font="default" size="100%">Tarp, K. H. H.</style></author><author><style face="normal" font="default" size="100%">Holmberg, T. T.</style></author><author><style face="normal" font="default" size="100%">Mathiasen, K.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Digital psychiatry, Mental Health Services in the Region of Southern, Denmark.&#xD;Clinic on Gambling- and Binge Eating Disorder, Department of Occupational and Environmental Medicine, Odense University Hospital, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Days between sessions predict attrition in text-based internet intervention of Binge Eating Disorder</style></title><secondary-title><style face="normal" font="default" size="100%">Internet Interv</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Internet Interv</style></full-title></periodical><pages><style face="normal" font="default" size="100%">100607</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><edition><style face="normal" font="default" size="100%">20230211</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Binge-eating disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Internet-based intervention</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment adherence and compliance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2214-7829 (Electronic)&#xD;2214-7829 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36819741</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The number of days between treatment sessions is often overlooked as a predictor of attrition in psychotherapy. In text-based Internet interventions, days between sessions may be a simple yet powerful predictor of attrition. OBJECTIVE: We hypothesized that a larger number of days between sessions increased the likelihood of attrition among participants with Binge Eating Disorder (BED) in a 12-session Internet-based cognitive behavioral therapy (iCBT) program. Participants could work on the sessions whenever convenient for them and received written support from a psychologist. MATERIAL AND METHODS: We compared 201 adult participants with mild to moderate BED (85 non-completers and 116 completers) on the number of days between sessions to predict attrition rates. RESULTS: Mixed model binomial logistic regression showed that non-completers spent significantly more days between sessions across the first four treatment sessions (1-4) when controlling for age, gender, and intake measures of BMI, BED, overall health status (EQ VAS), and depression symptoms (MDI) (OR = 1.042, p &lt; .001). Age (OR = 0.976, p &lt; .001) and EQ VAS (OR = 0.984, p &lt; .001) were also significant. The risk of attrition increased by 4.2 % for each additional day participants spent completing a session.A receiver operating characteristic (ROC) curve analysis showed that classification accuracy increased across sessions from 61.1 % in session 1 and 65.7 % in session 2 to 68.8 % in session 3 and 73.2 % in session 4. The optimal cut-off point in session 4 was 17.5 days, which detected 60.4 % of non-completers (sensitivity) and 78.4 % of completers (specificity).An exploratory repeated measures of ANOVA of days between sessions showed a significant within-subjects effect, where both non-completers and completers spent more days between sessions as they progressed from sessions 1 through 4 (F = 20.54, df = 3, p &lt; .001). There was no interaction effect, suggesting that the increase in slope did not differ between non-completers and completers. CONCLUSIONS: Participants spending more days between sessions are at increased risk of dropping out of treatment. This may have important implications for identifying measures to reduce attrition, e.g., intensifying interventions through automated reminders or therapist messages. Our findings may have important transdiagnostic implications for text-based Internet interventions. Further studies should investigate the predictive value of days between sessions in other diagnoses.</style></abstract><notes><style face="normal" font="default" size="100%">Linnet, Jakob&#xD;Hertz, Soren Peter Thygesen&#xD;Jensen, Esben Skov&#xD;Runge, Eik&#xD;Tarp, Kristine Haestrup Hindkjaer&#xD;Holmberg, Trine Theresa&#xD;Mathiasen, Kim&#xD;Lichtenstein, Mia Beck&#xD;eng&#xD;Netherlands&#xD;2023/02/24&#xD;Internet Interv. 2023 Feb 11;31:100607. doi: 10.1016/j.invent.2023.100607. eCollection 2023 Mar.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36819741</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9930145</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.invent.2023.100607</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sorensen von Essen, H.</style></author><author><style face="normal" font="default" size="100%">Stacey, D.</style></author><author><style face="normal" font="default" size="100%">Dahl Steffensen, K.</style></author><author><style face="normal" font="default" size="100%">Guldager, R.</style></author><author><style face="normal" font="default" size="100%">Rom Poulsen, F.</style></author><author><style face="normal" font="default" size="100%">Piil, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Odense University Hospital, Odense, Denmark.&#xD;Clinical Institute and BRIDGE (Brain Research-Interdisciplinary Guided Excellence), University of Southern Denmark, Odense, Denmark.&#xD;Center for Shared Decision Making, Region of Southern Denmark, Vejle, Denmark.&#xD;Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;School of Nursing and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.&#xD;Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.&#xD;Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Copenhagen, Denmark.&#xD;Department of Public Health, Aarhus University, Aarhus C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Decisional needs of patients with recurrent high-grade glioma and their families</style></title><secondary-title><style face="normal" font="default" size="100%">Neurooncol Pract</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">402-410</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">20220611</style></edition><keywords><keyword><style face="normal" font="default" size="100%">decisional needs</style></keyword><keyword><style face="normal" font="default" size="100%">family support</style></keyword><keyword><style face="normal" font="default" size="100%">high-grade glioma</style></keyword><keyword><style face="normal" font="default" size="100%">patient involvement</style></keyword><keyword><style face="normal" font="default" size="100%">shared decision making</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Oxford University Press (OUP)</style></publisher><isbn><style face="normal" font="default" size="100%">2054-2577 (Print)&#xD;2054-2585 (Electronic)&#xD;2054-2577 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36127893</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: High-grade gliomas are aggressive and life-threatening brain tumors. At the time of recurrence, the patients and their families need to decide on future treatment. None of the treatment options are curative, and tradeoffs between benefits and harms must be made. This study aimed to explore the patients&apos; and family members&apos; decisional needs when making the decision. METHODS: We performed semi-structured individual interviews with patients and family members to explore their experiences during the decision making. A phenomenological hermeneutical analysis was conducted. RESULTS: A total of 15 patients and 14 family members aged 22-79 years participated in the study. Most of the family members were partners to the patient. The findings were centered around three interrelated and concurrently occurring themes: (I) A patient- and family-centered decision making, including the subtheme of being a supportive family member; (II) Balanced information and a trustful professional encounter; and (III) The value of hope. We found that both the patients and family members preferred to be involved in the decision making and that a trustful relationship with the surgeon, balanced and tailored information, and sufficient time to make the decision were essential. The experience of hope had a significant influence on patients&apos; decisions. CONCLUSION: This study found that patient and family involvement, balanced information, and hope were the primary decisional needs of patients and family members at the time of recurrent high-grade glioma. Patients and family members can have different decisional needs, making individual needs assessment essential to decisional support.</style></abstract><notes><style face="normal" font="default" size="100%">Sorensen von Essen, Helle&#xD;Stacey, Dawn&#xD;Dahl Steffensen, Karina&#xD;Guldager, Rikke&#xD;Rom Poulsen, Frantz&#xD;Piil, Karin&#xD;eng&#xD;England&#xD;2022/09/22&#xD;Neurooncol Pract. 2022 Jun 11;9(5):402-410. doi: 10.1093/nop/npac046. eCollection 2022 Oct.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36127893</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9476966</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/nop/npac046</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>302</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">302</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuettel, Andreas</style></author><author><style face="normal" font="default" size="100%">Melin, Anna</style></author><author><style face="normal" font="default" size="100%">Larsen, Carsten H.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, Mia Beck</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Depressive Symptoms in Danish Elite Athletes Using the Major Depressive Inventory (MDI) and the Center for Epidemiological Studies Depression Scale (CES-D)</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Sport and Exercise Psychology</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-9</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">1</style></number><section><style face="normal" font="default" size="100%">1</style></section><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">2596-741X</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7146/sjsep.v4i1.128360</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kristensen, K. B.</style></author><author><style face="normal" font="default" size="100%">Lund, L. C.</style></author><author><style face="normal" font="default" size="100%">Jensen, P. B.</style></author><author><style face="normal" font="default" size="100%">Broe, A.</style></author><author><style face="normal" font="default" size="100%">Rotbain, E.</style></author><author><style face="normal" font="default" size="100%">Damkier, P.</style></author><author><style face="normal" font="default" size="100%">Pottegard, A.</style></author><author><style face="normal" font="default" size="100%">Andersen, J. H.</style></author><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Olesen, M.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, L.</style></author><author><style face="normal" font="default" size="100%">Hansen, M. R.</style></author><author><style face="normal" font="default" size="100%">Ernst, M. T.</style></author><author><style face="normal" font="default" size="100%">Wesselhoeft, R.</style></author><author><style face="normal" font="default" size="100%">Henriksen, D. P.</style></author><author><style face="normal" font="default" size="100%">Reilev, M.</style></author><author><style face="normal" font="default" size="100%">Bliddal, M.</style></author><author><style face="normal" font="default" size="100%">Hallas, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Department of Hematology, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark.&#xD;Child and Adolescent Psychiatry Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development and Validation of a Nordic Multimorbidity Index Based on Hospital Diagnoses and Filled Prescriptions</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Epidemiol</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">567-579</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><edition><style face="normal" font="default" size="100%">20220427</style></edition><keywords><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">multimorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacoepidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">risk score</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/4/27</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1179-1349 (Print)&#xD;1179-1349 (Electronic)&#xD;1179-1349 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35509520</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: To develop the Nordic Multimorbidity Index (NMI), a multimorbidity measure specifically suited to the Nordic health and administrative registry data based on current diagnosis, treatment, and coding practices. METHODS: The NMI was developed to predict 5-year mortality in a population-based cohort of randomly sampled Danish residents aged &gt;/=40 years (n = 425,087) followed from 2013 to 2018. Included predictors were selected from hospital diagnoses and filled drug prescriptions based on a combination of subject matter knowledge and a data-driven approach using backwards elimination. The performance of the NMI was assessed in a temporal validation cohort of Danish residents followed from 2007 to 2012 and in six cohorts of new users of selected drugs. The discriminative performance of the NMI, Charlson Comorbidity Index (CCI) and the Elixhauser Comorbidity Index (ECI) was assessed using the c-statistic from logistic regression models with 5-year mortality as dependent variable and the multimorbidity index score, age, and sex as independent variables. RESULTS: The NMI included 50 predictors. In the temporal validation cohort, the c-statistic of the NMI (0.887, 95% CI 0.883-0.890) exceeded that of the CCI (0.871, 95% CI 0.868-0.874) and ECI (0.866, 95% CI 0.863-0.870). In all new user cohorts, the NMI outperformed the other indices with c-statistics ranging from 0.781 (95% CI 0.779-0.784) to 0.838 (95% CI 0.834-0.842). CONCLUSION: The NMI predicted 5-year mortality in a general Danish population and six cohorts of new users of selected drugs and was superior to the CCI and ECI. The NMI could be preferred over these indices to quantify the level of multimorbidity for, eg, descriptive purposes or confounding control. The NMI should be validated in other patient populations and other Nordic countries.</style></abstract><notes><style face="normal" font="default" size="100%">Kristensen, Kasper Bruun&#xD;Lund, Lars Christian&#xD;Jensen, Peter Bjodstrup&#xD;Broe, Anne&#xD;Rotbain, Emelie&#xD;Damkier, Per&#xD;Pottegard, Anton&#xD;Andersen, Jacob Harbo&#xD;Hojlund, Mikkel&#xD;Olesen, Morten&#xD;Rasmussen, Lotte&#xD;Hansen, Morten Rix&#xD;Ernst, Martin Thomsen&#xD;Wesselhoeft, Rikke&#xD;Henriksen, Daniel Pilsgaard&#xD;Reilev, Mette&#xD;Bliddal, Mette&#xD;Hallas, Jesper&#xD;eng&#xD;New Zealand&#xD;2022/05/06&#xD;Clin Epidemiol. 2022 Apr 27;14:567-579. doi: 10.2147/CLEP.S353398. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35509520</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">AP and JH report participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier and LEO Pharma, all regulator-mandated Phase IV-studies, all with funds paid to the institution where they were employed (no personal fees) and with no relation to the work reported in this paper. ECR received consultancy fees or travel grants from AbbVie, AstraZeneca and Janssen, outside the submitted work. LCL reports participation in research projects funded by Menarini Pharmaceutical and LEO Pharma, with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. MH received honoraria for consultancy for the Lundbeck Foundation without relation to the submitted work. MRH has received grants from Pfizer, paid to his employer, outside the submitted work, has received speaking fees from Novartis outside the submitted work, owns stocks in Novo Nordisk, and is employed in Novo Nordisk from February 1, 2022. LR reports participation in research projects funded by Novo Nordisk, with funds paid to the institution where she was employed (no personal fees) and with no relation to the work reported in this paper. MR reports grants from LEO Pharma, outside the submitted work. The remaining authors declare that they have no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9058012</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2147/CLEP.S353398</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sorensen von Essen, H.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author><author><style face="normal" font="default" size="100%">Dahlrot, R. H.</style></author><author><style face="normal" font="default" size="100%">Piil, K.</style></author><author><style face="normal" font="default" size="100%">Steffensen, K. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Odense University Hospital, Kloevervaenget 47, Indgang 44, 46, 1. sal, DK-5000 Odense, Denmark.&#xD;Clinical Institute, University of Southern Denmark, J.B. Winsloews Vej 19, DK-5000 Odense, Denmark.&#xD;BRIDGE (Brain Research-Interdisciplinary Guided Excellence), University of Southern Denmark, J.B. Winsloews Vej 19, DK-5000 Odense, Denmark.&#xD;Department of Oncology, Odense University Hospital, Kloevervaenget 19, DK-5000 Odense, Denmark.&#xD;The Danish Center for Particle Therapy, Palle Juul-Jensens Blvd. 99, DK-8200 Aarhus, Denmark.&#xD;Department of Oncology, Center for Cancer and Organ Diseases, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.&#xD;Department of Public Health, Aarhus University, Bartholins Alle 2, DK-8000 Aarhus, Denmark.&#xD;Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, J.B. Winsloews Vej 19, DK-5000 Odense, Denmark.&#xD;Center for Shared Decision Making, Region of Southern Denmark, Beriderbakken 4, DK-7100 Vejle, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Development of a Patient Decision Aid to Support Shared Decision Making for Patients with Recurrent High-Grade Glioma</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Environ Res Public Health</style></secondary-title></titles><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">20220616</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Decision Making</style></keyword><keyword><style face="normal" font="default" size="100%">*Decision Making, Shared</style></keyword><keyword><style face="normal" font="default" size="100%">Decision Support Techniques</style></keyword><keyword><style face="normal" font="default" size="100%">*Glioma/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasm Recurrence, Local/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Participation</style></keyword><keyword><style face="normal" font="default" size="100%">decision support</style></keyword><keyword><style face="normal" font="default" size="100%">family involvement</style></keyword><keyword><style face="normal" font="default" size="100%">high-grade glioma</style></keyword><keyword><style face="normal" font="default" size="100%">neuro-oncology</style></keyword><keyword><style face="normal" font="default" size="100%">patient decision aids</style></keyword><keyword><style face="normal" font="default" size="100%">patient involvement</style></keyword><keyword><style face="normal" font="default" size="100%">shared decision making</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1660-4601 (Electronic)&#xD;1661-7827 (Print)&#xD;1660-4601 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35742644</style></accession-num><abstract><style face="normal" font="default" size="100%">When high-grade gliomas recur, patients, their families, and clinicians face difficult medical decisions. There is no curable treatment, and the treatment options all come with a risk of complications and adverse effects. The patients are often cognitively affected, and they need tailored decision support. The objective of this study was to develop a patient decision aid (PtDA) targeted at patients with recurrent high-grade gliomas. Based on existing knowledge and the International Patient Decision Aids Standards, the PtDA was developed through an iterative process. The PtDA was alpha-tested by potential users to assess its acceptability and usability. The development team comprised three clinicians, two patients, two family members, and a researcher. The fifth version of the PtDA was submitted to the alpha test. Eleven patients, nine family members, and eleven clinicians assessed the PtDA and found it acceptable. Three changes were made during the alpha test. Most participants perceived the PtDA to prepare patients for decision making and improve consultations. The involvement of potential users was emphasized during the development and alpha test process. The PtDA was assessed as useful and acceptable by patients, family members, and clinicians in the decision-making situation of recurrent high-grade glioma.</style></abstract><notes><style face="normal" font="default" size="100%">Sorensen von Essen, Helle&#xD;Poulsen, Frantz Rom&#xD;Dahlrot, Rikke Hedegaard&#xD;Piil, Karin&#xD;Steffensen, Karina Dahl&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Switzerland&#xD;2022/06/25&#xD;Int J Environ Res Public Health. 2022 Jun 16;19(12):7396. doi: 10.3390/ijerph19127396.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35742644</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest. The sponsors had no role in the design, execution, interpretation, or writing of the study.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9223526</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/ijerph19127396</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>196</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">196</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andersen, M. S.</style></author><author><style face="normal" font="default" size="100%">Guler, D. B.</style></author><author><style face="normal" font="default" size="100%">Larsen, J.</style></author><author><style face="normal" font="default" size="100%">Rich, K. K.</style></author><author><style face="normal" font="default" size="100%">Svenningsen, A. F.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Medicine, University of Southern Denmark, DK-5000 Odense, Denmark.&#xD;BRIDGE, University of Southern Denmark, DK-5000 Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Development of Hindlimb Postural Asymmetry Induced by Focal Traumatic Brain Injury Is Not Related to Serotonin 2A/C Receptor Expression in the Spinal Cord</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">5358</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">20220511</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Brain Injuries/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Brain Injuries, Traumatic/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Hindlimb</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal Cord/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">gait deficit</style></keyword><keyword><style face="normal" font="default" size="100%">postural asymmetry</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin receptor</style></keyword><keyword><style face="normal" font="default" size="100%">traumatic brain injury</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 11</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">MDPI AG</style></publisher><isbn><style face="normal" font="default" size="100%">1422-0067 (Electronic)&#xD;1422-0067 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35628167</style></accession-num><abstract><style face="normal" font="default" size="100%">Brain injury and stroke are leading causes of adult disability. Motor deficits are common problems, and their underlying pathological mechanisms remain poorly understood. The serotoninergic system is implicated in both functional recovery from and the occurrence of spasticity after injuries to the central nervous system. This study, which was conducted on rats, investigated the development of limb postural changes and their relationship to the expression of serotonin (5-HT) 2A and 2C receptors in the spinal cord in the 4 weeks after focal traumatic brain injury (TBI) to the right hindlimb sensorimotor cortex. The limb motor deficits were assessed by measuring gait pattern changes during walking and hindlimb postural asymmetry at different time intervals (3-28 days) after surgery. The expressions of the 5-HT2A and 2C receptors in the lumbar spinal cord were investigated using immunohistochemistry. The results showed that all the rats with TBI, independently of the duration of the interval, displayed postural asymmetry with flexion on the contralateral (left) side (&amp;gt;2 mm), while the sham-operated rats showed no apparent postural asymmetry. The TBI rats also had longer stride lengths during walking in both their hindlimbs and their forelimbs compared with the sham rats. For both the TBI and the sham rats, the hind-paw placement angles were larger on the contralateral side in some of the groups. Compared to the sham-operated rats, the 5-HT2A and 2C receptor expression did not significantly change on either side of the lumbar spinal cords of the TBI rats in any of the groups. These results suggest that focal TBI can induce motor deficits lasting a relatively long time, and that these deficits are not related to the expression of the 5-HT2A and 2C receptors in the spinal cord.</style></abstract><notes><style face="normal" font="default" size="100%">Andersen, Marlene Storm&#xD;Guler, Dilara Bedriye&#xD;Larsen, Jonas&#xD;Rich, Karen Kalhoj&#xD;Svenningsen, Asa Fex&#xD;Zhang, Mengliang&#xD;eng&#xD;NNF20OC0065099/Novo Nordisk Foundation/&#xD;Switzerland&#xD;2022/05/29&#xD;Int J Mol Sci. 2022 May 11;23(10):5358. doi: 10.3390/ijms23105358.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35628167</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9140651</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/ijms23105358</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>234</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">234</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wismann, J.</style></author><author><style face="normal" font="default" size="100%">Sommer-Sorensen, R. H.</style></author><author><style face="normal" font="default" size="100%">Kofoed, M. S.</style></author><author><style face="normal" font="default" size="100%">Halle, B.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. B.</style></author><author><style face="normal" font="default" size="100%">Schulz, M. K.</style></author><author><style face="normal" font="default" size="100%">Gronhoj, M. H.</style></author><author><style face="normal" font="default" size="100%">Larsen, T. S.</style></author><author><style face="normal" font="default" size="100%">Moller, M. B.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Odense University Hospital, Odense, Denmark. Joakim_wismann@hotmail.com.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Joakim_wismann@hotmail.com.&#xD;BRIDGE - Brain Research Inter-Disciplinary Guided Excellence, Odense, Denmark. Joakim_wismann@hotmail.com.&#xD;Department of Neurosurgery, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;BRIDGE - Brain Research Inter-Disciplinary Guided Excellence, Odense, Denmark.&#xD;Department of Hematology, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Pathology, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis, treatment, and outcome of primary CNS lymphoma-a single-center experience</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1365-1373</style></pages><volume><style face="normal" font="default" size="100%">164</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">20220307</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Central Nervous System Neoplasms/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lymphoma, Non-Hodgkin/diagnosis/pathology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Neurosurgical Procedures/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Progression-Free Survival</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Brain biopsy</style></keyword><keyword><style face="normal" font="default" size="100%">Overall survival</style></keyword><keyword><style face="normal" font="default" size="100%">Pcnsl</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0942-0940 (Electronic)&#xD;0001-6268 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35257217</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Primary CNS lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma (NHL) that occurs in the CNS (e.g. brain, meninges, spinal cord, cerebrospinal fluid, or intraocular involvement) in the absence of systemic NHL. Tumor resection does not improve survival, and neurosurgical intervention is generally limited to stereotactic biopsy to provide a histopathological diagnosis. OBJECTIVE: The objective of this single-center study was to evaluate the management and outcome of PCNSL patients diagnosed by biopsy, using overall survival and progression-free survival as endpoints. METHODS: At our department of neurosurgery, 140 patients were diagnosed with PCNSL by biopsy between January 1, 2009, and December 31, 2018. Of these, 37 patients were included in the study and were divided into three groups according to their postoperative therapy. RESULTS: Median OS was 35.7 months for the intensive treatment group, 29.5 months for the moderate treatment group, and 8.6 months for the palliative treatment group. The intensive and moderate treatment groups had similar progression-free survival, while the palliative treatment group had poor overall and progression-free survival. Six patients were long-term survivors (&gt; 80 months). Age under 65 years was the main significant parameter affecting overall survival. CONCLUSION: In this cohort, patients with PCNSL had an overall fair prognosis if they (1) were under 65 years old, (2) had a performance score &lt; 2 at the time of diagnosis, and (3) received either intensive or moderate chemotherapeutic treatment. Biopsy is still the primary diagnostic tool; other methods have been investigated but are not yet recommended.</style></abstract><notes><style face="normal" font="default" size="100%">Wismann, Joakim&#xD;Sommer-Sorensen, Rune Horlykke&#xD;Kofoed, Mikkel Seremet&#xD;Halle, Bo&#xD;Pedersen, Christian Bonde&#xD;Schulz, Mette Katrine&#xD;Gronhoj, Mads Hjortdal&#xD;Larsen, Thomas Stauffer&#xD;Moller, Michael Boe&#xD;Poulsen, Frantz Rom&#xD;eng&#xD;Austria&#xD;2022/03/09&#xD;Acta Neurochir (Wien). 2022 May;164(5):1365-1373. doi: 10.1007/s00701-022-05170-5. Epub 2022 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35257217</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00701-022-05170-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Falster, C.</style></author><author><style face="normal" font="default" size="100%">Jacobsen, N.</style></author><author><style face="normal" font="default" size="100%">Coman, K. E.</style></author><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Gaist, T. A.</style></author><author><style face="normal" font="default" size="100%">Posth, S.</style></author><author><style face="normal" font="default" size="100%">Moller, J. E.</style></author><author><style face="normal" font="default" size="100%">Brabrand, M.</style></author><author><style face="normal" font="default" size="100%">Laursen, C. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark Casper.falster@rsyd.dk.&#xD;Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.&#xD;Department of Oncology, Odense University Hospital, Odense, Denmark.&#xD;Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Neurology, Odense University Hospital, Odense, Denmark.&#xD;Department of Emergency Medicine, Odense University Hospital, Odense, Denmark.&#xD;Department of Cardiology, Odense University Hospital, Odense, Denmark.&#xD;Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnostic accuracy of focused deep venous, lung, cardiac and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Thorax</style></full-title></periodical><pages><style face="normal" font="default" size="100%">679-689</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">7</style></number><edition><style face="normal" font="default" size="100%">20210908</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Lung/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Pulmonary Embolism/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default" size="100%">emergency medicine</style></keyword><keyword><style face="normal" font="default" size="100%">pulmonary embolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">BMJ</style></publisher><isbn><style face="normal" font="default" size="100%">1468-3296 (Electronic)&#xD;0040-6376 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34497138</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine the diagnostic accuracy of point-of-care ultrasound in suspected pulmonary embolism. DESIGN: Systematic review and meta-analysis. DATA SOURCES: MEDLINE, Embase, CINAHL and Cochrane library were searched on 2 July 2020 with no restrictions on the date of publication. Subject headings or subheadings combined with text words for the concepts of pulmonary embolism, ultrasound and diagnosis were used. ELIGIBILITY CRITERIA AND DATA ANALYSIS: Eligible studies reported sensitivity and specificity of deep venous, lung, cardiac or multiorgan ultrasound in patients with suspected pulmonary embolism, using an adequate reference-test. Prospective, cross-sectional and retrospective studies were considered for eligibility. No restrictions were made on language. Studies were excluded if a control group consisted of healthy volunteers or if transesophageal or endobronchial ultrasound was used. Risk of bias was assessed using quality assessment of diagnostic accuracy studies-2. Meta-analysis of sensitivity and specificity was performed by construction of hierarchical summary receiver operator curves. I(2) was used to assess the study heterogeneity. MAIN OUTCOME MEASURES: The primary outcome was overall sensitivity and specificity of reported ultrasound signs, stratified by organ approach (deep venous, lung, cardiac and multiorgan). Secondary outcomes were stratum-specific sensitivity and specificity within subgroups defined by pretest probability of pulmonary embolism. RESULTS: 6378 references were identified, and 70 studies included. The study population comprised 9664 patients with a prevalence of pulmonary embolism of 39.9% (3852/9664). Risk of bias in at least one domain was found in 98.6% (69/70) of included studies. Most frequently, 72.8% (51/70) of studies reported &gt;24 hours between ultrasound examination and reference test or did not disclose time interval at all. Level of heterogeneity ranged from 0% to 100%. Most notable ultrasound signs were bilateral compression of femoral and popliteal veins (22 studies; 4708 patients; sensitivity 43.7% (36.3% to 51.4%); specificity 96.7% (95.4% to 97.6%)), presence of at least one hypoechoic pleural-based lesion (19 studies; 2134 patients; sensitivity 81.4% (73.2% to 87.5%); specificity 87.4% (80.9% to 91.9%)), D-sign (13 studies; 1579 patients; sensitivity 29.7% (24.6% to 35.4%); specificity 96.2% (93.1% to 98.0%)), visible right ventricular thrombus (5 studies; 995 patients; sensitivity 4.7% (2.7% to 8.1%); specificity 100% (99.0% to 100%)) and McConnell&apos;s sign (11 studies; 1480 patients; sensitivity 29.1% (20.0% to 40.1%); specificity 98.6% (96.7% to 99.4%)). CONCLUSION: Several ultrasound signs exhibit a high specificity for pulmonary embolism, suggesting that implementation of ultrasound in the initial assessment of patients with suspected pulmonary embolism may improve the selection of patients for radiation imaging. PROSPERO REGISTRATION NUMBER: CRD42020184313.</style></abstract><notes><style face="normal" font="default" size="100%">Falster, Casper&#xD;Jacobsen, Niels&#xD;Coman, Karen Ehlers&#xD;Hojlund, Mikkel&#xD;Gaist, Thomas Agerbo&#xD;Posth, Stefan&#xD;Moller, Jacob Eifer&#xD;Brabrand, Mikkel&#xD;Laursen, Christian B&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;England&#xD;2021/09/10&#xD;Thorax. 2022 Jul;77(7):679-689. doi: 10.1136/thoraxjnl-2021-216838. Epub 2021 Sep 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34497138</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Competing interests: JEM has received grants and personal fees from Abiomed, personal fees from Novartis, personal fees from Orion Pharma and personal fees from Boeinger Ingleheim outside the submitted work.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/thoraxjnl-2021-216838</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Larsen, E. R.</style></author><author><style face="normal" font="default" size="100%">Juel, A.</style></author><author><style face="normal" font="default" size="100%">Jensen, E.</style></author><author><style face="normal" font="default" size="100%">Hollyer, T. R.</style></author><author><style face="normal" font="default" size="100%">Wegener, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mental Health Department Odense, University Clinic, Mental Health Service, Region of Southern Denmark, Odense, Denmark.&#xD;Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark.&#xD;Arla Foods Ingredients Group P/S, Viby J, Denmark.&#xD;Department of Clinical Medicine, Translational Neuropsychiatry Unit, Aarhus C., Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary supplementation with casein glycomacropeptide, leucine and tryptophan reduces plasma amino acid levels in men</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neuropsychiatr</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">69-76</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20211020</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Caseins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Double-Blind Method</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Leucine</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Peptide Fragments</style></keyword><keyword><style face="normal" font="default" size="100%">*Tryptophan</style></keyword><keyword><style face="normal" font="default" size="100%">bipolar disorder</style></keyword><keyword><style face="normal" font="default" size="100%">casein glycomacropeptide</style></keyword><keyword><style face="normal" font="default" size="100%">dopamine</style></keyword><keyword><style face="normal" font="default" size="100%">mania</style></keyword><keyword><style face="normal" font="default" size="100%">phenylalanine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Cambridge University Press (CUP)</style></publisher><isbn><style face="normal" font="default" size="100%">1601-5215 (Electronic)&#xD;0924-2708 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34666854</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The treatment of mania in bipolar disorders needs to be more efficient, as the manic condition creates severe problems for the patient when it comes to work, finances, relationships and health. This proof-of-concept study examines to what extent casein glycomacropeptide (CGMP) may reduce the precursors of dopamine, phenylalanine and tyrosine, in plasma, and therefore be a potential new intervention to treat acute manic episodes. METHOD: The study was designed as a double-blind randomised dose-response study of CGMP (with added leucine and tryptophan) in 15 healthy men, receiving 3 different doses of CGMP with an interval of at least 14 days. RESULTS: Administration of CGMP produced a dose-dependent depletion of plasma aromatic amino acids. The total area under the curve of plasma ratios of phenylalanine-tyrosine compared to the level of leucine-isoleucine-valine--tryptophan was CGMP (20 g): 3.648 [SE:0.3281]; CGMP (40 g): 2.368 [SE:0.1858]; and CGMP (60 g)1.887 [SE:0.2591]. A comparison of the groups showed a dose-dependent statistical difference, with a one-way ANOVA summary (Dunnett) F = 11.87, p = 0.0003, CGMP 20 g versus CGMP 40 g, p = 0.0042, CGMP 20 g versus CGMP 60 g, p = 0.0002. No significant side effects were observed. CONCLUSIONS: This study demonstrate CGMP is a well-tolerated and effective mixture, and that 60 g of CGMP produced the highest depletion of plasma aromatic amino acids (phenylalanine and tyrosine). The effect seems to be highest after 3-4 h. We therefore conclude that this dose should be the one considered for future studies involving CGMP in humans.</style></abstract><notes><style face="normal" font="default" size="100%">Larsen, Erik Roj&#xD;Juel, Anette&#xD;Jensen, Erik&#xD;Hollyer, Tristan R&#xD;Wegener, Gregers&#xD;eng&#xD;Randomized Controlled Trial&#xD;England&#xD;2021/10/21&#xD;Acta Neuropsychiatr. 2022 Apr;34(2):69-76. doi: 10.1017/neu.2021.34. Epub 2021 Oct 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34666854</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/neu.2021.34</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>124</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kramer Schmidt, L.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Sogaard Nielsen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Southern Denmark, Odense, Denmark.&#xD;Region of Southern Denmark, Odense, Denmark.&#xD;Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differences in the delivery of motivational interviewing across three countries</style></title><secondary-title><style face="normal" font="default" size="100%">J Ethn Subst Abuse</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">823-844</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20201009</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcoholism/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Motivational Interviewing</style></keyword><keyword><style face="normal" font="default" size="100%">Motivational interviewing</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">elderly</style></keyword><keyword><style face="normal" font="default" size="100%">multisite</style></keyword><keyword><style face="normal" font="default" size="100%">treatment integrity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul-Sep</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1533-2659 (Electronic)&#xD;1533-2640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33032500</style></accession-num><abstract><style face="normal" font="default" size="100%">We do not know if the delivery of Motivational Interviewing (MI) differs across countries. In an international study targeting Elderly people with Alcohol Use Disorder, The Elderly Study, MI was part of the treatment applied. Treatment delivery was measured by means of the Motivational Interviewing Treatment Integrity code version 4 (MITI 4). Mixed effects models explored potential differences in delivery of MI between the countries. Delivery of MI differed significantly between participating countries: Denmark, Germany and the US. These findings are important to consider when comparing measures of MI integrity across studies from different cultures.</style></abstract><notes><style face="normal" font="default" size="100%">Kramer Schmidt, Lotte&#xD;Andersen, Kjeld&#xD;Sogaard Nielsen, Anette&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2020/10/10&#xD;J Ethn Subst Abuse. 2022 Jul-Sep;21(3):823-844. doi: 10.1080/15332640.2020.1824838. Epub 2020 Oct 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33032500</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/15332640.2020.1824838</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>233</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">233</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fruekilde, S. K.</style></author><author><style face="normal" font="default" size="100%">Bailey, C. J.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Clausen, B. H.</style></author><author><style face="normal" font="default" size="100%">Carlsen, J.</style></author><author><style face="normal" font="default" size="100%">Xu, N. L.</style></author><author><style face="normal" font="default" size="100%">Drasbek, K. R.</style></author><author><style face="normal" font="default" size="100%">Gutierrez-Jimenez, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Functionally Integrative Neuroscience (CFIN), Department of Clinical Medicine, 1006Aarhus University, Aarhus C, Denmark.&#xD;Sino-Danish Center for Education and Research (SDC), University of Chinese Academy of Sciences, Beijing, P.R. China.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, 6174University of Southern Denmark, Odense C, Denmark.&#xD;BRIDGE - Brain Research - Inter-Disciplinary Guided Excellence, Department of Clinical Research, 6174University of Southern Denmark, Odense C, Denmark.&#xD;Department of Neurology, Odense University Hospital, Odense C, Denmark.&#xD;Research Unit for Molecular Medicine (MMF), Department of Clinical Medicine, 1006Aarhus University, Aarhus N, Denmark.&#xD;Institute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, P.R. China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Disturbed microcirculation and hyperaemic response in a murine model of systemic inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Cereb Blood Flow Metab</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2303-2317</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">20220823</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Microcirculation</style></keyword><keyword><style face="normal" font="default" size="100%">*Lipopolysaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Capillaries</style></keyword><keyword><style face="normal" font="default" size="100%">*Hyperemia</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen</style></keyword><keyword><style face="normal" font="default" size="100%">Capillary stalling</style></keyword><keyword><style face="normal" font="default" size="100%">cerebral microcirculation</style></keyword><keyword><style face="normal" font="default" size="100%">hyperaemic response</style></keyword><keyword><style face="normal" font="default" size="100%">optical imaging</style></keyword><keyword><style face="normal" font="default" size="100%">systemic inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1559-7016 (Electronic)&#xD;0271-678X (Print)&#xD;0271-678X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35999817</style></accession-num><abstract><style face="normal" font="default" size="100%">Systemic inflammation affects cognitive functions and increases the risk of dementia. This phenomenon is thought to be mediated in part by cytokines that promote neuronal survival, but the continuous exposure to which may lead to neurodegeneration. The effects of systemic inflammation on cerebral blood vessels, and their provision of adequate oxygen to support critical brain parenchymal cell functions, remains unclear. Here, we demonstrate that neurovascular coupling is profoundly disturbed in lipopolysaccharide (LPS) induced systemic inflammation in awake mice. In the 24 hours following LPS injection, the hyperaemic response of pial vessels to functional activation was attenuated and delayed. Concurrently, under steady-state conditions, the capillary network displayed a significant increase in the number of capillaries with blocked blood flow, as well as increased duration of &apos;capillary stalls&apos;-a phenomenon previously reported in animal models of stroke and Alzheimer&apos;s disease pathology. We speculate that vascular changes and impaired oxygen availability may affect brain functions following acute systemic inflammation and contribute to the long-term risk of neurodegenerative changes associated with chronic, systemic inflammation.</style></abstract><notes><style face="normal" font="default" size="100%">Fruekilde, Signe Kirk&#xD;Bailey, Christopher J&#xD;Lambertsen, Kate Lykke&#xD;Clausen, Bettina Hjelm&#xD;Carlsen, Jasper&#xD;Xu, Ning-Long&#xD;Drasbek, Kim Ryun&#xD;Gutierrez-Jimenez, Eugenio&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/08/25&#xD;J Cereb Blood Flow Metab. 2022 Dec;42(12):2303-2317. doi: 10.1177/0271678X221112278. Epub 2022 Aug 23.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35999817</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9670001</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/0271678X221112278</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>287</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">287</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knudsen, L. V.</style></author><author><style face="normal" font="default" size="100%">Sheldrick, A. J.</style></author><author><style face="normal" font="default" size="100%">Vafaee, M. S.</style></author><author><style face="normal" font="default" size="100%">Michel, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Southern Denmark, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diversifying autism neuroimaging research: An arterial spin labeling review</style></title><secondary-title><style face="normal" font="default" size="100%">Autism</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Autism</style></full-title></periodical><pages><style face="normal" font="default" size="100%">13623613221137230</style></pages><edition><style face="normal" font="default" size="100%">20221121</style></edition><keywords><keyword><style face="normal" font="default" size="100%">arterial spin labeling</style></keyword><keyword><style face="normal" font="default" size="100%">autism</style></keyword><keyword><style face="normal" font="default" size="100%">autism spectrum disorder</style></keyword><keyword><style face="normal" font="default" size="100%">cerebral blood flow</style></keyword><keyword><style face="normal" font="default" size="100%">magnetic resonance imaging</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1461-7005 (Electronic)&#xD;1362-3613 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36409027</style></accession-num><abstract><style face="normal" font="default" size="100%">Brain function and health depend on cerebral blood flow to secure the necessary delivery of oxygen and nutrients to the brain tissue. However, cerebral blood flow appears to be altered in autistic compared to non-autistic individuals, potentially suggesting this difference to be a cause and potential identification point of autism. Recent technological development enables precise and non-invasive measurement of cerebral blood flow via the magnetic resonance imaging method referred to as arterial spin labeling. However, most neuroimaging studies still prefer using the physiologically indirect measure derived from functional magnetic resonance imaging. Therefore, this review examines the use of arterial spin labeling to further investigate the neurobiology of autism. Furthermore, the review includes a comparison of results from molecular imaging and arterial spin labeling followed by a discussion concerning the future direction and potential of arterial spin labeling. We found that arterial spin labeling study results are consistent with those of molecular imaging, especially after considering the effect of age and sex. In addition, arterial spin labeling has numerous application possibilities besides the quantification of cerebral blood flow. Therefore, we encourage researchers to explore and consider the application of arterial spin labeling for future scientific studies in the quest to better understand the neurobiology of autism.</style></abstract><notes><style face="normal" font="default" size="100%">Knudsen, Laust V&#xD;Sheldrick, Abigail J&#xD;Vafaee, Manouchehr S&#xD;Michel, Tanja Maria&#xD;eng&#xD;Review&#xD;England&#xD;2022/11/22&#xD;Autism. 2022 Nov 21:13623613221137230. doi: 10.1177/13623613221137230.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36409027</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/13623613221137230</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pearson, G.</style></author><author><style face="normal" font="default" size="100%">Song, C.</style></author><author><style face="normal" font="default" size="100%">Hohmann, S.</style></author><author><style face="normal" font="default" size="100%">Prokhorova, T.</style></author><author><style face="normal" font="default" size="100%">Sheldrick-Michel, T. M.</style></author><author><style face="normal" font="default" size="100%">Knopfel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory for Neuronal Circuit Dynamics, Imperial College London, London W12 0NN, UK.&#xD;Department of Psychiatry, Department of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">DNA Methylation Profiles of GAD1 in Human Cerebral Organoids of Autism Indicate Disrupted Epigenetic Regulation during Early Development</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">9188</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">16</style></number><edition><style face="normal" font="default" size="100%">20220816</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Autistic Disorder/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style face="normal" font="default" size="100%">Epigenesis, Genetic</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Organoids</style></keyword><keyword><style face="normal" font="default" size="100%">Ctcf</style></keyword><keyword><style face="normal" font="default" size="100%">Gaba</style></keyword><keyword><style face="normal" font="default" size="100%">Gad1</style></keyword><keyword><style face="normal" font="default" size="100%">autism</style></keyword><keyword><style face="normal" font="default" size="100%">epigenetics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 16</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">MDPI AG</style></publisher><isbn><style face="normal" font="default" size="100%">1422-0067 (Electronic)&#xD;1422-0067 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36012452</style></accession-num><abstract><style face="normal" font="default" size="100%">DNA methylation profiling has become a promising approach towards identifying biomarkers of neuropsychiatric disorders including autism spectrum disorder (ASD). Epigenetic markers capture genetic risk factors and diverse exogenous and endogenous factors, including environmental risk factors and complex disease pathologies. We analysed the differential methylation profile of a regulatory region of the GAD1 gene using cerebral organoids generated from induced pluripotent stem cells (iPSCs) from adults with a diagnosis of ASD and from age- and gender-matched healthy individuals. Both groups showed high levels of methylation across the majority of CpG sites within the profiled GAD1 region of interest. The ASD group exhibited a higher number of unique DNA methylation patterns compared to controls and an increased CpG-wise variance. We detected six differentially methylated CpG sites in ASD, three of which reside within a methylation-dependent transcription factor binding site. In ASD, GAD1 is subject to differential methylation patterns that may not only influence its expression, but may also indicate variable epigenetic regulation among cells.</style></abstract><notes><style face="normal" font="default" size="100%">Pearson, Georgina&#xD;Song, Chenchen&#xD;Hohmann, Sonja&#xD;Prokhorova, Tatyana&#xD;Sheldrick-Michel, Tanja Maria&#xD;Knopfel, Thomas&#xD;eng&#xD;Switzerland&#xD;2022/08/27&#xD;Int J Mol Sci. 2022 Aug 16;23(16):9188. doi: 10.3390/ijms23169188.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36012452</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9408997</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/ijms23169188</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>126</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">126</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author><author><style face="normal" font="default" size="100%">Skot, L.</style></author><author><style face="normal" font="default" size="100%">Guala, M. M.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author><author><style face="normal" font="default" size="100%">Ascone, L.</style></author><author><style face="normal" font="default" size="100%">Stenager, E.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.&#xD;Research Unit for Telepsychiatry and E-Mental Health, Center for Telepsychiatry, Region of Southern Denmark, Odense C, Denmark.&#xD;Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.&#xD;Center for Eating Disorders, Odense University Hospital, Odense C, Denmark.&#xD;Research Unit for Medical Endocrinology, Institute of Clinical Research, University of South Denmark, Odense C, Denmark.&#xD;Neuroplasticity Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.&#xD;Unit for Psychiatric Research, Department of Regional Health Services Research, University of Southern Denmark, 6200 Aabenraa, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Does receiving an eating disorder diagnosis increase the risk of a subsequent alcohol use disorder? A Danish nationwide register-based cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Addiction</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Addiction</style></full-title></periodical><pages><style face="normal" font="default" size="100%">354-367</style></pages><volume><style face="normal" font="default" size="100%">117</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20210808</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alcoholism/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Feeding and Eating Disorders/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">bulimia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">register study</style></keyword><keyword><style face="normal" font="default" size="100%">unspecified eating disorders</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1360-0443 (Electronic)&#xD;0965-2140 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34251067</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND AIM: No large-scale, longitudinal clinical study has examined whether patients with different types of eating disorders (ED) have an increased risk of a subsequent alcohol use disorder (AUD). This study aimed to assess the ongoing risk of receiving a diagnosis of AUD following a first-time diagnosis of anorexia nervosa (AN), bulimia nervosa (BN), or unspecified ED (USED). DESIGN: Retrospective cohort study. SETTING: Danish nationwide registries, January 1994 to December 2018. PARTICIPANTS: A total of 20 759 ED patients and 83 036 controls were followed from the date of first ED diagnosis (index date) until the date of first AUD diagnosis, death, emigration, or the end of the study. Controls were selected in a 1:4 ratio and matched on month and year of birth, gender and ethnicity. MEASUREMENTS: We obtained data on ED (AN, BN, USED; exposure) and AUD (abuse/dependence; outcome) diagnoses as well as sociodemographics and other psychiatric diagnoses. Time to AUD was generated from the index date. Risk of AUD after the index date was assessed among those without a prior AUD diagnosis while adjusting for sociodemographics and prior psychiatric diagnoses. FINDINGS: Compared with controls, an increased relative risk of AUD after the index date was observed in AN patients throughout the study lasting 15 + years (adjusted hazard ratios [HRs] ranging from 2.49 [99% CI = 1.46, 4.25] to 6.83 [2.84, 16.41]), in BN patients during the first year of follow-up and from 2 years onward (2.72 [1.66, 4.44] to 17.44 [6.01, 50.63]), and in USED patients during the first year and 2-15 years of follow-up (2.52 [1.54, 4.14] to 14.17 [5.86, 34.27]). In all three groups, estimates were highest during the first year, particularly among BN patients. CONCLUSIONS: Patients with anorexia nervosa, bulimia nervosa, or unspecified eating disorders appear to have an increased ongoing risk of receiving a diagnosis of alcohol use disorder following their first eating disorder diagnosis compared with controls.</style></abstract><notes><style face="normal" font="default" size="100%">Mellentin, Angelina Isabella&#xD;Skot, Lotte&#xD;Guala, Maria Mercedes&#xD;Stoving, Rene Klinkby&#xD;Ascone, Leonie&#xD;Stenager, Elsebeth&#xD;Mejldal, Anna&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2021/07/13&#xD;Addiction. 2022 Feb;117(2):354-367. doi: 10.1111/add.15639. Epub 2021 Aug 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34251067</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/add.15639</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>293</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">293</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Runge, E.</style></author><author><style face="normal" font="default" size="100%">Jensen, E. K.</style></author><author><style face="normal" font="default" size="100%">Mathiasen, K.</style></author><author><style face="normal" font="default" size="100%">Larsen, P. V.</style></author><author><style face="normal" font="default" size="100%">Hertz, S. P. T.</style></author><author><style face="normal" font="default" size="100%">Holmberg, T. T.</style></author><author><style face="normal" font="default" size="100%">Tarp, K.</style></author><author><style face="normal" font="default" size="100%">Linnet, J.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mental Health Services in the Region of Southern Denmark, Research Unit for Digital Psychiatry, Centre for Digital Psychiatry, Odense, Denmark.&#xD;Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;Mental Health Services in the Region of Southern Denmark, Vejle, Denmark.&#xD;Clinic on Gambling- and Binge Eating Disorder, Department of Occupational and Environmental Medicine, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early development of treatment motivation predicts adherence and symptom reduction in an internet-based guided self-help program for binge eating disorder</style></title><secondary-title><style face="normal" font="default" size="100%">Front Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">969338</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20221006</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adherence - compliance - persistence</style></keyword><keyword><style face="normal" font="default" size="100%">binge eating disorder (BED)</style></keyword><keyword><style face="normal" font="default" size="100%">early measurements</style></keyword><keyword><style face="normal" font="default" size="100%">iCBT</style></keyword><keyword><style face="normal" font="default" size="100%">motivation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">1664-0640 (Print)&#xD;1664-0640 (Electronic)&#xD;1664-0640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36276339</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Lack of motivation is widely acknowledged as a significant factor in treatment discontinuity and poor treatment outcomes in eating disorders. Treatment adherence is lower in internet-based treatment. The current study aimed to assess the relationship between treatment motivation and treatment outcomes in an internet-based therapist-guided intervention for Binge Eating Disorder (BED). METHOD: Adults (N = 153) with mild to moderate symptoms of BED participated in a 10-session internet-based treatment program. Baseline and between-session scores of &quot;Readiness to change&quot; and &quot;Belief in change&quot; were used to predict treatment completion and eating disorder symptom reduction (EDE-Q Global, BED-Q, and weekly number of binge eating episodes) at post-treatment. RESULTS: Baseline treatment motivation could not predict treatment completion or symptom reduction. Early measures of treatment motivation (regression slope from sessions 1-5) significantly predicted both treatment completion and post-treatment symptom reduction. &quot;Belief in change&quot; was the strongest predictor for completing treatment (OR = 2.18, 95%-CI: 1.06, 4.46) and reducing symptoms (EDE-Q Global: B = -0.53, p = 0.001; number of weekly binge eating episodes: B = 0.81, p &lt; 0.01). DISCUSSION: The results indicated that patients entering online treatment for BED feel highly motivated. However, baseline treatment motivation could not significantly predict treatment completion, which contradicts previous research. The significant predictive ability of early measures of treatment motivation supports the clinical relevance of monitoring the development of early changes to tailor and optimize individual patient care. Further research is needed to examine treatment motivation in regard to internet-based treatment for BED with more validated measures.</style></abstract><notes><style face="normal" font="default" size="100%">Runge, Eik&#xD;Jensen, Esben Kjems&#xD;Mathiasen, Kim&#xD;Larsen, Pia Veldt&#xD;Hertz, Soren Peter Thygesen&#xD;Holmberg, Trine Theresa&#xD;Tarp, Kristine&#xD;Linnet, Jakob&#xD;Lichtenstein, Mia Beck&#xD;eng&#xD;Switzerland&#xD;2022/10/25&#xD;Front Psychiatry. 2022 Oct 6;13:969338. doi: 10.3389/fpsyt.2022.969338. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36276339</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9583526</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fpsyt.2022.969338</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>230</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">230</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johansen, K. K.</style></author><author><style face="normal" font="default" size="100%">Marcussen, J.</style></author><author><style face="normal" font="default" size="100%">Hansen, J. P.</style></author><author><style face="normal" font="default" size="100%">Hounsgaard, L.</style></author><author><style face="normal" font="default" size="100%">Fluttert, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mental Health Department Esbjerg, University Clinic Region of Southern Denmark, Esbjerg N, Denmark.&#xD;OPEN, Institute of Clinical Research, University of Southern Denmark, Aarhus C, Denmark.&#xD;Department of Nursing and Health Sciences, University of Greenland, Nuuk, Greenland.&#xD;Faculty of Nursing, Health Science Research Center, University College Lillebaelt, Svendborg, Denmark.&#xD;Faculty of Health Sciences, CPS/Institute of Regional Health Research, University of Southern Denmark, Aarhus C, Denmark.&#xD;FPC Dr. S. Van Mesdag, Groningen, The Netherlands.&#xD;Molde University College &amp; Oslo University Hospital, Molde, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Early recognition method for patients with schizophrenia or bipolar disorder in community mental health care: Illness insight, self-management and control</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Nurs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3535-3549</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">23-24</style></number><edition><style face="normal" font="default" size="100%">20211221</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Bipolar Disorder/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Self-Management</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Health</style></keyword><keyword><style face="normal" font="default" size="100%">Self Concept</style></keyword><keyword><style face="normal" font="default" size="100%">Relapse prevention</style></keyword><keyword><style face="normal" font="default" size="100%">bipolar disorder</style></keyword><keyword><style face="normal" font="default" size="100%">community mental healthcare</style></keyword><keyword><style face="normal" font="default" size="100%">individualised intervention</style></keyword><keyword><style face="normal" font="default" size="100%">patient involvement</style></keyword><keyword><style face="normal" font="default" size="100%">risk management</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">shared decision-making</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1365-2702 (Electronic)&#xD;0962-1067 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34935221</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS AND OBJECTIVE: To investigate how participating in the early recognition method treatment strategy affect illness insight and management, in patients with schizophrenia or bipolar disorder in community mental healthcare. BACKGROUND: The current practice in mental healthcare focus on shared decision-making and self-managing capacity, but poor insight is a predictor of poor adherence and dropout. Engagement in illness management and recovery predict the treatment response. DESIGN: Semi-structured interviews with a phenomenological-hermeneutic approach. METHODS: We conducted 36 semi-structured interviews with 26 patients. The interviews were conducted before and after participating in the intervention using the early recognition method strategy. The analysis was based on Ricoeur&apos;s theory of interpretation: Naive reading, structural analysis, interpretation and discussion. The COREQ checklist was used as reporting guideline. RESULTS: The experience of participating in treatment as usual and early recognition method revealed two main themes. The first theme &apos;patient care&apos; describes how dialogue and collaboration increase awareness of the illness and how to gain control. The second theme &apos;insight and experience&apos; describes how illness affects personality and self-image, and how insight entails control and self-confidence. CONCLUSION: Managing life with severe mental illness is complex and challenging. However, the experience of guidance, support and collaboration between patient and nurse are essential to improve these circumstances. RELEVANCE TO CLINICAL PRACTICE: A systematic approach to the patient&apos; symptoms, as in the early recognition method strategy, enhances knowledge of the individual patient&apos; symptoms, both for nurse and patient. A knowledge that is significant for meeting individual treatment needs. Therefore, applying this strategy is likely to enhance collaboration and improve treatment outcome.</style></abstract><notes><style face="normal" font="default" size="100%">Johansen, Kirsten Kjaer&#xD;Marcussen, Jette&#xD;Hansen, Jens Peter&#xD;Hounsgaard, Lise&#xD;Fluttert, Frans&#xD;eng&#xD;HR mental Services Vejle, Region of Southern Denmark/&#xD;Mental Health Department Esbjerg, University Clinic Region of Southern Denmark/&#xD;Psychiatric research Foundation, Region of Southern Denmark/&#xD;England&#xD;2021/12/23&#xD;J Clin Nurs. 2022 Dec;31(23-24):3535-3549. doi: 10.1111/jocn.16181. Epub 2021 Dec 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34935221</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jocn.16181</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skot, L.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author><author><style face="normal" font="default" size="100%">Guala, M. M.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author><author><style face="normal" font="default" size="100%">Ascone, L.</style></author><author><style face="normal" font="default" size="100%">Stenager, E.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark. lskoet@health.sdu.dk.&#xD;Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.&#xD;Center for Eating Disorders, Odense University Hospital, Odense C, Denmark.&#xD;Research Unit for Medical Endocrinology, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.&#xD;Neuroplasticity Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.&#xD;Unit for Psychiatric Research, Children and Adults, Department of Regional Health Services Research, University of Southern Denmark, 6200, Aabenraa, Denmark.&#xD;Center for Telepsychiatry, Research Unit for Telepsychiatry and E-Mental Health, Region of Southern Denmark, Odense C, Denmark.&#xD;Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Eating disorders and subsequent risk of substance use disorders involving illicit drugs: a Danish nationwide register-based cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Soc Psychiatry Psychiatr Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Soc Psychiatry Psychiatr Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">695-708</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220105</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Anorexia Nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">*Bulimia Nervosa/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Feeding and Eating Disorders/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Illicit Drugs/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Substance-Related Disorders/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Anorexia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">Bulimia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">Illicit substances</style></keyword><keyword><style face="normal" font="default" size="100%">Substance use disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Unspecified eating disorder</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1433-9285 (Electronic)&#xD;0933-7954 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34985528</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: No study has investigated the ongoing risk of substance use disorders involving illicit drugs (ISUD) after first eating disorder (ED) and whether the pattern of risk differs according to types of ED and ISUD. Therefore, we aimed to longitudinally assess the risk of a subsequent diagnosis of any ISUD (pooled category) and specific ISUD after a first-time diagnosis of anorexia nervosa (AN), bulimia nervosa (BN), or unspecified ED (USED). METHODS: A retrospective cohort study using data from Danish nationwide registers identified 20,759 ED patients and 83,038 matched controls (1:4 ratio). Risk of any ISUD diagnosis after first ED diagnosis was estimated by generating hazard ratios (HR). Logistic regression was applied to assess associations between each ED and specific ISUD. RESULTS: Patients with AN, BN, and USED (without a prior ISUD diagnosis) exhibited an increased relative risk of a subsequent diagnosis of any ISUD compared with respective controls, and the elevated risk persisted over 10 years (AN, adjusted HRs ranging from 1.60 [99% CI 1.15-2.24] to 5.16 [3.14-8.47]; BN, 2.35 [1.46-3.79] to 14.24 [6.88-29.47]; USED, 2.86 [1.35-3.79] to 8.56 [3.31-29.47]). The highest estimates were observed during the first year of follow-up. Each ED type was associated with an increased likelihood of all types of ISUD. AN and USED were most strongly associated with sedatives/hypnotics, BN with other illegal substances (e.g., ecstasy and hallucinogens). CONCLUSIONS: ED patients have a considerable risk for subsequent ISUD. Prevention efforts and treatment targeting ISUD are likely required to improve ED treatment prognosis.</style></abstract><notes><style face="normal" font="default" size="100%">Skot, Lotte&#xD;Mejldal, Anna&#xD;Guala, Maria Mercedes&#xD;Stoving, Rene Klinkby&#xD;Ascone, Leonie&#xD;Stenager, Elsebeth&#xD;Lichtenstein, Mia Beck&#xD;Mellentin, Angelina Isabella&#xD;eng&#xD;R67-A3037-B1261/Psychiatric Research Foundation, University of Southern Denmark/&#xD;Germany&#xD;2022/01/06&#xD;Soc Psychiatry Psychiatr Epidemiol. 2022 Apr;57(4):695-708. doi: 10.1007/s00127-021-02201-x. Epub 2022 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34985528</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00127-021-02201-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>300</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">300</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Langergaard, A.</style></author><author><style face="normal" font="default" size="100%">Mathiasen, K.</style></author><author><style face="normal" font="default" size="100%">Sondergaard, J.</style></author><author><style face="normal" font="default" size="100%">Sorensen, S. S.</style></author><author><style face="normal" font="default" size="100%">Laursen, S. L.</style></author><author><style face="normal" font="default" size="100%">Xylander, A. A. P.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Ehlers, L. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Danish Center for Healthcare Improvements, Department of Clinical Medicine, Aalborg University, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Denmark.&#xD;Center for Telepsychiatry, Mental Health Services in the Region of Southern Denmark, Denmark.&#xD;Odense Patient Data Exploratory Network, Odense University Hospital, Denmark.&#xD;Medical Informatics, Department of Health Science and Technology, Aalborg University, Denmark.&#xD;Nordic Institute of Health Economics A/S, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Economic evaluation alongside a randomized controlled trial of blended cognitive-behavioral therapy for patients suffering from major depressive disorder</style></title><secondary-title><style face="normal" font="default" size="100%">Internet Interv</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Internet Interv</style></full-title></periodical><pages><style face="normal" font="default" size="100%">100513</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><edition><style face="normal" font="default" size="100%">20220219</style></edition><keywords><keyword><style face="normal" font="default" size="100%">B-CBT, blended cognitive-behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">CBT, cognitive-behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cost-utility</style></keyword><keyword><style face="normal" font="default" size="100%">DRG, diagnosis-related group</style></keyword><keyword><style face="normal" font="default" size="100%">DSM-IV, Diagnostic and Statistical Manual of Mental Disorders 4th edition</style></keyword><keyword><style face="normal" font="default" size="100%">ENTER, Emental Health Research</style></keyword><keyword><style face="normal" font="default" size="100%">EQ-5D-5L, EuroQoL 5-Dimensions 5-Levels</style></keyword><keyword><style face="normal" font="default" size="100%">Economic evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">HRQoL, health-related quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">ICER, incremental cost-effectiveness ratio</style></keyword><keyword><style face="normal" font="default" size="100%">Internet intervention</style></keyword><keyword><style face="normal" font="default" size="100%">M.I.N.I., International Neuropsychiatric Interview version 5.0</style></keyword><keyword><style face="normal" font="default" size="100%">MDD, major depressive disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Major depressive disorder</style></keyword><keyword><style face="normal" font="default" size="100%">PHQ-9, Patient Health Questionnaire-9</style></keyword><keyword><style face="normal" font="default" size="100%">PSA, probabilistic sensitivity analysis</style></keyword><keyword><style face="normal" font="default" size="100%">QALY, quality-adjusted life-years</style></keyword><keyword><style face="normal" font="default" size="100%">SE, standard error</style></keyword><keyword><style face="normal" font="default" size="100%">SUREG, seemingly unrelated regression</style></keyword><keyword><style face="normal" font="default" size="100%">TiC-P, Treatment Inventory of Costs in Psychiatric Patients questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">WHO, World Health Organization</style></keyword><keyword><style face="normal" font="default" size="100%">iCBT, interned-based cognitive-behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">mHealth</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2214-7829 (Electronic)&#xD;2214-7829 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35242594</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: This study aimed to investigate the cost-effectiveness of blended cognitive-behavioral therapy (CBT) compared to standard CBT for adult patients suffering from major depressive disorder (MDD). DESIGN: A cost-utility analysis alongside the randomized controlled ENTER trial. SETTING: Center for Telepsychiatry, Mental Health Services in the Region of Southern Denmark, Denmark. PARTICIPANTS: The study included 76 patients suffering from MDD. INTERVENTIONS: The patients in the intervention group received blended CBT treatment comprising a combination of online modules and face-to-face consultations with a psychologist. The patients in the control group received standard CBT treatment, that is, solely face-to-face consultations with a psychologist. The treatment period was 12 weeks. OUTCOME MEASURES: Cost-effectiveness was reported as incremental cost-effectiveness ratio. A micro-costing approach was applied to evaluate the savings derived. Changes in quality-adjusted life-years (QALYs) were estimated using the EuroQol 5-Dimensions 5-Levels questionnaire at the baseline and the six-month follow-up. RESULTS: Data for 74 patients were included in the primary analysis. The adjusted QALY difference between blended CBT and standard CBT was -0.0291 (95% CI: -0.0535 to -0.0047), and the adjusted difference in costs was - pound226.32 (95% CI: -300.86 to -151.77). Blended CBT was estimated to have a 6.6% and 3.1% probability of being cost-effective based on thresholds of pound20,000 and pound30,000. CONCLUSION: Compared to standard CBT, blended CBT represents a cost-saving but also a loss in QALYs for patients suffering from MDD. However, results should be carefully interpreted, given the small sample size. Future research involving larger replication studies focusing on other aspects of blended CBT with more patient involvement is advised. TRIAL REGISTRATION NUMBER: ClinicalTrial.gov: S-20150150.</style></abstract><notes><style face="normal" font="default" size="100%">Langergaard, Astrid&#xD;Mathiasen, Kim&#xD;Sondergaard, Jesper&#xD;Sorensen, Sabrina S&#xD;Laursen, Sidsel L&#xD;Xylander, Alexander A P&#xD;Lichtenstein, Mia B&#xD;Ehlers, Lars H&#xD;eng&#xD;Netherlands&#xD;2022/03/05&#xD;Internet Interv. 2022 Feb 19;28:100513. doi: 10.1016/j.invent.2022.100513. eCollection 2022 Apr.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35242594</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The software NoDep was developed jointly by the Region of Southern Denmark and the private partner Context Consulting. Kim Mathiasen participated in the development process as a representative of the public partner Region of Southern Denmark. Kim Mathiasen has no affiliation with any of the private vendors involved in the project, including Context Consulting, and obtains no financial benefit from the sale of licenses. The authors declare that they have no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8886051</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.invent.2022.100513</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jensen, E. S.</style></author><author><style face="normal" font="default" size="100%">Ladegaard, N.</style></author><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author><author><style face="normal" font="default" size="100%">Ebert, D. D.</style></author><author><style face="normal" font="default" size="100%">Titzler, I.</style></author><author><style face="normal" font="default" size="100%">Araya, R.</style></author><author><style face="normal" font="default" size="100%">Cerga Pashoja, A.</style></author><author><style face="normal" font="default" size="100%">Hazo, J. B.</style></author><author><style face="normal" font="default" size="100%">Holtzmann, J.</style></author><author><style face="normal" font="default" size="100%">Cieslak, R.</style></author><author><style face="normal" font="default" size="100%">Smoktunowicz, E.</style></author><author><style face="normal" font="default" size="100%">Banos, R.</style></author><author><style face="normal" font="default" size="100%">Herrero, R.</style></author><author><style face="normal" font="default" size="100%">Garcia-Palacios, A.</style></author><author><style face="normal" font="default" size="100%">Botella, C.</style></author><author><style face="normal" font="default" size="100%">Berger, T.</style></author><author><style face="normal" font="default" size="100%">Krieger, T.</style></author><author><style face="normal" font="default" size="100%">Holmberg, T. T.</style></author><author><style face="normal" font="default" size="100%">Topooco, N.</style></author><author><style face="normal" font="default" size="100%">Andersson, G.</style></author><author><style face="normal" font="default" size="100%">van Straten, A.</style></author><author><style face="normal" font="default" size="100%">Kemmeren, L.</style></author><author><style face="normal" font="default" size="100%">Kleiboer, A.</style></author><author><style face="normal" font="default" size="100%">Riper, H.</style></author><author><style face="normal" font="default" size="100%">Mathiasen, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Telepsychiatry, Mental Health Services of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;Department of Affective Disorders, Aarhus University Hospital, Aarhus, Denmark.&#xD;Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department for Sport and Health Sciences, Chair for Psychology &amp; Digital Mental Health Care, Technical University Munich, Munich, Germany.&#xD;Department of Clinical Psychology and Psychotherapy, Friedrich-Alexander University of Erlangen-Nurnberg, Erlangen, Germany.&#xD;Centre for Global Mental Health, King&apos;s College London, London, United Kingdom.&#xD;Department of Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.&#xD;Global Public Health, Public Health England, London, United Kingdom.&#xD;URC Eco Ile-de-France (AP-HP), Hotel Dieu, Paris, France.&#xD;Assistance Publique-Hopitaux de Paris, Health Economics Research Unit, University of Paris, Paris, France.&#xD;Fondation FondaMental, Creteil, France.&#xD;Service de Psychiatrie de l&apos;adulte, Centre Expert Depression Resistante FondaMental, Grenoble University Hospital, Grenoble, France.&#xD;Faculty of Psychology, SWPS University of Social Sciences and Humanities, Warsaw, Poland.&#xD;Lyda Hill Institute for Human Resilience, University of Colorado, Colorado Springs, CO, United States.&#xD;Instituto Polibienestar, University of Valencia, Valencia, Spain.&#xD;CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Madrid, Spain.&#xD;Department of Basic Psychology, Clinic and Psychobiology, University Jaume I, Castellon, Spain.&#xD;Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland.&#xD;Department of Behavioural Sciences and Learning, Linkoping University, Linkoping, Sweden.&#xD;Center for m2Health, Palo Alto University, Palo Alto, CA, United States.&#xD;Department of Biomedical and Clinical Sciences, Linkoping University, Linkoping, Sweden.&#xD;Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.&#xD;Department of Clinical, Neuro, and Developmental Psychology, Vrije Universiteit, Amsterdam, Netherlands.&#xD;Amsterdam Public Health Research Institute, Amsterdam, Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of Sleep Disturbance Symptoms on Treatment Outcome in Blended Cognitive Behavioral Therapy for Depression (E-COMPARED Study): Secondary Analysis</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Internet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Internet Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e30231</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20220321</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Cognitive Behavioral Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Depression/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Depressive Disorder, Major/psychology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Sleep</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">bCBT</style></keyword><keyword><style face="normal" font="default" size="100%">blended care</style></keyword><keyword><style face="normal" font="default" size="100%">cognitive behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">digital health</style></keyword><keyword><style face="normal" font="default" size="100%">digital intervention</style></keyword><keyword><style face="normal" font="default" size="100%">major depressive disorder</style></keyword><keyword><style face="normal" font="default" size="100%">mental health</style></keyword><keyword><style face="normal" font="default" size="100%">mobile phone</style></keyword><keyword><style face="normal" font="default" size="100%">sleep disorder</style></keyword><keyword><style face="normal" font="default" size="100%">sleep disturbance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 21</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">JMIR Publications Inc.</style></publisher><isbn><style face="normal" font="default" size="100%">1438-8871 (Electronic)&#xD;1439-4456 (Print)&#xD;1438-8871 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35311687</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sleep disturbance symptoms are common in major depressive disorder (MDD) and have been found to hamper the treatment effect of conventional face-to-face psychological treatments such as cognitive behavioral therapy. To increase the dissemination of evidence-based treatment, blended cognitive behavioral therapy (bCBT) consisting of web-based and face-to-face treatment is on the rise for patients with MDD. To date, no study has examined whether sleep disturbance symptoms have an impact on bCBT treatment outcomes and whether it affects bCBT and treatment-as-usual (TAU) equally. OBJECTIVE: The objectives of this study are to investigate whether baseline sleep disturbance symptoms have an impact on treatment outcomes independent of treatment modality and whether sleep disturbance symptoms impact bCBT and TAU in routine care equally. METHODS: The study was based on data from the E-COMPARED (European Comparative Effectiveness Research on Blended Depression Treatment Versus Treatment-as-Usual) study, a 2-arm, multisite, parallel randomized controlled, noninferiority trial. A total of 943 outpatients with MDD were randomized to either bCBT (476/943, 50.5%) or TAU consisting of routine clinical MDD treatment (467/943, 49.5%). The primary outcome of this study was the change in depression symptom severity at the 12-month follow-up. The secondary outcomes were the change in depression symptom severity at the 3- and 6-month follow-up and MDD diagnoses at the 12-month follow-up, assessed using the Patient Health Questionnaire-9 and Mini-International Neuropsychiatric Interview, respectively. Mixed effects models were used to examine the association of sleep disturbance symptoms with treatment outcome and treatment modality over time. RESULTS: Of the 943 patients recruited for the study, 558 (59.2%) completed the 12-month follow-up assessment. In the total sample, baseline sleep disturbance symptoms did not significantly affect change in depressive symptom severity at the 12-month follow-up (beta=.16, 95% CI -0.04 to 0.36). However, baseline sleep disturbance symptoms were negatively associated with treatment outcome for bCBT (beta=.49, 95% CI 0.22-0.76) but not for TAU (beta=-.23, 95% CI -0.50 to 0.05) at the 12-month follow-up, even when adjusting for baseline depression symptom severity. The same result was seen for the effect of sleep disturbance symptoms on the presence of depression measured with Mini-International Neuropsychiatric Interview at the 12-month follow-up. However, for both treatment formats, baseline sleep disturbance symptoms were not associated with depression symptom severity at either the 3- (beta=.06, 95% CI -0.11 to 0.23) or 6-month (beta=.09, 95% CI -0.10 to 0.28) follow-up. CONCLUSIONS: Baseline sleep disturbance symptoms may have a negative impact on long-term treatment outcomes in bCBT for MDD. This effect was not observed for TAU. These findings suggest that special attention to sleep disturbance symptoms might be warranted when MDD is treated with bCBT. Future studies should investigate the effect of implementing modules specifically targeting sleep disturbance symptoms in bCBT for MDD to improve long-term prognosis.</style></abstract><notes><style face="normal" font="default" size="100%">Jensen, Esben Skov&#xD;Ladegaard, Nicolai&#xD;Mellentin, Angelina Isabella&#xD;Ebert, David Daniel&#xD;Titzler, Ingrid&#xD;Araya, Ricardo&#xD;Cerga Pashoja, Arlinda&#xD;Hazo, Jean-Baptiste&#xD;Holtzmann, Jerome&#xD;Cieslak, Roman&#xD;Smoktunowicz, Ewelina&#xD;Banos, Rosa&#xD;Herrero, Rocio&#xD;Garcia-Palacios, Azucena&#xD;Botella, Cristina&#xD;Berger, Thomas&#xD;Krieger, Tobias&#xD;Holmberg, Trine Theresa&#xD;Topooco, Naira&#xD;Andersson, Gerhard&#xD;van Straten, Annemieke&#xD;Kemmeren, Lise&#xD;Kleiboer, Annet&#xD;Riper, Heleen&#xD;Mathiasen, Kim&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Canada&#xD;2022/03/22&#xD;J Med Internet Res. 2022 Mar 21;24(3):e30231. doi: 10.2196/30231.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35311687</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflicts of Interest: None declared.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8981003</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2196/30231</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>197</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">197</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abildgren, L.</style></author><author><style face="normal" font="default" size="100%">Lebahn-Hadidi, M.</style></author><author><style face="normal" font="default" size="100%">Mogensen, C. B.</style></author><author><style face="normal" font="default" size="100%">Toft, P.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. B.</style></author><author><style face="normal" font="default" size="100%">Frandsen, T. F.</style></author><author><style face="normal" font="default" size="100%">Steffensen, S. V.</style></author><author><style face="normal" font="default" size="100%">Hounsgaard, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Anesthesiology and Intensive Care Unit, Odense University Hospital, Odense, Denmark. lotte.abildgren@rsyd.dk.&#xD;OPEN, Open Patient data Explorative Network, Odense University Hospital/Department of Clinical Research, University of Southern Denmark, Odense, Denmark. lotte.abildgren@rsyd.dk.&#xD;Emergency Research Unit, Hospital Sonderjylland, University Hospital of Southern Denmark, Odense, Denmark. lotte.abildgren@rsyd.dk.&#xD;Emergency Research Unit, Hospital Sonderjylland, University Hospital of Southern Denmark, Odense, Denmark.&#xD;Centre for Human Interactivity, Department of Language and Communication, University of Southern Denmark, Odense, Denmark.&#xD;Anesthesiology and Intensive Care Unit, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;OPEN, Open Patient data Explorative Network, Odense University Hospital/Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;SimC, Regional Center for Technical Simulation, Region of Southern Denmark, Odense, Denmark.&#xD;Department of Design and Communication, University of Southern Denmark, Kolding, Denmark.&#xD;Danish Institute for Advanced Study, University of Southern Denmark, Odense, Denmark.&#xD;Center for Ecolinguistics, South China Agricultural University, Guangzhou, People&apos;s Republic of China.&#xD;College of International Studies, Southwest University, Chongqing, People&apos;s Republic of China.&#xD;Institute of Nursing &amp; Health Science, Ilisimartusarfik, University of Greenland, Nuuk, Greenland.&#xD;Center for Mental Health Nursing and Health Research (CPS), Mental Health Services, Region of Southern Denmark, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effectiveness of improving healthcare teams&apos; human factor skills using simulation-based training: a systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Adv Simul (Lond)</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">12</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220507</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adverse events</style></keyword><keyword><style face="normal" font="default" size="100%">Crisis resource management (CRM)</style></keyword><keyword><style face="normal" font="default" size="100%">Human factor skills</style></keyword><keyword><style face="normal" font="default" size="100%">In-hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Medical simulation</style></keyword><keyword><style face="normal" font="default" size="100%">Non-technical skills (NTS)</style></keyword><keyword><style face="normal" font="default" size="100%">Qualified healthcare team</style></keyword><keyword><style face="normal" font="default" size="100%">Simulation-based training</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Teamwork</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 7</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">2059-0628 (Electronic)&#xD;2059-0628 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35526061</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Simulation-based training used to train healthcare teams&apos; skills and improve clinical practice has evolved in recent decades. While it is evident that technical skills training is beneficial, the potential of human factor training has not been described to the same extent. Research on human factor training has been limited to marginal and acute care scenarios and often to validate instruments. This systematic review aimed to investigate the effectiveness of simulation-based training in improving in-hospital qualified healthcare teams&apos; human factor skills. METHOD: A review protocol outlining the study was registered in PROSPERO. Using the PRISMA guidelines, the systematic search was conducted on September 28th, 2021, in eight major scientific databases. Three independent reviewers assessed title and abstract screening; full texts were evaluated by one reviewer. Content analysis was used to evaluate the evidence from the included studies. RESULTS: The search yielded 19,767 studies, of which 72 were included. The included studies were published between 2004 and 2021 and covered research from seven different in-hospital medical specialisms. Studies applied a wide range of assessment tools, which made it challenging to compare the effectiveness of human factor skills training across studies. The content analysis identified evidence for the effectiveness. Four recurring themes were identified: (1) Training human factor skills in qualified healthcare teams; (2) assessment of human factor skills; (3) combined teaching methods, and (4) retention and transfer of human factor skills. Unfortunately, the human factor skills assessments are variable in the literature, affecting the power of the result. CONCLUSION: Simulation-based training is a successful learning tool to improve qualified healthcare teams&apos; human factor skills. Human factor skills are not innate and appear to be trainable similar to technical skills, based on the findings of this review. Moreover, research on retention and transfer is insufficient. Further, research on the retention and transfer of human factor skills from simulation-based training to clinical practice is essential to gain knowledge of the effect on patient safety.</style></abstract><notes><style face="normal" font="default" size="100%">Abildgren, Lotte&#xD;Lebahn-Hadidi, Malte&#xD;Mogensen, Christian Backer&#xD;Toft, Palle&#xD;Nielsen, Anders Bo&#xD;Frandsen, Tove Faber&#xD;Steffensen, Sune Vork&#xD;Hounsgaard, Lise&#xD;eng&#xD;England&#xD;2022/05/08&#xD;Adv Simul (Lond). 2022 May 7;7(1):12. doi: 10.1186/s41077-022-00207-2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35526061</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9077986</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s41077-022-00207-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>129</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ivanova, M. Y.</style></author><author><style face="normal" font="default" size="100%">Achenbach, T. M.</style></author><author><style face="normal" font="default" size="100%">Turner, L.</style></author><author><style face="normal" font="default" size="100%">Almqvist, F.</style></author><author><style face="normal" font="default" size="100%">Begovac, I.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Bird, H.</style></author><author><style face="normal" font="default" size="100%">Broberg, A. G.</style></author><author><style face="normal" font="default" size="100%">Cordova Calderon, M. A.</style></author><author><style face="normal" font="default" size="100%">Chahed, M.</style></author><author><style face="normal" font="default" size="100%">Dang, H. M.</style></author><author><style face="normal" font="default" size="100%">Dobrean, A.</style></author><author><style face="normal" font="default" size="100%">Dopfner, M.</style></author><author><style face="normal" font="default" size="100%">Erol, N.</style></author><author><style face="normal" font="default" size="100%">Forns, M.</style></author><author><style face="normal" font="default" size="100%">Guethmundsson, H. S.</style></author><author><style face="normal" font="default" size="100%">Hannesdottir, H.</style></author><author><style face="normal" font="default" size="100%">Hewitt-Ramirez, N.</style></author><author><style face="normal" font="default" size="100%">Kanbayashi, Y.</style></author><author><style face="normal" font="default" size="100%">Karki, S.</style></author><author><style face="normal" font="default" size="100%">Koot, H. M.</style></author><author><style face="normal" font="default" size="100%">Lambert, M. C.</style></author><author><style face="normal" font="default" size="100%">Leung, P.</style></author><author><style face="normal" font="default" size="100%">Magai, D. N.</style></author><author><style face="normal" font="default" size="100%">Maggiolini, A.</style></author><author><style face="normal" font="default" size="100%">Metzke, C. W.</style></author><author><style face="normal" font="default" size="100%">Minaei, A.</style></author><author><style face="normal" font="default" size="100%">Monzani da Rocha, M.</style></author><author><style face="normal" font="default" size="100%">Moreira, P. A. S.</style></author><author><style face="normal" font="default" size="100%">Mulatu, M. S.</style></author><author><style face="normal" font="default" size="100%">Novik, T. S.</style></author><author><style face="normal" font="default" size="100%">Oh, K. J.</style></author><author><style face="normal" font="default" size="100%">Petot, D.</style></author><author><style face="normal" font="default" size="100%">Petot, J. M.</style></author><author><style face="normal" font="default" size="100%">Pisa, C.</style></author><author><style face="normal" font="default" size="100%">Pomalima, R.</style></author><author><style face="normal" font="default" size="100%">Roussos, A.</style></author><author><style face="normal" font="default" size="100%">Rudan, V.</style></author><author><style face="normal" font="default" size="100%">Sawyer, M. G.</style></author><author><style face="normal" font="default" size="100%">Shahini, M.</style></author><author><style face="normal" font="default" size="100%">Simsek, Z.</style></author><author><style face="normal" font="default" size="100%">Steinhausen, H. C.</style></author><author><style face="normal" font="default" size="100%">Verhulst, F. C.</style></author><author><style face="normal" font="default" size="100%">Weintraub, S.</style></author><author><style face="normal" font="default" size="100%">Weiss, B.</style></author><author><style face="normal" font="default" size="100%">Wolanczyk, T.</style></author><author><style face="normal" font="default" size="100%">Zhang, E. Y.</style></author><author><style face="normal" font="default" size="100%">Zilber, N.</style></author><author><style face="normal" font="default" size="100%">Zukauskiene, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry, University of Vermont, Burlington, VT, USA.&#xD;Department of Child Psychiatry, Helsinki University Hospital, Helsinki, Finland.&#xD;Department of Psychiatry and Psychological Medicine, School of Medicine, Clinical Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.&#xD;Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry, Columbia University, New York, NY, USA.&#xD;Department of Psychology, University of Gothenburg, Gothenburg, Sweden.&#xD;Department of Psychology, Fiscalia Provincial of Orellana, Puerto Francisco de Orellana, Ecuador.&#xD;Department of Psychology, Universite Paris-Nanterre, Paris, France.&#xD;VNU University of Education, Hanoi, Vietnam.&#xD;Department of Clinical Psychology and Psychotherapy, Babes-Bolyai University, Cluj-Napoca, Romania.&#xD;Department of Psychiatry and Psychotherapy of Childhood and Adolescence, University of Cologne, Cologne, Germany.&#xD;Department of Mental Health and Illness, Ankara University, Ankara, Turkey.&#xD;Department of Personality, Assessment and Psychological Treatment, University of Barcelona, Barcelona, Spain.&#xD;Faculty of Social Work, University of Iceland, Reykjavik, Iceland.&#xD;Landspitali University Hospital, Reykjavik, Iceland.&#xD;Psychology Department, University of San Buenaventura, Bogota, Colombia.&#xD;Faculty of Letters, Chuo University, Hachioji, Japan.&#xD;Department of Nursing Science, University of Eastern Finland, Kuopio, Finland.&#xD;Department of Clinical, Neuro- and Developmental Psychology, Vrije Universiteit, Amsterdam, The Netherlands.&#xD;School of Social Work, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.&#xD;Department of Psychology, Chinese University of Hong Kong, Hong Kong, China.&#xD;Minotauro Istituto Di Analisi Dei Codici Affettivi, Milan, Italy.&#xD;Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland.&#xD;Department of Educational and Psychological Measurement, Allameh Tabataba&apos;i University, Tehran, Iran.&#xD;Centro de Ciencias Biologicas e da Saude (CCBS), Universidade Presbiteriana Mackenzie, Sao Paulo, Brazil.&#xD;Instituto de Psicologia e Ciencias da Educacao, Centro de Investigacao em Psicologia para o Desenvolvimento (CIPD), Universidade Lusiada Norte (Porto), Porto, Portugal.&#xD;National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.&#xD;Department of Child and Adolescent Psychiatry, St. Olav University Hospital, Trondheim, Norway.&#xD;Regional Centre for Child and Youth Mental Health and Child Welfare, Norwegian University of Science and Technology, Trondheim, Norway.&#xD;Department of Psychology, Yonsei University, Seoul, South Korea.&#xD;Instituto Nacional de Salud Mental Honorio Delgado Hideyo Noguchi, Lima, Peru.&#xD;Attiki Child Psychiatric Hospital, Athens, Greece.&#xD;School of Psychology and Adelaide Medical School, University of Adelaide, Adelaide, Australia.&#xD;Faculty of Psychology, AAB College, Prishtine, Kosovo.&#xD;Faculty of Health Sciences, Istanbul Bilgi University, Istanbul, Turkey.&#xD;Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands.&#xD;Child and Adolescent Mental Health Center, Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark.&#xD;Department of Psychology and Human Development, Vanderbilt University, Nashville, TN, USA.&#xD;Department of Child Psychiatry, Medical University of Warsaw, Warsaw, Poland.&#xD;Institute of Psychology, Chinese Academy of Sciences, Beijing, China.&#xD;Kfar Shaul Mental Health Center, Falk Institute for Mental Health Studies, Jerusalem, Israel.&#xD;Institute of Psychology, Mykolas Romeris University, Vilnius, Lithuania.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of individual differences, society, and culture on youth-rated problems and strengths in 38 societies</style></title><secondary-title><style face="normal" font="default" size="100%">J Child Psychol Psychiatry</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1297-1307</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">20220215</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Individuality</style></keyword><keyword><style face="normal" font="default" size="100%">*Parents/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Self Report</style></keyword><keyword><style face="normal" font="default" size="100%">Individual differences</style></keyword><keyword><style face="normal" font="default" size="100%">Youth Self-Report</style></keyword><keyword><style face="normal" font="default" size="100%">multicultural</style></keyword><keyword><style face="normal" font="default" size="100%">psychopathology</style></keyword><keyword><style face="normal" font="default" size="100%">strengths</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1469-7610 (Electronic)&#xD;0021-9630 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35167140</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clinicians increasingly serve youths from societal/cultural backgrounds different from their own. This raises questions about how to interpret what such youths report. Rescorla et al. (2019, European Child &amp; Adolescent Psychiatry, 28, 1107) found that much more variance in 72,493 parents&apos; ratings of their offspring&apos;s mental health problems was accounted for by individual differences than by societal or cultural differences. Although parents&apos; reports are essential for clinical assessment of their offspring, they reflect parents&apos; perceptions of the offspring. Consequently, clinical assessment also requires self-reports from the offspring themselves. To test effects of individual differences, society, and culture on youths&apos; self-ratings of their problems and strengths, we analyzed Youth Self-Report (YSR) scores for 39,849 11-17 year olds in 38 societies. METHODS: Indigenous researchers obtained YSR self-ratings from population samples of youths in 38 societies representing 10 culture cluster identified in the Global Leadership and Organizational Behavioral Effectiveness study. Hierarchical linear modeling of scores on 17 problem scales and one strengths scale estimated the percent of variance accounted for by individual differences (including measurement error), society, and culture cluster. ANOVAs tested age and gender effects. RESULTS: Averaged across the 17 problem scales, individual differences accounted for 92.5% of variance, societal differences 6.0%, and cultural differences 1.5%. For strengths, individual differences accounted for 83.4% of variance, societal differences 10.1%, and cultural differences 6.5%. Age and gender had very small effects. CONCLUSIONS: Like parents&apos; ratings, youths&apos; self-ratings of problems were affected much more by individual differences than societal/cultural differences. Most variance in self-rated strengths also reflected individual differences, but societal/cultural effects were larger than for problems, suggesting greater influence of social desirability. The clinical significance of individual differences in youths&apos; self-reports should thus not be minimized by societal/cultural differences, which-while important-can be taken into account with appropriate norms, as can gender and age differences.</style></abstract><notes><style face="normal" font="default" size="100%">Ivanova, Masha Y&#xD;Achenbach, Thomas M&#xD;Turner, Lori&#xD;Almqvist, Fredrik&#xD;Begovac, Ivan&#xD;Bilenberg, Niels&#xD;Bird, Hector&#xD;Broberg, Anders G&#xD;Cordova Calderon, Mery A&#xD;Chahed, Myriam&#xD;Dang, Hoang-Minh&#xD;Dobrean, Anca&#xD;Dopfner, Mandred&#xD;Erol, Nese&#xD;Forns, Maria&#xD;Guethmundsson, Halldor S&#xD;Hannesdottir, Helga&#xD;Hewitt-Ramirez, Nohelia&#xD;Kanbayashi, Yasuko&#xD;Karki, Suyen&#xD;Koot, Hans M&#xD;Lambert, Michael C&#xD;Leung, Patrick&#xD;Magai, Dorcas N&#xD;Maggiolini, Alfio&#xD;Metzke, Christa Winkler&#xD;Minaei, Asghar&#xD;Monzani da Rocha, Marina&#xD;Moreira, Paulo A S&#xD;Mulatu, Mesfin S&#xD;Novik, Torunn Stene&#xD;Oh, Kyung Ja&#xD;Petot, Djaouida&#xD;Petot, Jean-Michel&#xD;Pisa, Cecilia&#xD;Pomalima, Rolando&#xD;Roussos, Alexandra&#xD;Rudan, Vlasta&#xD;Sawyer, Michael G&#xD;Shahini, Mimoza&#xD;Simsek, Zeynep&#xD;Steinhausen, Hans-Christoph&#xD;Verhulst, Frank C&#xD;Weintraub, Sheila&#xD;Weiss, Bahr&#xD;Wolanczyk, Tomasz&#xD;Zhang, Eugene Yuqing&#xD;Zilber, Nelly&#xD;Zukauskiene, Rita&#xD;eng&#xD;England&#xD;2022/02/16&#xD;J Child Psychol Psychiatry. 2022 Nov;63(11):1297-1307. doi: 10.1111/jcpp.13569. Epub 2022 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35167140</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jcpp.13569</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>130</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mohammadzadeh, P.</style></author><author><style face="normal" font="default" size="100%">Rosenberg, J. B.</style></author><author><style face="normal" font="default" size="100%">Vinding, R.</style></author><author><style face="normal" font="default" size="100%">Mollegaard Jepsen, J. R.</style></author><author><style face="normal" font="default" size="100%">Lindberg, U.</style></author><author><style face="normal" font="default" size="100%">Folsgaard, N.</style></author><author><style face="normal" font="default" size="100%">Erlang Sorensen, M.</style></author><author><style face="normal" font="default" size="100%">Sulaiman, D.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Mitta Raghava, J.</style></author><author><style face="normal" font="default" size="100%">Fagerlund, B.</style></author><author><style face="normal" font="default" size="100%">Vestergaard, M.</style></author><author><style face="normal" font="default" size="100%">Pantelis, C.</style></author><author><style face="normal" font="default" size="100%">Stokholm, J.</style></author><author><style face="normal" font="default" size="100%">Chawes, B.</style></author><author><style face="normal" font="default" size="100%">Larsson, H.</style></author><author><style face="normal" font="default" size="100%">Glenthoj, B. Y.</style></author><author><style face="normal" font="default" size="100%">Bonnelykke, K.</style></author><author><style face="normal" font="default" size="100%">Ebdrup, B. H.</style></author><author><style face="normal" font="default" size="100%">Bisgaard, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Neuropsychiatric Schizophrenia Research (CNSR) &amp; Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.&#xD;Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.&#xD;Functional Imaging Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet Glostrup, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;Department of Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychology, University of Copenhagen, Copenhagen, Denmark.&#xD;Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia.&#xD;Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark bisgaard@copsac.com.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of prenatal nutrient supplementation and early life exposures on neurodevelopment at age 10: a randomised controlled trial - the COPSYCH study protocol</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Open</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e047706</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20220201</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary Supplements</style></keyword><keyword><style face="normal" font="default" size="100%">*Fatty Acids, Omega-3</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins</style></keyword><keyword><style face="normal" font="default" size="100%">*child &amp; adolescent psychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">*mental health</style></keyword><keyword><style face="normal" font="default" size="100%">*paediatric infectious disease &amp; immunisation</style></keyword><keyword><style face="normal" font="default" size="100%">*paediatric radiology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 1</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">BMJ</style></publisher><isbn><style face="normal" font="default" size="100%">2044-6055 (Electronic)&#xD;2044-6055 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35105560</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Nutrient deficiency and immune and inflammatory disturbances in early life may compromise neurodevelopment and be implicated in the aetiology of psychiatric disorders. However, current evidence is limited by its predominantly observational nature. COpenhagen Prospective Study on Neuro-PSYCHiatric Development (COPSYCH) is a research alliance between Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research with the overall aim to investigate effects of prenatal and early life exposures on neurodevelopment at 10 years. COPSYCH will investigate the impact of prenatal n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA) and high-dose vitamin D supplementation on neurodevelopment reflected by brain development, neurocognition and psychopathology. Moreover, the neurodevelopmental impact of early life exposures such as infections, low grade inflammation and the gut microbiome will be scrutinised. METHODS AND ANALYSIS: COPSYCH is based on the prospective and ongoing COPSAC(2010) birth cohort of 700 mother-child pairs. Randomised controlled trials of supplementation with n-3 LCPUFA and/or high-dose vitamin D or placebo in the third trimester were embedded in a factorial 2x2 design (ClinicalTrials.gov: NCT01233297 and NCT00856947). This unique cohort provides deep phenotyping data from 14 previous clinical follow-up visits and exposure assessments since birth. The ongoing 10-year visit is a 2-day visit. Day 1 includes a comprehensive neurocognitive examination, and assessment of psychopathological dimensions, and assessment of categorical psychopathology. Day 2 includes acquisition of brain structural, diffusion and functional sequences using 3 Tesla MRI. Study outcomes are neurocognitive, psychopathological and MRI measures. ETHICS AND DISSEMINATION: This study has been approved by the Danish National Committee on Health Research Ethics and The Danish Data Protection Agency. The study is conducted in accordance with the guiding principles of the Declaration of Helsinki. Parents gave written informed consent before enrolment.</style></abstract><notes><style face="normal" font="default" size="100%">Mohammadzadeh, Parisa&#xD;Rosenberg, Julie Bojstrup&#xD;Vinding, Rebecca&#xD;Mollegaard Jepsen, Jens Richardt&#xD;Lindberg, Ulrich&#xD;Folsgaard, Nilo&#xD;Erlang Sorensen, Mikkel&#xD;Sulaiman, Daban&#xD;Bilenberg, Niels&#xD;Mitta Raghava, Jayachandra&#xD;Fagerlund, Birgitte&#xD;Vestergaard, Mark&#xD;Pantelis, Christos&#xD;Stokholm, Jakob&#xD;Chawes, Bo&#xD;Larsson, Henrik&#xD;Glenthoj, Birte Yding&#xD;Bonnelykke, Klaus&#xD;Ebdrup, Bjorn H&#xD;Bisgaard, Hans&#xD;eng&#xD;Clinical Trial Protocol&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/02/03&#xD;BMJ Open. 2022 Feb 1;12(2):e047706. doi: 10.1136/bmjopen-2020-047706.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35105560</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Competing interests: BHE is part of the Advisory Board of Eli Lilly Denmark A/S, JanssenCilag, Lundbeck Pharma A/S and Takeda Pharmaceutical Company; and has received lecture fees from Bristol Myers Squibb, Otsuka Pharma Scandinavia AB, Eli Lilly Company, Boehringer Ingelheim Danmark A/S and Lundbeck Pharma A/S.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8808389</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmjopen-2020-047706</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>131</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">131</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sivasaravanaparan, M.</style></author><author><style face="normal" font="default" size="100%">Olesen, L. O.</style></author><author><style face="normal" font="default" size="100%">Severino, M.</style></author><author><style face="normal" font="default" size="100%">von Linstow, C. U.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Gramsbergen, J. B.</style></author><author><style face="normal" font="default" size="100%">Hasselstrom, J.</style></author><author><style face="normal" font="default" size="100%">Metaxas, A.</style></author><author><style face="normal" font="default" size="100%">Wiborg, O.</style></author><author><style face="normal" font="default" size="100%">Finsen, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Denmark.&#xD;Department of Clinical Medicine, Aarhus University Hospital, Denmark.&#xD;Department of Neurology, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, University of Southern Denmark, Denmark.&#xD;Forensic Chemistry Department, Aarhus University, Denmark.&#xD;Department of Life Sciences, School of Science, European University Cyprus, Nicosia, Cyprus.&#xD;Department of Health Science and Technology, Aalborg University, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of Chronic Paroxetine Treatment in Mitigating Amyloid Pathology and Microgliosis in APPSWE/PS1DeltaE9 Transgenic Mice</style></title><secondary-title><style face="normal" font="default" size="100%">J Alzheimers Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Alzheimers Dis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">685-699</style></pages><volume><style face="normal" font="default" size="100%">87</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/complications/drug therapy/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid beta-Peptides/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Amyloid beta-Protein Precursor/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">*Amyloidosis</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Transgenic</style></keyword><keyword><style face="normal" font="default" size="100%">Paroxetine/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Plaque, Amyloid/drug therapy/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Presenilin-1/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin Plasma Membrane Transport Proteins/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral amyloidosis</style></keyword><keyword><style face="normal" font="default" size="100%">Y-maze</style></keyword><keyword><style face="normal" font="default" size="100%">chronic paroxetine treatment</style></keyword><keyword><style face="normal" font="default" size="100%">hippocampus</style></keyword><keyword><style face="normal" font="default" size="100%">microgliosis</style></keyword><keyword><style face="normal" font="default" size="100%">neurogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin selective reuptake inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">serotonin transporter occupancy</style></keyword><keyword><style face="normal" font="default" size="100%">stereology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">IOS Press</style></publisher><isbn><style face="normal" font="default" size="100%">1875-8908 (Electronic)&#xD;1387-2877 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35342093</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Modulation of serotonergic signaling by treatment with selective serotonin reuptake inhibitors (SSRIs) has been suggested to mitigate amyloid-beta (Abeta) pathology in Alzheimer&apos;s disease, in addition to exerting an anti-depressant action. OBJECTIVE: To investigate the efficacy of chronic treatment with the SSRI paroxetine, in mitigating Abeta pathology and Abeta plaque-induced microgliosis in the hippocampus of 18-month-old APPswe/PS1DeltaE9 mice. METHODS: Plaque-bearing APPswe/PS1DeltaE9 and wildtype mice were treated with paroxetine per os at a dose of 5 mg/kg/day, from 9 to 18 months of age. The per os treatment was monitored by recording of the body weights and serum paroxetine concentrations, and by assessment of the serotonin transporter occupancy by [3H]DASB-binding in wildtype mice. Additionally, 5,7-dihydroxytryptamine was administered to 9-month-old APPswe/PS1DeltaE9 mice, to examine the effect of serotonin depletion on Abeta pathology. Abeta pathology was evaluated by Abeta plaque load estimation and the Abeta42/Abeta40 ratio by ELISA. RESULTS: Paroxetine treatment led to &gt; 80% serotonin transporter occupancy. The treatment increased the body weight of wildtype mice, but not of APPswe/PS1DeltaE9 mice. The treatment had no effect on the Abeta plaque load (p = 0.39), the number and size of plaques, or the Abeta plaque-induced increases in microglial numbers in the dentate gyrus. Three months of serotonin depletion did not significantly impact the Abeta plaque load or Abeta42/Abeta40 ratio in APPswe/PS1DeltaE9 mice at 12 months. CONCLUSION: Our results show that chronic treatment with the SSRI paroxetine does not mitigate Abeta pathology and Abeta plaque-induced microgliosis in the hippocampus of APPswe/PS1DeltaE9 mice.</style></abstract><notes><style face="normal" font="default" size="100%">Sivasaravanaparan, Mithula&#xD;Olesen, Louise Orum&#xD;Severino, Maurizio&#xD;von Linstow, Christian Ulrich&#xD;Lambertsen, Kate Lykke&#xD;Gramsbergen, Jan Bert&#xD;Hasselstrom, Jorgen&#xD;Metaxas, Athanasios&#xD;Wiborg, Ove&#xD;Finsen, Bente&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;2022/03/29&#xD;J Alzheimers Dis. 2022;87(2):685-699. doi: 10.3233/JAD-220019.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35342093</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3233/JAD-220019</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>132</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Langeskov-Christensen, M.</style></author><author><style face="normal" font="default" size="100%">Hvid, L. G.</style></author><author><style face="normal" font="default" size="100%">Jensen, H. B.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H. H.</style></author><author><style face="normal" font="default" size="100%">Petersen, T.</style></author><author><style face="normal" font="default" size="100%">Stenager, E.</style></author><author><style face="normal" font="default" size="100%">Dalgas, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Exercise Biology, Department of Public Health, Aarhus University, Aarhus, Denmark.&#xD;Brain and Nerve Diseases, Lillebaelt Hospital, Kolding, Denmark.&#xD;Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Neurology, Odense University Hospital, Odense, Denmark.&#xD;BRIDGE - Brain Research - Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;The Multiple Sclerosis Clinic, Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of high-intensity aerobic exercise on common multiple sclerosis symptoms</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurol Scand</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurol Scand</style></full-title></periodical><pages><style face="normal" font="default" size="100%">229-238</style></pages><volume><style face="normal" font="default" size="100%">145</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20211022</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">Fatigue/etiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiple Sclerosis/complications/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Walking</style></keyword><keyword><style face="normal" font="default" size="100%">aerobic training</style></keyword><keyword><style face="normal" font="default" size="100%">exercise therapy</style></keyword><keyword><style face="normal" font="default" size="100%">fatigue</style></keyword><keyword><style face="normal" font="default" size="100%">rehabilitation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1600-0404 (Electronic)&#xD;0001-6314 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34687036</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Fatigue and walking impairment are disabling symptoms of multiple sclerosis (MS). We investigated the effects of progressive aerobic exercise (PAE) on fatigue, walking, cardiorespiratory fitness (VO(2) max), and quality of life in people with MS (pwMS). MATERIALS &amp; METHODS: Randomized controlled trial (1:1 ratio, stratified by sex) with a 24-week crossover follow-up and intention-to-treat analysis. Allocation to an exercise (24 weeks of PAE followed by self-guided physical activity) and a waitlist (24 weeks of habitual lifestyle followed by PAE) group. PAE comprised two supervised sessions per week; 30-60 min, 65-95% of maximum heart rate. Fatigue impact (Modified Fatigue Impact Scale; MFIS) and severity (Fatigue Severity Scale; FSS), walking ability (12-item MS Walking Scale; MSWS-12) and capacity (Six-Minute Walk Test; 6MWT, Six Spot Step Test; SSST), quality of life (Short Form 36 health survey; SF-36), and VO(2) max were measured at baseline, 24 weeks, and 48 weeks. RESULTS: Eighty-six pwMS were enrolled. Following PAE between-group differences showed reductions in MFIS(total) (-5.3 [95% CI: -10.9;0.4], point estimate &gt;clinical relevance), MFIS(physical) subscore (-2.8 [-5.6;-0.1]), and MFIS(psychosocial) subscore (-0.9 [-1.6;-0.2]), and an increase in VO(2) max (+3.5 ml O(2) /min/kg [2.0;5.1]). MSWS-12 (-5.9 [-11.9; 0.2]) and 6MWT (+14 m [-5;33]) differences suggested potential small walking improvements. No changes observed in FSS, SSST, or SF-36. CONCLUSIONS: In a representative sample of pwMS, PAE induced a clinically relevant reduction in fatigue impact, whereas small and no effects were seen for walking and quality of life, respectively. The results need confirmation in a future trial due to the study limitations.</style></abstract><notes><style face="normal" font="default" size="100%">Langeskov-Christensen, Martin&#xD;Hvid, Lars Grondahl&#xD;Jensen, Henrik Boye&#xD;Nielsen, Helle Hvilsted&#xD;Petersen, Thor&#xD;Stenager, Egon&#xD;Dalgas, Ulrik&#xD;eng&#xD;Jascha Foundation; Foundation for Research in Neurology/&#xD;A34935/The Danish Multiple Sclerosis Society/&#xD;Aase and Ejnar Danielsens Foundation/&#xD;Knud and Edith Eriksens Foundation/&#xD;Augustinus Foundation/&#xD;Direktor Emil C. Hertz og Hustru Inger Hertz&apos; Fond/&#xD;Else and Mogens Wedell-Wedellsborgs Foundation/&#xD;Karen A. Tolstrups Foundation/&#xD;Randomized Controlled Trial&#xD;Denmark&#xD;2021/10/24&#xD;Acta Neurol Scand. 2022 Feb;145(2):229-238. doi: 10.1111/ane.13540. Epub 2021 Oct 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34687036</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ane.13540</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>232</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">232</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schriver, Karen Nissen</style></author><author><style face="normal" font="default" size="100%">Ong, Ben</style></author><author><style face="normal" font="default" size="100%">Rossen, Camilla Blach</style></author><author><style face="normal" font="default" size="100%">Buus, Niels</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Empathic my side tellings: Three therapist strategies that argue understanding in open dialogue reflections</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pragmatics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pragmatics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">44-53</style></pages><volume><style face="normal" font="default" size="100%">196</style></volume><section><style face="normal" font="default" size="100%">44</style></section><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">03782166</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.pragma.2022.05.004</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>228</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">228</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bruun, H.</style></author><author><style face="normal" font="default" size="100%">Milling, L.</style></author><author><style face="normal" font="default" size="100%">Mikkelsen, S.</style></author><author><style face="normal" font="default" size="100%">Huniche, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Prehospital Research Unit, Region of Southern Denmark, Odense University Hospital, Odense, Denmark. Henriette.Bruun@rsyd.dk.&#xD;Psychiatric Department Middelfart, Mental Health Services in the Region of Southern Denmark, Middelfart, Denmark. Henriette.Bruun@rsyd.dk.&#xD;The Prehospital Research Unit, Region of Southern Denmark, Odense University Hospital, Odense, Denmark.&#xD;The Mobile Emergency Care Unit, Department Anaesthesiology and Intensive Care Medicine, Odense University Hospital, Odense, Denmark.&#xD;Department of Psychology, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ethical challenges experienced by prehospital emergency personnel: a practice-based model of analysis</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Med Ethics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Med Ethics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">80</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220812</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Allied Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Death</style></keyword><keyword><style face="normal" font="default" size="100%">*Emergency Medical Services</style></keyword><keyword><style face="normal" font="default" size="100%">Focus Groups</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Morals</style></keyword><keyword><style face="normal" font="default" size="100%">Challenges</style></keyword><keyword><style face="normal" font="default" size="100%">Emergency</style></keyword><keyword><style face="normal" font="default" size="100%">Ethics</style></keyword><keyword><style face="normal" font="default" size="100%">Prehospital</style></keyword><keyword><style face="normal" font="default" size="100%">Qualitative research</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 12</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1472-6939 (Electronic)&#xD;1472-6939 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35962434</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Ethical challenges constitute an inseparable part of daily decision-making processes in all areas of healthcare. In prehospital emergency medicine, decision-making commonly takes place in everyday life, under time pressure, with limited information about a patient and with few possibilities of consultation with colleagues. This paper explores the ethical challenges experienced by prehospital emergency personnel. METHODS: The study was grounded in the tradition of action research related to interventions in health care. Ethical challenges were explored in three focus groups, each attended by emergency medical technicians, paramedics, and prehospital anaesthesiologists. The participants, 15 in total, were recruited through an internal information network of the emergency services. Focus groups were audio-recorded and transcribed verbatim. RESULTS: The participants described ethical challenges arising when clinical guidelines, legal requirements, and clinicians&apos; professional and personal value systems conflicted and complicated decision-making processes. The challenges centred around treatment at the end of life, intoxicated and non-compliant patients, children as patients-and their guardians, and the collaboration with relatives in various capacities. Other challenges concerned guarding the safety of oneself, colleagues and bystanders, prioritising scarce resources, and staying loyal to colleagues with different value systems. Finally, challenges arose when summoned to situations where other professionals had failed to make a decision or take action when attending to patients whose legitimate needs were not met by the appropriate medical or social services, and when working alongside representatives of authorities with different roles, responsibilities and tasks. CONCLUSION: From the perspective of the prehospital emergency personnel, ethical challenges arise in three interrelated contexts: when caring for patients, in the prehospital emergency unit, and during external collaboration. Value conflicts may be identified within these contexts as well as across them. A proposed model of analysis integrating the above contexts can assist in shedding light on ethical challenges and value conflicts in other health care settings. The model emphasises that ethical challenges are experienced from a particular professional perspective, in the context of the task at hand, and in a particular, the organisational setting that includes work schedules, medical guidelines, legal requirements, as well as professional and personal value systems.</style></abstract><notes><style face="normal" font="default" size="100%">Bruun, Henriette&#xD;Milling, Louise&#xD;Mikkelsen, Soren&#xD;Huniche, Lotte&#xD;eng&#xD;England&#xD;2022/08/13&#xD;BMC Med Ethics. 2022 Aug 12;23(1):80. doi: 10.1186/s12910-022-00821-9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35962434</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">All authors declare that they have no conflicts of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9373324</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12910-022-00821-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>253</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">253</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Oxholm, C.</style></author><author><style face="normal" font="default" size="100%">Christensen, A. S.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for the Study of Culture, Faculty of Humanities, University of Southern Denmark, 5230Odense, Denmark.&#xD;Clinical Alcohol Research Unit, Department of Clinical Research, Faculty of Health, University of Southern Denmark, 5230Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Ethics of Algorithms in Healthcare</style></title><secondary-title><style face="normal" font="default" size="100%">Camb Q Healthc Ethics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Camb Q Healthc Ethics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">119-130</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">Decision Making</style></keyword><keyword><style face="normal" font="default" size="100%">Delivery of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Morals</style></keyword><keyword><style face="normal" font="default" size="100%">*Privacy</style></keyword><keyword><style face="normal" font="default" size="100%">black box</style></keyword><keyword><style face="normal" font="default" size="100%">clinical decision support algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">clinical decision-making algorithms</style></keyword><keyword><style face="normal" font="default" size="100%">data</style></keyword><keyword><style face="normal" font="default" size="100%">ethics</style></keyword><keyword><style face="normal" font="default" size="100%">patient-centered</style></keyword><keyword><style face="normal" font="default" size="100%">patient-practitioner relationship</style></keyword><keyword><style face="normal" font="default" size="100%">privacy</style></keyword><keyword><style face="normal" font="default" size="100%">professional autonomy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1469-2147 (Electronic)&#xD;0963-1801 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35049457</style></accession-num><abstract><style face="normal" font="default" size="100%">The amount of data available to healthcare practitioners is growing, and the rapid increase in available patient data is becoming a problem for healthcare practitioners, as they are often unable to fully survey and process the data relevant for the treatment or care of a patient. Consequently, there are currently several efforts to develop systems that can aid healthcare practitioners with reading and processing patient data and, in this way, provide them with a better foundation for decision-making about the treatment and care of patients. There are also efforts to develop algorithms that provide suggestions for such decisions. However, the development of these systems and algorithms raises several concerns related to the privacy of patients, the patient-practitioner relationship, and the autonomy of healthcare practitioners. The aim of this article is to provide a foundation for understanding the ethical challenges related to the development of a specific form of data-processing systems, namely clinical algorithms.</style></abstract><notes><style face="normal" font="default" size="100%">Oxholm, Christina&#xD;Christensen, Anne-Marie S&#xD;Nielsen, Anette S&#xD;eng&#xD;2022/01/21&#xD;Camb Q Healthc Ethics. 2022 Jan;31(1):119-130. doi: 10.1017/S0963180121000864.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35049457</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S0963180121000864</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pedersen, M. L.</style></author><author><style face="normal" font="default" size="100%">Gildberg, F.</style></author><author><style face="normal" font="default" size="100%">Baker, J.</style></author><author><style face="normal" font="default" size="100%">Damsgaard, J. B.</style></author><author><style face="normal" font="default" size="100%">Tingleff, E. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health, Aarhus University, Bartholins Alle 2, 8000, Aarhus C, Denmark. marlpedersen@health.sdu.dk.&#xD;Forensic Mental Health Research Unit Middelfart (RFM), Department of Regional Health Research, Faculty of Health Science, University of Southern Denmark, Ostre Hougvej 70, 5500, Middelfart, Denmark. marlpedersen@health.sdu.dk.&#xD;Psychiatric Department Middelfart, Mental Health Services in the Region of Southern Denmark, Ostre Hougvej 70, 5500, Middelfart, Denmark. marlpedersen@health.sdu.dk.&#xD;Forensic Mental Health Research Unit Middelfart (RFM), Department of Regional Health Research, Faculty of Health Science, University of Southern Denmark, Ostre Hougvej 70, 5500, Middelfart, Denmark.&#xD;Psychiatric Department Middelfart, Mental Health Services in the Region of Southern Denmark, Ostre Hougvej 70, 5500, Middelfart, Denmark.&#xD;School of Healthcare, University of Leeds, Baines Wing, Woodhouse Lane, Leeds, LS2 9JT, UK.&#xD;Department of Public Health, Aarhus University, Bartholins Alle 2, 8000, Aarhus C, Denmark.&#xD;OPEN, Odense Patient Data Explorative Network, Odense University Hospital/Department of Clinical Research, University of Southern Denmark, J.B. Winslows Vej 9 A, 5000, Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ethnic disparities in the use of restrictive practices in adult mental health inpatient settings: a scoping review</style></title><secondary-title><style face="normal" font="default" size="100%">Soc Psychiatry Psychiatr Epidemiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Soc Psychiatry Psychiatr Epidemiol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-18</style></pages><edition><style face="normal" font="default" size="100%">20221201</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Ethnicity</style></keyword><keyword><style face="normal" font="default" size="100%">Manual restraint</style></keyword><keyword><style face="normal" font="default" size="100%">Mechanical restraint</style></keyword><keyword><style face="normal" font="default" size="100%">Psychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">Rapid tranquillisation</style></keyword><keyword><style face="normal" font="default" size="100%">Seclusion</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 1</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1433-9285 (Electronic)&#xD;0933-7954 (Print)&#xD;0933-7954 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36454269</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: To identify and summarise extant knowledge about patient ethnicity and the use of various types of restrictive practices in adult mental health inpatient settings. METHODS: A scoping review methodological framework recommended by the JBI was used. A systematic search was conducted in APA PsycINFO, CINAHL with Full Text, Embase, PubMed and Scopus. Additionally, grey literature searches were conducted in Google, OpenGrey and selected websites, and the reference lists of included studies were explored. RESULTS: Altogether, 38 studies were included: 34 were primary studies; 4, reviews. The geographical settings were as follows: Europe (n = 26), Western Pacific (n = 8), Americas (n = 3) and South-East Asia (n = 1). In primary studies, ethnicity was reported according to migrant/national status (n = 16), mixed categories (n = 12), indigenous vs. non-indigenous (n = 5), region of origin (n = 1), sub-categories of indigenous people (n = 1) and religion (n = 1). In reviews, ethnicity was not comparable. The categories of restrictive practices included seclusion, which was widely reported across the studies (n = 20), multiple restrictive practices studied concurrently (n = 17), mechanical restraint (n = 8), rapid tranquillisation (n = 7) and manual restraint (n = 1). CONCLUSIONS: Ethnic disparities in restrictive practice use in adult mental health inpatient settings has received some scholarly attention. Evidence suggests that certain ethnic minorities were more likely to experience restrictive practices than other groups. However, extant research was characterised by a lack of consensus and continuity. Furthermore, widely different definitions of ethnicity and restrictive practices were used, which hampers researchers&apos; and clinicians&apos; understanding of the issue. Further research in this field may improve mental health practice.</style></abstract><notes><style face="normal" font="default" size="100%">Pedersen, Martin Locht&#xD;Gildberg, Frederik&#xD;Baker, John&#xD;Damsgaard, Janne Brammer&#xD;Tingleff, Ellen Boldrup&#xD;eng&#xD;Review&#xD;Germany&#xD;2022/12/02&#xD;Soc Psychiatry Psychiatr Epidemiol. 2022 Dec 1:1-18. doi: 10.1007/s00127-022-02387-8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36454269</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9713127</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00127-022-02387-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>282</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">282</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scharff, F. B.</style></author><author><style face="normal" font="default" size="100%">Lau, M. E.</style></author><author><style face="normal" font="default" size="100%">Gondan, M.</style></author><author><style face="normal" font="default" size="100%">Folke, S.</style></author><author><style face="normal" font="default" size="100%">Arendt, I. T. P.</style></author><author><style face="normal" font="default" size="100%">Moeller, S. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stolpegaard Psychotherapy Centre, Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark.&#xD;Department of Psychology, University of Innsbruck, Innsbruck, Austria.&#xD;Danish Veterans Centre, Danish Ministry of Defense, Ringsted, Denmark.&#xD;Clinic for Affective Disorders, Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark.&#xD;Department of Psychology, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of a standardized posttraumatic stress disorder treatment framework in routine mental health care: Effectiveness and predictors of treatment outcome in a consecutive sample</style></title><secondary-title><style face="normal" font="default" size="100%">J Trauma Stress</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Trauma Stress</style></full-title></periodical><pages><style face="normal" font="default" size="100%">827-838</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20220325</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Cognitive Behavioral Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Health</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Stress Disorders, Post-Traumatic/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-6598 (Electronic)&#xD;0894-9867 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35338519</style></accession-num><abstract><style face="normal" font="default" size="100%">The primary aim of the present study was to evaluate the effectiveness of standardized care package (CP) treatment for posttraumatic stress disorder (PTSD) in a Danish sample of adult psychiatric outpatients (N = 948). Secondary aims were to identify baseline predictors of treatment outcomes and investigate between-group differences in outcomes with regard to sex and treatment modality (i.e., group vs. individual therapy). The naturalistic, nonrandomized study followed a pre-post design. Patient data from five psychiatric outpatient clinics were collected between March 2011 and November 2017. Data were drawn from self-report questionnaires (i.e., SCL-90-R, WHO-5, BHS) and therapist-reported measures (i.e., GAF-S, GAF-F) administered at baseline and posttreatment. Between-group effects for sex and therapy modality (group vs. individual) were analyzed using analyses of variance, and possible predictors of outcomes were selected through LASSO regression and analyzed via hierarchical regression. Pre-post effects were small to moderate, ds = 0.39-0.69. No differences emerged regarding treatment modality, but women had significantly better outcomes than men. Aside from sex, only baseline symptom severity predicted outcomes. The effectiveness of the CP treatment was generally limited, indicating the need to implement improved therapeutic practices, such as the use of evidence-based treatments, and to provide better training to mental health clinicians. The findings underscore the need for further comparisons of group and individual treatment modalities using evidence-based therapies as well as the need to investigate factors that may affect treatment outcome.</style></abstract><notes><style face="normal" font="default" size="100%">Scharff, Frederik B&#xD;Lau, Marianne E&#xD;Gondan, Matthias&#xD;Folke, Sofie&#xD;Arendt, Ida-Marie T P&#xD;Moeller, Stine B&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/03/27&#xD;J Trauma Stress. 2022 Jun;35(3):827-838. doi: 10.1002/jts.22790. Epub 2022 Mar 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35338519</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jts.22790</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>134</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Skov, C. D.</style></author><author><style face="normal" font="default" size="100%">Sorensen, C. B.</style></author><author><style face="normal" font="default" size="100%">Thorning, M.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Frich, L. H.</style></author><author><style face="normal" font="default" size="100%">Jensen, H. B.</style></author><author><style face="normal" font="default" size="100%">Holsgaard-Larsen, A.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4 C, Odense 5000, Denmark.&#xD;Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4 C, Odense 5000, Denmark; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern, J.B. Winsloewsvej 21, st. C, Odense 5000, Denmark; BRIDGE - Brain Research - Inter Disciplinary Guided Excellence, Department of Clinical Research, J.B. Winsloewsvej 19, 3. C, Odense 5000, Denmark; Department of Orthopaedics and Traumatology, Odense University Hospital, J.B. Winsloewsvej 4 C, Odense 5000, Denmark; Orthopaedic Research Unit, Department of Clinical Research, University of Southern Denmark, Denmark.&#xD;Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4 C, Odense 5000, Denmark; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern, J.B. Winsloewsvej 21, st. C, Odense 5000, Denmark; BRIDGE - Brain Research - Inter Disciplinary Guided Excellence, Department of Clinical Research, J.B. Winsloewsvej 19, 3. C, Odense 5000, Denmark.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern, J.B. Winsloewsvej 21, st. C, Odense 5000, Denmark; Orthopaedic research Unit, Department of Regional Health Research, University of Southern Denmark.&#xD;Department of Brain and Nerve Diseases, Sygehus Lillebaelt, Kolding, Denmark; Department of Regional Health Research, University of Southern Denmark, Denmark.&#xD;Department of Orthopaedics and Traumatology, Odense University Hospital, J.B. Winsloewsvej 4 C, Odense 5000, Denmark; Orthopaedic Research Unit, Department of Clinical Research, University of Southern Denmark, Denmark.&#xD;Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4 C, Odense 5000, Denmark; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern, J.B. Winsloewsvej 21, st. C, Odense 5000, Denmark; BRIDGE - Brain Research - Inter Disciplinary Guided Excellence, Department of Clinical Research, J.B. Winsloewsvej 19, 3. C, Odense 5000, Denmark. Electronic address: hhnielsen@health.sdu.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study</style></title><secondary-title><style face="normal" font="default" size="100%">Mult Scler Relat Disord</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">104034</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">104034</style></number><edition><style face="normal" font="default" size="100%">20220705</style></edition><keywords><keyword><style face="normal" font="default" size="100%">4-Aminopyridine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Disability Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mobility Limitation</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiple Sclerosis/complications/diagnosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Outcome Assessment, Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Walking/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">2-minute walk test</style></keyword><keyword><style face="normal" font="default" size="100%">4-aminopyridine</style></keyword><keyword><style face="normal" font="default" size="100%">Clinically meaningful improvement</style></keyword><keyword><style face="normal" font="default" size="100%">Edss</style></keyword><keyword><style face="normal" font="default" size="100%">Multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">Subjective outcome</style></keyword><keyword><style face="normal" font="default" size="100%">Walking measures</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">2211-0356 (Electronic)&#xD;2211-0348 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35843140</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: The purpose of this interventional study on participants with multiple sclerosis (MS) with walking disability was to evaluate changes in functional hand and walking measurements after fampridine treatment, after stratifying by the Expanded Disability Status Scale (EDSS). We furthermore wanted to investigate different functional measurements to evaluate their ability to detect responders to fampridine with a clinically relevant improvement. METHODS: Patients were recruited from the MS Clinic at Odense University Hospital and were classified into two disability groups based on their EDSS score (moderate EDSS (EDSS(Mod)) 4.5-5.5 [n = 19] and severe EDSS (EDSS(Sev)) 6.0-7.0 [n = 14]). At baseline (visit 1) they completed the Timed 25-Foot Walk (T25FW), 2-Minute Walk Test (2MWT), Nine Hold Peg Test (9HPT), 12-item Multiple Sclerosis Walking Scale (MSWS-12), and the Six Spot Step Test (SSST). Participants were given 10 mg twice daily fampridine for 14 days before retested (visit 2). For each measurement, cut-off values were used to define responders with a clinically relevant improvement to treatment. The measurements were evaluated separately and in combination. RESULTS: Of the 33 participants, 25 (75.8%) were identified as having a clinically relevant improvement (CRI). For all patients combined (EDSS(All)), all five measurements showed significant functional improvement after treatment. For the individual measurements, the highest participant response rates after 14 days of fampridine treatment were seen on the MSWS-12 (57.6%) and 2MWT (42.4%). The 2MWT also showed the largest performance improvement (18.5%) from visit 1 to visit 2. For patients with severe disability (EDSS(Sev)), no significant improvement was seen after fampridine treatment on the T25FW, and most of the responders to T25FW had moderate disability (EDSS(Mod), 71.5%). Conversely for the SSST, most responders were EDSS(Sev) (83.3%). No participants had a clinically relevant improvement on the 9HPT. The combination of T25FW, SSST, and MSWS-12 was less sensitive in distinguishing responders from non-responders, whereas the combination of 2MWT and MSWS-12 identified the same responders and could better distinguish fampridine responders from non-responders. CONCLUSION: EDSS level did not influence the effect of fampridine treatment on functional hand and walking measures and the responsiveness of the measurements differed only a little between moderate and severe EDSS levels. The combination of self-reported walking capacity (MSWS-12) and walking endurance (2MWT) was better than T25FW, SSST, and MSWS-12 at detecting clinically meaningful improvement after fampridine treatment, which could prove useful in the clinical monitoring of walking disabilities in MS during fampridine treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Skov, Cecilie Dollerup&#xD;Sorensen, Christina Borgen&#xD;Thorning, Maria&#xD;Lambertsen, Kate Lykke&#xD;Frich, Lars Henrik&#xD;Jensen, Henrik Boye&#xD;Holsgaard-Larsen, Anders&#xD;Nielsen, Helle H&#xD;eng&#xD;Netherlands&#xD;2022/07/18&#xD;Mult Scler Relat Disord. 2022 Oct;66:104034. doi: 10.1016/j.msard.2022.104034. Epub 2022 Jul 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35843140</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.msard.2022.104034</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>135</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moeller, A. M.</style></author><author><style face="normal" font="default" size="100%">Hansen, J. P.</style></author><author><style face="normal" font="default" size="100%">Andersen, P. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit for Health Promotion Research, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Research Unit for Telepsychiatry and E-Mental Health, Centre for Telepsychiatry, The Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Psychiatric Research Unit Esbjerg, The Mental Health Services in the Region of Southern Denmark, Esbjerg, Denmark.&#xD;Department of Clinical Research, Center for Clinical Nursing Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Factors that determine mental health professionals&apos; decision to support home-based video consultations - A qualitative study</style></title><secondary-title><style face="normal" font="default" size="100%">Front Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">984026</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20220928</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Grounded Theory</style></keyword><keyword><style face="normal" font="default" size="100%">access</style></keyword><keyword><style face="normal" font="default" size="100%">health care service</style></keyword><keyword><style face="normal" font="default" size="100%">mental health professionals</style></keyword><keyword><style face="normal" font="default" size="100%">video consultation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/9/28</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1664-0640 (Print)&#xD;1664-0640 (Electronic)&#xD;1664-0640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36245860</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Using videoconferencing for consulting with patients in the mental health services has been shown in interventions to be similarly effective as when meeting in person. In practice, it often makes more sense to use video consultations with patients in a more flexible way than interventions permit. The aim of this study was to investigate what constitutes a professional video consultation from the perspectives of mental health professionals and explore what is of importance for the establishment and realization of video consultations in practice. MATERIALS AND METHODS: A Grounded Theory methodology approach based on Corbin and Strauss was used. Data collection consisted of participant observations of introductory events followed by individual interviews with mental health professionals who had used video consultations with patients. FINDINGS: Mental health professionals believed that a professional video consultation was one that was not inferior to an in-person consultation but offered something else, such as more and easier access, accommodating patients&apos; needs and wishes. At the same time, it should not interfere with the treatment quality, e.g., by hampering communication and therapeutic tasks. The expected treatment quality was based on an individual assessment of the patient and varied from clinician to clinician. The implementation process and support which the organization provided affected the clinicians&apos; attitudes as well as the clinicians&apos; experiences and hence how the clinicians assessed the quality of the service. CONCLUSION: Perceived usefulness, patient demands, and close IT support will positively impact the establishment and realization of video consultations whereas high workload and technical problems would hamper it.</style></abstract><notes><style face="normal" font="default" size="100%">Moeller, Anne Marie&#xD;Hansen, Jens Peter&#xD;Andersen, Pernille Tanggaard&#xD;eng&#xD;Switzerland&#xD;2022/10/18&#xD;Front Psychiatry. 2022 Sep 28;13:984026. doi: 10.3389/fpsyt.2022.984026. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36245860</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9553986</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fpsyt.2022.984026</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>225</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">225</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zacher Kjeldsen, M. M.</style></author><author><style face="normal" font="default" size="100%">Bricca, A.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Frokjaer, V. G.</style></author><author><style face="normal" font="default" size="100%">Madsen, K. B.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Department of Public Health, Aarhus University, Aarhus, Denmark.&#xD;Research Unit for Musculoskeletal Function and Physiotherapy, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.&#xD;The Research Unit PROgrez, Department of Physiotherapy and Occupational Therapy, Naestved-Slagelse-Ringsted Hospitals, Slagelse, Denmark.&#xD;Neurobiology Research Unit, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.&#xD;Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark.&#xD;Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Family History of Psychiatric Disorders as a Risk Factor for Maternal Postpartum Depression: A Systematic Review and Meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1004-1013</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Depression, Postpartum/epidemiology/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mothers</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2168-6238 (Electronic)&#xD;2168-622X (Print)&#xD;2168-622X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35976654</style></accession-num><abstract><style face="normal" font="default" size="100%">IMPORTANCE: Current evidence on the association between family history of psychiatric disorders and postpartum depression is inconsistent; family studies have identified familial risk of postpartum depression, whereas systematic reviews and umbrella reviews, compiling all risk factors for postpartum depression, often have not. OBJECTIVE: To investigate the association between family history of psychiatric disorders and risk of developing postpartum depression within 12 months post partum. DATA SOURCES: Literature searches were conducted in PubMed, Embase, and PsycINFO in September 2021 and updated in March 2022, accompanied by citation and reference search. STUDY SELECTION: Studies eligible for inclusion comprised peer-reviewed cohort and case-control studies reporting an odds ratio (OR) or sufficient data to calculate one for the association between family history of any psychiatric disorder and postpartum depression. Study selection was made by 2 independent reviewers: title and abstract screening followed by full-text screening. DATA EXTRACTION AND SYNTHESIS: Reporting was performed using the MOOSE checklist. Two reviewers independently extracted predefined information and assessed included studies for risk of bias using the Newcastle-Ottawa Scale. Data were pooled in a meta-analysis using a random-effects model. Heterogeneity was investigated with meta-regression, subgroup, and sensitivity analyses. Publication bias was investigated using a funnel plot, and GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to evaluate the overall certainty of the findings. MAIN OUTCOMES AND MEASURES: The primary outcome was the pooled association between family history of psychiatric disorders and postpartum depression. RESULTS: A total of 26 studies were included, containing information on 100877 women. Meta-analysis showed an increased OR of developing postpartum depression when mothers had a family history of psychiatric disorders (OR, 2.08; 95% CI, 1.67-2.59; I2 = 57.14%) corresponding to a risk ratio of 1.79 (95% CI, 1.52-2.09), assuming a 15% postpartum depression prevalence in the general population. Subgroup, sensitivity, and meta-regression analyses were in line with the primary analysis. The overall certainty of evidence was deemed as moderate according to GRADE. CONCLUSIONS AND RELEVANCE: In this study, there was moderate certainty of evidence for an almost 2-fold higher risk of developing postpartum depression among mothers who have a family history of any psychiatric disorder compared with mothers without.</style></abstract><notes><style face="normal" font="default" size="100%">Zacher Kjeldsen, Mette-Marie&#xD;Bricca, Alessio&#xD;Liu, Xiaoqin&#xD;Frokjaer, Vibe G&#xD;Madsen, Kathrine Bang&#xD;Munk-Olsen, Trine&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Systematic Review&#xD;2022/08/18&#xD;JAMA Psychiatry. 2022 Oct 1;79(10):1004-1013. doi: 10.1001/jamapsychiatry.2022.2400.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35976654</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflict of Interest Disclosures: Dr Frokjaer has served as consultant and lecturer for H. Lundbeck and Sage Therapeutics. No other disclosures were reported.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9386615</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jamapsychiatry.2022.2400</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>137</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ren, P.</style></author><author><style face="normal" font="default" size="100%">Emiliussen, J.</style></author><author><style face="normal" font="default" size="100%">Christiansen, R.</style></author><author><style face="normal" font="default" size="100%">Engelsen, S.</style></author><author><style face="normal" font="default" size="100%">Klausen, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for the Study of Culture, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark. GRID: grid.10825.3e. ISNI: 0000 0001 0728 0170&#xD;Unit for Clinical Alcohol Research, Department of Clinical Research, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark. GRID: grid.10825.3e. ISNI: 0000 0001 0728 0170&#xD;Department of People and Technology, Roskilde University, Universitetsvej 1, DK-4000 Roskilde, Denmark. GRID: grid.11702.35. ISNI: 0000 0001 0672 1325</style></auth-address><titles><title><style face="normal" font="default" size="100%">Filial Piety, Generativity and Older Adults&apos; Wellbeing and Loneliness in Denmark and China</style></title><secondary-title><style face="normal" font="default" size="100%">Appl Res Qual Life</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">3069-3090</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">20220421</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Chinese philosophy</style></keyword><keyword><style face="normal" font="default" size="100%">Comparison of Denmark and China</style></keyword><keyword><style face="normal" font="default" size="100%">Filial piety</style></keyword><keyword><style face="normal" font="default" size="100%">Generativity</style></keyword><keyword><style face="normal" font="default" size="100%">Intergenerational encounters and wellbeing</style></keyword><keyword><style face="normal" font="default" size="100%">Interpretative philosophical analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Loneliness</style></keyword><keyword><style face="normal" font="default" size="100%">Older adults</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/4/21</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1871-2584 (Print)&#xD;1871-2576 (Electronic)&#xD;1871-2576 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35469258</style></accession-num><abstract><style face="normal" font="default" size="100%">The article considers the potential of intergenerational encounters and family and social ties for alleviating loneliness and promoting older adults&apos; wellbeing. Loneliness has been widely recognized as one of the factors that are most deeply and pervasively detrimental to older adults&apos; wellbeing. We combine theoretical reflections with a comparative study of older adults in Denmark and China. Both countries have to deal with an aging population and growing number of cases of isolation and loneliness in an increasingly individualized society. They differ, however, with regard to how far they have developed a system of institutionalized care, as well as with regard to their culture-specific views of family life and parent-child relationships. We apply the notions of filial piety, known from Confucian philosophy but often misinterpreted as conservative and conformist, and generativity, to qualitative studies of older adults in Denmark and China. The great potential of intergenerational ties is confirmed. Our study also shows that filial piety is still highly valued, in both China and Denmark, and can be maintained even in a highly individualized society. There is, however, considerable uncertainty among both older adults and their younger relatives as to what is required and what can be expected; realism, and an emphasis on the quality, rather than the quantity of interaction, may be sensible coping strategies, but can also lead to unnecessary acquiescence and self-abnegation. Our study also serves to distinguish different aspects and effects on wellbeing of intergenerational relationships.</style></abstract><notes><style face="normal" font="default" size="100%">Ren, Puxiang&#xD;Emiliussen, Jakob&#xD;Christiansen, Regina&#xD;Engelsen, Soren&#xD;Klausen, Soren Harnow&#xD;eng&#xD;Netherlands&#xD;2022/04/27&#xD;Appl Res Qual Life. 2022;17(5):3069-3090. doi: 10.1007/s11482-022-10053-z. Epub 2022 Apr 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35469258</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflict of InterestThe authors declare that they have no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9021826</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11482-022-10053-z</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>138</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kofoed, M. S.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. B.</style></author><author><style face="normal" font="default" size="100%">Schulz, M. K.</style></author><author><style face="normal" font="default" size="100%">Kristensen, B. W.</style></author><author><style face="normal" font="default" size="100%">Hansen, R. W.</style></author><author><style face="normal" font="default" size="100%">Markovic, L.</style></author><author><style face="normal" font="default" size="100%">Halle, B.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Odense University Hospital, Odense, Denmark. mikkel.seremet.kofoed@rsyd.dk.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark. mikkel.seremet.kofoed@rsyd.dk.&#xD;BRIDGE (Brain Research-Interdisciplinary Guided Excellence), Odense, Denmark. mikkel.seremet.kofoed@rsyd.dk.&#xD;Department of Neurosurgery, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;BRIDGE (Brain Research-Interdisciplinary Guided Excellence), Odense, Denmark.&#xD;Department of Pathology, Odense University Hospital, Odense, Denmark.&#xD;Department of Radiology, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fluorescein-guided resection of cerebral metastases is associated with greater tumor resection</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurochir (Wien)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">451-457</style></pages><volume><style face="normal" font="default" size="100%">164</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20210315</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Brain Neoplasms/diagnostic imaging/pathology/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescein</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescent Dyes</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neurosurgical Procedures</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Supratentorial Neoplasms/surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral metastases</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor resection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">0942-0940 (Electronic)&#xD;0001-6268 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33721109</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sodium fluorescein (fluorescein) crosses a disrupted blood-brain barrier similarly to gadolinium contrast in contrast-enhancing cerebral tumors. When exposed to light with 560 nm wavelength during surgery, fluorescein emits a yellow-green fluorescent light that can be visualized through an operating microscope equipped with an appropriate emission filter. The distribution of the fluorescence correlates with the contrast on a gadolinium contrast-enhanced MRI. OBJECTIVE: The objective of this single-center retrospective study was to investigate if the use of fluorescein would increase the extent of resection and to examine if fluorescein guided resection influences postoperative neurological status. METHODS: During the study period from August 2014 to August 2018, 117 patients were operated for cerebral metastases. Of these, 56 operations were guided by fluorescein and 61 by traditional white light. All patients had an early postoperative MRI within 72 h after surgery. RESULTS: The use of fluorescein increased the extent of resection in patients with cerebral metastases. The use of fluorescein was not associated with increased postoperative sequelae or neurological damage regardless of underlying primary cancer. CONCLUSION: Fluorescein is a helpful supplement in the neurosurgical treatment of cerebral metastases.</style></abstract><notes><style face="normal" font="default" size="100%">Kofoed, Mikkel S&#xD;Pedersen, Christian B&#xD;Schulz, Mette K&#xD;Kristensen, Bjarne W&#xD;Hansen, Rasmus W&#xD;Markovic, Ljubo&#xD;Halle, Bo&#xD;Poulsen, Frantz R&#xD;eng&#xD;Austria&#xD;2021/03/16&#xD;Acta Neurochir (Wien). 2022 Feb;164(2):451-457. doi: 10.1007/s00701-021-04796-1. Epub 2021 Mar 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33721109</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00701-021-04796-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>139</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">139</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rohde, C.</style></author><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Gasse, C.</style></author><author><style face="normal" font="default" size="100%">Hallas, J.</style></author><author><style face="normal" font="default" size="100%">Kohler-Forsberg, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Department of Affective Disorders, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.&#xD;Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark.&#xD;Psychosis Research Unit, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Free-of-charge dispensing of antipsychotics for schizophrenia in Denmark: Impact on the nationwide prescription registry and redemption of somatic medications</style></title><secondary-title><style face="normal" font="default" size="100%">Basic Clin Pharmacol Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Basic Clin Pharmacol Toxicol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">294-300</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220805</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antidepressive Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Prescriptions</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotropic Drugs/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Danish National Prescription Register</style></keyword><keyword><style face="normal" font="default" size="100%">antipsychotics</style></keyword><keyword><style face="normal" font="default" size="100%">free-of-charge medication</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1742-7843 (Electronic)&#xD;1742-7835 (Print)&#xD;1742-7835 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35834287</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Free-of-charge dispensing of antipsychotics for schizophrenia was introduced in Denmark around 2008. However, free-of-charge dispensing is not recorded in the Danish National Prescription Register (DNPR), potentially introducing bias and misclassification. METHODS: We identified all 30 275 individuals with a first-episode schizophrenia diagnosis in Denmark between 1 January 1999 and 1 March 2017 including all redeemed prescriptions registered in the DNPR during the 2 years after the schizophrenia diagnosis. For each calendar year, we calculated the proportion of individuals who had filled &gt;/=1 prescription for psychotropic and/or somatic medications within the first 2 years after the schizophrenia diagnosis. RESULTS: From 2007 to 2017, the proportion of individuals with prescription-records for any psychotropic medication during the 2 years after the schizophrenia diagnosis decreased from 88% to 74%, particularly antipsychotics (from 83% to 61%) and antidepressants (from 49% to 35%). This was particularly observed among those aged 18-30 years at the schizophrenia diagnosis. A similar decrease was not observed for prescription-records of somatic medications. CONCLUSION: The introduction of free-of-charge antipsychotics has affected the redemption of specific psychotropic drugs in the DNPR in first-episode schizophrenia. This limitation needs to be considered in register-based studies and emphasizes the need to identify solutions.</style></abstract><notes><style face="normal" font="default" size="100%">Rohde, Christopher&#xD;Hojlund, Mikkel&#xD;Gasse, Christiane&#xD;Hallas, Jesper&#xD;Kohler-Forsberg, Ole&#xD;eng&#xD;Mental Health Services in the Region of Southern Denmark/&#xD;England&#xD;2022/07/15&#xD;Basic Clin Pharmacol Toxicol. 2022 Oct;131(4):294-300. doi: 10.1111/bcpt.13772. Epub 2022 Aug 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35834287</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">CR received the 2020 Lundbeck Foundation Talent Prize. MH has received personal honoraria for consultancy from the Lundbeck Foundation. OKF has received speaker fees from Lundbeck Pharma A/S and is a consultant for WCG Clinical, Inc., all unrelated to the present work.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9545438</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/bcpt.13772</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>140</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thorning, M.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H. H.</style></author><author><style face="normal" font="default" size="100%">Frich, L. H.</style></author><author><style face="normal" font="default" size="100%">Jensen, H. B.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Holsgaard-Larsen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Odense University Hospital, J.B. Winsloews Vej 4, 5000 Odense C, Denmark; Orthopaedic Research Unit, Department of Clinical Research, University of Southern Denmark, J.B. Winsloews Vej 19,3, 5000 Odense C, Denmark; Department of Neurobiology Research, Department of Molecular Medicine, University of Southern Denmark, J.B. Winsloews Vej 21, st., 5000 Odense C, Denmark; BRIDGE - Brain Research - Inter Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloews Vej 19.3, 5000 Odense C, Denmark. Electronic address: maria.thorning.christensen@rsyd.dk.&#xD;Department of Neurology, Odense University Hospital, J.B. Winsloews Vej 4, 5000 Odense C, Denmark; Department of Neurobiology Research, Department of Molecular Medicine, University of Southern Denmark, J.B. Winsloews Vej 21, st., 5000 Odense C, Denmark; BRIDGE - Brain Research - Inter Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloews Vej 19.3, 5000 Odense C, Denmark.&#xD;Department of Neurobiology Research, Department of Molecular Medicine, University of Southern Denmark, J.B. Winsloews Vej 21, st., 5000 Odense C, Denmark; Department of Orthopaedics, Hospital Soenderjylland, Kresten Philipsens Vej 15, 6200 Aabenraa, Denmark; Department of Regional Health Research, University of Southern Denmark, J.B Winsloews Vej 19.3, 5000 Odense C, Denmark.&#xD;Department of Brain and Nerve Diseases, Sygehus Lillebaelt, Sygehusvej 24, 6000 Kolding, Denmark; Department of Regional Health Research, University of Southern Denmark, J.B Winsloews Vej 19.3, 5000 Odense C, Denmark.&#xD;Orthopaedic Research Unit, Department of Clinical Research, University of Southern Denmark, J.B. Winsloews Vej 19,3, 5000 Odense C, Denmark; Department of Orthopaedics and Traumatology, Odense University Hospital, J.B. Winsloews Vej 4, 5000 Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gait quality and function after fampridine treatment in patients with multiple sclerosis - A prospective cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Biomech (Bristol, Avon)</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">105826</style></pages><volume><style face="normal" font="default" size="100%">100</style></volume><number><style face="normal" font="default" size="100%">105826</style></number><edition><style face="normal" font="default" size="100%">20221117</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiple Sclerosis/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Walking</style></keyword><keyword><style face="normal" font="default" size="100%">Gait</style></keyword><keyword><style face="normal" font="default" size="100%">Fampridine</style></keyword><keyword><style face="normal" font="default" size="100%">Gait function</style></keyword><keyword><style face="normal" font="default" size="100%">Gait quality</style></keyword><keyword><style face="normal" font="default" size="100%">Multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">Three-dimensional gait analysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1879-1271 (Electronic)&#xD;0268-0033 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36436320</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Fampridine has shown to improve walking speed, motor control, and balance in patients with multiple sclerosis. However, potential fampridine-induced changes in gait quality and underlying mechanisms, evaluated by three-dimensional gait analysis, are poorly examined. The aim was to examine if two weeks of fampridine treatment would improve gait quality (using Gait Profile Score and Gait Variable Scores from three-dimensional gait analysis) and gait function (using performance-based tests, spatiotemporal parameters, and self-perceived gait function). METHODS: 14 participants with multiple sclerosis were included (9 women and 5 men, age 53.6 +/- 12.8 years, disease duration 21 +/- 9.1 years) in this cohort study. Tests were completed prior to fampridine and after 14 (+/- 1) days of treatment. Three-dimensional gait analyses were completed, and kinematic measures were calculated for overall gait quality using Gait Profile Score, and for joint-specific variables, Gait Variable Scores. Gait function was assessed using spatiotemporal parameters, performance-based tests, and a patient-reported outcome measure. Student&apos;s paired t-test/Wilcoxon signed rank test were used to compare baseline and follow-up variables. Sample size calculation for Gait Profile Score required at least 9 participants. FINDINGS: No fampridine-induced improvements in gait quality were demonstrated. For gait function, improvements were found in performance-based tests (Timed 25-Foot Walk: -11.5%; Six Spot Step Test: -13.9%; 2-Minute Walk Test: 18.2%) and self-perceived gait function (12-itemMS Walking Scale: -35.2%). INTERPRETATION: Although two weeks of fampridine treatment in patients with multiple sclerosis improved gait function, there was no change in overall kinematic quality of gait. TRIAL REGISTRATION: This work was collected as a part of a registered clinical trial (MUST): ClinicalTrials.govNCT03847545.</style></abstract><notes><style face="normal" font="default" size="100%">Thorning, Maria&#xD;Nielsen, Helle Hvilsted&#xD;Frich, Lars Henrik&#xD;Jensen, Henrik Boye&#xD;Lambertsen, Kate Lykke&#xD;Holsgaard-Larsen, Anders&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/11/28&#xD;Clin Biomech (Bristol, Avon). 2022 Dec;100:105826. doi: 10.1016/j.clinbiomech.2022.105826. Epub 2022 Nov 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36436320</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Helle Hvilsted Nielsen reports a relationship with Biogen that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Helle Hvilsted Nielsen reports a relationship with Roche that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Helle Hvilsted Nielsen reports a relationship with Sanofi Genzyme that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Helle Hvilsted Nielsen reports a relationship with Merck &amp; Co Inc. that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Helle Hvilsted Nielsen reports a relationship with Novartis that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Helle Hvilsted Nielsen reports a relationship with Teva Pharmaceutical Industries Ltd. that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Henrik Boye Jensen reports a relationship with Biogen that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Henrik Boye Jensen reports a relationship with Roche that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Henrik Boye Jensen reports a relationship with Sanofi Genzyme that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Henrik Boye Jensen reports a relationship with Merck &amp; Co Inc. that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Henrik Boye Jensen reports a relationship with Novartis that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Henrik Boye Jensen reports a relationship with Teva Pharmaceutical Industries Ltd. that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.clinbiomech.2022.105826</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>141</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Plomgaard, P.</style></author><author><style face="normal" font="default" size="100%">Hansen, J. S.</style></author><author><style face="normal" font="default" size="100%">Townsend, L. K.</style></author><author><style face="normal" font="default" size="100%">Gudiksen, A.</style></author><author><style face="normal" font="default" size="100%">Secher, N. H.</style></author><author><style face="normal" font="default" size="100%">Clemmesen, J. O.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author><author><style face="normal" font="default" size="100%">Goetze, J. P.</style></author><author><style face="normal" font="default" size="100%">Wright, D. C.</style></author><author><style face="normal" font="default" size="100%">Pilegaard, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.&#xD;Centre of Inflammation and Metabolism and Centre for Physical Activity Research, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Human Health and Nutritional Sciences, University of Guelph, Copenhagen, ON, Canada.&#xD;Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Anaesthesiology, Copenhagen Muscle Research Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.&#xD;Department of Hepatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.&#xD;Center for Eating Disorders, Elite Research Center for Medical Endocrinology, Odense University Hospital, Odense, Denmark.&#xD;Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Clinical Institute, University of Southern Denmark, Odense, Denmark.&#xD;Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;School of kinesiology, Faculty of Land and Food Systems and British Columbia (BC) Children&apos;s Hospital Research Foundation, University of British Columbia, Vancouver, BC, Canada.</style></auth-address><titles><title><style face="normal" font="default" size="100%">GDF15 is an exercise-induced hepatokine regulated by glucagon and insulin in humans</style></title><secondary-title><style face="normal" font="default" size="100%">Front Endocrinol (Lausanne)</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1037948</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20221205</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Insulin/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Glucagon/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Pancreatic Hormones</style></keyword><keyword><style face="normal" font="default" size="100%">Pancreas/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style face="normal" font="default" size="100%">Growth Differentiation Factor 15/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">appetite</style></keyword><keyword><style face="normal" font="default" size="100%">fasting</style></keyword><keyword><style face="normal" font="default" size="100%">insulin resistance</style></keyword><keyword><style face="normal" font="default" size="100%">liver</style></keyword><keyword><style face="normal" font="default" size="100%">splanchnic bed</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/12/5</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Frontiers Media SA</style></publisher><isbn><style face="normal" font="default" size="100%">1664-2392 (Print)&#xD;1664-2392 (Electronic)&#xD;1664-2392 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36545337</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Growth differentiation factor (GDF)-15 is implicated in regulation of metabolism and circulating GDF15 increases in response to exercise. The source and regulation of the exercise-induced increase in GDF15 is, however not known. METHOD: Plasma GDF15 was measured by ELISA under the following conditions: 1) Arterial-to-hepatic venous differences sampled before, during, and after exercise in healthy male subjects (n=10); 2) exogenous glucagon infusion compared to saline infusion in resting healthy subjects (n=10); 3) an acute exercise bout with and without a pancreatic clamp (n=6); 4) healthy subjects for 36 hours (n=17), and 5) patients with anorexia nervosa (n=25) were compared to healthy age-matched subjects (n=25). Tissue GDF15 mRNA content was determined in mice in response to exhaustive exercise (n=16). RESULTS: The splanchnic bed released GDF15 to the circulation during exercise and increasing the glucagon-to-insulin ratio in resting humans led to a 2.7-fold (P&lt;0.05) increase in circulating GDF15. Conversely, inhibiting the exercise-induced increase in the glucagon-to-insulin ratio blunted the exercise-induced increase in circulating GDF15. Fasting for 36 hours did not affect circulating GDF15, whereas resting patients with anorexia nervosa displayed elevated plasma concentrations (1.4-fold, P&lt;0.05) compared to controls. In mice, exercise increased GDF15 mRNA contents in liver, muscle, and adipose tissue. CONCLUSION: In humans, GDF15 is a &quot;hepatokine&quot; which increases during exercise and is at least in part regulated by the glucagon-to-insulin ratio. Moreover, chronic energy deprivation is associated with elevated plasma GDF15, which supports that GDF15 is implicated in metabolic signalling in humans.</style></abstract><notes><style face="normal" font="default" size="100%">Plomgaard, Peter&#xD;Hansen, Jakob S&#xD;Townsend, Logan K&#xD;Gudiksen, Anders&#xD;Secher, Niels H&#xD;Clemmesen, Jens O&#xD;Stoving, Rene K&#xD;Goetze, Jens P&#xD;Wright, David C&#xD;Pilegaard, Henriette&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Switzerland&#xD;2022/12/23&#xD;Front Endocrinol (Lausanne). 2022 Dec 5;13:1037948. doi: 10.3389/fendo.2022.1037948. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36545337</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9760804</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fendo.2022.1037948</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>142</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamand, M.</style></author><author><style face="normal" font="default" size="100%">Hohmann, S.</style></author><author><style face="normal" font="default" size="100%">Louise Forsberg, S.</style></author><author><style face="normal" font="default" size="100%">Thomassen, M.</style></author><author><style face="normal" font="default" size="100%">Ilieva, M.</style></author><author><style face="normal" font="default" size="100%">Fex Svenningsen, A.</style></author><author><style face="normal" font="default" size="100%">Meyer, M.</style></author><author><style face="normal" font="default" size="100%">Maria Michel, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research, Department of Psychiatry, University of Southern Denmark, Odense, Denmark; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Psychiatry in the Region of Southern Denmark, Odense University Hospital, Denmark; Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia, Denmark. Electronic address: Mkamand@hotmail.dk.&#xD;Department of Clinical Research, Department of Psychiatry, University of Southern Denmark, Odense, Denmark; Psychiatry in the Region of Southern Denmark, Odense University Hospital, Denmark.&#xD;Department of Clinical Research, Department of Human Genetics, Odense University Hospital, Denmark.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Brain Research - Inter-Disciplinary Guided Excellence (BRIDGE), Odense, Denmark.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Brain Research - Inter-Disciplinary Guided Excellence (BRIDGE), Odense, Denmark; Department of Neurology, Odense University Hospital, Denmark.&#xD;Department of Clinical Research, Department of Psychiatry, University of Southern Denmark, Odense, Denmark; Brain Research - Inter-Disciplinary Guided Excellence (BRIDGE), Odense, Denmark; Psychiatry in the Region of Southern Denmark, Odense University Hospital, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Generation and characterization of induced pluripotent stem (iPS) cell line (SDUCTi001-A) using fibroblasts derived from male-healthy donor</style></title><secondary-title><style face="normal" font="default" size="100%">Stem Cell Res</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">102961</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">102961</style></number><edition><style face="normal" font="default" size="100%">20221107</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Cell Line</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1876-7753 (Electronic)&#xD;1873-5061 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36402078</style></accession-num><abstract><style face="normal" font="default" size="100%">Induced pluripotent stem (iPS) cell lines have wide valuable applications in experimental research, including developmental, pathological, and drug screening studies. Using integration-free episomal plasmids, we have generated a new iPS cell line from a 26-year-old healthy male donor. Characterization of the established cell line confirmed the expression of pluripotency markers, differentiation into the three germ layers, and absence of chromosomal abnormalities.</style></abstract><notes><style face="normal" font="default" size="100%">Kamand, Morad&#xD;Hohmann, Sonja&#xD;Louise Forsberg, Sheena&#xD;Thomassen, Mads&#xD;Ilieva, Mirolyuba&#xD;Fex Svenningsen, Asa&#xD;Meyer, Morten&#xD;Maria Michel, Tanja&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/11/20&#xD;Stem Cell Res. 2022 Dec;65:102961. doi: 10.1016/j.scr.2022.102961. Epub 2022 Nov 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36402078</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.scr.2022.102961</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>274</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">274</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bang Madsen, K.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Albinana, C.</style></author><author><style face="normal" font="default" size="100%">Johann Vilhjalmsson, B.</style></author><author><style face="normal" font="default" size="100%">Agerbo, E.</style></author><author><style face="normal" font="default" size="100%">Mortensen, P. B.</style></author><author><style face="normal" font="default" size="100%">Hougaard, D. M.</style></author><author><style face="normal" font="default" size="100%">Nordentoft, M.</style></author><author><style face="normal" font="default" size="100%">Werge, T.</style></author><author><style face="normal" font="default" size="100%">Mors, O.</style></author><author><style face="normal" font="default" size="100%">Borglum, A. D.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NCRR - National Centre for Register-based Research, Business and Social Sciences, Aarhus University, Aarhus, Denmark.&#xD;iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Denmark.&#xD;Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.&#xD;CIRRAU - Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.&#xD;CORE - Copenhagen Research Centre for Mental Health, Mental Health Centre Copenhagen, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark.&#xD;Lundbeck Foundation Center for GeoGenetics, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark.&#xD;Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.&#xD;Department of Biomedicine and the iSEQ Center, Aarhus University, Aarhus, Denmark.&#xD;Center for Genomics and Personalized Medicine, CGPM, Aarhus, Denmark.&#xD;Research Unit of Psychiatry, Institute for Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genetic liability to posttraumatic stress disorder and its association with postpartum depression</style></title><secondary-title><style face="normal" font="default" size="100%">Psychol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Psychol Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-8</style></pages><edition><style face="normal" font="default" size="100%">20220711</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Childbirth</style></keyword><keyword><style face="normal" font="default" size="100%">genetics</style></keyword><keyword><style face="normal" font="default" size="100%">postpartum depression</style></keyword><keyword><style face="normal" font="default" size="100%">posttraumatic stress disorder</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1469-8978 (Electronic)&#xD;0033-2917 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35811373</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Childbirth may be a traumatic experience and vulnerability to posttraumatic stress disorder (PTSD) may increase the risk of postpartum depression (PPD). We investigated whether genetic vulnerability to PTSD as measured by polygenic score (PGS) increases the risk of PPD and whether a predisposition to PTSD in PPD cases exceeds that of major depressive disorder (MDD) outside the postpartum period. METHODS: This case-control study included participants from the iPSYCH2015, a case-cohort of all singletons born in Denmark between 1981 and 2008. Restricting to women born between 1981 and 1997 and excluding women with a first diagnosis other than depression (N = 22 613), 333 were identified with PPD. For each PPD case, 999 representing the background population and 993 with MDD outside the postpartum were matched by calendar year at birth, cohort selection, and age. PTSD PGS was calculated from summary statistics from the Psychiatric Genomics Consortium with LDpred2-auto. Odds ratios (ORs) were estimated using conditional logistic regression adjusted for parental psychiatric history and country of origin, PGS for MDD and age at first birth, and the first 10 principal components. RESULTS: The PTSD PGS was significantly associated with PPD (OR 1.42, 95% CI 1.20-1.68 per standard deviation increase in PTSD PGS) compared to healthy female controls. Genetic PTSD vulnerability in PPD cases did not exceed that of matched female depression cases outside the postpartum period (OR 1.10, 95% CI 0.94-1.30 per standard deviation increase). CONCLUSIONS: Genetic vulnerability to PTSD increased the risk of PPD but did not differ between PPD cases and women with depression at other times.</style></abstract><notes><style face="normal" font="default" size="100%">Bang Madsen, Kathrine&#xD;Liu, Xiaoqin&#xD;Albinana, Clara&#xD;Johann Vilhjalmsson, Bjarni&#xD;Agerbo, Esben&#xD;Mortensen, Preben Bo&#xD;Hougaard, David Michael&#xD;Nordentoft, Merete&#xD;Werge, Thomas&#xD;Mors, Ole&#xD;Borglum, Anders D&#xD;Munk-Olsen, Trine&#xD;eng&#xD;(R313-2019-569/Lundbeckfonden/&#xD;England&#xD;2022/07/12&#xD;Psychol Med. 2022 Jul 11:1-8. doi: 10.1017/S0033291722002045.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35811373</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S0033291722002045</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>276</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">276</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suppli, N. P.</style></author><author><style face="normal" font="default" size="100%">Andersen, K. K.</style></author><author><style face="normal" font="default" size="100%">Agerbo, E.</style></author><author><style face="normal" font="default" size="100%">Rajagopal, V. M.</style></author><author><style face="normal" font="default" size="100%">Appadurai, V.</style></author><author><style face="normal" font="default" size="100%">Coleman, J. R. I.</style></author><author><style face="normal" font="default" size="100%">Breen, G.</style></author><author><style face="normal" font="default" size="100%">Bybjerg-Grauholm, J.</style></author><author><style face="normal" font="default" size="100%">Baekvad-Hansen, M.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. B.</style></author><author><style face="normal" font="default" size="100%">Pedersen, M. G.</style></author><author><style face="normal" font="default" size="100%">Thompson, W. K.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author><author><style face="normal" font="default" size="100%">Benros, M. E.</style></author><author><style face="normal" font="default" size="100%">Als, T. D.</style></author><author><style face="normal" font="default" size="100%">Grove, J.</style></author><author><style face="normal" font="default" size="100%">Werge, T.</style></author><author><style face="normal" font="default" size="100%">Borglum, A. D.</style></author><author><style face="normal" font="default" size="100%">Hougaard, D. M.</style></author><author><style face="normal" font="default" size="100%">Mors, O.</style></author><author><style face="normal" font="default" size="100%">Nordentoft, M.</style></author><author><style face="normal" font="default" size="100%">Mortensen, P. B.</style></author><author><style face="normal" font="default" size="100%">Musliner, K. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark.&#xD;Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.&#xD;Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark.&#xD;National Centre for Register-based Research, Department of Economics, Aarhus University, Aarhus, Denmark.&#xD;Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Department of Biomedicine, Aarhus University, Aarhus, Denmark.&#xD;Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark.&#xD;Center for Genomics and Personalized Medicine, Aarhus, Denmark.&#xD;Institute of Biological Psychiatry, Copenhagen Mental Health Services, Copenhagen, Denmark.&#xD;Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, United Kingdom.&#xD;National Institute for Health Research Biomedical Research Centre, South London and Maudsley NHS Trust, London, United Kingdom.&#xD;Department for Congenital Disorders, Statens Serum Institute, Copenhagen, Denmark.&#xD;Division of Biostatistics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California.&#xD;Department of Clinical Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark.&#xD;Psychosis Research Unit, Aarhus University Hospital-Psychiatry, Aarhus.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Department of Affective Disorders, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Genome-wide by Environment Interaction Study of Stressful Life Events and Hospital-Treated Depression in the iPSYCH2012 Sample</style></title><secondary-title><style face="normal" font="default" size="100%">Biol Psychiatry Glob Open Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biol Psychiatry Glob Open Sci</style></full-title></periodical><pages><style face="normal" font="default" size="100%">400-410</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20211109</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Case-cohort studies</style></keyword><keyword><style face="normal" font="default" size="100%">Depression</style></keyword><keyword><style face="normal" font="default" size="100%">Gxe</style></keyword><keyword><style face="normal" font="default" size="100%">Genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Register-based research</style></keyword><keyword><style face="normal" font="default" size="100%">Stress</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2667-1743 (Electronic)&#xD;2667-1743 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36324662</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Researchers have long investigated a hypothesized interaction between genetic risk and stressful life events in the etiology of depression, but studies on the topic have yielded inconsistent results. METHODS: We conducted a genome-wide by environment interaction study (GWEIS) in 18,532 patients with depression from hospital-based settings and 20,184 population controls. All individuals were drawn from the iPSYCH2012 case-cohort study, a nationally representative sample identified from Danish national registers. Information on stressful life events including family disruption, serious medical illness, death of a first-degree relative, parental disability, and child maltreatment was identified from the registers and operationalized as a time-varying count variable. Hazard ratios for main and interaction effects were estimated using Cox regressions weighted to accommodate the case-cohort design. Our replication sample included 22,880 depression cases and 50,378 controls from the UK Biobank. RESULTS: The GWEIS in the iPSYCH2012 sample yielded three novel, genome-wide-significant (p &lt; 5 x 10(-8)) loci located in the ABCC1 gene (rs56076205, p = 3.7 x 10(-10)), the AKAP6 gene (rs3784187, p = 1.2 x 10(-8)), and near the MFSD1 gene (rs340315, p = 4.5 x 10(-8)). No hits replicated in the UK Biobank (rs56076205: p = .87; rs3784187: p = .93; rs340315: p = .71). CONCLUSIONS: In this large, population-based GWEIS, we did not find any replicable hits for interaction. Future gene-by-stress research in depression should focus on establishing even larger collaborative GWEISs to attain sufficient power.</style></abstract><notes><style face="normal" font="default" size="100%">Suppli, Nis P&#xD;Andersen, Klaus K&#xD;Agerbo, Esben&#xD;Rajagopal, Veera M&#xD;Appadurai, Vivek&#xD;Coleman, Jonathan R I&#xD;Breen, Gerome&#xD;Bybjerg-Grauholm, Jonas&#xD;Baekvad-Hansen, Marie&#xD;Pedersen, Carsten B&#xD;Pedersen, Marianne G&#xD;Thompson, Wesley K&#xD;Munk-Olsen, Trine&#xD;Benros, Michael E&#xD;Als, Thomas D&#xD;Grove, Jakob&#xD;Werge, Thomas&#xD;Borglum, Anders D&#xD;Hougaard, David M&#xD;Mors, Ole&#xD;Nordentoft, Merete&#xD;Mortensen, Preben B&#xD;Musliner, Katherine L&#xD;eng&#xD;2022/11/04&#xD;Biol Psychiatry Glob Open Sci. 2021 Nov 9;2(4):400-410. doi: 10.1016/j.bpsgos.2021.11.003. eCollection 2022 Oct.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36324662</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9616262</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bpsgos.2021.11.003</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>143</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">143</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maier, A. D.</style></author><author><style face="normal" font="default" size="100%">Mirian, C.</style></author><author><style face="normal" font="default" size="100%">Haslund-Vinding, J.</style></author><author><style face="normal" font="default" size="100%">Bartek, J.</style></author><author><style face="normal" font="default" size="100%">Guldager, R.</style></author><author><style face="normal" font="default" size="100%">Moller, S.</style></author><author><style face="normal" font="default" size="100%">Munch, T. N.</style></author><author><style face="normal" font="default" size="100%">Fugleholm, K.</style></author><author><style face="normal" font="default" size="100%">Poulsgaard, L.</style></author><author><style face="normal" font="default" size="100%">Skjoth-Rasmussen, J.</style></author><author><style face="normal" font="default" size="100%">Ziebell, M.</style></author><author><style face="normal" font="default" size="100%">Eriksson, L. E.</style></author><author><style face="normal" font="default" size="100%">Scheie, D.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author><author><style face="normal" font="default" size="100%">Mathiesen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1Departments of Neurosurgery.&#xD;2Pathology, and.&#xD;3Department of Neurosurgery, Karolinska University Hospital, Solna, Stockholm, Sweden.&#xD;4Department of Clinical Neuroscience, Karolinska Institutet, Solna, Stockholm, Sweden.&#xD;5Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.&#xD;6Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.&#xD;7Department of Clinical Medicine, University of Copenhagen, Denmark.&#xD;8Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.&#xD;9School of Health Sciences, City, University of London, United Kingdom.&#xD;10Medical Unit Infectious Diseases, Karolinska University Hospital, Huddinge, Sweden.&#xD;11Odense University Hospital, Department of Neurosurgery, Odense, Denmark; and.&#xD;12University of Southern Denmark and BRIDGE, Clinical Institute, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Granular clinical history and outcome in 51 patients with primary and secondary malignant meningioma</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosurg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-11</style></pages><edition><style face="normal" font="default" size="100%">20220311</style></edition><keywords><keyword><style face="normal" font="default" size="100%">malignant meningioma</style></keyword><keyword><style face="normal" font="default" size="100%">neurosurgical complications</style></keyword><keyword><style face="normal" font="default" size="100%">oncology</style></keyword><keyword><style face="normal" font="default" size="100%">outcome</style></keyword><keyword><style face="normal" font="default" size="100%">palliation</style></keyword><keyword><style face="normal" font="default" size="100%">survival</style></keyword><keyword><style face="normal" font="default" size="100%">treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar 11</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Journal of Neurosurgery Publishing Group (JNSPG)</style></publisher><isbn><style face="normal" font="default" size="100%">1933-0693 (Electronic)&#xD;0022-3085 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35276654</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: WHO grade III meningiomas, also known as malignant meningiomas (MMs), are rare, and the heterogenous clinical course in patients with MM is not well described. To characterize the clinical course of patients with MM, granular clinical data were gathered from 51 patients treated at the Department of Neurosurgery and Radiation Oncology, Rigshospitalet, in Copenhagen, Denmark, between 2000 and 2020. METHODS: The authors investigated outcome and timing in terms of 1) tumor progression and grade transformation in patients previously diagnosed with WHO grade I or II meningiomas (patients with a secondary MM [sMM]); 2) performance status and complications following surgery; and 3) transition to noncurative treatment and ultimately death. Complications, time between recurrences, and outcome (modified Rankin Scale [mRS] score) for every surgery were analyzed, both malignant and premalignant. RESULTS: Of the 51 patients, 24 (47%) had an sMM. The time to WHO grade III transformation in the sMM group varied widely (median 5.5 years, range 0.5-22 years), but after transformation to a WHO grade III tumor, patients with an sMM and those with a primary MM (pMM) did not differ significantly in overall survival and cumulative risk of progression. Median overall survival for all 51 patients was 4.2 years (95% CI 2.6-7.2 years). Time from the decision to shift from curative to noncurative treatment until death was 3.8 months and the 30-day mortality rate following surgery was 11.8%. From a cumulative number of 151 surgeries, 10 surgeries were followed by improvement on the mRS, mRS score was unchanged in 70, and it worsened in 71. The MM was the underlying cause of death in 30 of 31 patients who had died at the end of follow-up. CONCLUSIONS: Together, these findings clearly show a significant morbidity and mortality from the disease itself and from the treatment. These findings warrant studies of prognostic factors for earlier support and adjuvant measures in MM and identify a need for better palliative strategies in this patient group.</style></abstract><notes><style face="normal" font="default" size="100%">Maier, Andrea D&#xD;Mirian, Christian&#xD;Haslund-Vinding, Jeppe&#xD;Bartek, Jiri&#xD;Guldager, Rikke&#xD;Moller, Soren&#xD;Munch, Tina N&#xD;Fugleholm, Kare&#xD;Poulsgaard, Lars&#xD;Skjoth-Rasmussen, Jane&#xD;Ziebell, Morten&#xD;Eriksson, Lars E&#xD;Scheie, David&#xD;Poulsen, Frantz R&#xD;Mathiesen, Tiit&#xD;eng&#xD;2022/03/12&#xD;J Neurosurg. 2022 Mar 11:1-11. doi: 10.3171/2022.1.JNS212723.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35276654</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3171/2022.1.JNS212723</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>222</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">222</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hellum, R.</style></author><author><style face="normal" font="default" size="100%">Bilberg, R.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Southern Denmark, Odense C, Denmark; and Psychiatric Department, Odense University Hospital, Odense C, Region of Southern Denmark, Denmark. RINGGOLD: 6174&#xD;University of Southern Denmark, Odense C, Denmark; and Psychiatric Department, Odense University Hospital, Odense C, Region of Southern Denmark, Denmark; and OPEN, Open Patient data Explorative Network, Odense University Hospital, Odense C, Denmark. RINGGOLD: 6174</style></auth-address><titles><title><style face="normal" font="default" size="100%">&quot;He is lovely and awful&quot;: The challenges of being close to an individual with alcohol problems</style></title><secondary-title><style face="normal" font="default" size="100%">Nordisk Alkohol Nark</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nordisk Alkohol Nark</style></full-title></periodical><pages><style face="normal" font="default" size="100%">89-104</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20211013</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Craft</style></keyword><keyword><style face="normal" font="default" size="100%">affected family members</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol problem</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">community reinforcement and family training</style></keyword><keyword><style face="normal" font="default" size="100%">concerned significant others</style></keyword><keyword><style face="normal" font="default" size="100%">help-seeking</style></keyword><keyword><style face="normal" font="default" size="100%">qualitative</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1458-6126 (Electronic)&#xD;1455-0725 (Print)&#xD;1455-0725 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35308468</style></accession-num><abstract><style face="normal" font="default" size="100%">Introduction: In the last 20 years, there has been growing evidence that heavy drinking causes serious harm not only to the person who drinks but also to the person&apos;s relations and concerned significant others (CSOs). A relationship with a heavy drinker is often full of conflicts, and CSOs are frequently exposed to aggression, psychological, and sometimes physical violence from the heavy drinker. Despite their struggles, CSOs often feel it is difficult to seek professional help for these problems. The aim of this study was to investigate what problems CSOs of people with alcohol problems experience prior to seeking professional help to handle these issues. Moreover, to investigate what led to seeking professional help at all. Methods: This is a qualitative study with 12 female help-seeking CSOs of persons with alcohol problems. The participants were recruited from a randomised controlled trial (RCT) on Community Reinforcement and Family Training (CRAFT). Semi-structured interviews were conducted, audio-recorded, and transcribed. The analysis was based on interpretative phenomenological analysis. Results: Three overall themes and one sub-theme emerged from the analysis: (1) The CSO&apos;s feelings and experiences of the situation prior to help-seeking, (2) The relationship with the drinker, (3) Reasons for help-seeking and its trajectory; and the sub-theme, What the CSOs hoped to gain from help-seeking. Conclusion: The present study showed that female CSOs of people with alcohol problems had suffered for a long time before seeking professional help. They felt their daily lives were unpredictable and stressful. They were often exposed to verbal and mental abuse and their relationships with the drinking relative were often characterised by frequent rowing. The CSOs had tried to cope for a long time using a number of different strategies; seeking help seemed to be the last option considered. Despite all the struggles and pain, the CSOs also felt a lot of love for their drinking relative and hoped for the return of their once sober relative. Our findings can be viewed as a support to the stress-strain-coping-support (SSCS) model proposed by Orford and colleagues.</style></abstract><notes><style face="normal" font="default" size="100%">Hellum, Rikke&#xD;Bilberg, Randi&#xD;Nielsen, Anette Sogaard&#xD;eng&#xD;2022/03/22&#xD;Nordisk Alkohol Nark. 2022 Feb;39(1):89-104. doi: 10.1177/14550725211044861. Epub 2021 Oct 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35308468</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of conflicting interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8899274</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/14550725211044861</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>266</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">266</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ingeman, K.</style></author><author><style face="normal" font="default" size="100%">Hulgaard, D. R.</style></author><author><style face="normal" font="default" size="100%">Rask, C. U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Child and Adolescent Psychiatry, 11297Aarhus University Hospital, Aarhus, Denmark.&#xD;Department of Clinical Medicine, 1006Aarhus University, Aarhus, Denmark.&#xD;Research Clinic for Functional Disorders and Psychosomatics, Aarhus University Hospital, Denmark.&#xD;Department of Clinical Research, 6174University of Southern Denmark, Odense, Denmark.&#xD;Child and Adolescent Psychiatry Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Health anxiety by proxy - through the eyes of the parents</style></title><secondary-title><style face="normal" font="default" size="100%">J Child Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Child Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">13674935221095648</style></pages><edition><style face="normal" font="default" size="100%">20220505</style></edition><keywords><keyword><style face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style face="normal" font="default" size="100%">hypochondriasis</style></keyword><keyword><style face="normal" font="default" size="100%">parents</style></keyword><keyword><style face="normal" font="default" size="100%">qualitative research</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 5</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1741-2889 (Electronic)&#xD;1367-4935 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35510964</style></accession-num><abstract><style face="normal" font="default" size="100%">Health anxiety by proxy is a newly described phenomenon where parents worry excessively that their child suffers from a serious illness. In a former study, six parents with distressing worries about their child&apos;s health were interviewed to develop the Health Anxiety by Proxy Scale. The present study is a secondary analysis of these semi-structured interview data using interpretative phenomenological analysis aiming to explore for the first time the lived experience of parents with health anxiety by proxy. Analysis revealed three main themes: &apos;Faces of distress&apos; describing various aspects of parents&apos; experienced distress; &apos;Invasive insecurity and mistrust&apos; portraying how anxiety affects parents&apos; relationship with their children, health professionals and family; and &apos;Making sense of own worries&apos; covering parents&apos; ambivalence regarding their anxiety and rationalization of their worries. Knowledge about perspectives of parents who suffer from health anxiety by proxy can inform communication in clinical encounters where validation of parents&apos; experiences may be key to forging an alliance for further treatment; and to recognising and potentially lowering barriers to receiving help that lies in parents&apos; potential mistrust in professional help.</style></abstract><notes><style face="normal" font="default" size="100%">Ingeman, Katrine&#xD;Hulgaard, Ditte Roth&#xD;Rask, Charlotte U&#xD;eng&#xD;England&#xD;2022/05/06&#xD;J Child Health Care. 2022 May 5:13674935221095648. doi: 10.1177/13674935221095648.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35510964</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/13674935221095648</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>144</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">144</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hulgaard, D.</style></author><author><style face="normal" font="default" size="100%">Rask, C. U.</style></author><author><style face="normal" font="default" size="100%">Boye, H.</style></author><author><style face="normal" font="default" size="100%">Larsen, P. V.</style></author><author><style face="normal" font="default" size="100%">Christesen, H. T.</style></author><author><style face="normal" font="default" size="100%">Andersen, M. S.</style></author><author><style face="normal" font="default" size="100%">Jensen, T. K.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Child and Adolescent Psychiatry Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department for Child and Adolescent Psychiatry, Aarhus University Hospital, Research Unit, Aarhus, Denmark.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Odense University Hospital, Hans Christian Andersen Children&apos;s Hospital, Odense, Denmark.&#xD;OPEN Patient data Explorative Network (OPEN), University of Southern Denmark, Odense, Denmark.&#xD;Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Endocrinology, Odense University Hospital, Odense, Denmark.&#xD;IST - Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Health anxiety symptoms in Danish children during the first lockdown period of the COVID-19 pandemic: an Odense Child Cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">330-337</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">20210930</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anxiety/epidemiology/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Communicable Disease Control</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">coronavirus</style></keyword><keyword><style face="normal" font="default" size="100%">family</style></keyword><keyword><style face="normal" font="default" size="100%">health anxiety</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1502-4725 (Electronic)&#xD;0803-9488 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34591725</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: The coronavirus disease 2019 (COVID-19) pandemic has a severe impact on the general population. During the pandemic, children may develop emotional and psychological symptoms, including increased worries about health and illness, known as health anxiety symptoms (HASs). We aimed to explore HAS in 7-9-year-old children from the Danish Odense Child Cohort (OCC) during the first COVID-19 lockdown period in Denmark, and to examine associations with potential risk factors. MATERIAL AND METHODS: OCC is a cohort of children born between 2010 and 2012, which originally recruited 2874 of 6707 pregnancies (43%). Among the current OCC population of 2430 singleton children, 994 participated in this study (response rate 40%). Children and their parents filled out questionnaires about child HAS, family exposure to COVID-19 infection and parental HAS. Adjusted odds ratios (aORs) were calculated between high score child HAS (&gt;/=90th percentile) and covariates by use of logistic regression. RESULTS: Most children (n = 686, 69%) reported few worries about their health. Children reporting high score HAS also had higher levels of internalizing symptoms at age 5; aOR 2.15 (1.20;3.85), p = .010, and higher levels of maternal and paternal HAS; aOR 2.40 (1.44;3.97), p = .001, and 2.00 (1.10;3.65), p = .023, whereas no association with child sex or familial exposure to COVID-19 was detected (n = 65, 6.5%). CONCLUSIONS: High score child HAS during the first lockdown period of the COVID-19 pandemic was not associated with family exposure to COVID-19 infection, but to being a more anxious child a priori and to HAS in parents.</style></abstract><notes><style face="normal" font="default" size="100%">Hulgaard, Ditte&#xD;Rask, Charlotte Ulrikka&#xD;Boye, Henriette&#xD;Larsen, Pia Veldt&#xD;Christesen, Henrik Thybo&#xD;Andersen, Marianne Skovsager&#xD;Jensen, Tina Kold&#xD;Bilenberg, Niels&#xD;eng&#xD;England&#xD;2021/10/01&#xD;Nord J Psychiatry. 2022 Jul;76(5):330-337. doi: 10.1080/08039488.2021.1970804. Epub 2021 Sep 30.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34591725</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08039488.2021.1970804</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>146</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">146</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">van der Vlegel, M.</style></author><author><style face="normal" font="default" size="100%">Mikolic, A.</style></author><author><style face="normal" font="default" size="100%">Lee Hee, Q.</style></author><author><style face="normal" font="default" size="100%">Kaplan, Z. L. R.</style></author><author><style face="normal" font="default" size="100%">Retel Helmrich, I. R. A.</style></author><author><style face="normal" font="default" size="100%">van Veen, E.</style></author><author><style face="normal" font="default" size="100%">Andelic, N.</style></author><author><style face="normal" font="default" size="100%">Steinbuechel, N. V.</style></author><author><style face="normal" font="default" size="100%">Plass, A. M.</style></author><author><style face="normal" font="default" size="100%">Zeldovich, M.</style></author><author><style face="normal" font="default" size="100%">Wilson, L.</style></author><author><style face="normal" font="default" size="100%">Maas, A. I. R.</style></author><author><style face="normal" font="default" size="100%">Haagsma, J. A.</style></author><author><style face="normal" font="default" size="100%">Polinder, S.</style></author><author><style face="normal" font="default" size="100%">Center-Tbi Participants</style></author><author><style face="normal" font="default" size="100%">Investigators,</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, Rotterdam, CA 3000, The Netherlands. Electronic address: m.vandervlegel@erasmusmc.nl.&#xD;Department of Public Health, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, Rotterdam, CA 3000, The Netherlands.&#xD;Department of Public Health, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, Rotterdam, CA 3000, The Netherlands; Department of Intensive Care Adults, Rotterdam, the Netherlands.&#xD;Department of Physical Medicine and Rehabilitation, Oslo University Hospital and University of Oslo, 0424 Oslo, Norway.&#xD;Institute of Medical Psychology and Medical Sociology, University Medical Center Gottingen (UMG)/ Georg-August-University, Gottingen, Germany.&#xD;Division of Psychology, University of Stirling, Stirling, UK.&#xD;Department of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Health care utilization and outcomes in older adults after Traumatic Brain Injury: A CENTER-TBI study</style></title><secondary-title><style face="normal" font="default" size="100%">Injury</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Injury</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2774-2782</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">20220526</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Brain Injuries, Traumatic</style></keyword><keyword><style face="normal" font="default" size="100%">Glasgow Outcome Scale</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Acceptance of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Quality of Life/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Health care utilization</style></keyword><keyword><style face="normal" font="default" size="100%">Health-related quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">Mental health</style></keyword><keyword><style face="normal" font="default" size="100%">Older adults</style></keyword><keyword><style face="normal" font="default" size="100%">Outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">Traumatic Brain Injury</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1879-0267 (Electronic)&#xD;0020-1383 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35725508</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: The incidence of Traumatic Brain Injury (TBI) is increasingly common in older adults aged &gt;/=65 years, forming a growing public health problem. However, older adults are underrepresented in TBI research. Therefore, we aimed to provide an overview of health-care utilization, and of six-month outcomes after TBI and their determinants in older adults who sustained a TBI. METHODS: We used data from the prospective multi-center Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. In-hospital and post-hospital health care utilization and outcomes were described for patients aged &gt;/=65 years. Ordinal and linear regression analyses were performed to identify determinants of the Glasgow Outcome Scale Extended (GOSE), health-related quality of life (HRQoL), and mental health symptoms six-months post-injury. RESULTS: Of 1254 older patients, 45% were admitted to an ICU with a mean length of stay of 9 days. Nearly 30% of the patients received inpatient rehabilitation. In total, 554/1254 older patients completed the six-month follow-up questionnaires. The mortality rate was 9% after mild and 60% after moderate/severe TBI, and full recovery based on GOSE was reported for 44% of patients after mild and 6% after moderate/severe TBI. Higher age and increased injury severity were primarily associated with functional impairment, while pre-injury systemic disease, psychiatric conditions and lower educational level were associated with functional impairment, lower generic and disease-specific HRQoL and mental health symptoms. CONCLUSION: The rate of impairment and disability following TBI in older adults is substantial, and poorer outcomes across domains are associated with worse preinjury health. Nonetheless, a considerable number of patients fully or partially returns to their preinjury functioning. There should not be pessimism about outcomes in older adults who survive.</style></abstract><notes><style face="normal" font="default" size="100%">van der Vlegel, Marjolein&#xD;Mikolic, Ana&#xD;Lee Hee, Quentin&#xD;Kaplan, Z L Rana&#xD;Retel Helmrich, Isabel R A&#xD;van Veen, Ernest&#xD;Andelic, Nada&#xD;Steinbuechel, Nicole V&#xD;Plass, Anne Marie&#xD;Zeldovich, Marina&#xD;Wilson, Lindsay&#xD;Maas, Andrew I R&#xD;Haagsma, Juanita A&#xD;Polinder, Suzanne&#xD;eng&#xD;Netherlands&#xD;2022/06/21&#xD;Injury. 2022 Aug;53(8):2774-2782. doi: 10.1016/j.injury.2022.05.009. Epub 2022 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35725508</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of Competing Interest None.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.injury.2022.05.009</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>270</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">270</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jensen, R. C.</style></author><author><style face="normal" font="default" size="100%">Glintborg, D.</style></author><author><style face="normal" font="default" size="100%">Timmermann, C. A. G.</style></author><author><style face="normal" font="default" size="100%">Nielsen, F.</style></author><author><style face="normal" font="default" size="100%">Boye, H.</style></author><author><style face="normal" font="default" size="100%">Madsen, J. B.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Grandjean, P.</style></author><author><style face="normal" font="default" size="100%">Jensen, T. K.</style></author><author><style face="normal" font="default" size="100%">Andersen, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Endocrinology, Odense University Hospital, Sondre Blvd. 29, 5000, Odense C, Denmark; Department of Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, J.B. Winslows Vej 17A, 5000, Odense C, Denmark. Electronic address: rcjensen@health.sdu.dk.&#xD;Department of Endocrinology, Odense University Hospital, Sondre Blvd. 29, 5000, Odense C, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, 5000, Odense, Denmark.&#xD;Department of Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, J.B. Winslows Vej 17A, 5000, Odense C, Denmark; National Institute of Public Health, University of Southern Denmark, Studiestraede 6, 1455, Kobenhavn K, Denmark.&#xD;Department of Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, J.B. Winslows Vej 17A, 5000, Odense C, Denmark.&#xD;Odense Child Cohort, Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Klovervaenget 23C, 5000, Odense C, Denmark.&#xD;Department of Biochemistry and Immunology, Lillebaelt Hospital, Kabbeltoft 25, University Hospital of Southern Denmark, 7100, Vejle, Denmark.&#xD;Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, 5000, Odense, Denmark; Odense Child Cohort, Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Klovervaenget 23C, 5000, Odense C, Denmark; Department of Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, J. B. Winslows Vej 16, 5000, Odense, Denmark.&#xD;Department of Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, J.B. Winslows Vej 17A, 5000, Odense C, Denmark; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, 677 Huntington Avenue Boston, MA, 02115, USA.&#xD;Department of Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, J.B. Winslows Vej 17A, 5000, Odense C, Denmark; Odense Child Cohort, Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Klovervaenget 23C, 5000, Odense C, Denmark; OPEN, University of Southern Denmark, J. B. Winslows Vej 9a, 5000, Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Higher free thyroxine associated with PFAS exposure in first trimester. The Odense Child Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Environ Res</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">113492</style></pages><volume><style face="normal" font="default" size="100%">212</style></volume><number><style face="normal" font="default" size="100%">Pt D</style></number><edition><style face="normal" font="default" size="100%">20220518</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alkanesulfonic Acids</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Environmental Pollutants</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Fluorocarbons</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Placenta</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy Trimester, First</style></keyword><keyword><style face="normal" font="default" size="100%">Thyroid Hormones</style></keyword><keyword><style face="normal" font="default" size="100%">Thyrotropin</style></keyword><keyword><style face="normal" font="default" size="100%">Thyroxine</style></keyword><keyword><style face="normal" font="default" size="100%">Developmental toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Early pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Perfluoroalkyl substances</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1096-0953 (Electronic)&#xD;0013-9351 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35597289</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Perfluoroalkyl substances (PFAS) are endocrine disrupting chemicals with elimination half-lives ranging from four to eight years. Experimental studies found PFAS able to interfere with thyroid hormone-binding proteins. During the first 20 weeks of gestation (GW), the fetus is reliant on placental transfer of maternal thyroid hormones, mainly free thyroxine (FT4). However, previous studies investigating associations between exposure to PFAS and thyroid hormone status mainly focused on blood samples from late pregnancy or umbilical cord with mixed findings. OBJECTIVES: To investigate associations between serum-PFAS concentrations and thyroid hormone status in early pregnancy as reflected by FT4 and thyroid-stimulating hormone (TSH). METHODS: In the Odense Child Cohort, a single-center study, we measured maternal pregnancy serum concentrations of five PFAS: perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA); and FT4 and TSH in 1048 pregnant women at median GW 12 (25th, 75th percentile: 10, 15). Multivariate linear regression models were performed to estimate associations between PFAS exposure and thyroid hormone status. RESULTS: A doubling in PFOS, PFOA, and PFNA concentrations was associated with an increment in FT4 concentration by 1.85% (95% CI: 0.66%, 3.05%), 1.29% (95% CI: 0.21%, 2.39%), and 1.70% (95% CI: 0.48%, 2.94%), respectively, in adjusted analyses. A statistically significant dose-response relationship was observed across exposure quartiles for PFOS, PFOA, and PFNA in the association with FT4. No association was found between concentrations of PFAS and TSH in adjusted analyses. CONCLUSION: Exposure to PFOS, PFOA, and PFNA was associated with higher FT4 concentrations in women during early pregnancy. The potential clinical implications of these findings remain to be clarified.</style></abstract><notes><style face="normal" font="default" size="100%">Jensen, Richard Christian&#xD;Glintborg, Dorte&#xD;Timmermann, Clara Amalie Gade&#xD;Nielsen, Flemming&#xD;Boye, Henriette&#xD;Madsen, Jeppe Buur&#xD;Bilenberg, Niels&#xD;Grandjean, Philippe&#xD;Jensen, Tina Kold&#xD;Andersen, Marianne S&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;2022/05/22&#xD;Environ Res. 2022 Sep;212(Pt D):113492. doi: 10.1016/j.envres.2022.113492. Epub 2022 May 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35597289</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.envres.2022.113492</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>148</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">148</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pedersen, A. L. W.</style></author><author><style face="normal" font="default" size="100%">Gildberg, F. A.</style></author><author><style face="normal" font="default" size="100%">Hjorth, P.</style></author><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CPS, Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Middelfart, Mental Health Services Region of Southern Denmark, Middelfart, Denmark.&#xD;Department of Psychiatry Vejle, Mental Health Services Region of Southern Denmark, Vejle, Denmark.&#xD;Clinical Pharmacology, Pharmacy, and Environmental Medicine, Institute of Public Health, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services Region of Southern Denmark, Aabenraa, Denmark.&#xD;Department of Mental Health Odense, University Clinic, Mental Health Services, Region of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hospitalisation time is associated with weight gain in forensic mental health patients with schizophrenia or bipolar disorder</style></title><secondary-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">46-54</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220407</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Bipolar Disorder/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Health</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Weight Gain</style></keyword><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Body Mass Index</style></keyword><keyword><style face="normal" font="default" size="100%">Waist Circumference</style></keyword><keyword><style face="normal" font="default" size="100%">Blood Glucose</style></keyword><keyword><style face="normal" font="default" size="100%">Forensic psychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">blood lipids</style></keyword><keyword><style face="normal" font="default" size="100%">blood pressure</style></keyword><keyword><style face="normal" font="default" size="100%">body weight</style></keyword><keyword><style face="normal" font="default" size="100%">hospitalisation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1502-4725 (Electronic)&#xD;0803-9488 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35389309</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: People with mental disorders have higher mortality from lifestyle diseases than the general population. Forensic mental health patients (FMHPs) are often hospitalised for longer periods of time than non-FMHPs. Thus, hospitalisation may have a greater effect on the risk of lifestyle diseases in FMHPs. OBJECTIVE: Investigate associations between proportional hospitalisation time (PHT) and change in body weight or other cardiometabolic risk factors among FMHPs. METHODS: Retrospective cohort study including all FMHPs with schizophrenia or bipolar disorder, prescribed antipsychotics, and treated between 01 January 2016 and 06 April 2020 in the Region of Southern Denmark either in forensic units or as outpatients. Associations between PHT and, respectively, primary and secondary outcomes were analysed using linear regression. PHT was determined between each measurement of the outcomes as the number of days hospitalised divided by the total number of days within the time-period. The primary outcome was weight change and secondary outcomes were change in waist circumference (WC), blood pressure, estimated average glucose (eAG), HDL, LDL, total cholesterol, and triglycerides. Analyses were adjusted for gender, age, smoking, and antipsychotics. RESULTS: The cohort included 490 FMHPs, of which 440 were diagnosed with schizophrenia. PHT had a significant positive dose-response association with weight change, with an estimated difference of +4.0 kg/year for FMHPs who were hospitalised 100% of the time, compared to FMHPs who were exclusively treated as outpatients. The association interacted with baseline BMI. From the secondary outcomes, the association with PHT was only statistically significant for WC. CONCLUSIONS: PHT was positively associated with weight gain.</style></abstract><notes><style face="normal" font="default" size="100%">Pedersen, Anne Louise Winkler&#xD;Gildberg, Frederik Alkier&#xD;Hjorth, Peter&#xD;Hojlund, Mikkel&#xD;Andersen, Kjeld&#xD;eng&#xD;England&#xD;2022/04/08&#xD;Nord J Psychiatry. 2023 Jan;77(1):46-54. doi: 10.1080/08039488.2022.2053202. Epub 2022 Apr 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35389309</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08039488.2022.2053202</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>149</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niclasen, B. H.</style></author><author><style face="normal" font="default" size="100%">Schelde-Olesen, M. T.</style></author><author><style face="normal" font="default" size="100%">Astvad, M.</style></author><author><style face="normal" font="default" size="100%">Lokke, A.</style></author><author><style face="normal" font="default" size="100%">Kroigard, T.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark.&#xD;Department of Clinical Genetics, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark.&#xD;Department of Intensive Care, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark.&#xD;Department of Medicine, Little Belt Hospital, 7100 Vejle, Denmark.&#xD;Department of Regional Health Research, University of Southern Denmark, 5230 Odense, Denmark.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, J.B. Winsloewsvej 21, 5000 Odense, Denmark.&#xD;BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, J.B. Winsloewsvej 19, 5000 Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hyperammonaemic Encephalopathy Caused by Adult-Onset Ornithine Transcarbamylase Deficiency</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Sci</style></secondary-title></titles><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20220208</style></edition><keywords><keyword><style face="normal" font="default" size="100%">adult onset</style></keyword><keyword><style face="normal" font="default" size="100%">brain oedema</style></keyword><keyword><style face="normal" font="default" size="100%">hyperammonaemia</style></keyword><keyword><style face="normal" font="default" size="100%">ornithine transcarbamylase deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">subacute encephalopathy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 8</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2076-3425 (Print)&#xD;2076-3425 (Electronic)&#xD;2076-3425 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35203994</style></accession-num><abstract><style face="normal" font="default" size="100%">Hyperammonaemic encephalopathy in adults is a rare condition in the absence of liver disease and is associated with a high mortality and risk of permanent neurological deficits. Seldomly, the condition is caused by an inborn error of metabolism in the urea cycle, triggered by an exogenic factor such as gastrointestinal haemorrhage, gastric bypass surgery, starvation, seizures, vigorous exercise, burn injuries, or drugs hampering the elimination of ammonia. Here, we present a fatal case of an unrecognized genetic ornithine transcarbamylase deficiency (OTCD) presenting with a subacute progressive encephalopathy. We review the current literature and discuss the differential diagnosis and treatment options. As swift diagnosis and initiation of treatment is vital, awareness of hyperammonaemic encephalopathy and its possible causes can help improve the prognosis of this condition.</style></abstract><notes><style face="normal" font="default" size="100%">Niclasen, Bjarke Hammer&#xD;Schelde-Olesen, Maria Therese&#xD;Astvad, Mads&#xD;Lokke, Anders&#xD;Kroigard, Thomas&#xD;Nielsen, Helle H&#xD;eng&#xD;Case Reports&#xD;Switzerland&#xD;2022/02/26&#xD;Brain Sci. 2022 Feb 8;12(2):231. doi: 10.3390/brainsci12020231.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35203994</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8870301</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/brainsci12020231</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>150</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">150</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elkjaer, M. L.</style></author><author><style face="normal" font="default" size="100%">Simon, L.</style></author><author><style face="normal" font="default" size="100%">Frisch, T.</style></author><author><style face="normal" font="default" size="100%">Bente, L. M.</style></author><author><style face="normal" font="default" size="100%">Kacprowski, T.</style></author><author><style face="normal" font="default" size="100%">Thomassen, M.</style></author><author><style face="normal" font="default" size="100%">Reynolds, R.</style></author><author><style face="normal" font="default" size="100%">Baumbach, J.</style></author><author><style face="normal" font="default" size="100%">Rottger, R.</style></author><author><style face="normal" font="default" size="100%">Illes, Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Odense University Hospital, Odense, Denmark.&#xD;BRIDGE, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, United States.&#xD;Department of Mathematics and Computer Science, University of Southern Denmark, Odense, Denmark.&#xD;Division Data Science in Biomedicine, Peter L. Reichertz Institute for Medical Informatics, Technische Universitat Braunschweig and Hannover Medical School, Braunschweig, Germany.&#xD;Braunschweig Integrated Centre of Systems Biology (BRICS), Technische Universitat Braunschweig, Braunchweig, Germany.&#xD;Research Unit of Human Genetics, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Brain Sciences, Imperial College, London, United Kingdom.&#xD;Centre for Molecular Neuropathology, LKC School of Medicine, Nanyang Technological University, Singapore, Singapore.&#xD;Chair of Computational Systems Biology, University of Hamburg, Hamburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hypothesis of a potential BrainBiota and its relation to CNS autoimmune inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Front Immunol</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1043579</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20221202</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Gastrointestinal Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">*Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiple Sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">CNS autoimmunity</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial transcripts</style></keyword><keyword><style face="normal" font="default" size="100%">brainbiome</style></keyword><keyword><style face="normal" font="default" size="100%">brainbiota</style></keyword><keyword><style face="normal" font="default" size="100%">gut-brain axis</style></keyword><keyword><style face="normal" font="default" size="100%">microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">smoldering MS</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/12/2</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Frontiers Media SA</style></publisher><isbn><style face="normal" font="default" size="100%">1664-3224 (Electronic)&#xD;1664-3224 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36532064</style></accession-num><abstract><style face="normal" font="default" size="100%">Infectious agents have been long considered to play a role in the pathogenesis of neurological diseases as part of the interaction between genetic susceptibility and the environment. The role of bacteria in CNS autoimmunity has also been highlighted by changes in the diversity of gut microbiota in patients with neurological diseases such as Parkinson&apos;s disease, Alzheimer disease and multiple sclerosis, emphasizing the role of the gut-brain axis. We discuss the hypothesis of a brain microbiota, the BrainBiota: bacteria living in symbiosis with brain cells. Existence of various bacteria in the human brain is suggested by morphological evidence, presence of bacterial proteins, metabolites, transcripts and mucosal-associated invariant T cells. Based on our data, we discuss the hypothesis that these bacteria are an integral part of brain development and immune tolerance as well as directly linked to the gut microbiome. We further suggest that changes of the BrainBiota during brain diseases may be the consequence or cause of the chronic inflammation similarly to the gut microbiota.</style></abstract><notes><style face="normal" font="default" size="100%">Elkjaer, Maria L&#xD;Simon, Lukas&#xD;Frisch, Tobias&#xD;Bente, Lisa-Marie&#xD;Kacprowski, Tim&#xD;Thomassen, Mads&#xD;Reynolds, Richard&#xD;Baumbach, Jan&#xD;Rottger, Richard&#xD;Illes, Zsolt&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Switzerland&#xD;2022/12/20&#xD;Front Immunol. 2022 Dec 2;13:1043579. doi: 10.3389/fimmu.2022.1043579. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36532064</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9756883</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fimmu.2022.1043579</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>151</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">151</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebrahimi, A.</style></author><author><style face="normal" font="default" size="100%">Wiil, U. K.</style></author><author><style face="normal" font="default" size="100%">Naemi, A.</style></author><author><style face="normal" font="default" size="100%">Mansourvar, M.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">SDU Health Informatics and Technology, The Maersk Mc-Kinney Moller Institute, University of Southern Denmark, Odense, Denmark. aleb@mmmi.sdu.dk.&#xD;SDU Health Informatics and Technology, The Maersk Mc-Kinney Moller Institute, University of Southern Denmark, Odense, Denmark.&#xD;Department of Mathematics and Computer Science, University of Southern Denmark, Odense, Denmark.&#xD;Unit for Clinical Alcohol Research, Clinical Institute, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Identification of clinical factors related to prediction of alcohol use disorder from electronic health records using feature selection methods</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Med Inform Decis Mak</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">304</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20221123</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcoholism/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Electronic Health Records</style></keyword><keyword><style face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Support Vector Machine</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical factor identification</style></keyword><keyword><style face="normal" font="default" size="100%">Feature selection</style></keyword><keyword><style face="normal" font="default" size="100%">Gender disparity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 23</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1472-6947 (Electronic)&#xD;1472-6947 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36424597</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: High dimensionality in electronic health records (EHR) causes a significant computational problem for any systematic search for predictive, diagnostic, or prognostic patterns. Feature selection (FS) methods have been indicated to be effective in feature reduction as well as in identifying risk factors related to prediction of clinical disorders. This paper examines the prediction of patients with alcohol use disorder (AUD) using machine learning (ML) and attempts to identify risk factors related to the diagnosis of AUD. METHODS: A FS framework consisting of two operational levels, base selectors and ensemble selectors. The first level consists of five FS methods: three filter methods, one wrapper method, and one embedded method. Base selector outputs are aggregated to develop four ensemble FS methods. The outputs of FS method were then fed into three ML algorithms: support vector machine (SVM), K-nearest neighbor (KNN), and random forest (RF) to compare and identify the best feature subset for the prediction of AUD from EHRs. RESULTS: In terms of feature reduction, the embedded FS method could significantly reduce the number of features from 361 to 131. In terms of classification performance, RF based on 272 features selected by our proposed ensemble method (Union FS) with the highest accuracy in predicting patients with AUD, 96%, outperformed all other models in terms of AUROC, AUPRC, Precision, Recall, and F1-Score. Considering the limitations of embedded and wrapper methods, the best overall performance was achieved by our proposed Union Filter FS, which reduced the number of features to 223 and improved Precision, Recall, and F1-Score in RF from 0.77, 0.65, and 0.71 to 0.87, 0.81, and 0.84, respectively. Our findings indicate that, besides gender, age, and length of stay at the hospital, diagnosis related to digestive organs, bones, muscles and connective tissue, and the nervous systems are important clinical factors related to the prediction of patients with AUD. CONCLUSION: Our proposed FS method could improve the classification performance significantly. It could identify clinical factors related to prediction of AUD from EHRs, thereby effectively helping clinical staff to identify and treat AUD patients and improving medical knowledge of the AUD condition. Moreover, the diversity of features among female and male patients as well as gender disparity were investigated using FS methods and ML techniques.</style></abstract><notes><style face="normal" font="default" size="100%">Ebrahimi, Ali&#xD;Wiil, Uffe Kock&#xD;Naemi, Amin&#xD;Mansourvar, Marjan&#xD;Andersen, Kjeld&#xD;Nielsen, Anette Sogaard&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/11/25&#xD;BMC Med Inform Decis Mak. 2022 Nov 23;22(1):304. doi: 10.1186/s12911-022-02051-w.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36424597</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9686074</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12911-022-02051-w</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>252</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">252</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fluttert, F. A. J.</style></author><author><style face="normal" font="default" size="100%">Bjrkly, Stl</style></author><author><style face="normal" font="default" size="100%">Dale, Karl Yngvar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The impact of a discarded diagnosis and focus on early warning signs of aggression on relations between user and municipal service providers - a narrative of a complex case</style></title><secondary-title><style face="normal" font="default" size="100%">Current Psychology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Psychology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5503-5513</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">8</style></number><section><style face="normal" font="default" size="100%">5503</style></section><dates><year><style face="normal" font="default" size="100%">2020</style></year></dates><isbn><style face="normal" font="default" size="100%">1046-1310&#xD;1936-4733</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12144-020-01055-x</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>303</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">303</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author><author><style face="normal" font="default" size="100%">Guala, M. M.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author><author><style face="normal" font="default" size="100%">Eriksen, L. S.</style></author><author><style face="normal" font="default" size="100%">Stenager, E.</style></author><author><style face="normal" font="default" size="100%">Skot, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, Odense (Mellentin, Mejldal, Guala, Stoving, Eriksen, Skot); Research Unit for Telepsychiatry and E-Mental Health, Center for Telepsychiatry, Region of Southern Denmark, Odense (Mellentin); Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, University of Southern Denmark, Odense (Mellentin); Center for Eating Disorders, Odense University Hospital, Odense (Guala, Stoving); Research Unit for Medical Endocrinology, Department of Clinical Research, University of Southern Denmark, Odense (Stoving);Unit for Psychiatric Research, Institute of Regional Health Services Research, University of Southern Denmark, Aabenraa (Stenager).</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Impact of Alcohol and Other Substance Use Disorders on Mortality in Patients With Eating Disorders: A Nationwide Register-Based Retrospective Cohort Study</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Am J Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">46-57</style></pages><volume><style face="normal" font="default" size="100%">179</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Alcoholism/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Anorexia Nervosa/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Bulimia Nervosa/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Feeding and Eating Disorders/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Substance-Related Disorders/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Feeding and Eating Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">*Substance-Related and Addictive Disorders</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1535-7228 (Electronic)&#xD;0002-953X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34974750</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Research is lacking on the contribution of different types of substance use disorders (SUDs) to excess mortality across the full spectrum of eating disorders. The authors assessed the association of alcohol use disorders and other SUDs with mortality in anorexia nervosa, bulimia nervosa, and unspecified eating disorder compared with matched control subjects. METHODS: A retrospective cohort study was conducted using Danish nationwide registers. The study included 20,759 patients with eating disorders and 83,036 matched control subjects. Hazard ratios were calculated to compare all-cause mortality risk between eating disorder patients and control subjects both with and without a lifetime SUD diagnosis (abuse or dependence of alcohol, cannabis, or hard drugs). RESULTS: For patients with each type of eating disorder, a higher risk of all-cause mortality was observed relative to control subjects without SUDs among those who abused alcohol and/or cannabis (adjusted hazard ratios for the anorexia nervosa, bulimia nervosa, and unspecified eating disorder patients, respectively, were 11.28 [95% CI=7.01, 18.16], 5.86 [95% CI=3.37, 10.1], and 10.86 [95% CI=6.74, 17.50]), or hard drugs alone or in combination with alcohol and/or cannabis (adjusted hazard ratios, respectively, were 22.34 [95% CI=15.13, 33.00], 11.43 [95% CI=7.14, 18.28], and 15.53 [95% CI=10.15, 23.78]), than in those without SUDs (adjusted hazard ratios, respectively, were 3.21 [95% CI=2.43, 4.23], 1.24 [95% CI=0.88, 1.77], and 4.75 [95% CI=3.57, 6.31]). Control subjects with SUDs also exhibited an elevated risk of all-cause mortality relative to control subjects without SUDs, although to a much lesser extent than eating disorder patients with SUDs. CONCLUSIONS: SUDs have an additive effect on excess mortality in patients with eating disorders. The prevention and treatment of SUDs in this patient group is thus imperative to reduce mortality.</style></abstract><notes><style face="normal" font="default" size="100%">Mellentin, Angelina Isabella&#xD;Mejldal, Anna&#xD;Guala, Maria Mercedes&#xD;Stoving, Rene Klinkby&#xD;Eriksen, Lene Stryhn&#xD;Stenager, Elsebeth&#xD;Skot, Lotte&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/01/04&#xD;Am J Psychiatry. 2022 Jan;179(1):46-57. doi: 10.1176/appi.ajp.2021.21030274.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34974750</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1176/appi.ajp.2021.21030274</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>273</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">273</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Momen, N. C.</style></author><author><style face="normal" font="default" size="100%">Robakis, T.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Reichenberg, A.</style></author><author><style face="normal" font="default" size="100%">Bergink, V.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Centre for Register-based Research, Aarhus University, Aarhus, Denmark. ncm@econ.au.dk.&#xD;Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.&#xD;National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Seaver Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Psychiatry, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.&#xD;iPSYCH-Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark.&#xD;CIRRAU-Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">In utero exposure to antipsychotic medication and psychiatric outcomes in the offspring</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropsychopharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropsychopharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">759-766</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20211108</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Disorders/diagnosis/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">*Prenatal Exposure Delayed Effects/chemically induced/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Proportional Hazards Models</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1740-634X (Electronic)&#xD;0893-133X (Print)&#xD;0893-133X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34750566</style></accession-num><abstract><style face="normal" font="default" size="100%">Information on neurodevelopmental effects of antenatal exposure to antipsychotics is limited to 10 studies, all examining children up to 5 years of age or less. The paper aimed to investigate the association between in utero exposure to antipsychotics and psychiatric outcomes in children using Danish nationwide registers. In total, 9011 liveborn singletons born 1998-2015 in Denmark whose mothers took antipsychotic medication before pregnancy were identified. Children whose mothers continued to take antipsychotics during pregnancy were compared with children of mothers who discontinued antipsychotics before pregnancy. As a negative control, paternal antipsychotic use in the same window was investigated. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression for the primary outcome of psychiatric disorders, as well for subcategories of psychiatric disorders. In total, 9.9% of children in the discontinuation group and 11.0% of children in the continuation group received a psychiatric disorder diagnosis during follow-up. The adjusted HR for psychiatric disorders among offspring in the continuation group compared to the discontinuation group was 1.10 (95% CI 0.93-1.30). For antipsychotic use in the fathers, the HR was 1.05 (95% CI 0.89-1.24). The study does not provide evidence of increased risk of psychiatric disorders among children of women who continue antipsychotic treatment during pregnancy. This was observed after accounting for the underlying risk conferred by maternal psychiatric disorders. This suggests women who need to continue antipsychotic medications during pregnancy can do so without adverse psychiatric outcomes for offspring.</style></abstract><notes><style face="normal" font="default" size="100%">Momen, Natalie C&#xD;Robakis, Thalia&#xD;Liu, Xiaoqin&#xD;Reichenberg, Abraham&#xD;Bergink, Veerle&#xD;Munk-Olsen, Trine&#xD;eng&#xD;R01 MH122869/MH/NIMH NIH HHS/&#xD;England&#xD;2021/11/10&#xD;Neuropsychopharmacology. 2022 Feb;47(3):759-766. doi: 10.1038/s41386-021-01223-y. Epub 2021 Nov 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34750566</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8782838</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41386-021-01223-y</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>277</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">277</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Molenaar, N. M.</style></author><author><style face="normal" font="default" size="100%">Maegbaek, M. L.</style></author><author><style face="normal" font="default" size="100%">Rommel, A. S.</style></author><author><style face="normal" font="default" size="100%">Ibroci, E.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author><author><style face="normal" font="default" size="100%">Bergink, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: nina.molenaar@mssm.edu.&#xD;NCRR-The National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark.&#xD;Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Psychiatry, Erasmus Medical Center, Rotterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The incidence of depressive episodes is different before, during, and after pregnancy: A population-based study</style></title><secondary-title><style face="normal" font="default" size="100%">J Affect Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Affect Disord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">273-276</style></pages><volume><style face="normal" font="default" size="100%">322</style></volume><edition><style face="normal" font="default" size="100%">20221114</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">*Parturition</style></keyword><keyword><style face="normal" font="default" size="100%">*Research</style></keyword><keyword><style face="normal" font="default" size="100%">Inpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Ambulatory Care</style></keyword><keyword><style face="normal" font="default" size="100%">Dsm-v</style></keyword><keyword><style face="normal" font="default" size="100%">Depression</style></keyword><keyword><style face="normal" font="default" size="100%">Postpartum</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-2517 (Electronic)&#xD;0165-0327 (Print)&#xD;0165-0327 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36395991</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Depressive episodes during pregnancy are widely investigated but it is still unknown whether pregnancy is a high-risk period compared to the pre-pregnancy period. Therefore, we aimed to investigate the incidence and recurrence of depressive episodes before, during, and after pregnancy. METHODS: In the current population-based registry study, we calculated monthly incidence and recurrence of psychiatric inpatient admissions and outpatient psychiatric contact for depressive episodes. We identified a population consisting of all first childbirths in Denmark from 1999 through 2015 (N = 392,287). RESULTS: Incidence of inpatient admission during pregnancy was lower than before pregnancy. After childbirth, a significant increase in first-time and recurrent psychiatric inpatient admissions was observed, especially in the first months. In contrast, outpatient psychiatric treatment incidence and recurrence were increased both during pregnancy as well as in the postpartum period, as compared to pre-pregnancy. LIMITATIONS: Analyses were performed on depressive episodes representing the severe end of the spectrum, questioning generalizability to milder forms of depression treated outside psychiatric specialist treatment facilities. CONCLUSION: We found a different pattern of severe episodes of depression compared to moderate episodes before, during, and after pregnancy. In light of our findings and those of others, we suggest distinguishing between timing of onset in the classification of depression in the perinatal period: Depression with pregnancy onset OR with postpartum onset (instead of the current DSM classifier &quot;with perinatal onset&quot;), as well as severity of depression, which is important for both clinical and future research endeavors.</style></abstract><notes><style face="normal" font="default" size="100%">Molenaar, Nina M&#xD;Maegbaek, Merete L&#xD;Rommel, Anna-Sophie&#xD;Ibroci, Erona&#xD;Liu, Xiaoqin&#xD;Munk-Olsen, Trine&#xD;Bergink, Veerle&#xD;eng&#xD;R01 MH122869/MH/NIMH NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Netherlands&#xD;2022/11/18&#xD;J Affect Disord. 2023 Feb 1;322:273-276. doi: 10.1016/j.jad.2022.11.031. Epub 2022 Nov 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36395991</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflict of Interest The authors state there is no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9768818</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jad.2022.11.031</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>152</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">152</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Christensen, T. N.</style></author><author><style face="normal" font="default" size="100%">Wallstrom, I. G.</style></author><author><style face="normal" font="default" size="100%">Eplov, L. F.</style></author><author><style face="normal" font="default" size="100%">Laursen, T. M.</style></author><author><style face="normal" font="default" size="100%">Nordentoft, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mental Health Centre Copenhagen, Copenhagen Research Center for Mental Health - CORE, Hellerup, Denmark.&#xD;Research Unit of Psychiatry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;National Centre for Register-Based Research, University of Aarhus, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Incidence rates and employment trends in schizophrenia spectrum disorders, bipolar affective disorders and recurrent depression in the years 2000-2013: a Danish nationwide register-based study</style></title><secondary-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">225-232</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20210802</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Bipolar Disorder/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Depression</style></keyword><keyword><style face="normal" font="default" size="100%">*Depressive Disorder, Major</style></keyword><keyword><style face="normal" font="default" size="100%">Employment</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence rates</style></keyword><keyword><style face="normal" font="default" size="100%">bipolar affective disorders</style></keyword><keyword><style face="normal" font="default" size="100%">employment trends</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent depression</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia spectrum disorders</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1502-4725 (Electronic)&#xD;0803-9488 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34339349</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: The study aimed to investigate time trends in incidence rates in schizophrenic spectrum disorders (ICD-10: F20-F29), bipolar affective disorder (ICD-10: F30, F31), and recurrent depression (ICD-10: F33) and to investigate the rates of employment for all incident cases. METHOD: We used nationwide longitudinal data from 2000 to 2013 on all psychiatric inpatients and outpatients contacts in Denmark. Age-adjusted incidence rate ratios were calculated for the three diagnostic groups, and rates of employment, education, and disability pension were measured 1 year before and 2 years after the diagnosis for all the incident cases. RESULTS: The incidence rates increased significantly in all diagnostic groups and both sexes. Comparing the incidence rates in 2013 with 2000 yielded an incidence rate ratio of 1.67 (95% CI 1.51-1.84) for schizophrenic spectrum disorders, 3.82 (95% CI 3.23-4.52) for bipolar affective disorder, and 2.80 (95% CI 2.58-3.04) for recurrent depression. During the same observation period, the employment rates decreased, both 1 year before and 2 years after diagnosis in all three subgroups. In the year 2002, employment rates, 2 years after diagnosis, were 24.6% for schizophrenia spectrum disorder, 35.0% for bipolar affective disorder and 47.1% for recurrent depression. These rates had declined to 15.8%, 26.8%, and 34.7%, respectively, in 2013. CONCLUSION: This study of three severe mental illness subgroups shows significant increasing incidence rates and decreasing employment rates both before and after the diagnosis between 2000 and 2013, highlighting the importance of timely and correct volume of the psychiatric treatment and vocational rehabilitation programs.</style></abstract><notes><style face="normal" font="default" size="100%">Christensen, Thomas Nordahl&#xD;Wallstrom, Iben Gammelgard&#xD;Eplov, Lene Falgaard&#xD;Laursen, Thomas Munk&#xD;Nordentoft, Merete&#xD;eng&#xD;England&#xD;2021/08/03&#xD;Nord J Psychiatry. 2022 Apr;76(3):225-232. doi: 10.1080/08039488.2021.1952304. Epub 2021 Aug 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34339349</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08039488.2021.1952304</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>264</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">264</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jakobsen, S.</style></author><author><style face="normal" font="default" size="100%">Christiansen, E.</style></author><author><style face="normal" font="default" size="100%">Andersen, P.</style></author><author><style face="normal" font="default" size="100%">Lauritsen, J.</style></author><author><style face="normal" font="default" size="100%">Stenager, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Incidence rates of suicide attempts and self-harm in Europe. What can we learn? A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">European Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S841-S842</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">S1</style></number><section><style face="normal" font="default" size="100%">S841</style></section><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">0924-9338&#xD;1778-3585</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1192/j.eurpsy.2022.2179</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>220</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">220</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Steinhausen, H. C.</style></author><author><style face="normal" font="default" size="100%">Villumsen, M. D.</style></author><author><style face="normal" font="default" size="100%">Horder, K.</style></author><author><style face="normal" font="default" size="100%">Winkler, L. A.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, University of Southern Denmark, Odense, Denmark.&#xD;Child and Adolescent Mental Health Centre, Capital Region Psychiatry, Copenhagen, Denmark.&#xD;Department of Child and Adolescent Psychiatry, Psychiatric University Hospital of Zurich, Zurich, Switzerland.&#xD;Clinical Psychology and Epidemiology, Institute of Psychology, University of Basel, Basel, Switzerland.&#xD;Department of Epidemiology, Biostatistics, and Biodemography, Institute of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Center for Eating Disorders, Odense University Hospital, Odense, Denmark.&#xD;Psychiatric Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Endocrine Research Unit, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increased risk of somatic diseases following anorexia nervosa in a controlled nationwide cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Eat Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Eat Disord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">754-762</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">20220422</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anorexia Nervosa/diagnosis/epidemiology/etiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">anorexia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">cohort study</style></keyword><keyword><style face="normal" font="default" size="100%">comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">somatic disease</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1098-108X (Electronic)&#xD;0276-3478 (Print)&#xD;0276-3478 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35451527</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To assess the risk of somatic diseases in connection with anorexia nervosa (AN). METHOD: This matched cohort study was based on Danish registries of all patients born 1961-2008 with a first-time diagnosis of AN in 1994-2018 at age 8-32 and matched controls without an eating disorder. For 13 somatic disease categories, time from inclusion date to time of first somatic diagnosis, accounting for censoring, was studied by use of time-stratified Cox models. RESULTS: A total of 9985 AN patients born 1961-2008 and 49,351 controls were followed for a median (interquartile range) of 9.0 (4.4-15.7) years. During the first 2 years after entry there was a 60% higher hazard for any somatic disease among patients with AN than among controls, while the ratio from three to 11 years was reduced to 1.18. Regardless of age at diagnosis, the hazard among patients and controls were no different at approximately a decade after diagnosis of AN and the cumulative risk for patients for 12 of 13 disease categories was always higher or no less that for controls. For all disease categories, the hazard ratio (HR) was higher when close to entry. For most disease categories, age at diagnosis of AN did not modify the effect. DISCUSSION: While around 90% of all individuals had any somatic disease at the end of follow-up, the cumulative incidence over time was higher for patients with AN than for controls. Large HRs were seen in the early years after diagnosis during which patients require extensive medical interventions. PUBLIC SIGNIFICANCE: Based on Danish registries, a large sample of almost 10,000 patients with AN born 1961-2008 and almost 50,000 matched controls were followed for a median of 9 years. While around 90% of all individuals had any somatic disease at the end of follow-up, the cumulative incidence over time was higher for patients with AN than for controls.</style></abstract><notes><style face="normal" font="default" size="100%">Steinhausen, Hans-Christoph&#xD;Villumsen, Martin Dalgaard&#xD;Horder, Kirsten&#xD;Winkler, Laura Al-Dakhiel&#xD;Bilenberg, Niels&#xD;Stoving, Rene Klinkby&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/04/23&#xD;Int J Eat Disord. 2022 Jun;55(6):754-762. doi: 10.1002/eat.23718. Epub 2022 Apr 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35451527</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">In the past 3 years, Hans-Christoph Steinhausen has worked as a speaker for Medice and has received book royalties from Cambridge University Press, Elsevier, Hogrefe, Klett, and Kohlhammer publishers. Other authors declare no conflicts of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9323483</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/eat.23718</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>262</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">262</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ziegler, Sonja M. T.</style></author><author><style face="normal" font="default" size="100%">Morrier, Michael J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Increasing Social Interactions of Preschool Children With Autism Through Cooperative Outdoor Play</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Special Education</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The Journal of Special Education</style></full-title></periodical><pages><style face="normal" font="default" size="100%">49-60</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">1</style></number><section><style face="normal" font="default" size="100%">49</style></section><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">0022-4669&#xD;1538-4764</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/00224669211032556</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>153</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">153</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Byg, K. E.</style></author><author><style face="normal" font="default" size="100%">Illes, Z.</style></author><author><style face="normal" font="default" size="100%">Sejbaek, T.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Ellingsen, T.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Rheumatology Research Unit, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark; Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark; BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Open Patient data Explorative Network, Odense University Hospital, J.B. Winsloewsvej 9a, 5000 Odense, Denmark.. Electronic address: keld-erik.byg@rsyd.dk.&#xD;Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark; BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, J.B. Winsloewsvej 21, 5000 Odense, Denmark.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, J.B. Winsloewsvej 21, 5000 Odense, Denmark; Department of Neurology, South West Jutland University Hospital of Southern Denmark, Finsensgade 35, 6700 Esbjerg, Denmark; Department of Regional Health Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark.&#xD;BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, J.B. Winsloewsvej 21, 5000 Odense, Denmark.&#xD;Rheumatology Research Unit, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark; Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inflammatory profiles in plasma and cerebrospinal fluid of patients with neurosarcoidosis</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroimmunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroimmunol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">577849</style></pages><volume><style face="normal" font="default" size="100%">367</style></volume><number><style face="normal" font="default" size="100%">577849</style></number><edition><style face="normal" font="default" size="100%">20220326</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">*Central Nervous System Diseases/blood/cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">*Chemokines</style></keyword><keyword><style face="normal" font="default" size="100%">*Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Sarcoidosis/blood/cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokines</style></keyword><keyword><style face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">Neurosarcoidosis</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular angiogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Vascular injury</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 15</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1872-8421 (Electronic)&#xD;0165-5728 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35366560</style></accession-num><abstract><style face="normal" font="default" size="100%">METHODS: Cerebrospinal fluid (CSF) and plasma levels of 38 biomarkers from 20 neurosarcoidosis (NS) patients were compared to healthy controls (HC). RESULTS: In CSF, 25 biomarkers were significantly elevated compared to HC: IFNgamma, TNFalpha, TNFbeta, IL-2, IL-6, IL-10, IL-12B, IL-15, IL-16, CCL2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10, TNFR2, VEGF-A, PIGF, SAA, VCAM1, and ICAM1. In plasma, 12 biomarkers were significantly elevated compared to HC: IFNgamma, TNFalpha, CCL2, CCL3, CCL4, CCL17, CXCL10, VEGFR1, PIGF, SAA, VCAM1, and ICAM1. CONCLUSION: NS patients have profoundly elevated cytokines, chemokines, vascular angiogenesis, and vascular injury biomarkers in CSF and plasma.</style></abstract><notes><style face="normal" font="default" size="100%">Byg, Keld-Erik&#xD;Illes, Zsolt&#xD;Sejbaek, Tobias&#xD;Lambertsen, Kate L&#xD;Ellingsen, Torkell&#xD;Nielsen, Helle H&#xD;eng&#xD;Netherlands&#xD;2022/04/03&#xD;J Neuroimmunol. 2022 Jun 15;367:577849. doi: 10.1016/j.jneuroim.2022.577849. Epub 2022 Mar 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35366560</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jneuroim.2022.577849</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>198</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">198</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lund, M. C.</style></author><author><style face="normal" font="default" size="100%">Ellman, D. G.</style></author><author><style face="normal" font="default" size="100%">Nissen, M.</style></author><author><style face="normal" font="default" size="100%">Nielsen, P. S.</style></author><author><style face="normal" font="default" size="100%">Nielsen, P. V.</style></author><author><style face="normal" font="default" size="100%">Jorgensen, C.</style></author><author><style face="normal" font="default" size="100%">Andersen, D. C.</style></author><author><style face="normal" font="default" size="100%">Gao, H.</style></author><author><style face="normal" font="default" size="100%">Brambilla, R.</style></author><author><style face="normal" font="default" size="100%">Degn, M.</style></author><author><style face="normal" font="default" size="100%">Clausen, B. H.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense C, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, 5000 Odense C, Denmark.&#xD;Andersen Group, Department of Clinical Biochemistry, Odense University Hospital, 5000 Odense C, Denmark.&#xD;Danish Center for Regenerative Medicine, Odense University Hospital, 5000 Odense C, Denmark.&#xD;Department of Spine Surgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.&#xD;Guangdong Provincial Center for Engineering and Technology Research of Minimally Invasive Spine Surgery, Guangzhou 510630, China.&#xD;The Miami Project to Cure Paralysis, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.&#xD;Brain Research Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, University of Southern Denmark, 5000 Odense C, Denmark.&#xD;Department of Pediatrics and Adolescent Medicine, Rigshospitalet, 2100 Copenhagen, Denmark.&#xD;Department of Neurology, Odense University Hospital, 5000 Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Inflammatory Response after Moderate Contusion Spinal Cord Injury: A Time Study</style></title><secondary-title><style face="normal" font="default" size="100%">Biology (Basel)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biology (Basel)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">939</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">20220620</style></edition><keywords><keyword><style face="normal" font="default" size="100%">cytokines</style></keyword><keyword><style face="normal" font="default" size="100%">immune cells</style></keyword><keyword><style face="normal" font="default" size="100%">microglia</style></keyword><keyword><style face="normal" font="default" size="100%">neuroinflammation</style></keyword><keyword><style face="normal" font="default" size="100%">tumor necrosis factor</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 20</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">MDPI AG</style></publisher><isbn><style face="normal" font="default" size="100%">2079-7737 (Print)&#xD;2079-7737 (Electronic)&#xD;2079-7737 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35741460</style></accession-num><abstract><style face="normal" font="default" size="100%">Spinal cord injury (SCI) initiates detrimental cellular and molecular events that lead to acute and delayed neuroinflammation. Understanding the role of the inflammatory response in SCI requires insight into the temporal and cellular synthesis of inflammatory mediators. We subjected C57BL/6J mice to SCI and investigated inflammatory reactions. We examined activation, recruitment, and polarization of microglia and infiltrating immune cells, focusing specifically on tumor necrosis factor (TNF) and its receptors TNFR1 and TNFR2. In the acute phase, TNF expression increased in glial cells and neuron-like cells, followed by infiltrating immune cells. TNFR1 and TNFR2 levels increased in the delayed phase and were found preferentially on neurons and glial cells, respectively. The acute phase was dominated by the infiltration of granulocytes and macrophages. Microglial/macrophage expression of Arg1 increased from 1-7 days after SCI, followed by an increase in Itgam, Cx3cr1, and P2ry12, which remained elevated throughout the study. By 21 and 28 days after SCI, the lesion core was populated by galectin-3(+), CD68(+), and CD11b(+) microglia/macrophages, surrounded by a glial scar consisting of GFAP(+) astrocytes. Findings were verified in postmortem tissue from individuals with SCI. Our findings support the consensus that future neuroprotective immunotherapies should aim to selectively neutralize detrimental immune signaling while sustaining pro-regenerative processes.</style></abstract><notes><style face="normal" font="default" size="100%">Lund, Minna Christiansen&#xD;Ellman, Ditte Gry&#xD;Nissen, Maiken&#xD;Nielsen, Pernille Sveistrup&#xD;Nielsen, Pernille Vinther&#xD;Jorgensen, Carina&#xD;Andersen, Ditte Caroline&#xD;Gao, Han&#xD;Brambilla, Roberta&#xD;Degn, Matilda&#xD;Clausen, Bettina Hjelm&#xD;Lambertsen, Kate Lykke&#xD;eng&#xD;R230-2016-3019/The Lundbeck Foundation/&#xD;NA/Fonden til Laegevidenskabens Fremme/&#xD;NA/Overlaegeradets Legatudvalg - Odense Universitetshospital/&#xD;2017YFA0105403/the National Key R&amp;amp;D Program of China/&#xD;82001316/the National Science Foundation for Distinguished Young Scholars of China/&#xD;Switzerland&#xD;2022/06/25&#xD;Biology (Basel). 2022 Jun 20;11(6):939. doi: 10.3390/biology11060939.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35741460</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest and the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9220050</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/biology11060939</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>199</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">199</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bjerck-Amundsen, F.</style></author><author><style face="normal" font="default" size="100%">Opsahl, T.</style></author><author><style face="normal" font="default" size="100%">Emiliussen, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychology, University of Southern Denmark, Odense, Denmark.&#xD;Unit for Clinical Alcohol Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The interaction between good life conceptions and psychotherapeutic practice - an interpretative phenomenological study of psychologists&apos; experiences</style></title><secondary-title><style face="normal" font="default" size="100%">Scand J Psychol</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">8-18</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20211206</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Adaptation, Psychological</style></keyword><keyword><style face="normal" font="default" size="100%">*Empathy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Qualitative Research</style></keyword><keyword><style face="normal" font="default" size="100%">Good life</style></keyword><keyword><style face="normal" font="default" size="100%">Interpretative Phenomenological Analysis</style></keyword><keyword><style face="normal" font="default" size="100%">psychologists</style></keyword><keyword><style face="normal" font="default" size="100%">psychotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">well-being</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1467-9450 (Electronic)&#xD;0036-5564 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34873708</style></accession-num><abstract><style face="normal" font="default" size="100%">Based on qualitative interviews with four Danish psychologists and employing Interpretative Phenomenological Analysis (IPA), this study explored psychologists&apos; understandings about the good life and how these influence the participants&apos; clinical practice. The study found that the participants were quite aware of how their conceptions of the good life play a role in their work. Good life understandings that influenced therapeutic practice were quite similar amongst participants and were largely characterized by traits often associated with good mental health. Themes identified were: &quot;Everyday well-being,&quot; &quot;presence&quot;, and &quot;taking care of oneself and others,&quot; and subthemes were &quot;contact with the self,&quot; &quot;awareness of the good things in life,&quot; &quot;connectedness,&quot; &quot;to mean something to others,&quot; &quot;coping with distress,&quot; and &quot;compassion for oneself and others.&quot; Among participants, these good life conceptions had a similar influence on different areas of their practice in terms of how the participants understand their clients&apos; issues, which impacted what they talk to their clients about, and what they seek to achieve with the clients in therapy. Therefore, the good life conceptions influenced the methods, techniques, personal behaviors, and therapeutic approaches used to provide good and effective therapy. Another finding was that participants&apos; clinical experiences also seemed to impact their good life conceptions. The interpretation of the participants&apos; experiences represented a hermeneutic model suggesting that the participants&apos; good life conceptions and their clinical practice experiences might inform and reinforce each other in a continuously expanding overlap. The actual nature of this interaction and its implications are relevant for future research.</style></abstract><notes><style face="normal" font="default" size="100%">Bjerck-Amundsen, Freja&#xD;Opsahl, Tobias&#xD;Emiliussen, Jakob&#xD;eng&#xD;England&#xD;2021/12/08&#xD;Scand J Psychol. 2022 Feb;63(1):8-18. doi: 10.1111/sjop.12778. Epub 2021 Dec 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34873708</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/sjop.12778</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>154</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">154</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schadlich, I. S.</style></author><author><style face="normal" font="default" size="100%">Vienhues, J. H.</style></author><author><style face="normal" font="default" size="100%">Jander, A.</style></author><author><style face="normal" font="default" size="100%">Piepke, M.</style></author><author><style face="normal" font="default" size="100%">Magnus, T.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Clausen, B. H.</style></author><author><style face="normal" font="default" size="100%">Gelderblom, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg-Eppendorf, Germany. i.schaedlich@uke.de.&#xD;Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg-Eppendorf, Germany.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.&#xD;BRIDGE - Brain Research - Inter Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Deparment of Neurology, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interleukin-1 Mediates Ischemic Brain Injury via Induction of IL-17A in gammadelta T Cells and CXCL1 in Astrocytes</style></title><secondary-title><style face="normal" font="default" size="100%">Neuromolecular Med</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">437-451</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220406</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-17/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Chemokine CXCL1/genetics/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style face="normal" font="default" size="100%">*Stroke/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">T-Lymphocytes</style></keyword><keyword><style face="normal" font="default" size="100%">*Brain Injuries</style></keyword><keyword><style face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style face="normal" font="default" size="100%">Astrocytes</style></keyword><keyword><style face="normal" font="default" size="100%">Cxcl1</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-1</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-17A</style></keyword><keyword><style face="normal" font="default" size="100%">Ischemic stroke</style></keyword><keyword><style face="normal" font="default" size="100%">gammadelta T cells</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1559-1174 (Electronic)&#xD;1535-1084 (Print)&#xD;1535-1084 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35384588</style></accession-num><abstract><style face="normal" font="default" size="100%">As a prototypical proinflammatory cytokine, interleukin-1 (IL-1) exacerbates the early post-stroke inflammation, whereas its neutralization is protective. To further investigate the underlying cell-type-specific IL-1 effects, we subjected IL-1 (alpha/beta) knockout (Il1(-/-)) and wildtype (WT) littermate mice to permanent middle cerebral artery occlusion (pMCAO) and assessed immune cell infiltration and cytokine production in the ischemic hemisphere by flow cytometry 24 h and 72 h after stroke. Il1(-/-) mice showed smaller infarcts and reduced neutrophil infiltration into the ischemic brain. We identified gammadelta T cells and astrocytes as target cells of IL-1 signaling-mediated neutrophil recruitment. First, IL-1-induced IL-17A production in gammadelta T cells in vivo, and IL-17A enhanced the expression of the main neutrophil attracting chemokine CXCL1 by astrocytes in the presence of tumor necrosis factor (TNF) in vitro. Second, IL-1 itself was a potent activator of astrocytic CXCL1 production in vitro. By employing a novel FACS sorting strategy for the acute isolation of astrocytes from ischemic brains, we confirmed that IL-1 is pivotal for Cxcl1 upregulation in astrocytes in vivo. Our results underscore the pleiotropic effects of IL-1 on immune and non-immune cells within the CNS to mount and amplify the post-stroke inflammatory response.</style></abstract><notes><style face="normal" font="default" size="100%">Schadlich, Ines Sophie&#xD;Vienhues, Jonas Heinrich&#xD;Jander, Alina&#xD;Piepke, Marius&#xD;Magnus, Tim&#xD;Lambertsen, Kate Lykke&#xD;Clausen, Bettina Hjelm&#xD;Gelderblom, Mathias&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/04/07&#xD;Neuromolecular Med. 2022 Dec;24(4):437-451. doi: 10.1007/s12017-022-08709-y. Epub 2022 Apr 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35384588</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9684245</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s12017-022-08709-y</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tingleff, E. B.</style></author><author><style face="normal" font="default" size="100%">Rowaert, S.</style></author><author><style face="normal" font="default" size="100%">Vinding, S.</style></author><author><style face="normal" font="default" size="100%">Vestphal, T. K.</style></author><author><style face="normal" font="default" size="100%">Wilson, R.</style></author><author><style face="normal" font="default" size="100%">Gildberg, F. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Forensic Mental Health Research Unit Middelfart (RFM), Department of Regional Health Research, Faculty of Health Science, University of Southern Denmark, Denmark; Psychiatric Department Middelfart, Mental Health Services in the Region of Southern Denmark, Denmark; Nursing Education, Vejle, and Health Sciences Research Center, UCL University College, Denmark; OPEN, Odense Service user data Explorative Network, Odense University Hospital/Department of Clinical Research, University of Southern Denmark, Denmark. Electronic address: ellen.boldrup.tingleff@rsyd.dk.&#xD;Department of Special Needs Education, Faculty of Psychology and Educational Sciences, Ghent University, Belgium.&#xD;Nursing Education, Vejle, and Health Sciences Research Center, UCL University College, Denmark.&#xD;Forensic Mental Health Research Unit Middelfart (RFM), Department of Regional Health Research, Faculty of Health Science, University of Southern Denmark, Denmark; Psychiatric Department Middelfart, Mental Health Services in the Region of Southern Denmark, Denmark.&#xD;School of Nursing and Midwifery, College of Health, Medicine, and Wellbeing, The University of Newcastle, Australia; School of Nursing, Massey University, New Zealand.</style></auth-address><titles><title><style face="normal" font="default" size="100%">&quot;It&apos;s still our child&quot;. A qualitative interview study with parent carers in forensic mental health</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Psychiatr Nurs</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">124-131</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><edition><style face="normal" font="default" size="100%">20220716</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Caregivers/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Health</style></keyword><keyword><style face="normal" font="default" size="100%">Parents/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Qualitative Research</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">Family</style></keyword><keyword><style face="normal" font="default" size="100%">Forensic mental health services</style></keyword><keyword><style face="normal" font="default" size="100%">Qualitative studies</style></keyword><keyword><style face="normal" font="default" size="100%">Semi-structured interview</style></keyword><keyword><style face="normal" font="default" size="100%">Service user</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1532-8228 (Electronic)&#xD;0883-9417 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36428040</style></accession-num><abstract><style face="normal" font="default" size="100%">The purpose of this study was to explore the experiences and perceptions of parents in forensic mental health services with regard to their cooperation with healthcare professionals and their role as parent carers. 15 participants were interviewed using qualitative, in-depth interviews and transcripts were analysed thematically. The identified themes were &apos;Medical dominance&apos;, &apos;Interactions with healthcare professionals&apos;, and &apos;Advocating for their daughter/son&apos;. The themes were associated with the overall theme &apos;perceived impact on the parents&apos; everyday lives&apos;. The results suggest that parent carers perceive a malalignment between the institutional medicalised treatment focus and the need for an integrated holistic approach, which would include them as partners.</style></abstract><notes><style face="normal" font="default" size="100%">Tingleff, Ellen Boldrup&#xD;Rowaert, Sara&#xD;Vinding, Stinne&#xD;Vestphal, Tina Kirstine&#xD;Wilson, Rhonda&#xD;Gildberg, Frederik Alkier&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/11/26&#xD;Arch Psychiatr Nurs. 2022 Dec;41:124-131. doi: 10.1016/j.apnu.2022.07.017. Epub 2022 Jul 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36428040</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of competing interest None.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.apnu.2022.07.017</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>241</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">241</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mathiesen, T.</style></author><author><style face="normal" font="default" size="100%">Haslund-Vinding, J.</style></author><author><style face="normal" font="default" size="100%">Skjoth-Rasmussen, J.</style></author><author><style face="normal" font="default" size="100%">Poulsgaard, L.</style></author><author><style face="normal" font="default" size="100%">Fugleholm, K.</style></author><author><style face="normal" font="default" size="100%">Mirian, C.</style></author><author><style face="normal" font="default" size="100%">Daniela Maier, A.</style></author><author><style face="normal" font="default" size="100%">Santarius, T.</style></author><author><style face="normal" font="default" size="100%">Rom Poulsen, F.</style></author><author><style face="normal" font="default" size="100%">Andree Larsen, V.</style></author><author><style face="normal" font="default" size="100%">Winther Kristensen, B.</style></author><author><style face="normal" font="default" size="100%">Scheie, D.</style></author><author><style face="normal" font="default" size="100%">Law, I.</style></author><author><style face="normal" font="default" size="100%">Ziebell, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">1Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.&#xD;2University of Copenhagen, Denmark.&#xD;3Karolinska Institutet, Stockholm, Sweden.&#xD;4Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.&#xD;5Odense University Hospital, Clinical Institute, University of Southern Denmark, Odense, Denmark.&#xD;6BRIDGE-Brain Research Inter Disciplinary Guided Excellence, Clinical Institute, University of Southern Denmark, Odense, Denmark.&#xD;7Nuclear Medicine and PET, Copenhagen University Hospital, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Letter to the Editor. Copenhagen grading of meningioma</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurosurg</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neurosurg</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-3</style></pages><edition><style face="normal" font="default" size="100%">20220121</style></edition><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 21</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1933-0693 (Electronic)&#xD;0022-3085 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35061983</style></accession-num><notes><style face="normal" font="default" size="100%">Mathiesen, Tiit&#xD;Haslund-Vinding, Jeppe&#xD;Skjoth-Rasmussen, Jane&#xD;Poulsgaard, Lars&#xD;Fugleholm, Kare&#xD;Mirian, Christian&#xD;Daniela Maier, Andrea&#xD;Santarius, Thomas&#xD;Rom Poulsen, Frantz&#xD;Andree Larsen, Vibeke&#xD;Winther Kristensen, Bjarne&#xD;Scheie, David&#xD;Law, Ian&#xD;Ziebell, Morten&#xD;eng&#xD;Letter&#xD;2022/01/22&#xD;J Neurosurg. 2022 Jan 21:1-3. doi: 10.3171/2021.10.JNS204467.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35061983</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3171/2021.10.JNS204467</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>242</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">242</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Haddad, P. M.</style></author><author><style face="normal" font="default" size="100%">Correll, C. U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry Aabenraa, Mental Health Services Region of Southern Denmark, Aabenraa, Denmark.&#xD;Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, United Kingdom.&#xD;Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">85-86</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Schizophrenic Psychology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2168-6238 (Electronic)&#xD;2168-622X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34817573</style></accession-num><notes><style face="normal" font="default" size="100%">Hojlund, Mikkel&#xD;Haddad, Peter M&#xD;Correll, Christoph U&#xD;eng&#xD;Comment&#xD;2021/11/25&#xD;JAMA Psychiatry. 2022 Jan 1;79(1):85-86. doi: 10.1001/jamapsychiatry.2021.3452.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34817573</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jamapsychiatry.2021.3452</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>243</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">243</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Winkel, J. S.</style></author><author><style face="normal" font="default" size="100%">Nybo, M.</style></author><author><style face="normal" font="default" size="100%">Hallas, J.</style></author><author><style face="normal" font="default" size="100%">Henriksen, D. P.</style></author><author><style face="normal" font="default" size="100%">Damkier, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark.&#xD;Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lithium and the risk of chronic kidney disease: A population-based case-control study</style></title><secondary-title><style face="normal" font="default" size="100%">Basic Clin Pharmacol Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Basic Clin Pharmacol Toxicol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">129-137</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20220606</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney Function Tests</style></keyword><keyword><style face="normal" font="default" size="100%">*Lithium/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">*Renal Insufficiency, Chronic/chemically induced/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">case-control study</style></keyword><keyword><style face="normal" font="default" size="100%">chronic kidney disease</style></keyword><keyword><style face="normal" font="default" size="100%">lithium</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacoepidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">psychopharmacology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1742-7843 (Electronic)&#xD;1742-7835 (Print)&#xD;1742-7835 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35644911</style></accession-num><abstract><style face="normal" font="default" size="100%">The association between lithium use and chronic kidney disease (CKD) needs further evaluation. We aimed to investigate this association using Danish nationwide healthcare registers and routinely collected plasma creatinine measurements from the Funen Laboratory Cohort. We conducted a case-control study nested within the population of Funen, 2001-2015. Incident cases of CKD (estimated glomerular filtration rate &lt;60 ml/min/1.73m(2) ; n = 21 432) were matched with four CKD-free controls on age, sex and calendar time (n = 85 532). We estimated odds ratios (OR) for the association between lithium exposure and CKD using conditional logistic regression models, adjusted for known risk factors for CKD. Ever-use of lithium was associated with an increased risk of CKD (adjusted OR [aOR]: 1.57; 95% confidence interval [CI]: 1.33-1.85). A stronger association was seen with current use of lithium (aOR: 1.92; 95%CI: 1.58-2.33) and long-term use of lithium (&gt;10 years: aOR: 3.02; 95%CI: 2.00-4.56). Furthermore, we found evidence of a dose-response relationship between cumulative dose of lithium and the risk of CKD. In conclusion, the use of lithium, especially long-term, is associated with an increased risk of CKD, although the extent to which detection bias and confounding by indication contribute to the association is unclear. Monitoring of kidney function in lithium users remains mandatory to identify individuals in which switching to alternative medications should be considered.</style></abstract><notes><style face="normal" font="default" size="100%">Hojlund, Mikkel&#xD;Winkel, Jane Sterndorff&#xD;Nybo, Mads&#xD;Hallas, Jesper&#xD;Henriksen, Daniel Pilsgaard&#xD;Damkier, Per&#xD;eng&#xD;42282/The Beckett foundation/&#xD;The Hede-Nielsen Family Foundation/&#xD;England&#xD;2022/06/02&#xD;Basic Clin Pharmacol Toxicol. 2022 Aug;131(2):129-137. doi: 10.1111/bcpt.13758. Epub 2022 Jun 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35644911</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9541887</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/bcpt.13758</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>155</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">155</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maier, A. D.</style></author><author><style face="normal" font="default" size="100%">Brochner, C. B.</style></author><author><style face="normal" font="default" size="100%">Mirian, C.</style></author><author><style face="normal" font="default" size="100%">Haslund-Vinding, J.</style></author><author><style face="normal" font="default" size="100%">Bartek, J., Jr.</style></author><author><style face="normal" font="default" size="100%">Ekstrom, T. J.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author><author><style face="normal" font="default" size="100%">Scheie, D.</style></author><author><style face="normal" font="default" size="100%">Mathiesen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Inge Lehmanns Vej 6, Copenhagen, Denmark. andrea.maier@regionh.dk.&#xD;Pathology Department, Copenhagen University Hospital, Rigshospitalet, Inge Lehmanns Vej 7, Copenhagen, Denmark. andrea.maier@regionh.dk.&#xD;Pathology Department, Copenhagen University Hospital, Rigshospitalet, Inge Lehmanns Vej 7, Copenhagen, Denmark.&#xD;Department of Neurosurgery, Copenhagen University Hospital, Rigshospitalet, Inge Lehmanns Vej 6, Copenhagen, Denmark.&#xD;Department of Neurosurgery, Karolinska University Hospital, Eugeniavagen 3, Solna, 171 64, Stockholm, Sweden.&#xD;Department of Clinical Neuroscience, Karolinska Institutet, Solnavagen 1, Solna, 171 77, Stockholm, Sweden.&#xD;Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.&#xD;Department of Molecular Medicine and Surgery, Karolinska Institutet, Solnavagen 1, Solna, 171 77, Stockholm, Sweden.&#xD;Department of Neurosurgery, Odense University Hospital, Klovervaenget 47, Odense, Denmark.&#xD;Clinical Institute, University of Southern Denmark and BRIDGE, Winslowparken 19, Odense, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Loss of H3K27me3 in WHO grade 3 meningioma</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Tumor Pathol</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">200-209</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220609</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Histones/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Meningeal Neoplasms/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">*Meningioma/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">World Health Organization</style></keyword><keyword><style face="normal" font="default" size="100%">H3K27me3</style></keyword><keyword><style face="normal" font="default" size="100%">Heterogeneity</style></keyword><keyword><style face="normal" font="default" size="100%">Meningioma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1861-387X (Electronic)&#xD;1433-7398 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35678886</style></accession-num><abstract><style face="normal" font="default" size="100%">Immunohistochemical quantification of H3K27me3 was reported to distinguish meningioma patients with an unfavorable prognosis but is not yet established as a prognostic biomarker within WHO grade 3 meningiomas. We studied H3K27me3 loss in a series of biopsies from primary and secondary malignant meningioma to validate its prognostic performance and describe if loss of H3K27me3 occurs during malignant transformation. Two observers quantified H3K27me3 status as &quot;complete loss&quot;, &lt; 50% and &gt; 50% stained cells in 110 tumor samples from a population-based consecutive cohort of 40 WHO grade 3 meningioma patients. We found no difference in overall survival (OS) in patients with &gt; 50% H3K27me3 retention compared to &lt; 50% in the cohort of patients with WHO grade 3 meningioma (Wald test p = 0.5). H3K27me3 staining showed heterogeneity in full section tumor slides while staining of the Barr body and peri-necrotic cells complicated quantification further. H3K27me3 expression differed without a discernible pattern between biopsies from repeated surgeries of meningioma recurrences. In conclusion, our results were not compatible with a systematic pattern of immunohistochemical H3K27me3 loss being associated with OS or malignant transformation of meningiomas and did not support H3K27me3 loss as a useful immunohistochemical biomarker within grade 3 meningiomas due to staining-specific challenges in quantification.</style></abstract><notes><style face="normal" font="default" size="100%">Maier, Andrea Daniela&#xD;Brochner, Christian Beltoft&#xD;Mirian, Christian&#xD;Haslund-Vinding, Jeppe&#xD;Bartek, Jiri Jr&#xD;Ekstrom, Tomas J&#xD;Poulsen, Frantz Rom&#xD;Scheie, David&#xD;Mathiesen, Tiit&#xD;eng&#xD;R278-A16459/Kraeftens Bekaempelse/&#xD;R266-2017-4029/Lundbeckfonden/&#xD;Japan&#xD;2022/06/10&#xD;Brain Tumor Pathol. 2022 Oct;39(4):200-209. doi: 10.1007/s10014-022-00436-3. Epub 2022 Jun 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35678886</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10014-022-00436-3</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aunan-Diop, J. S.</style></author><author><style face="normal" font="default" size="100%">Halle, B.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. B.</style></author><author><style face="normal" font="default" size="100%">Jensen, U.</style></author><author><style face="normal" font="default" size="100%">Munthe, S.</style></author><author><style face="normal" font="default" size="100%">Harbo, F.</style></author><author><style face="normal" font="default" size="100%">Andersen, M. S.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Odense University Hospital, 5000 Odense, Denmark.&#xD;Clinical Institute, University of Southern Denmark, BRIDGE (Brain Research - Inter Disciplinary Guided Excellence), University of Southern Denmark, 5000 Odense C, Denmark.&#xD;Department of Radiology, Odense University Hospital, 5000 Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Magnetic Resonance Elastography in Intracranial Neoplasms: A Scoping Review</style></title><secondary-title><style face="normal" font="default" size="100%">Top Magn Reson Imaging</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">9-22</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Brain Neoplasms/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">*Elasticity Imaging Techniques/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Glioblastoma/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">*Glioma</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/methods</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 1</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Ovid Technologies (Wolters Kluwer Health)</style></publisher><isbn><style face="normal" font="default" size="100%">1536-1004 (Electronic)&#xD;0899-3459 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35225840</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Magnetic resonance elastography (MRE) allows noninvasive assessment of intracranial tumor mechanics and may thus be predictive of intraoperative conditions. Variations in the use of technical terms complicate reading of current literature, and there is need of a review using consolidated nomenclature. OBJECTIVES: We present an overview of current literature on MRE relating to human intracranial neoplasms using standardized nomenclature suggested by the MRE guidelines committee. We then discuss the implications of the findings, and suggest approaches for future research. METHOD: We performed a systematic literature search in PubMed, Embase, and Web of Science; the articles were screened for relevance and then subjected to full text review. Technical terms were consolidated. RESULTS: We identified 12 studies on MRE in patients with intracranial tumors, including meningiomas, glial tumors including glioblastomas, vestibular schwannomas, hemangiopericytoma, central nervous system lymphoma, pituitary macroadenomas, and brain metastases. The studies had varying objectives that included prediction of intraoperative consistency, histological separation, prediction of adhesiveness, and exploration of the mechanobiology of tumor invasiveness and malignancy. The technical terms were translated using standardized nomenclature. The literature was highly heterogeneous in terms of image acquisition techniques, post-processing, and study design and was generally limited by small and variable cohorts. CONCLUSIONS: MRE shows potential in predicting tumor consistency, adhesion, and mechanical homogeneity. Furthermore, MRE provides insight into malignant tumor behavior and its relation to tissue mechanics. MRE is still at a preclinical stage, but technical advances, improved understanding of soft tissue rheological impact, and larger samples are likely to enable future clinical introduction.</style></abstract><notes><style face="normal" font="default" size="100%">Aunan-Diop, Jan Saip&#xD;Halle, Bo&#xD;Pedersen, Christian Bonde&#xD;Jensen, Ulla&#xD;Munthe, Sune&#xD;Harbo, Frederik&#xD;Andersen, Mikkel Schou&#xD;Poulsen, Frantz Rom&#xD;eng&#xD;Review&#xD;2022/03/01&#xD;Top Magn Reson Imaging. 2022 Feb 1;31(1):9-22. doi: 10.1097/RMR.0000000000000292.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35225840</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors report no conflicts of interest.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/RMR.0000000000000292</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>279</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">279</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Coghill, D.</style></author><author><style face="normal" font="default" size="100%">Banaschewski, T.</style></author><author><style face="normal" font="default" size="100%">Cortese, S.</style></author><author><style face="normal" font="default" size="100%">Asherson, P.</style></author><author><style face="normal" font="default" size="100%">Brandeis, D.</style></author><author><style face="normal" font="default" size="100%">Buitelaar, J.</style></author><author><style face="normal" font="default" size="100%">Daley, D.</style></author><author><style face="normal" font="default" size="100%">Danckaerts, M.</style></author><author><style face="normal" font="default" size="100%">Dittmann, R. W.</style></author><author><style face="normal" font="default" size="100%">Doepfner, M.</style></author><author><style face="normal" font="default" size="100%">Ferrin, M.</style></author><author><style face="normal" font="default" size="100%">Hollis, C.</style></author><author><style face="normal" font="default" size="100%">Holtmann, M.</style></author><author><style face="normal" font="default" size="100%">Paramala, S.</style></author><author><style face="normal" font="default" size="100%">Sonuga-Barke, E.</style></author><author><style face="normal" font="default" size="100%">Soutullo, C.</style></author><author><style face="normal" font="default" size="100%">Steinhausen, H. C.</style></author><author><style face="normal" font="default" size="100%">Van der Oord, S.</style></author><author><style face="normal" font="default" size="100%">Wong, I. C. K.</style></author><author><style face="normal" font="default" size="100%">Zuddas, A.</style></author><author><style face="normal" font="default" size="100%">Simonoff, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.&#xD;Murdoch Children&apos;s Research Institute, Melbourne, Australia.&#xD;Royal Children&apos;s Hospital, Melbourne, Australia.&#xD;Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.&#xD;Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK.&#xD;Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Solent NHS Trust, Southampton, UK.&#xD;Hassenfeld Children&apos;s Hospital at NYU Langone, New York University Child Study Center, New York City, New York, USA.&#xD;Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.&#xD;NIHR MindTech Mental Health MedTech Cooperative &amp; Centre for ADHD and Neurodevelopmental Disorders Across the Lifespan CANDAL, Institute of Mental Health, University of Nottingham, Nottingham, UK.&#xD;Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK.&#xD;Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.&#xD;Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.&#xD;Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.&#xD;Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.&#xD;Research Group of Developmental Psychiatry, Center for Developmental Psychiatry, KU Leuven, Kapucijnenvoer 7, Blok H, 3000, Leuven, Belgium.&#xD;Department of Child and Adolescent Psychiatry, UPC KU Leuven, Leuven, Belgium.&#xD;Paediatric Psychopharmacology, Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.&#xD;Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.&#xD;Haringey CAMHS, NHS, and ReCognition Health, London, UK.&#xD;LWL-University Hospital for Child and Adolescent Psychiatry, Ruhr-University Bochum, Hamm, Germany.&#xD;Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK.&#xD;Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.&#xD;Louis A Fallace Department of Psychiatry and Behavioral Science, University of Texas, Houston, TX, USA.&#xD;Department of Child and Adolescent Psychiatry, Aarhus University, Aarhus, Denmark.&#xD;Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry, Zurich, Switzerland.&#xD;Clinical Psychology and Epidemiology, Institute of Psychology, University of Basel, Basel, Switzerland.&#xD;Department of Child and Adolescent Mental Health, University of Southern Denmark, Odense, Denmark.&#xD;Child and Adolescent Mental Health Centre, Capital Region Psychiatry, Copenhagen, Denmark.&#xD;Clinical Psychology, KU Leuven, Leuven, Belgium.&#xD;Developmental Psychology, University of Amsterdam, Amsterdam, The Netherlands.&#xD;School of Pharmacy, University College London, London, UK.&#xD;Child and Adolescent Neuropsychiatry Unit, Department of Biomedical Sciences, University of Cagliari and Antonio Cao Paediatric Hospital, G. Brotzu Hospital Trust, Cagliari, Italy.&#xD;LWL-University Hospital for Child and Adolescent Psychiatry, Ruhr-University Bochum, Hamm, Germany. emily.simonoff@kcl.ac.uk.&#xD;Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK. emily.simonoff@kcl.ac.uk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-25</style></pages><edition><style face="normal" font="default" size="100%">20211022</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Attention deficit hyperactivity disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence-based medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Guideline</style></keyword><keyword><style face="normal" font="default" size="100%">Intervention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 22</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1435-165X (Electronic)&#xD;1018-8827 (Print)&#xD;1018-8827 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34677682</style></accession-num><abstract><style face="normal" font="default" size="100%">ADHD is the most common neurodevelopmental disorder presenting to child and adolescent mental health, paediatric, and primary care services. Timely and effective interventions to address core ADHD symptoms and co-occurring problems are a high priority for healthcare and society more widely. While much research has reported on the benefits and adverse effects of different interventions for ADHD, these individual research reports and the reviews, meta-analyses and guidelines summarizing their findings are sometimes inconsistent and difficult to interpret. We have summarized the current evidence and identified several methodological issues and gaps in the current evidence that we believe are important for clinicians to consider when evaluating the evidence and making treatment decisions. These include understanding potential impact of bias such as inadequate blinding and selection bias on study outcomes; the relative lack of high-quality data comparing different treatments and assessing long-term effectiveness, adverse effects and safety for both pharmacological and non-pharmacological treatments; and the problems associated with observational studies, including those based on large national registries and comparing treatments with each other. We highlight key similarities across current international clinical guidelines and discuss the reasons for divergence where these occur. We discuss the integration of these different perspective into a framework for person/family-centered evidence-based practice approach to care that aims to achieve optimal outcomes that prioritize individual strengths and impairments, as well as the personal treatment targets of children and their families. Finally, we consider how access to care for this common and impairing disorder can be improved in different healthcare systems.</style></abstract><notes><style face="normal" font="default" size="100%">Coghill, David&#xD;Banaschewski, Tobias&#xD;Cortese, Samuele&#xD;Asherson, Philip&#xD;Brandeis, Daniel&#xD;Buitelaar, Jan&#xD;Daley, David&#xD;Danckaerts, Marina&#xD;Dittmann, Ralf W&#xD;Doepfner, Manfred&#xD;Ferrin, Maite&#xD;Hollis, Chris&#xD;Holtmann, Martin&#xD;Paramala, Santosh&#xD;Sonuga-Barke, Edmund&#xD;Soutullo, Cesar&#xD;Steinhausen, Hans-Christoph&#xD;Van der Oord, Saskia&#xD;Wong, Ian C K&#xD;Zuddas, Alessandro&#xD;Simonoff, Emily&#xD;eng&#xD;Review&#xD;Germany&#xD;2021/10/23&#xD;Eur Child Adolesc Psychiatry. 2021 Oct 22:1-25. doi: 10.1007/s00787-021-01871-x.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34677682</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">SC reports honoraria and reimbursement for talks on ADHD from the Association of Child and Adolescent Mental Health, British Association of Psychopharmacology, and the Canadian ADHD Resource Alliance and Healthcare Convention. PA reports honoraria for consultancy to Shire/Takeda, Eli Lilly, and Novartis; educational and research awards from Shire, Lilly, Novartis, Vifor Pharma, GW Pharma, and QbTech; and speaking at sponsored events for Shire, Lilly, Flynn Pharma, and Novartis. ES-B reports personal fees from Shire and Neurotech Solutions. TB reports personal fees for being on the advisory board from ADHS digital, Infectopharm, Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Roche, and Takeda. He received conference support or speaker&apos;s fee by Medice and Takeda. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press, outside the submitted work. DB is an unpaid scientific advisor for an EU-funded Neurofeedback trial. JB reports personal fees for lectures from Janssen, Takeda/Shire, and Medice; and personal fees for being on the advisory board from Roche, Medice, Servier, and Angelini, outside the submitted work. DC reports grants and personal fees from Shire and Takeda, and personal fees from Medice, Servier, and Oxford University Press, outside the submitted work. DD reports grants, personal fees, and non-financial support from Shire/Takeda, personal fees and non-financial support from Eli Lilly and Medice, non-financial support from Qb Tech, book royalties from Hachette, and training and supervision fees from the New Forest Parent Training Programme, outside the submitted work. RWD has received compensation for serving as consultant or speaker, or he or the institution he works for have received research support or royalties from the following organizations or companies: EU (FP7 Programme), US National Institute of Mental Health, German Federal Ministry of Health/Regulatory Agency, German Federal Ministry of Education and Research, German Research Foundation, Volkswagen Foundation, Boehringer Ingelheim, Ferring, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Servier, Shire, Sunovion/Takeda, and Theravance. He was an employee of Eli Lilly in clinical CNS research until August 2008, and owns Eli Lilly stock (small part of the respective annual salary). The drug marketed by Eli Lilly is not mentioned in this guidance. MDo reports grants and personal fees from Eli Lilly, Medice, Shire, Janssen Cilag, Takeda, and Vifor; grants from the German Research Foundation, German Ministry of Health, and Innovation Fund; personal fees from the National Association of Statutory Health Insurance Physicians in Germany, Beltz Publisher, Elsevier, Guilford, Hogrefe, Springer, Wiley, Kohlhammer, and Schattauer. MF reports fees for lectures from Medice and ROVI. CH was an expert member of the National Institute for Health and Care Excellence Guideline (NG87): Attention deficit hyperactivity disorder: diagnosis and management, published in 2018. MH reports personal fees from Medice, Shire, Takeda, Neuroconn, and Hogrefe, outside the submitted work. EK is CSO and Board Member of NLS Pharmaceutics, investigating drugs that are not mentioned in the current guidance. PS reports speaker&apos;s fees paid to his department; and is the CEO and shareholder of HealthTracker Ltd, which is unrelated to the submitted work. CS reports non-personal research funds from Lundbeck and Shire paid to his institution; is a consultant and advisory board member of Editorial Medica Panamericana, Medice, NeuroTech Solutions Ltd, and Shire; received speaker&apos;s bureau from Medice and Shire, and royalties from Editorial Medica Panamericana, Mayo Ediciones, and Springer SBM Spain. H-CS reports speaker&apos;s fees from Medice and book royalties from Cambridge University Press, Elsevier, Hogrefe, Huber, Klett, and Kohlhammer. IW reports grants from Research Grant Council Hong Kong; personal fees from Medice; and grants and personal fees from Janssen, outside the submitted work. AZ reports personal fees for being on advisory boards from Angelini, Edu Pharma, and Shire-Takeda; research grants from Angelini, Janssen, Lundbeck, Otsuka, and Servier; and royalties from Giunti OS and Oxford University Press, outside the submitted work. All other authors declare no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8532460</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00787-021-01871-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>244</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">244</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pedersen, Martin Locht</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mangler der mnd eller mennesker i sygeplejen?</style></title><secondary-title><style face="normal" font="default" size="100%">Nordisk sygeplejeforskning</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nordisk sygeplejeforskning</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-9</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">4</style></number><section><style face="normal" font="default" size="100%">1</style></section><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">1892-2678&#xD;1892-2686</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.18261/nsf.12.4.2</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>251</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">251</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klausen, Sren Harnow</style></author><author><style face="normal" font="default" size="100%">Emiliussen, Jakob</style></author><author><style face="normal" font="default" size="100%">Christiansen, Regina</style></author><author><style face="normal" font="default" size="100%">Hasandedic-Dapo, Lejla</style></author><author><style face="normal" font="default" size="100%">Engelsen, Sren</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The many faces of hedonic adaptation</style></title><secondary-title><style face="normal" font="default" size="100%">Philosophical Psychology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Philosophical Psychology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">253-278</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">2</style></number><section><style face="normal" font="default" size="100%">253</style></section><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">0951-5089&#xD;1465-394X</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/09515089.2021.1967308</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>257</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stripp, T. K.</style></author><author><style face="normal" font="default" size="100%">Bussing, A.</style></author><author><style face="normal" font="default" size="100%">Wehberg, S.</style></author><author><style face="normal" font="default" size="100%">Andersen, H. S.</style></author><author><style face="normal" font="default" size="100%">Korup, A. K.</style></author><author><style face="normal" font="default" size="100%">Pedersen, H. F.</style></author><author><style face="normal" font="default" size="100%">Sondergaard, J.</style></author><author><style face="normal" font="default" size="100%">Hvidt, N. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, J. B. Winslovsvej 9, 5000, Odense C, Denmark. tkstripp@health.sdu.dk.&#xD;Institute of Integrative Medicine, Faculty of Medicine, Witten/Herdecke University, 58313, Herdecke, Germany.&#xD;Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, 5000, Odense C, Denmark.&#xD;Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, J. B. Winslovsvej 9, 5000, Odense C, Denmark.&#xD;Department of Mental Health Service, Vejle, Region of Southern Denmark, Denmark.&#xD;Research Clinic for Functional Disorders and Psychosomatics, Aarhus University Hospital, 8000, Aarhus C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Measuring Spiritual Needs in a Secular Society: Validation and Clinimetric Properties of the Danish 20-Item Spiritual Needs Questionnaire</style></title><secondary-title><style face="normal" font="default" size="100%">J Relig Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Relig Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3542-3565</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220301</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">Factor Analysis, Statistical</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Psychometrics</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">*Spirituality</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Clinimetrics</style></keyword><keyword><style face="normal" font="default" size="100%">Secular society</style></keyword><keyword><style face="normal" font="default" size="100%">Spiritual needs</style></keyword><keyword><style face="normal" font="default" size="100%">Test-retest</style></keyword><keyword><style face="normal" font="default" size="100%">Validation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-6571 (Electronic)&#xD;0022-4197 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35230599</style></accession-num><abstract><style face="normal" font="default" size="100%">In secular cultures, such as Denmark, tools to measure spiritual needs are warranted to guide existential and spiritual care. We examined the clinimetric properties of the Danish version of the Spiritual Needs Questionnaire (DA-SpNQ-20) based on a digital survey in a test-retest setup. A convenience sample was reached via social media and student platforms. A total of 325 (148 for retest) respondents were included in the analysis. The sample was randomly split into two groups (A and B) and used for exploratory (EFA) and confirmatory factor analysis (CFA) by structural equation modeling, respectively. SpNQ dimensions had an internal consistency with Cronbach&apos;s alpha between 0.73 and 0.93. The four factors of the SpNQ were supported by both EFA and CFA as follows: religious needs, existential needs, inner peace needs, and generativity needs. The instrument showed good internal consistency, good test-retest reliability, and acceptable structural validity in the sample of relatively young and healthy persons.</style></abstract><notes><style face="normal" font="default" size="100%">Stripp, Tobias Kvist&#xD;Bussing, Arndt&#xD;Wehberg, Sonja&#xD;Andersen, Helene Stottrup&#xD;Korup, Alex Kappel&#xD;Pedersen, Heidi Frolund&#xD;Sondergaard, Jens&#xD;Hvidt, Niels Christian&#xD;eng&#xD;R247-A14755/Kraeftens Bekaempelse/&#xD;ID 3610/Jascha Fonden/&#xD;2022/03/02&#xD;J Relig Health. 2022 Aug;61(4):3542-3565. doi: 10.1007/s10943-022-01533-5. Epub 2022 Mar 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35230599</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10943-022-01533-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>260</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">260</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bliddal, M.</style></author><author><style face="normal" font="default" size="100%">Kildegaard, H.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, L.</style></author><author><style face="normal" font="default" size="100%">Ernst, M.</style></author><author><style face="normal" font="default" size="100%">Jennum, P. J.</style></author><author><style face="normal" font="default" size="100%">Mogensen, S. H.</style></author><author><style face="normal" font="default" size="100%">Pottegard, A.</style></author><author><style face="normal" font="default" size="100%">Wesselhoeft, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. mette.bliddal@rsyd.dk.&#xD;Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. mette.bliddal@rsyd.dk.&#xD;Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Rigshospitalet, Glostrup, Denmark.&#xD;Danish Medicines Agency&apos;s Data Analytic Centre, Copenhagen, Denmark.&#xD;Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Melatonin use among children, adolescents, and young adults: a Danish nationwide drug utilization study</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></full-title></periodical><edition><style face="normal" font="default" size="100%">20220706</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Drug utilization study</style></keyword><keyword><style face="normal" font="default" size="100%">Melatonin</style></keyword><keyword><style face="normal" font="default" size="100%">Register-based cohort study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 6</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1435-165X (Electronic)&#xD;1018-8827 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35792937</style></accession-num><abstract><style face="normal" font="default" size="100%">We aimed to provide a detailed description of the use of melatonin in Danish children, adolescents, and young adults during 2012-2019. We identified melatonin users 0-24 years of age (n = 43,652; median age 16 years) via the Danish nationwide health registers. Melatonin is a prescription drug in Denmark. The incidence of melatonin use increased from 2.4 to 3.9/1000 person-years during 2012 to 2019. Among 6,557 incident users in 2019, 53% filled only a single prescription within the first 6 months. Long-term use was most common among the younger age groups, with 17% of 5-9-year-olds and 14% of 10-13-year-olds being in continued treatment (no treatment breaks) 12 months after their first melatonin prescription. Disregarding treatment breaks, 3 in 10 were using melatonin 12 months after their first melatonin prescription and this proportion was also highest among 5-9-year-olds (63%) and 10-13-year-olds (51%). Psychopathology was common among melatonin users with 75% registered with either a psychiatric disorder diagnosis (54%), a filled prescription for another psychotropic (58%), or a contact to a private practice psychiatrist (15%) within +/- 12 months of treatment initiation. General practitioners authorized melatonin prescriptions to almost half of all new users (48%), while psychiatric specialists authorized 37% of first prescriptions. In conclusion, the incidence of melatonin use increased in Denmark from 2012 to 2019. A substantial proportion of users had concurrent psychopathology most likely explaining their use of melatonin. Long-term melatonin use was more common among the youngest age groups, which should be a focus of interest due to limited safety data.</style></abstract><notes><style face="normal" font="default" size="100%">Bliddal, Mette&#xD;Kildegaard, Helene&#xD;Rasmussen, Lotte&#xD;Ernst, Martin&#xD;Jennum, Poul Jorgen&#xD;Mogensen, Stine Hasling&#xD;Pottegard, Anton&#xD;Wesselhoeft, Rikke&#xD;eng&#xD;Germany&#xD;2022/07/07&#xD;Eur Child Adolesc Psychiatry. 2022 Jul 6. doi: 10.1007/s00787-022-02035-1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35792937</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00787-022-02035-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>157</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Davidsen, K. A.</style></author><author><style face="normal" font="default" size="100%">Munk-Laursen, T.</style></author><author><style face="normal" font="default" size="100%">Foli-Andersen, P.</style></author><author><style face="normal" font="default" size="100%">Ranning, A.</style></author><author><style face="normal" font="default" size="100%">Harder, S.</style></author><author><style face="normal" font="default" size="100%">Nordentoft, M.</style></author><author><style face="normal" font="default" size="100%">Thorup, A. A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychology, University of Southern Denmark, Odense, Denmark.&#xD;Child and Adolescent Mental Health Services, Region of Southern Denmark, Odense, Denmark.&#xD;Department of Economics and Business Economics, National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Copenhagen, Denmark.&#xD;Department of Neonatology, University Hospital, Hvidovre, Denmark.&#xD;Mental Health Services Copenhagen, Capital Region of Denmark, Copenhagen, Denmark.&#xD;Department of Psychology, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Child and Adolescent Mental Health Center, Capital Region of Denmark, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mental and pediatric disorders among children 0-6 years of parents with severe mental illness</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Psychiatr Scand</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Psychiatr Scand</style></full-title></periodical><pages><style face="normal" font="default" size="100%">244-254</style></pages><volume><style face="normal" font="default" size="100%">145</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20210815</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Child of Impaired Parents</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Fathers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Infant</style></keyword><keyword><style face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Disorders/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Parents/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">child health</style></keyword><keyword><style face="normal" font="default" size="100%">child psychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">mental disorders</style></keyword><keyword><style face="normal" font="default" size="100%">parents</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1600-0447 (Electronic)&#xD;0001-690X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34351617</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Parental severe mental illness (SMI) increases the lifetime risk of mental and pediatric disorders in the offspring but little is known about specific disorders during early childhood. The primary aim was to investigate the incidence of mental and pediatric disorders among children 0-6 years old exposed to parental SMI, and secondarily to investigate the distribution of disorders on specific child age. METHODS: A nationwide, register-based cohort study of 1,477,185 children born in Denmark between 1994.01.01 and 2016.12.31. Incidence rate ratios were calculated using Poisson regression analysis for any and specific mental and pediatric disorders. RESULTS: IRR for any psychiatric disorder was elevated by a factor 2-5 among SMI offspring. Maternal schizophrenia resulted in the highest IRR = 5.23 (4.80-5.69) of any child psychiatric disorder. The risk of anxiety/OCD and attachment disorder among offspring exposed to parental, and in particular maternal, SMI was markedly raised with IRRs for anxiety/OCD between 7.59 and 17.02 and attachment disorders between 6.26 and 15.40. IRRs of mental disorders were highest at age 0-1 year and declined with age. IRR for any pediatric disorder was also elevated with IRRs between 1.01 and 1.28. Disorders of the digestive system and ill-defined symptoms were associated with the highest IRRs. Maternal (vs. paternal) SMI was associated with higher IRRs. IRRs declined slightly with child age. CONCLUSION: Children exposed to parental SMI are at increased risk of mental and pediatric disorders during early childhood, particularly anxiety/OCD and attachment disorders. If associations are estimates of a modifiable causal relationship, our results indicate a need for early intervention to promote mental and pediatric health among SMI offspring.</style></abstract><notes><style face="normal" font="default" size="100%">Davidsen, Kirstine Agnete&#xD;Munk-Laursen, Thomas&#xD;Foli-Andersen, Pia&#xD;Ranning, Anne&#xD;Harder, Susanne&#xD;Nordentoft, Merete&#xD;Thorup, Anne Amalie Elgaard&#xD;eng&#xD;2021/08/06&#xD;Acta Psychiatr Scand. 2022 Mar;145(3):244-254. doi: 10.1111/acps.13358. Epub 2021 Aug 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34351617</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/acps.13358</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>245</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">245</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pedersen, Martin Locht</style></author><author><style face="normal" font="default" size="100%">Handberg, Charlotte</style></author><author><style face="normal" font="default" size="100%">Dreyer, Pia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mental health reported in adult invasive home mechanical ventilation through a tracheostomy: A scoping review</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Nursing Studies Advances</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Nursing Studies Advances</style></full-title></periodical><volume><style face="normal" font="default" size="100%">4</style></volume><section><style face="normal" font="default" size="100%">100110</style></section><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">2666142X</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijnsa.2022.100110</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>158</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hjaeresen, S.</style></author><author><style face="normal" font="default" size="100%">Sejbaek, T.</style></author><author><style face="normal" font="default" size="100%">Axelsson, M.</style></author><author><style face="normal" font="default" size="100%">Mortensen, S. K.</style></author><author><style face="normal" font="default" size="100%">Vinslov-Jensen, H.</style></author><author><style face="normal" font="default" size="100%">Pihl-Jensen, G.</style></author><author><style face="normal" font="default" size="100%">Novakova, L.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. B.</style></author><author><style face="normal" font="default" size="100%">Halle, B.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author><author><style face="normal" font="default" size="100%">Zhang, M.</style></author><author><style face="normal" font="default" size="100%">Benedikz, E.</style></author><author><style face="normal" font="default" size="100%">Frederiksen, J. L.</style></author><author><style face="normal" font="default" size="100%">Lycke, J.</style></author><author><style face="normal" font="default" size="100%">Illes, Z.</style></author><author><style face="normal" font="default" size="100%">Fex-Svenningsen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Southern Denmark, Department of Molecular Medicine, J.B. Winslows vej 21, 5000 Odense, Denmark; BRIDGE - Brain Research InterDisciplinary Guided Excellence, University of Southern Denmark, Odense, Denmark. Electronic address: shjaresen@health.sdu.dk.&#xD;University of Southern Denmark, Department of Regional Health Research, 5000 Odense, Denmark; University of Copenhagen, Department of Neurology, Southwest Jutland University Hospital, 6700 Esbjerg, Denmark. Electronic address: tobias.sejbaek@rsyd.dk.&#xD;University of Gothenburg, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: markus.axelsson@neuro.gu.se.&#xD;University of Southern Denmark, Department of Molecular Medicine, J.B. Winslows vej 21, 5000 Odense, Denmark. Electronic address: skmortensen@health.sdu.dk.&#xD;University of Southern Denmark, Department of Molecular Medicine, J.B. Winslows vej 21, 5000 Odense, Denmark.&#xD;University of Copenhagen, Department of Neurology, Rigshospitalet Glostrup, Copenhagen, Denmark.&#xD;University of Gothenburg, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: lenka.novakova@vgregion.se.&#xD;Odense University Hospital, Department of Neurosurgery, Clinical Institute and University of Southern Denmark, Denmark; BRIDGE - Brain Research InterDisciplinary Guided Excellence, University of Southern Denmark, Odense, Denmark. Electronic address: christian.bonde@rsyd.dk.&#xD;Odense University Hospital, Department of Neurosurgery, Clinical Institute and University of Southern Denmark, Denmark; BRIDGE - Brain Research InterDisciplinary Guided Excellence, University of Southern Denmark, Odense, Denmark. Electronic address: bo.halle@rsyd.dk.&#xD;Odense University Hospital, Department of Neurosurgery, Clinical Institute and University of Southern Denmark, Denmark; BRIDGE - Brain Research InterDisciplinary Guided Excellence, University of Southern Denmark, Odense, Denmark. Electronic address: frantz.r.poulsen@rsyd.dk.&#xD;University of Southern Denmark, Department of Molecular Medicine, J.B. Winslows vej 21, 5000 Odense, Denmark; BRIDGE - Brain Research InterDisciplinary Guided Excellence, University of Southern Denmark, Odense, Denmark. Electronic address: mzhang@health.sdu.dk.&#xD;University of Southern Denmark, Faculty of Health Sciences, J.B. Winslows vej 19., 5000 Odense, Denmark. Electronic address: eib@health.sdu.dk.&#xD;University of Copenhagen, Department of Neurology, Rigshospitalet Glostrup, Copenhagen, Denmark. Electronic address: jette.lautrup.battistini@regionh.dk.&#xD;University of Gothenburg, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: jan.lycke@neuro.gu.se.&#xD;University of Southern Denmark, Department of Molecular Medicine, J.B. Winslows vej 21, 5000 Odense, Denmark; Odense University Hospital, Department of Neurology, Odense, Denmark; BRIDGE - Brain Research InterDisciplinary Guided Excellence, University of Southern Denmark, Odense, Denmark. Electronic address: zsolt.illes@rsyd.dk.&#xD;University of Southern Denmark, Department of Molecular Medicine, J.B. Winslows vej 21, 5000 Odense, Denmark; BRIDGE - Brain Research InterDisciplinary Guided Excellence, University of Southern Denmark, Odense, Denmark. Electronic address: aasvenningsen@health.sdu.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurol Sci</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">120320</style></pages><volume><style face="normal" font="default" size="100%">439</style></volume><number><style face="normal" font="default" size="100%">120320</style></number><edition><style face="normal" font="default" size="100%">20220613</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Brain</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Intramolecular Oxidoreductases</style></keyword><keyword><style face="normal" font="default" size="100%">*Macrophage Migration-Inhibitory Factors/cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiple Sclerosis, Chronic Progressive/cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiple Sclerosis, Relapsing-Remitting/cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">Dimethyl fumarate</style></keyword><keyword><style face="normal" font="default" size="100%">Mif</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophage migration inhibitory factor</style></keyword><keyword><style face="normal" font="default" size="100%">Mitoxantrone</style></keyword><keyword><style face="normal" font="default" size="100%">Multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">Neurodegeneration</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroinflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Relapsing-remitting</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary progression</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 15</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1878-5883 (Electronic)&#xD;0022-510X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35717879</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Macrophage migration inhibitory factor (MIF) is involved in the function of both the innate and adaptive immune systems and in neuroprotection and has recently been implicated in multiple sclerosis (MS). OBJECTIVES: Determination of MIF levels in the cerebrospinal fluid (CSF) of patients with distinct subtypes of MS and the cellular localization of MIF in human brain tissue. METHODS: The levels of MIF were investigated in CSF from patients with clinically isolated syndrome (CIS) (n = 26), relapsing-remitting MS (RRMS) (n = 22), secondary progressive MS (SPMS) (n = 19), and healthy controls (HCs) (n = 24), using ELISA. The effect of disease-modifying therapies in the RRMS and SPMS cohorts were examined. Cellular distribution of MIF in the human brain was studied using immunochemistry and the newly available OligoInternode database. RESULTS: MIF was significantly decreased in treatment-naive CIS and RRMS patients compared to HCs but was elevated in SPMS. Interestingly, MIF levels were sex-dependent and significantly lower in women with CIS and RRMS. MIF expression in the human brain was localized to neurons, astrocytes, pericytes, and oligo5 oligodendrocytes but not in microglia. CONCLUSION: The finding that MIF was decreased in newly diagnosed CIS and RRMS patients but was high in patients with SPMS may suggest that MIF levels in CSF are regulated by local MIF receptor expression that affects the overall MIF signaling in the brain and may represent a protective mechanism that eventually fails.</style></abstract><notes><style face="normal" font="default" size="100%">Hjaeresen, Simone&#xD;Sejbaek, Tobias&#xD;Axelsson, Markus&#xD;Mortensen, Sif Klovedal&#xD;Vinslov-Jensen, Helle&#xD;Pihl-Jensen, Gorm&#xD;Novakova, Lenka&#xD;Pedersen, Christian Bonde&#xD;Halle, Bo&#xD;Poulsen, Frantz Rom&#xD;Zhang, Mengliang&#xD;Benedikz, Eirikur&#xD;Frederiksen, Jette Lautrup&#xD;Lycke, Jan&#xD;Illes, Zsolt&#xD;Fex-Svenningsen, Asa&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;2022/06/20&#xD;J Neurol Sci. 2022 Aug 15;439:120320. doi: 10.1016/j.jns.2022.120320. Epub 2022 Jun 13.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35717879</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jns.2022.120320</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>235</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">235</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Theodorsdottir, A.</style></author><author><style face="normal" font="default" size="100%">Larsen, P. V.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H. H.</style></author><author><style face="normal" font="default" size="100%">Illes, Z.</style></author><author><style face="normal" font="default" size="100%">Ravnborg, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Odense University Hospital, Odense, Denmark.&#xD;OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.&#xD;Mental Health Services at the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Research, BRIDGE - Brain Research - Inter Disciplinary Guided Excellence, University of Southern Denmark, Odense, Denmark.&#xD;Filadelfia Epilepsy Hospital, Dianalund, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Neurol Scand</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Neurol Scand</style></full-title></periodical><pages><style face="normal" font="default" size="100%">332-347</style></pages><volume><style face="normal" font="default" size="100%">145</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20211119</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Disability Evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiple Sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Multiple Sclerosis, Chronic Progressive/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Walking</style></keyword><keyword><style face="normal" font="default" size="100%">9hpt</style></keyword><keyword><style face="normal" font="default" size="100%">Mri</style></keyword><keyword><style face="normal" font="default" size="100%">Msis</style></keyword><keyword><style face="normal" font="default" size="100%">T25fw</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">observational study</style></keyword><keyword><style face="normal" font="default" size="100%">scale properties</style></keyword><keyword><style face="normal" font="default" size="100%">secondary progressive</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1600-0404 (Electronic)&#xD;0001-6314 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34799851</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To examine the Multiple Sclerosis Impairment Scale (MSIS) in secondary progressive MS (SPMS) in relation to the Expanded Disability Status Scale (EDSS), magnetic resonance imaging (MRI) outcomes, and mobility. METHODS: In this observational single-center study, 68 secondary progressive multiple sclerosis (SPMS) patients were examined by MSIS, EDSS, functional mobility tests of upper/lower extremities, and multimodal MRI. Participants had EDSS &gt;/=3.5, a decline in daily activities over the last year unrelated to relapses, and/or 6-month confirmed disability progression. RESULTS: Mean disease duration was 23.1 +/- 8.3 years and mean age 54.4 +/- 8.1 years. MSIS, EDSS, and their corresponding motor, cerebellar, and sensory subscores correlated (p &lt; .0001). Motor subscores of MSIS correlated stronger with Timed-25-Foot-Walk (T25FW) than pyramidal functional system score (FSS) (p = .03), but EDSS had a stronger correlation to T25FW than the total MSIS score (p = .01). MSIS cerebellar subscore correlated stronger with 9-Hole Peg Test (9-HPT) than cerebellar FSS (p = .04). The sensory MSIS subscore also showed correlation with 9-HPT in contrast to sensory FSS (p = .006). MSIS subscores had stronger correlations with MRI volumetry measures than FSS scores (lesion volume and putamen, thalamus, corpus callosum volumetry, p = .0001-0.0017). CONCLUSION: In patients with SPMS, MSIS correlated with functional motor tests. MSIS showed stronger correlations with atrophy of central nervous system areas, and may be more sensitive to scale cerebellar and sensory function than EDSS.</style></abstract><notes><style face="normal" font="default" size="100%">Theodorsdottir, Asta&#xD;Larsen, Pia Veldt&#xD;Nielsen, Helle Hvilsted&#xD;Illes, Zsolt&#xD;Ravnborg, Mads Henrik&#xD;eng&#xD;Novartis Healthcare/&#xD;Observational Study&#xD;Denmark&#xD;2021/11/21&#xD;Acta Neurol Scand. 2022 Mar;145(3):332-347. doi: 10.1111/ane.13554. Epub 2021 Nov 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34799851</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ane.13554</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>159</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yates, A. G.</style></author><author><style face="normal" font="default" size="100%">Weglinski, C. M.</style></author><author><style face="normal" font="default" size="100%">Ying, Y.</style></author><author><style face="normal" font="default" size="100%">Dunstan, I. K.</style></author><author><style face="normal" font="default" size="100%">Strekalova, T.</style></author><author><style face="normal" font="default" size="100%">Anthony, D. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, The University of Oxford, Mansfield Road, Oxford, UK.&#xD;School of Biomedical Sciences, The University of Queensland, Brisbane, Australia.&#xD;Sechenov First Moscow State Medical University, Moscow, Russia.&#xD;Institute of General Pathology and Pathophysiology, Moscow, Russia.&#xD;Department of Pharmacology, The University of Oxford, Mansfield Road, Oxford, UK. daniel.anthony@pharm.ox.ac.uk.&#xD;Sechenov First Moscow State Medical University, Moscow, Russia. daniel.anthony@pharm.ox.ac.uk.&#xD;University of Southern Denmark, Odense, Denmark. daniel.anthony@pharm.ox.ac.uk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroinflammation</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">8</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220106</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Benzamidines/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Guanidines/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Illness Behavior/drug effects</style></keyword><keyword><style face="normal" font="default" size="100%">Imidazoles/administration &amp; dosage/immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/*drug therapy/metabolism/virology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Serine Endopeptidases/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Serine Proteinase Inhibitors/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Toll-Like Receptor 7/agonists/*immunology</style></keyword><keyword><style face="normal" font="default" size="100%">Virus Diseases/*drug therapy/metabolism/virology</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Drug Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Nafamostat</style></keyword><keyword><style face="normal" font="default" size="100%">Sickness behaviour</style></keyword><keyword><style face="normal" font="default" size="100%">Viral infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 6</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1742-2094 (Electronic)&#xD;1742-2094 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34991643</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The serine protease inhibitor nafamostat has been proposed as a treatment for COVID-19, by inhibiting TMPRSS2-mediated viral cell entry. Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infection are lacking. In this study, we examined the potential of the dual TLR7/8 agonist R848 to mimic the host response to an ssRNA virus infection and the associated behavioural response. In addition, we evaluated the anti-inflammatory effects of nafamostat in this model. METHODS: CD-1 mice received an intraperitoneal injection of R848 (200 mug, prepared in DMSO, diluted 1:10 in saline) or diluted DMSO alone, and an intravenous injection of either nafamostat (100 muL, 3 mg/kg in 5% dextrose) or 5% dextrose alone. Sickness behaviour was determined by temperature, food intake, sucrose preference test, open field and forced swim test. Blood and fresh liver, lung and brain were collected 6 h post-challenge to measure markers of peripheral and central inflammation by blood analysis, immunohistochemistry and qPCR. RESULTS: R848 induced a robust inflammatory response, as evidenced by increased expression of TNF, IFN-gamma, CXCL1 and CXCL10 in the liver, lung and brain, as well as a sickness behaviour phenotype. Exogenous administration of nafamostat suppressed the hepatic inflammatory response, significantly reducing TNF and IFN-gamma expression, but had no effect on lung or brain cytokine production. R848 administration depleted circulating leukocytes, which was restored by nafamostat treatment. CONCLUSIONS: Our data indicate that R848 administration provides a useful model of ssRNA virus infection, which induces inflammation in the periphery and CNS, and virus infection-like illness. In turn, we show that nafamostat has a systemic anti-inflammatory effect in the presence of the TLR7/8 agonist. Therefore, the results indicate that nafamostat has anti-inflammatory actions, beyond its ability to inhibit TMPRSS2, that might potentiate its anti-viral actions in pathologies such as COVID-19.</style></abstract><notes><style face="normal" font="default" size="100%">Yates, Abi G&#xD;Weglinski, Caroline M&#xD;Ying, Yuxin&#xD;Dunstan, Isobel K&#xD;Strekalova, Tatyana&#xD;Anthony, Daniel C&#xD;eng&#xD;NRB2015/international spinal research trust/&#xD;MC-PC-15029/MRC_/Medical Research Council/United Kingdom&#xD;England&#xD;2022/01/08&#xD;J Neuroinflammation. 2022 Jan 6;19(1):8. doi: 10.1186/s12974-021-02357-y.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34991643</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8734544</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12974-021-02357-y</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>268</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">268</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Langballe, R.</style></author><author><style face="normal" font="default" size="100%">Dalton, S. O.</style></author><author><style face="normal" font="default" size="100%">Jakobsen, E.</style></author><author><style face="normal" font="default" size="100%">Karlsen, R. V.</style></author><author><style face="normal" font="default" size="100%">Iachina, M.</style></author><author><style face="normal" font="default" size="100%">Freund, K. M.</style></author><author><style face="normal" font="default" size="100%">Leclair, A.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Andersen, E. A. W.</style></author><author><style face="normal" font="default" size="100%">Rosthoj, S.</style></author><author><style face="normal" font="default" size="100%">Jorgensen, L. B.</style></author><author><style face="normal" font="default" size="100%">Skou, S. T.</style></author><author><style face="normal" font="default" size="100%">Bidstrup, P. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Psychological Aspects of Cancer, The Danish Cancer Society Research Center, Copenhagen, Denmark ril@cancer.dk.&#xD;Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark.&#xD;Survivorship and Inequality in Cancer, The Danish Cancer Society Research Center, Copenhagen, Denmark.&#xD;Department of Thoracic Surgery, Odense University Hospital, Odense, Denmark.&#xD;The Danish Lung Cancer Registry, Odense University Hospital, Odense, Denmark.&#xD;Psychological Aspects of Cancer, The Danish Cancer Society Research Center, Copenhagen, Denmark.&#xD;Center for Clinical Epidemiology and Research Unit of Clinical Epidemiology, Odense Universityhospital, Odense, Denmark.&#xD;Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.&#xD;Unit for Clinical Alcohol Research, University of Southern Denmark, Odense, Denmark.&#xD;Statistics and Data Analysis, The Danish Cancer Society Research Center, Copenhagen, Denmark.&#xD;Department of Physiotherapy and Occupational Therapy, Zealand University Hospital, Roskilde, Denmark.&#xD;Department of Physiotherapy and Occupational Therapy, The Research Unit PROgrez, Naestved-Slagelse-Ringsted Hospitals, Slagelse, Denmark.&#xD;Department of Sports Science and Clinical Biomechanics, Research Unit for Musculoskeletal Function and Physiotherapy, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">NAVIGATE: improving survival in vulnerable patients with lung cancer through nurse navigation, symptom monitoring and exercise - study protocol for a multicentre randomised controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Open</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e060242</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">20221031</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Carcinoma, Non-Small-Cell Lung</style></keyword><keyword><style face="normal" font="default" size="100%">Exercise</style></keyword><keyword><style face="normal" font="default" size="100%">*Lung Neoplasms/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Multicenter Studies as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Reported Outcome Measures</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">oncology</style></keyword><keyword><style face="normal" font="default" size="100%">rehabilitation medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 31</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2044-6055 (Electronic)&#xD;2044-6055 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36316074</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION AND AIM: Low socioeconomic position (SEP) has been shown to be strongly associated with impaired lung cancer survival. Barriers related to receiving recommended treatment among patients with lung cancer with low SEP may include adverse health behaviour and limited physical and psychosocial resources influencing the ability to react on high-risk symptoms and to navigate the healthcare system. To address the underlying factors that drive both decisions of treatment, adherence to treatment and follow-up in vulnerable patients with lung cancer, we developed the Navigate intervention. The aim of this randomised controlled trial is to investigate the effect of the intervention on survival (primary outcome), lung cancer treatment adherence, health-related quality of life and other psychosocial outcomes as well as health costs and process evaluation (secondary outcomes) in a study population of vulnerable patients with lung cancer. METHODS AND ANALYSIS: This two-armed multicentre randomised trial will recruit patients from five lung cancer clinics in Denmark identified as vulnerable according to a screening instrument with nine clinical and patient-reported vulnerability criteria developed for the study. We will enrol 518 vulnerable patients &gt;18 years old diagnosed with non-small cell lung cancer at all stages with a performance status &lt;2. Participants will be randomly allocated to either standard treatment and intervention or standard treatment alone. The Navigate intervention is based on principles from motivational interviewing and includes three components of nurse navigation, systematic monitoring of patient-reported outcomes (PROs) and physical exercise in a person-centred delivery model. Data will be collected at baseline and 3, 6, 12 months after randomisation using questionnaires, clinical data and physical function tests. ETHICS AND DISSEMINATION: Ethics Committee, Region Zealand (SJ-884/EMN-2020-37380) and the Data Protection Agency in Region Zealand (REG-080-2021) approved the trial. Participants will provide written informed consent. Results will be reported in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT05053997.</style></abstract><notes><style face="normal" font="default" size="100%">Langballe, Rikke&#xD;Dalton, Susanne Oksbjerg&#xD;Jakobsen, Erik&#xD;Karlsen, Randi Valbjorn&#xD;Iachina, Maria&#xD;Freund, Karen M&#xD;Leclair, Amy&#xD;Nielsen, Anette Sogaard&#xD;Andersen, Elisabeth Anne Wreford&#xD;Rosthoj, Susanne&#xD;Jorgensen, Lars Bo&#xD;Skou, Soren Thorgaard&#xD;Bidstrup, Pernille Envold&#xD;eng&#xD;Clinical Trial Protocol&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/11/01&#xD;BMJ Open. 2022 Oct 31;12(10):e060242. doi: 10.1136/bmjopen-2021-060242.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36316074</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Competing interests: None declared.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9628541</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmjopen-2021-060242</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>258</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hvidt, N. C.</style></author><author><style face="normal" font="default" size="100%">Curlin, F.</style></author><author><style face="normal" font="default" size="100%">Bussing, A.</style></author><author><style face="normal" font="default" size="100%">Baumann, K.</style></author><author><style face="normal" font="default" size="100%">Frick, E.</style></author><author><style face="normal" font="default" size="100%">Sondergaard, J.</style></author><author><style face="normal" font="default" size="100%">Nielsen, J. B.</style></author><author><style face="normal" font="default" size="100%">Lawrence, R.</style></author><author><style face="normal" font="default" size="100%">Lucchetti, G.</style></author><author><style face="normal" font="default" size="100%">Ramakrishnan, P.</style></author><author><style face="normal" font="default" size="100%">Wermuth, I.</style></author><author><style face="normal" font="default" size="100%">Hefti, R.</style></author><author><style face="normal" font="default" size="100%">Lee, E.</style></author><author><style face="normal" font="default" size="100%">Korup, A. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense, Denmark. nchvidt@health.sdu.dk.&#xD;Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark. nchvidt@health.sdu.dk.&#xD;Trent Center for Bioethics, Humanities, and History of Medicine, Duke University, Durham, NC, USA.&#xD;Faculty of Medicine, Institute of Integrative Medicine, Witten/Herdecke University, Herdecke, Gerhard-Kienle-Weg 4, 58313, Herdecke, Germany.&#xD;Caritas Science and Christian Social Work, Faculty of Theology, Freiburg University, Freiburg im Breisgau, Germany.&#xD;Department of Psychosomatic Medicine and Psychotherapy, Research Centre Spiritual Care, The University Hospital Klinikum Rechts der Isar, Langerstr. 3, 81675, Munich, Germany.&#xD;Forschungsstelle Spiritual Care, Klinik und Poliklinik fur Psychosomatische Medizin und Psychotherapie, Munich School of Philosophy, Kaulbachstr. 31, 80539, Munich, Germany.&#xD;Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry, Columbia University Medical Center, New York, USA.&#xD;Federal University of Juiz de Fora, Avenida Eugenio de Nascimento s/n - Aeroporto, Juiz de Fora, MG, 36038330, Brazil.&#xD;Harvard Divinity School, Harvard University, Cambridge, MA, USA.&#xD;AdiBhat Foundation, New Delhi, India.&#xD;Medical Faculty, Ludwig Maximilian University of Munich, Munich, Germany.&#xD;Medical Faculty, University of Bern, Bern, Switzerland.&#xD;Research Institute for Spirituality and Health (RISH), Langenthal, Switzerland.&#xD;Caritas Science and Christian Social Work, Faculty of Theology, Freiburg University Center for Social Cohesion, Daegu Catholic University, Hayang-Ro 13-13, Hayang-Eup, Gyeongsan-Si, Gyeongbuk, 38430, Republic of Korea.&#xD;Research Unit of General Practice, Department of Mental Health Kolding-Vejle, Institute of Public Health, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The NERSH Questionnaire and Pool of Data from 12 Countries: Development and Description</style></title><secondary-title><style face="normal" font="default" size="100%">J Relig Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Relig Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2605-2630</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20211001</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Attitude of Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Health Personnel</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Morals</style></keyword><keyword><style face="normal" font="default" size="100%">*Physicians</style></keyword><keyword><style face="normal" font="default" size="100%">Spirituality</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Communication</style></keyword><keyword><style face="normal" font="default" size="100%">Medical ethics</style></keyword><keyword><style face="normal" font="default" size="100%">Physician values</style></keyword><keyword><style face="normal" font="default" size="100%">Religion and health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-6571 (Electronic)&#xD;0022-4197 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34599478</style></accession-num><abstract><style face="normal" font="default" size="100%">Modern healthcare research has only in recent years investigated the impact of health care workers&apos; religious and other values on medical practice, interaction with patients, and ethically complex decision making. So far, only limited international data exist on the way such values vary across different countries. We therefore established the NERSH International Collaboration on Values in Medicine with datasets on physician religious characteristics and values based on the same questionnaire. The present article provides (a) an overview of the development of the original and optimized questionnaire, (b) an overview of the content of the NERSH data pool at this stage and (c) a brief review of insights gained from articles published with the questionnaire. The pool at this stage consists of data from 17 studies from research units in 12 different countries representing six continents with responses from more than 6000 health professionals. The joint data pool suggests that there are large differences in religious and other moral values across nations and cultures, and that these values contribute to the observed differences in health professionals&apos; clinical practices-across nations and cultures!</style></abstract><notes><style face="normal" font="default" size="100%">Hvidt, Niels Christian&#xD;Curlin, Farr&#xD;Bussing, Arndt&#xD;Baumann, Klaus&#xD;Frick, Eckhard&#xD;Sondergaard, Jens&#xD;Nielsen, Jesper Bo&#xD;Lawrence, Ryan&#xD;Lucchetti, Giancarlo&#xD;Ramakrishnan, Parameshwaran&#xD;Wermuth, Inga&#xD;Hefti, Rene&#xD;Lee, Eunmi&#xD;Korup, Alex Kappel&#xD;eng&#xD;2021/10/03&#xD;J Relig Health. 2022 Jun;61(3):2605-2630. doi: 10.1007/s10943-021-01428-x. Epub 2021 Oct 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34599478</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10943-021-01428-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>201</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">201</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fathabadipour, S.</style></author><author><style face="normal" font="default" size="100%">Mohammadi, Z.</style></author><author><style face="normal" font="default" size="100%">Roshani, F.</style></author><author><style face="normal" font="default" size="100%">Goharbakhsh, N.</style></author><author><style face="normal" font="default" size="100%">Alizadeh, H.</style></author><author><style face="normal" font="default" size="100%">Palizgar, F.</style></author><author><style face="normal" font="default" size="100%">Cumming, P.</style></author><author><style face="normal" font="default" size="100%">Michel, T. M.</style></author><author><style face="normal" font="default" size="100%">Vafaee, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychology, Islamic Azad University, Karaj Branch, Karaj, Iran.&#xD;Neurosciences Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.&#xD;Department of Cognitive Psychology, Semnan University, Semnan, Iran.&#xD;Department of Psychology and Educational Sciences, Semnan University, Semnan, Iran.&#xD;School of Psychology, Keele University, Newcastle Under Lyme, UK.&#xD;Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland; School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia.&#xD;Department of Clinical Research, BRIDGE, University of Southern Denmark, Odense, Denmark; Research Unit for Psychiatry, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, BRIDGE, University of Southern Denmark, Odense, Denmark; Research Unit for Psychiatry, Odense University Hospital, Odense, Denmark; Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark. Electronic address: Mvafaee@health.sdu.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The neural effects of oxytocin administration in autism spectrum disorders studied by fMRI: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">J Psychiatr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Psychiatr Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">80-90</style></pages><volume><style face="normal" font="default" size="100%">154</style></volume><edition><style face="normal" font="default" size="100%">20220804</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Administration, Intranasal</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder/diagnostic imaging/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Autistic Disorder/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Oxytocin/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Asd</style></keyword><keyword><style face="normal" font="default" size="100%">Asperger syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Oxt</style></keyword><keyword><style face="normal" font="default" size="100%">fMRI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1879-1379 (Electronic)&#xD;0022-3956 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35933858</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: Oxytocin (OXT) is a hypothalamic neuropeptide that is released from the posterior pituitary gland and at specific targets in the central nervous system (CNS). The prosocial effects of OXT acting in the CNS present it as a potential therapeutic agent for the treatment of aspects of autism spectrum disorder (ASD). In this article, we systematically review the functional MRI (fMRI) literature that reports task-state and resting-state fMRI (rsfMRI) studies of the neural effects of single or multiple dose intranasal OXT (IN-OXT) administration in individuals with ASD. METHOD: We searched four databases for relevant documents (PubMed, Web of Science, Scopus, and Google Scholar) using the keywords &quot;autism spectrum disorder&quot;, &quot;Asperger Syndrome&quot;, &quot;oxytocin&quot;, and &quot;fMRI&quot;. Moreover, we made a manual search to assess the quality of our automatic search. The search was confined to English language articles published in the interval February 2013 until March 2021. RESULTS: The search yielded 12 fMRI studies with OXT intervention, including 288 individuals with ASD (age 8-55 years) enrolled in randomized, double-blind, placebo-controlled, parallel designs, within-subject-crossover experimental OXT trials. Studies reporting activation task and rsfMRI were summarized with region of interest (ROI) or whole-brain voxel wise analysis. The systematic review of the 12 studies supported the proposition that IN-OXT administration alters brain activation in individuals with ASD. The effects of IN-OXT interacted with the type of the task and the overall results did not indicate restoration of normal brain activation in ASD signature regions albeit the lack of statistical evidence. CONCLUSION: A large body of evidence consistently indicates that OXT alters activation to fMRI in brain networks of individuals with ASD, but with uncertain implications for alleviation of their social deficits.</style></abstract><notes><style face="normal" font="default" size="100%">Fathabadipour, Sara&#xD;Mohammadi, Zohreh&#xD;Roshani, Fereshteh&#xD;Goharbakhsh, Niloofar&#xD;Alizadeh, Hadi&#xD;Palizgar, Fatemeh&#xD;Cumming, Paul&#xD;Michel, Tanja Maria&#xD;Vafaee, Manouchehr Seyedi&#xD;eng&#xD;Review&#xD;Systematic Review&#xD;England&#xD;2022/08/08&#xD;J Psychiatr Res. 2022 Oct;154:80-90. doi: 10.1016/j.jpsychires.2022.06.033. Epub 2022 Aug 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35933858</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of competing interest None.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jpsychires.2022.06.033</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>161</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wulf, M.</style></author><author><style face="normal" font="default" size="100%">Barkovits, K.</style></author><author><style face="normal" font="default" size="100%">Schork, K.</style></author><author><style face="normal" font="default" size="100%">Eisenacher, M.</style></author><author><style face="normal" font="default" size="100%">Riederer, P.</style></author><author><style face="normal" font="default" size="100%">Gerlach, M.</style></author><author><style face="normal" font="default" size="100%">Eggers, B.</style></author><author><style face="normal" font="default" size="100%">Marcus, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medizinisches Proteom-Center, Medical Faculty, Ruhr-University Bochum, Bochum, Germany.&#xD;Medical Proteome Analysis, Center for Proteindiagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany.&#xD;Center of Mental Health, Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Margarete-Hoeppel-Platz 1, 97080, Wuerzburg, Germany.&#xD;Psychiatry Department of Clinical Research, University of Southern Denmark Odense University Hospital, Odense C, Denmark.&#xD;Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, University of Wuerzburg, Wuerzburg, Germany.&#xD;Medizinisches Proteom-Center, Medical Faculty, Ruhr-University Bochum, Bochum, Germany. katrin.marcus@rub.de.&#xD;Medical Proteome Analysis, Center for Proteindiagnostics (PRODI), Ruhr-University Bochum, Bochum, Germany. katrin.marcus@rub.de.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes</style></title><secondary-title><style face="normal" font="default" size="100%">J Neural Transm (Vienna)</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1257-1270</style></pages><volume><style face="normal" font="default" size="100%">129</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">20220719</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Lysosomes/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Melanins/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteomics/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Stress Granules</style></keyword><keyword><style face="normal" font="default" size="100%">Substantia Nigra/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Tyrosine 3-Monooxygenase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Laser microdissection</style></keyword><keyword><style face="normal" font="default" size="100%">Mass spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Neuromelanin granules</style></keyword><keyword><style face="normal" font="default" size="100%">Neuromelanin synthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Substantia nigra pars compacta</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1435-1463 (Electronic)&#xD;0300-9564 (Print)&#xD;0300-9564 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35852604</style></accession-num><abstract><style face="normal" font="default" size="100%">Neuromelanin is a black-brownish pigment, present in so-called neuromelanin granules (NMGs) in the cell bodies of dopaminergic neurons in the substantia nigra (SN) pars compacta. These neurons are lost in neurodegenerative diseases, such as Parkinson&apos;s disease and dementia with Lewy bodies. Although it is known that lipids, proteins, and environmental toxins accumulate in NMGs, the function of NMGs has not yet been finally clarified as well as their origin and the synthesis of neuromelanin. We, therefore, isolated NMGs and surrounding SN tissue from control patients by laser microdissection and analyzed the proteomic profile by tandem mass spectrometry. With our improved workflow, we were able to (1) strengthen the regularly reported link between NMGs and lysosomes, (2) detect tyrosine hydroxylase to be highly abundant in NMGs, which may be related to neuromelanin synthesis and (3) indicate a yet undescribed link between stress granules (SGs) and NMGs. Based on our findings, we cautiously hypothesize, that SGs may be the origin of NMGs or form in close proximity to them, potentially due to the oxidative stress caused by neuromelanin-bound metals.</style></abstract><notes><style face="normal" font="default" size="100%">Wulf, Maximilian&#xD;Barkovits, Katalin&#xD;Schork, Karin&#xD;Eisenacher, Martin&#xD;Riederer, Peter&#xD;Gerlach, Manfred&#xD;Eggers, Britta&#xD;Marcus, Katrin&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Austria&#xD;2022/07/20&#xD;J Neural Transm (Vienna). 2022 Oct;129(10):1257-1270. doi: 10.1007/s00702-022-02530-4. Epub 2022 Jul 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35852604</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9468065</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00702-022-02530-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>162</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mueller, J. K.</style></author><author><style face="normal" font="default" size="100%">Riederer, P.</style></author><author><style face="normal" font="default" size="100%">Muller, W. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University Hospital Frankfurt, Frankfurt/M, Germany.&#xD;Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wurzburg, Wurzburg, Germany.&#xD;University of Southern Denmark Odense, J.B. Winslows Vey Odense, Denmark.&#xD;Department of Pharmacology und Clinical Pharmacy, University Frankfurt, Frankfurt/M, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence?</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacopsychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmacopsychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7-15</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220125</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*covid-19</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style face="normal" font="default" size="100%">*Pharmaceutical Preparations</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Selective Serotonin Reuptake Inhibitors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Georg Thieme Verlag KG</style></publisher><isbn><style face="normal" font="default" size="100%">1439-0795 (Electronic)&#xD;0176-3679 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35079985</style></accession-num><abstract><style face="normal" font="default" size="100%">Since the beginning of the coronavirus disease (COVID)-19 pandemic, the need for effective treatments for COVID-19 led to the idea of &quot;repurposing&quot; drugs for antiviral treatment. Several antipsychotics and antidepressants have been tested for in vitro activity against the severe acute respiratory syndrome coronavirus 2. Chlorpromazine, other phenothiazine antipsychotics, and the antidepressant fluoxetine were found to be rather potent in these studies. However, whether effective plasma concentrations can be obtained with clinically accepted doses of these drugs is not clear. Data of COVID-19 patients are not yet available but several clinical studies are currently underway.The specific serotonin reuptake inhibitor fluvoxamine is a potent Sigma-1 receptor agonist and reduces inflammation in animal models of cytokine-stress. Accordingly, fluvoxamine treatment was superior to placebo in reducing impaired respiratory function and other symptoms of inflammation in COVID-19 patients in a placebo-controlled clinical study and another open clinical trial. The beneficial effects of fluvoxamine on the course of COVID-19 were recently confirmed in a large placebo-controlled double-blind trial with several hundred patients.Inflammation represents a major risk factor for many psychiatric disorders which explains the high susceptibilitiy of COVID-19 patients for psychiatric diseases. Many antidepressants and antipsychotics possess anti-inflammatory properties independent of sigma-1 activity which might be important to reduce psychiatric symptoms of COVID-19 patients and to improve respiratory dysfunction and other consequences of inflammation. This might explain the rather unspecific benefit which has been reported for several cohorts of COVID-19 patients treated with different psychotropic drugs.</style></abstract><notes><style face="normal" font="default" size="100%">Mueller, Juliane K&#xD;Riederer, Peter&#xD;Muller, Walter E&#xD;eng&#xD;Randomized Controlled Trial&#xD;Germany&#xD;2022/01/27&#xD;Pharmacopsychiatry. 2022 Jan;55(1):7-15. doi: 10.1055/a-1717-2381. Epub 2022 Jan 25.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35079985</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no conflict of interest.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/a-1717-2381</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Homolak, J.</style></author><author><style face="normal" font="default" size="100%">Kodvanj, I.</style></author><author><style face="normal" font="default" size="100%">Babic Perhoc, A.</style></author><author><style face="normal" font="default" size="100%">Virag, D.</style></author><author><style face="normal" font="default" size="100%">Knezovic, A.</style></author><author><style face="normal" font="default" size="100%">Osmanovic Barilar, J.</style></author><author><style face="normal" font="default" size="100%">Riederer, P.</style></author><author><style face="normal" font="default" size="100%">Salkovic-Petrisic, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology, University of Zagreb School of Medicine, Zagreb, Croatia.&#xD;Research Centre of Excellence, Institute of Fundamental Clinical and Translational Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia.&#xD;Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wurzburg, Wurzburg, Germany.&#xD;Department and Research Unit of Psychiatry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nitrocellulose redox permanganometry: A simple method for reductive capacity assessment</style></title><secondary-title><style face="normal" font="default" size="100%">MethodsX</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">MethodsX</style></full-title></periodical><pages><style face="normal" font="default" size="100%">101611</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">101611</style></number><edition><style face="normal" font="default" size="100%">20211222</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrocellulose</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">Potassium permanganate</style></keyword><keyword><style face="normal" font="default" size="100%">Ros</style></keyword><keyword><style face="normal" font="default" size="100%">Reductive capacity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">2215-0161 (Print)&#xD;2215-0161 (Electronic)&#xD;2215-0161 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35004232</style></accession-num><abstract><style face="normal" font="default" size="100%">We propose a rapid, simple, and robust method for measurement of the reductive capacity of liquid and solid biological samples based on potassium permanganate reduction followed by trapping of manganese dioxide precipitate on a nitrocellulose membrane. Moreover, we discuss how nitrocellulose redox permanganometry (NRP) can be used for high-throughput analysis of biological samples and present HistoNRP, its modification used for detailed analysis of reductive capacity spatial distribution in tissue with preserved anatomical relations.*NRP is a rapid, cost-effective, and simple method for reductive capacity assessment*NRP is compatible with a high-throughput screening of solid and liquid biological samples*HistoNRP exploits passive diffusion slice print blotting for reductive capacity spatial analysis.</style></abstract><notes><style face="normal" font="default" size="100%">Homolak, Jan&#xD;Kodvanj, Ivan&#xD;Babic Perhoc, Ana&#xD;Virag, Davor&#xD;Knezovic, Ana&#xD;Osmanovic Barilar, Jelena&#xD;Riederer, Peter&#xD;Salkovic-Petrisic, Melita&#xD;eng&#xD;Netherlands&#xD;2022/01/11&#xD;MethodsX. 2021 Dec 22;9:101611. doi: 10.1016/j.mex.2021.101611. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35004232</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Authors have no conflict of interest to disclose.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8718987</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.mex.2021.101611</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nissen, M. S.</style></author><author><style face="normal" font="default" size="100%">Orvik, M. S.</style></author><author><style face="normal" font="default" size="100%">Nilsson, A. C.</style></author><author><style face="normal" font="default" size="100%">Ryding, M.</style></author><author><style face="normal" font="default" size="100%">Lydolph, M.</style></author><author><style face="normal" font="default" size="100%">Blaabjerg, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurology, Odense University Hospital, J.B. Winslows Vej 4, 5000, Odense C, Denmark. Mette.scheller.nissen2@rsyd.dk.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Mette.scheller.nissen2@rsyd.dk.&#xD;Brain Research-Inter Disciplinary Guided Excellence (BRIDGE), Odense, Denmark. Mette.scheller.nissen2@rsyd.dk.&#xD;Department of Neurology, Telemark Hospital, Skien, Norway.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.&#xD;Brain Research-Inter Disciplinary Guided Excellence (BRIDGE), Odense, Denmark.&#xD;Danish National Biobank, Statens Serum Institut, Copenhagen, Denmark.&#xD;Department of Neurology, Odense University Hospital, J.B. Winslows Vej 4, 5000, Odense C, Denmark. Morten.Blaabjerg1@rsyd.dk.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Morten.Blaabjerg1@rsyd.dk.&#xD;Brain Research-Inter Disciplinary Guided Excellence (BRIDGE), Odense, Denmark. Morten.Blaabjerg1@rsyd.dk.&#xD;Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Morten.Blaabjerg1@rsyd.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">J Neurol</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1618-1630</style></pages><volume><style face="normal" font="default" size="100%">269</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20210805</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anti-N-Methyl-D-Aspartate Receptor Encephalitis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">N-Methylaspartate</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasm Recurrence, Local</style></keyword><keyword><style face="normal" font="default" size="100%">*Receptors, N-Methyl-D-Aspartate</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-N-methyl-D-aspartate receptor encephalitis</style></keyword><keyword><style face="normal" font="default" size="100%">Autoimmune encephalitis</style></keyword><keyword><style face="normal" font="default" size="100%">NMDA-receptor</style></keyword><keyword><style face="normal" font="default" size="100%">Post-herpes simplex virus 1 encephalitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1432-1459 (Electronic)&#xD;0340-5354 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34351472</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: To describe the national Danish N-methyl-D-aspartate receptor encephalitis (NMDARE) cohort. METHODS: All NMDAR immunoglobulin G (IgG) positive cases in Denmark from 2009 to 2019 were included. Medical information was assessed retrospectively for clinical phenotype, workup, treatment and outcome. RESULTS: Seventy-seven patients were NMDAR IgG positive in serum/CSF. Fifty-five fulfilled the criteria of NMDARE, 18 did not and 4 had missing data. Incidence was 0.17/100,000 persons per year in 2018, and incidence rates increased since 2009. Of the 55 NMDARE patients (median age 27; 60% female), 9 had post-herpes simplex (HSE) NMDARE and 7 had a tumor (four teratomas). MRI was normal in 51% of patients. Brain FDG PET was performed in 17 patients, and was abnormal in 47% of patients with a normal MRI. First-line therapy was administered to 91%, and 24% required second-line therapy. Maintenance therapy during recovery was given 84% of patients, with no effect on relapse-risk. ICU admission occurred in 29%. Poor outcome (mRS &gt; 2) was reported in 27% and dependent on age and etiology. Patients &gt; 45 years had a poorer outcome (71% vs 8%, p &lt; 0.0001), more frequently post-HSE NMDARE (47% vs 3%, p &lt; 0.0001) and underlying malignancies (18% vs 0%). CONCLUSION: The incidence of NMDARE in Denmark is currently 0.17/100,000 persons per year, and has increased since 2009. NMDARE patients in Denmark display a higher median age, lower female:male ratio, a less frequent tumor association and need for ICU admission. Maintenance therapy did not reduce relapse rate. Poor outcome was seen with higher age, likely related to underlying etiology.</style></abstract><notes><style face="normal" font="default" size="100%">Nissen, Mette Scheller&#xD;Orvik, Maren Synnove&#xD;Nilsson, Anna Christine&#xD;Ryding, Matias&#xD;Lydolph, Magnus&#xD;Blaabjerg, Morten&#xD;eng&#xD;no grant number/odense universitetshospital/&#xD;no grant number/syddansk universitet/&#xD;Germany&#xD;2021/08/06&#xD;J Neurol. 2022 Mar;269(3):1618-1630. doi: 10.1007/s00415-021-10738-9. Epub 2021 Aug 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34351472</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00415-021-10738-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>165</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pedersen, J. K.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Svendsen, A. J.</style></author><author><style face="normal" font="default" size="100%">Horslev-Petersen, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit, Danish Hospital for Rheumatic Diseases, Sonderborg, Denmark.&#xD;Rheumatology Section, Department of Medicine M, Svendborg Hospital, Odense University Hospital, Svendborg, Denmark.&#xD;Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.&#xD;Mental Health Services Region of Southern Denmark, Odense, Denmark.&#xD;Epidemiology, Biostatistics, Biodemography, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">No difference in antidepressant prescription in rheumatoid arthritis and controls. Results from a population-based, matched inception cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Scand J Rheumatol</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">173-179</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20210629</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Antidepressive Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Arthritis, Rheumatoid/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prescriptions</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1502-7732 (Electronic)&#xD;0300-9742 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34182890</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Depression occurs at least two times more often in rheumatoid arthritis (RA) patients than in controls, but little is known about the treatment of depression in RA. The primary objective of this study was to compare the 1 year period prevalence of antidepressant prescription in patients with RA versus controls. METHOD: We included a retrospective inception cohort of 509 patients with incident RA and 2545 frequency-matched population controls ascertained from 1995 to 2002. The cohort was followed until 31 December 2017 and linked with nationwide Danish registers. From the Danish National Prescription Register, we obtained information on redeemed prescriptions of antidepressants (Anatomical Therapeutic Chemical code N06A). RESULTS: We did not demonstrate significant differences in the 1 year period prevalence ratios and the incidence rate ratios for either antidepressant prescription or the frequency of hospital admissions with depressive episode. The most frequent indication for antidepressant prescription in patients with RA was depression. Cox regression analyses showed no association between RA and antidepressant prescription. CONCLUSION: We found no significant differences in the occurrence of antidepressant prescription in patients with RA versus matched controls. The main indication for antidepressant prescription in RA was depression.</style></abstract><notes><style face="normal" font="default" size="100%">Pedersen, J K&#xD;Andersen, K&#xD;Svendsen, A J&#xD;Horslev-Petersen, K&#xD;eng&#xD;England&#xD;2021/06/30&#xD;Scand J Rheumatol. 2022 May;51(3):173-179. doi: 10.1080/03009742.2021.1923148. Epub 2021 Jun 29.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34182890</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/03009742.2021.1923148</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>166</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hansen, S. G.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Johansen, K. K.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Diabetes and Endocrinology, University Hospital Southern Denmark, Esbjerg, Denmark.&#xD;Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.&#xD;Center for Digital Psychiatry, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Center for Eating Disorders, Odense University Hospital, Research Unit for Medical Endocrinology, Odense University Hospital, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Normal bone mineral density and bone microarchitecture in adult males with high and low risk of exercise addiction</style></title><secondary-title><style face="normal" font="default" size="100%">Front Sports Act Living</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Sports Act Living</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1021442</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><edition><style face="normal" font="default" size="100%">20221114</style></edition><keywords><keyword><style face="normal" font="default" size="100%">bone microarchitecture</style></keyword><keyword><style face="normal" font="default" size="100%">bone mineral density (BMD)</style></keyword><keyword><style face="normal" font="default" size="100%">exercise addiction</style></keyword><keyword><style face="normal" font="default" size="100%">leptin</style></keyword><keyword><style face="normal" font="default" size="100%">testosterone</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/11/14</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Frontiers Media SA</style></publisher><isbn><style face="normal" font="default" size="100%">2624-9367 (Electronic)&#xD;2624-9367 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36451934</style></accession-num><abstract><style face="normal" font="default" size="100%">Exercise addiction describes a pattern of excessive and obsessive exercise and is associated with hypoleptinemia and low testosterone that may have adverse skeletal effects. We used a validated questionnaire to identify males with high and low risk of exercise addiction. In a cross-sectional design, males (aged 21-49 years) with high (n = 20, exercise addictive) and low risk (n = 20, exercise controls) of exercise addiction had examinations of bone mass, bone microarchitecture, and estimated bone strength performed using dual-energy x-ray absorptiometry of the hip and spine and high-resolution peripheral quantitative computed tomography of the distal radius and tibia. Findings were compared between the groups and to a population-based sample of healthy men aged 20-80 years (n = 236). We found similar hip and spine bone mineral density in exercise addictive and controls. Cortical and trabecular bone microarchitecture and estimated bone strength in radius and tibia did not differ significantly between the groups. Multiple regression analyses adjusting for age, body weight, free testosterone, and hours of weekly training did not alter findings. Also, bone indices from both groups were within 95% prediction bands derived from the population-based sample for the vast majority of indices. Neither group had no associations between circulating leptin or free testosterone and bone outcomes. In conclusion, in a study on younger males, we found no associations between high risk of exercise addiction and various indices of bone mass and bone quality indicative of altered skeletal health.</style></abstract><notes><style face="normal" font="default" size="100%">Hansen, Stinus Gadegaard&#xD;Lichtenstein, Mia Beck&#xD;Johansen, Karen Krogh&#xD;Stoving, Rene Klinkby&#xD;eng&#xD;Switzerland&#xD;2022/12/02&#xD;Front Sports Act Living. 2022 Nov 14;4:1021442. doi: 10.3389/fspor.2022.1021442. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36451934</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9701746</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fspor.2022.1021442</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>285</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">285</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jensen, A. M.</style></author><author><style face="normal" font="default" size="100%">Wilson, R. L.</style></author><author><style face="normal" font="default" size="100%">Pedersen, B. D.</style></author><author><style face="normal" font="default" size="100%">Hounsgaard, L.</style></author><author><style face="normal" font="default" size="100%">Tingleff, E. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Research Centre for Health and Welfare Technology, VIA University College, Holstebro, Denmark.&#xD;School of Nursing and Midwifery, University of Newcastle, Ourimbah, New South Wales, Australia.&#xD;School of Nursing, Massey University, Auckland, New Zealand.&#xD;Research Unit Forensic Mental Health Psychiatric Department Middelfart (RFM) and CPS, Mental Health Services in the Region of Southern Denmark &amp; Institute of Regional Health Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.&#xD;Nursing Education, Vejle, and Health Sciences Research Center, UCL University College, Svendborg, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nursing care of people with dementia in an orthopaedic acute care setting: An integrative literature review</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Clin Nurs</style></full-title></periodical><edition><style face="normal" font="default" size="100%">20221013</style></edition><keywords><keyword><style face="normal" font="default" size="100%">acute care</style></keyword><keyword><style face="normal" font="default" size="100%">dementia care</style></keyword><keyword><style face="normal" font="default" size="100%">integrative review</style></keyword><keyword><style face="normal" font="default" size="100%">nursing</style></keyword><keyword><style face="normal" font="default" size="100%">orthopaedic</style></keyword><keyword><style face="normal" font="default" size="100%">person-centred care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1365-2702 (Electronic)&#xD;0962-1067 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36229899</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS AND OBJECTIVES: This integrative literature review is to collect what is known about the care of people with dementia when they require a hospital admission for an orthopaedic surgical procedure and to contribute to developing an evidence-base to support nursing practice when caring for people with dementia in an orthopaedic setting. BACKGROUND: People with a dementia diagnosis are increasingly common in acute orthopaedic care settings and the admission exposes people with dementia to risks during their hospital stay. In addition, nurses find people with dementia challenging to care for due to the complexity of dual conditions. Little is known specifically about the care requirements for people with dementia in orthopaedic settings. DESIGN: Integrative literature review. METHODS: An integrative literature review and qualitative deductive content analysis using McCormack and McCance&apos;s theoretical nursing framework (Person-Centred Nursing Framework) of nine studies were undertaken. The process of the review was guided by PRISMA checklist. RESULTS: The care environment and resistance either in passive form, or through physical intervention, is common in orthopaedic nursing. Planning and delivering care for physical, cognitive and emotional needs is identified as being difficult, resulting in a lack of inclusion for patients, partly due to communication challenges. Finding ways to implement tailored care plans within standard ward routines proves difficult, and the consequence is a less than optimal care experience with adverse effects on patients characterised by an increase in dementia symptoms. CONCLUSIONS: Care for people with dementia in an orthopaedic setting is complex. It needs to be further studied so that more evidence and supporting literature can contribute to improved care for this group of patients. RELEVANCE TO CLINICAL PRACTICE: This study describes the complexity of providing fundamental care for people with dual conditions of dementia and orthopaedic injury and suggests opportunities for improvement.</style></abstract><notes><style face="normal" font="default" size="100%">Jensen, Anders M&#xD;Wilson, Rhonda L&#xD;Pedersen, Birthe D&#xD;Hounsgaard, Lise&#xD;Tingleff, Ellen B&#xD;eng&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark/&#xD;Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark/&#xD;VIA Ageing &amp; Dementia, Faculty of Health Sciences, VIA University College, Denmark/&#xD;Review&#xD;England&#xD;2022/10/15&#xD;J Clin Nurs. 2022 Oct 13. doi: 10.1111/jocn.16557.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36229899</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jocn.16557</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>167</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">167</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chang, N. H. S.</style></author><author><style face="normal" font="default" size="100%">Kumakura, Y.</style></author><author><style face="normal" font="default" size="100%">Moller, A.</style></author><author><style face="normal" font="default" size="100%">Linnet, J.</style></author><author><style face="normal" font="default" size="100%">Bender, D.</style></author><author><style face="normal" font="default" size="100%">Doudet, D. J.</style></author><author><style face="normal" font="default" size="100%">Vafaee, M. S.</style></author><author><style face="normal" font="default" size="100%">Gjedde, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research, University of Southern Denmark, Odense C, DK-5000, Denmark. Natalie.Hong.Siu.Chang2@rsyd.dk.&#xD;Department of Diagnostic Radiology and Nuclear Medicine, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan.&#xD;Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, DK-8200, Aarhus N, Denmark.&#xD;Gambling Disorder &amp; BED Clinic, Department of Occupational and Environmental Medicine, Odense University Hospital, Odense C, Dk-5000, Denmark.&#xD;Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, B.C. V6T 2B5, Canada.&#xD;Department of Clinical Research, BRIDGE, University of Southern Denmark, Odense M, DK-5230, Denmark.&#xD;Department of Neuroscience, University of Copenhagen, Copenhagen, DK-2200, Denmark.&#xD;Department of Clinical Medicine, University of Southern Denmark, Odense C, DK-5000, Denmark.&#xD;Translational Neuropsychiatry Unit, Aarhus University, Aarhus, DK-8000, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">On the learning of addictive behavior: Sensation-seeking propensity predicts dopamine turnover in dorsal striatum</style></title><secondary-title><style face="normal" font="default" size="100%">Brain Imaging Behav</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">355-365</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20210821</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Behavior, Addictive/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Corpus Striatum/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">*Dopamine</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography</style></keyword><keyword><style face="normal" font="default" size="100%">Sensation</style></keyword><keyword><style face="normal" font="default" size="100%">Brain imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Dopamine transmission</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroscience</style></keyword><keyword><style face="normal" font="default" size="100%">Sensation-seeking</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1931-7565 (Electronic)&#xD;1931-7557 (Print)&#xD;1931-7557 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34417966</style></accession-num><abstract><style face="normal" font="default" size="100%">We asked if sensation-seeking is linked to premorbid personality characteristics in patients with addictive disorders, or the characteristics follow the sensation-seeking activity. We interpreted the former as a state associated with normal rates of dopamine synthesis, and the latter as a trait of individuals with abnormally high rates of synthesis. We previously determined dopaminergic receptor density in striatum, and we now tested the hypothesis that an elevated dopaminergic condition with increased extracellular dopamine and receptor density follows increased dopamine synthesis capacity in highly sensation-seeking individuals, as measured by positron emission tomography of 18 men with tracer fluorodopa (FDOPA). We detected a site in left caudate nucleus where the volume of distribution of FDOPA-derived metabolites correlated negatively with FDOPA metabolite turnover, consistent with decreased metabolite breakdown in highly sensation-seeking subjects. High rates of sensation-seeking attenuated the dopamine turnover in association with a low rate of dopamine recycling, low dopamine oxidation, and elevated extracellular dopamine and receptors in caudate nucleus. In contrast, low rates of sensation-seeking were associated with rapid dopamine recycling, rapid dopamine oxidation, low extracellular dopamine, and low receptor density. We conclude that the modulation of dopaminergic neurotransmission associated with sensation-seeking is a state of sensation-seeking, rather than a trait of personality following abnormal regulation of dopaminergic neurotransmission.</style></abstract><notes><style face="normal" font="default" size="100%">Chang, Natalie Hong Siu&#xD;Kumakura, Yoshitaka&#xD;Moller, Arne&#xD;Linnet, Jakob&#xD;Bender, Dirk&#xD;Doudet, Doris J&#xD;Vafaee, Manouchehr Seyedi&#xD;Gjedde, Albert&#xD;eng&#xD;2021/08/22&#xD;Brain Imaging Behav. 2022 Feb;16(1):355-365. doi: 10.1007/s11682-021-00509-5. Epub 2021 Aug 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34417966</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8825434</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11682-021-00509-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Bejczy, A.</style></author><author><style face="normal" font="default" size="100%">Wallhed Finn, S.</style></author><author><style face="normal" font="default" size="100%">Soderpalm, B.</style></author><author><style face="normal" font="default" size="100%">Andreasson, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Alcohol Biology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.&#xD;Beroendekliniken, Sahlgrenska University Hospital, Gothenburg, Sweden.&#xD;Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.&#xD;Unit of Clinical Alcohol Research, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Outcome Measures in Alcohol Studies: A Comment on the ORBITAL Core Outcome Set (Shorter et al., 2021)</style></title><secondary-title><style face="normal" font="default" size="100%">J Stud Alcohol Drugs</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">296-297</style></pages><volume><style face="normal" font="default" size="100%">83</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Ethanol</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Outcome Assessment, Health Care</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1938-4114 (Electronic)&#xD;1937-1888 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35254253</style></accession-num><notes><style face="normal" font="default" size="100%">de Bejczy, Andrea&#xD;Wallhed Finn, Sara&#xD;Soderpalm, Bo&#xD;Andreasson, Sven&#xD;eng&#xD;Comment&#xD;2022/03/08&#xD;J Stud Alcohol Drugs. 2022 Mar;83(2):296-297.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35254253</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>169</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thorsen, M.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Thorsen, L.</style></author><author><style face="normal" font="default" size="100%">Michel, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit of the Department of Psychiatry, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. mbt90@live.dk.&#xD;Department of Psychiatry, Psychiatry in the Region of Southern Denmark, Odense, Denmark. mbt90@live.dk.&#xD;Center for applied Neuroscience Odense, BRIDGE, Odense, Denmark. mbt90@live.dk.&#xD;Department of Child and Adolescent Psychiatry, Aalborg University Hospital, Aalborg, Denmark. mbt90@live.dk.&#xD;Research Unit of Child- and Adolescent Psychiatry, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Center for applied Neuroscience Odense, BRIDGE, Odense, Denmark.&#xD;Research Unit of the Department of Psychiatry, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark.&#xD;Department of Psychiatry, Psychiatry in the Region of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oxidative Stress in Adults with Autism Spectrum Disorder: A Case Control Study</style></title><secondary-title><style face="normal" font="default" size="100%">J Autism Dev Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Autism Dev Disord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">275-282</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20210307</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder</style></keyword><keyword><style face="normal" font="default" size="100%">*Autistic Disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Autism Spectrum Disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Sex</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide Dismutase</style></keyword><keyword><style face="normal" font="default" size="100%">Xanthine Oxidase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1573-3432 (Electronic)&#xD;0162-3257 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33677727</style></accession-num><abstract><style face="normal" font="default" size="100%">Oxidative stress has been proposed as being important in the pathophysiology of autism spectrum disorders (ASD), and heightened levels of oxidative stress has found in children with ASD. Our aim was to investigate, whether this change is temporary or persist into adulthood. We included 89 adult patients with ASD and sex and age matched controls. Plasma levels of antioxidants superoxide dismutase 1 (SOD1) and superoxide dismutase 2 (SOD2) and pro-oxidant xanthine oxidase (XO) were measured. Individuals with ASD had higher levels of SOD1, which furthermore correlated with autism severity as measured by autism quotient-score. We found no difference regarding SOD2 and XO between ASD group and controls. However, SOD1 and SOD2 were elevated in males compared to females.</style></abstract><notes><style face="normal" font="default" size="100%">Thorsen, Morten&#xD;Bilenberg, Niels&#xD;Thorsen, Lena&#xD;Michel, Tanja Maria&#xD;eng&#xD;2021/03/08&#xD;J Autism Dev Disord. 2022 Jan;52(1):275-282. doi: 10.1007/s10803-021-04897-x. Epub 2021 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33677727</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10803-021-04897-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>301</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">301</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tarp, K.</style></author><author><style face="normal" font="default" size="100%">Holmberg, T. T.</style></author><author><style face="normal" font="default" size="100%">Moeller, A. M.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit for Telepsychiatry and E- The Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Health Promotion Research, Department of Public Health, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient and therapist experiences of using a smartphone application monitoring anxiety symptoms</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Qual Stud Health Well-being</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Qual Stud Health Well-being</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2044981</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anxiety/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Anxiety Disorders/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mobile Applications</style></keyword><keyword><style face="normal" font="default" size="100%">Smartphone</style></keyword><keyword><style face="normal" font="default" size="100%">Anxiety disorders</style></keyword><keyword><style face="normal" font="default" size="100%">anxiety monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">app-based assessment</style></keyword><keyword><style face="normal" font="default" size="100%">qualitative research</style></keyword><keyword><style face="normal" font="default" size="100%">smartphone application</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1748-2631 (Electronic)&#xD;1748-2623 (Print)&#xD;1748-2623 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35212602</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: A smartphone application (app) from the company Monsenso was developed to monitor anxiety symptoms in the treatment of anxiety disorders as an alternative to paper registrations. The aim of the study was to explore patient and therapist experiences of using the app in conjunction with standard treatment for anxiety disorder in a developmental and implementation phase. METHOD: The study design was qualitative. Semi-structured interviews were conducted with three therapists and seven patients from an outpatient clinic. The interviews were analysed using thematic analysis. FINDINGS: Three main themes emerged for both patients and therapists. The patient themes were usability (it was easier to use the app and remember daily mood registrations), insight in own disorder (awareness of symptom progress), and support to use the app (support from the therapist was wanted). The therapist themes were therapeutic quality (app registrations made it easier to prepare sessions), the role of the therapist (enthusiasm and technical assistance affected the patient), and implementation challenges (time allocation is important). CONCLUSION: The anxiety monitoring app is recommended in standard treatment as an alternative to paper registrations. However, a successful development and implementation process include ready available technical support, time allocation, and therapist effort and enthusiasm.</style></abstract><notes><style face="normal" font="default" size="100%">Tarp, Kristine&#xD;Holmberg, Trine Theresa&#xD;Moeller, Anne Marie&#xD;Lichtenstein, Mia Beck&#xD;eng&#xD;2022/02/26&#xD;Int J Qual Stud Health Well-being. 2022 Dec;17(1):2044981. doi: 10.1080/17482631.2022.2044981.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35212602</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">No potential conflict of interest was reported by the author(s).</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8925918</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/17482631.2022.2044981</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>171</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moeller, A. M.</style></author><author><style face="normal" font="default" size="100%">Christensen, L. F.</style></author><author><style face="normal" font="default" size="100%">Hansen, J. P.</style></author><author><style face="normal" font="default" size="100%">Andersen, P. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health, University of Southern Denmark, Denmark. RINGGOLD: 6174&#xD;Research Unit for Telepsychiatry and E-mental Health, The Mental Health Services in the Region of Southern Denmark, Denmark. RINGGOLD: 72736&#xD;Department for Clinical Development, Odense University Hospital, Region of Southern Denmark, Denmark. RINGGOLD: 72736&#xD;Psychiatric Research Unit Esbjerg, The Mental Health Services in the Region of Southern Denmark, Denmark. RINGGOLD: 72736&#xD;Center for Clinical Nursing Research, Department of Clinical Research, University of Southern Denmark, Denmark. RINGGOLD: 6174</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patients&apos; acceptance of video consultations in the mental health services: A systematic review and synthesis of qualitative research</style></title><secondary-title><style face="normal" font="default" size="100%">Digit Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Digit Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">20552076221075148</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><edition><style face="normal" font="default" size="100%">20220207</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Video consultation</style></keyword><keyword><style face="normal" font="default" size="100%">mental health patient</style></keyword><keyword><style face="normal" font="default" size="100%">synthesis of qualitative research</style></keyword><keyword><style face="normal" font="default" size="100%">telepsychiatry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan-Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2055-2076 (Print)&#xD;2055-2076 (Electronic)&#xD;2055-2076 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35154803</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Clinical effectiveness of video consultations in the mental health services is comparable with in-person consultations. Acceptance has typically been rated in surveys that do not give a deeper understanding behind the phenomenon. The aim of this synthesis is to explore mental health patients&apos; perceptions of factors that influence their acceptance of video consultations viewed from the perspective of the patient. METHODS: A literature search in scientific databases was conducted. Peer-reviewed reports of qualitative research exploring patients&apos; experiences with video consultations from the patients&apos; perspectives were included. Then a meta-summary and a taxonomic analysis were conducted. RESULTS: A total of 11 reports met the inclusion criteria. Through the analysis, a model was generated with five factors that precede each other and interact with each other. Patients thought video consultations were acceptable when (1) they experienced barriers and inconvenience to accessing the location of services, (2) they had already established a trustful relationship with their therapist, (3) technical interferences were minor and problems were resolved quickly, (4) patients expected a less personal meeting, and (5) the degree of the patients&apos; issues were less complex. DISCUSSION: This model is intended to help clinicians identify circumstances where offering video consultations make best sense to patients and help sustain meaningful use prospectively. When patients encounter barriers to in-person services, clinicians should consider offering video consultations when the technology is adequately integrated in practice, and it is perceived not to intervene with treatment or the therapeutic process.</style></abstract><notes><style face="normal" font="default" size="100%">Moeller, Anne Marie&#xD;Christensen, Lone F&#xD;Hansen, Jens Peter&#xD;Andersen, Pernille T&#xD;eng&#xD;Review&#xD;2022/02/15&#xD;Digit Health. 2022 Feb 7;8:20552076221075148. doi: 10.1177/20552076221075148. eCollection 2022 Jan-Dec.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35154803</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8832590</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/20552076221075148</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>170</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">170</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moeller, A. M.</style></author><author><style face="normal" font="default" size="100%">Hansen, J. P.</style></author><author><style face="normal" font="default" size="100%">Andersen, P. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit for Telepsychiatry and E-mental Health, Centre for Telepsychiatry in the Mental Health Services in the Region of Southern Denmark, Heden 11, 5000 Odense, Denmark; Health Promotion Research, Department of Public Health, University of Southern Denmark, Degnevej 14, 6705 Esbjerg, Denmark. Electronic address: ammoeller@health.sdu.dk.&#xD;Psychiatric Research Unit Esbjerg, The Mental Health Services in the Region of Southern Denmark, Gl. Vardevej 101, 6715 Esbjerg, Denmark; Center for Clinical Nursing Research, Department of Clinical Research, University of Southern Denmark, Winslowparken 19, 5000 Odense, Denmark. Electronic address: jens.peter.hansen@rsyd.dk.&#xD;Health Promotion Research, Department of Public Health, University of Southern Denmark, Degnevej 14, 6705 Esbjerg, Denmark. Electronic address: ptandersen@health.sdu.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patients&apos; experiences of home-based psychotherapy via videoconference: A qualitative study</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Psychiatr Nurs</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">91-96</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><edition><style face="normal" font="default" size="100%">20220314</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Qualitative Research</style></keyword><keyword><style face="normal" font="default" size="100%">*Telemedicine</style></keyword><keyword><style face="normal" font="default" size="100%">Videoconferencing</style></keyword><keyword><style face="normal" font="default" size="100%">Patient experience</style></keyword><keyword><style face="normal" font="default" size="100%">Telepsychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">Video consultation</style></keyword><keyword><style face="normal" font="default" size="100%">Videoconferencing-based psychotherapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1532-8228 (Electronic)&#xD;0883-9417 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35688550</style></accession-num><abstract><style face="normal" font="default" size="100%">The aim of this study is to explore adult outpatients&apos; experiences with home-based psychotherapy via videoconferencing in a Danish mental health service. Participants found videoconferencing-based psychotherapy for preventive relapse sessions very useful, and they believed that it was possible to maintain a good therapeutic relationship via videoconferencing when they knew their therapist in advance. However, experiences with more in-depth psychotherapy are more unclear as some felt alienated and preferred other ways to communicate. In general, participants found videoconferencing-based psychotherapy to be less personal but worth considering when travel hassles outweigh the need for meeting in person.</style></abstract><notes><style face="normal" font="default" size="100%">Moeller, Anne Marie&#xD;Hansen, Jens Peter&#xD;Andersen, Pernille Tanggaard&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/06/11&#xD;Arch Psychiatr Nurs. 2022 Aug;39:91-96. doi: 10.1016/j.apnu.2022.03.004. Epub 2022 Mar 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35688550</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.apnu.2022.03.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>172</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karalexi, M. A.</style></author><author><style face="normal" font="default" size="100%">Eberhard-Gran, M.</style></author><author><style face="normal" font="default" size="100%">Valdimarsdottir, U. A.</style></author><author><style face="normal" font="default" size="100%">Karlsson, H.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author><author><style face="normal" font="default" size="100%">Skalkidou, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for Women&apos;s and Children&apos;s Health, Uppsala University, Uppsala, Sweden.&#xD;Norwegian Research Centre for Women&apos;s Health, Women and Children&apos;s Division, Oslo University Hospital, Oslo, Norway.&#xD;Institute of Clinical Medicine, University of Oslo, Oslo, Norway.&#xD;Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.&#xD;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Epidemiology, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA.&#xD;Department of Psychiatry and Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.&#xD;The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Perinatal mental health: how nordic data sources have contributed to existing evidence and future avenues to explore</style></title><secondary-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">423-432</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">20220120</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Information Storage and Retrieval</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Health</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Registries</style></keyword><keyword><style face="normal" font="default" size="100%">Scandinavian and Nordic Countries/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Nordic countries</style></keyword><keyword><style face="normal" font="default" size="100%">Perinatal mental health</style></keyword><keyword><style face="normal" font="default" size="100%">longitudinal dataset</style></keyword><keyword><style face="normal" font="default" size="100%">national registers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1502-4725 (Electronic)&#xD;0803-9488 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35057712</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: Perinatal mental health disorders affect a significant number of women with debilitating and potentially life-threatening consequences. Researchers in Nordic countries have access to high quality, population-based data sources and the possibility to link data, and are thus uniquely positioned to fill current evidence gaps. We aimed to review how Nordic studies have contributed to existing evidence on perinatal mental health. METHODS: We summarized examples of published evidence on perinatal mental health derived from large population-based longitudinal and register-based data from Denmark, Finland, Iceland, Norway and Sweden. RESULTS: Nordic datasets, such as the Danish National Birth Cohort, the FinnBrain Birth Cohort Study, the Icelandic SAGA cohort, the Norwegian MoBa and ABC studies, as well as the Swedish BASIC and Mom2B studies facilitate the study of prevalence of perinatal mental disorders, and further provide opportunity to prospectively test etiological hypotheses, yielding comprehensive suggestions about the underlying causal mechanisms. The large sample size, extensive follow-up, multiple measurement points, large geographic coverage, biological sampling and the possibility to link data to national registries renders them unique. The use of novel approaches, such as the digital phenotyping data in the novel application-based Mom2B cohort recording even voice qualities and digital phenotyping, or the Danish study design paralleling a natural experiment are considered strengths of such research. CONCLUSIONS: Nordic data sources have contributed substantially to the existing evidence, and can guide future work focused on the study of background, genetic and environmental factors to ultimately define vulnerable groups at risk for psychiatric disorders following childbirth.</style></abstract><notes><style face="normal" font="default" size="100%">Karalexi, Maria A&#xD;Eberhard-Gran, Malin&#xD;Valdimarsdottir, Unnur Anna&#xD;Karlsson, Hasse&#xD;Munk-Olsen, Trine&#xD;Skalkidou, Alkistis&#xD;eng&#xD;Review&#xD;England&#xD;2022/01/22&#xD;Nord J Psychiatry. 2022 Aug;76(6):423-432. doi: 10.1080/08039488.2021.1998616. Epub 2022 Jan 20.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35057712</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08039488.2021.1998616</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>173</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hell, M. E.</style></author><author><style face="normal" font="default" size="100%">Muller, A.</style></author><author><style face="normal" font="default" size="100%">Horn, C. G.</style></author><author><style face="normal" font="default" size="100%">Sogaard Nielsen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Personality traits and alcohol consumption: Secondary analysis of the Self-Match Study</style></title><secondary-title><style face="normal" font="default" size="100%">Alcohol Clin Exp Res</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1110-1120</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">20220502</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alcohol Drinking/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcoholism/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroticism</style></keyword><keyword><style face="normal" font="default" size="100%">Personality</style></keyword><keyword><style face="normal" font="default" size="100%">Personality Inventory</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">personality traits</style></keyword><keyword><style face="normal" font="default" size="100%">psychotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">retention in care</style></keyword><keyword><style face="normal" font="default" size="100%">treatment planning</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1530-0277 (Electronic)&#xD;0145-6008 (Print)&#xD;0145-6008 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35429046</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: This secondary analysis of the Self-Match Study explores whether personality traits affect the treatment outcome for alcohol use disorders (AUD). We designed the Self-Match Study to investigate whether clients choosing between treatment options improves treatment outcomes. The primary outcome report revealed no difference in the outcome, whether treatment allocation was based on clinician matching or self-matching. Because willingness to choose, choice of treatment method, and compliance with treatment may be related to personality, this exploratory sub-study investigated the influence of personality traits on treatment outcome. METHOD: We enrolled 402 consecutive clients (female 46.7%, mean age 47.4) seeking treatment at the outpatient alcohol treatment center in Odense, Denmark. Clients were randomized to treatment by expert-match or self-matching. Data on alcohol consumption (Timeline Follow Back), personality traits (NEO-FFI-3), and retention in care were collected at baseline and 6-month follow-up. Outcomes were compliance, sensible drinking (alcohol intake below National Recommendations), and the number of heavy drinking days at follow-up. RESULTS: A high neuroticism score was negatively associated with treatment completion. Further, clients with a high score on neuroticism, openness, and extraversion, or a low score on conscientiousness were less likely to reduce their drinking to a sensible level at follow-up. We also found that low scores on conscientiousness were associated with having more heavy drinking days at follow-up. The personality traits neuroticism and openness were associated with treatment preferences. CONCLUSIONS: Personality traits influence 6 months drinking outcomes for people receiving AUD treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Hell, Morten Ellegaard&#xD;Muller, Anders&#xD;Horn, Christina Gehling&#xD;Sogaard Nielsen, Anette&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/04/17&#xD;Alcohol Clin Exp Res. 2022 Jun;46(6):1110-1120. doi: 10.1111/acer.14841. Epub 2022 May 2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35429046</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors have no conflicts of interest to declare. Anette Sogaard Nielsen (PI) and Morten Ellegaard Hell are employees at the University of Southern Denmark. Anders Muller and Christina Gehling Horn are students at the University of Southern Denmark. Morten Ellegaard Hell is employed in the Psychiatry of Region Syddanmark. None of the authors have associations with or financial interests in The Lundbeck Foundation.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9320843</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/acer.14841</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>246</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krplin, Anja</style></author><author><style face="normal" font="default" size="100%">Kupka, Kthe Friederike</style></author><author><style face="normal" font="default" size="100%">Frhner, Juliane H.</style></author><author><style face="normal" font="default" size="100%">Krnke, Klaus-Martin</style></author><author><style face="normal" font="default" size="100%">Wolff, Max</style></author><author><style face="normal" font="default" size="100%">Smolka, Michael N.</style></author><author><style face="normal" font="default" size="100%">Bhringer, Gerhard</style></author><author><style face="normal" font="default" size="100%">Goschke, Thomas</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Personality Traits Predict Non-Substance Related and Substance Related Addictive Behaviours</style></title><secondary-title><style face="normal" font="default" size="100%">Sucht</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sucht</style></full-title></periodical><pages><style face="normal" font="default" size="100%">263-277</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">5</style></number><section><style face="normal" font="default" size="100%">263</style></section><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">0939-5911&#xD;1664-2856</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1024/0939-5911/a000780</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>174</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lebiecka, Z.</style></author><author><style face="normal" font="default" size="100%">Skoneczny, T.</style></author><author><style face="normal" font="default" size="100%">Tyburski, E.</style></author><author><style face="normal" font="default" size="100%">Samochowiec, J.</style></author><author><style face="normal" font="default" size="100%">Jedrzejewski, A.</style></author><author><style face="normal" font="default" size="100%">Wirtz, J.</style></author><author><style face="normal" font="default" size="100%">Kuhn, S.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author><author><style face="normal" font="default" size="100%">Michelis, L. A.</style></author><author><style face="normal" font="default" size="100%">Kucharska-Mazur, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry, Pomeranian Medical University in Szczecin, Szczecin, Poland.&#xD;Department of Health Psychology, Pomeranian Medical University in Szczecin, Szczecin, Poland.&#xD;Neuroplasticity Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.&#xD;Unit for Clinical Alcohol Research, Unit for Psychiatric Research, Department of Clinical Research, Odense Center, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Personality-Related Factors and Depressive Symptomatology Predict Behavioral Control in Patients With Alcohol Use Disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Front Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">866657</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20220707</style></edition><keywords><keyword><style face="normal" font="default" size="100%">alcohol use disorders (AUDs)</style></keyword><keyword><style face="normal" font="default" size="100%">behavioral control</style></keyword><keyword><style face="normal" font="default" size="100%">depression</style></keyword><keyword><style face="normal" font="default" size="100%">impulsivity</style></keyword><keyword><style face="normal" font="default" size="100%">personality</style></keyword><keyword><style face="normal" font="default" size="100%">response inhibition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/7/7</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Frontiers Media SA</style></publisher><isbn><style face="normal" font="default" size="100%">1664-0640 (Print)&#xD;1664-0640 (Electronic)&#xD;1664-0640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35873248</style></accession-num><abstract><style face="normal" font="default" size="100%">In the face of increasing social, economic, and health consequences of alcohol use disorders (AUDs) and limited effects of available treatment options, the search for novel prevention and management methods continues to remain a timely and valid endeavor. This, however, requires a better grasp of the theoretical framework underlying addiction mechanisms. With the goal to extend the existing body of evidence on AUDs, we set out to investigate the effect of personality-related factors and depressive symptomatology on (i) impulsivity, (ii) cognitive response inhibition, and (iii) the links between the two measures of behavioral control (different facets of impulsivity and response inhibition) in a treatment-seeking AUD sample. To this end, 53 male (n = 45) and female (n = 8) inpatients at an alcohol rehabilitation center completed three self-report questionnaires: the International Personality Item Pool (IPIP-50), the Beck Depression Inventory Second Edition (BDI-II) and the Barratt Impulsiveness Scale (BIS-11) and performed one behavioral task-an alcohol go/no go task. Regression analyses revealed conscientiousness, intellect, and depression level to be important potential predictors of self-report impulsivity and processing speed in recovering drinkers. No significant links were observed between the two measures of behavioral control, thus complementing evidence that while they both encompass behavioral under-regulation, they may indeed represent distinct psychological constructs.</style></abstract><notes><style face="normal" font="default" size="100%">Lebiecka, Zofia&#xD;Skoneczny, Tomasz&#xD;Tyburski, Ernest&#xD;Samochowiec, Jerzy&#xD;Jedrzejewski, Adam&#xD;Wirtz, Janina&#xD;Kuhn, Simone&#xD;Nielsen, Anette Sogard&#xD;Mellentin, Angelina Isabella&#xD;Michelis, Leonie Ascone&#xD;Kucharska-Mazur, Jolanta&#xD;eng&#xD;Switzerland&#xD;2022/07/26&#xD;Front Psychiatry. 2022 Jul 7;13:866657. doi: 10.3389/fpsyt.2022.866657. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35873248</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9300871</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fpsyt.2022.866657</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>175</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">175</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mistarz, N.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Goudriaan, A. E.</style></author><author><style face="normal" font="default" size="100%">Michel, T. M.</style></author><author><style face="normal" font="default" size="100%">Skot, L.</style></author><author><style face="normal" font="default" size="100%">Anhoj, S. J.</style></author><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark. Electronic address: nimistarz@health.sdu.dk.&#xD;Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.&#xD;Amsterdam University Medical Centre, Department of Psychiatry, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Addiction Research, Department of Research, Arkin, Amsterdam, the Netherlands.&#xD;Unit for Psychiatric Research, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark; Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pharmacological compounds targeting emotional cognition in alcohol use disorder: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Prog Neuropsychopharmacol Biol Psychiatry</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">110535</style></pages><volume><style face="normal" font="default" size="100%">116</style></volume><number><style face="normal" font="default" size="100%">110535</style></number><edition><style face="normal" font="default" size="100%">20220217</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alcoholism/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Cognition</style></keyword><keyword><style face="normal" font="default" size="100%">Emotions</style></keyword><keyword><style face="normal" font="default" size="100%">Executive Function</style></keyword><keyword><style face="normal" font="default" size="100%">*Facial Recognition</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Affective cognition</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol dependence</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive bias</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive deficits</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive enhancers</style></keyword><keyword><style face="normal" font="default" size="100%">Emotion processing</style></keyword><keyword><style face="normal" font="default" size="100%">Emotional cognition</style></keyword><keyword><style face="normal" font="default" size="100%">Implicit cognition</style></keyword><keyword><style face="normal" font="default" size="100%">Nootropics</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacological agents</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Reward processing</style></keyword><keyword><style face="normal" font="default" size="100%">Social cognition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun 8</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1878-4216 (Electronic)&#xD;0278-5846 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35182608</style></accession-num><abstract><style face="normal" font="default" size="100%">Non-emotional (e.g., executive functions) and emotional cognitive (e.g., facial emotion recognition) impairments are a well-known aspect of alcohol use disorder (AUD). These deficits may impede on treatment outcomes, increase the risk of relapse, and lead to socio-occupational disabilities. Previous systematic reviews have examined the effectiveness of cognitive enhancing pharmacological agents (CEPAs) targeting non-emotional, but not emotional, cognition in AUD. Our aim was to systematically review the effectiveness of CEPAs targeting emotional cognition in subclinical and clinical AUD populations. A qualitative synthesis of controlled trials was conducted, and the studies were assessed for risk of bias. Eight studies were eligible (15 &lt;/= ns &lt;/= 143), and they all had a moderate risk of bias. Modafinil and nalmefene were the most examined agents, with the findings suggesting a potential beneficial effect of the agents on implicit emotional domains (i.e., reward processing). Methodological shortcomings and heterogeneous findings across the studies do not allow inferences about the effectiveness of these compounds in AUD. Future studies should examine CEPAs targeting emotional cognition in more detail.</style></abstract><notes><style face="normal" font="default" size="100%">Mistarz, Nicolaj&#xD;Andersen, Kjeld&#xD;Nielsen, Anette Sogaard&#xD;Goudriaan, Anneke E&#xD;Michel, Tanja Maria&#xD;Skot, Lotte&#xD;Anhoj, Simon Jesper&#xD;Mellentin, Angelina Isabella&#xD;eng&#xD;Review&#xD;Systematic Review&#xD;England&#xD;2022/02/20&#xD;Prog Neuropsychopharmacol Biol Psychiatry. 2022 Jun 8;116:110535. doi: 10.1016/j.pnpbp.2022.110535. Epub 2022 Feb 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35182608</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.pnpbp.2022.110535</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>289</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">289</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rosenstand, N. J.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Skot, L.</style></author><author><style face="normal" font="default" size="100%">Anhoj, S.</style></author><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Nielsen, D. G.</style></author><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research, Unit for Clinical Alcohol Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark.&#xD;Department of Psychiatry, Odense University Hospital, Region of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Research, Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry, Region of Southern Denmark, Svendborg, Denmark.&#xD;Department of Public Health, Clinical Pharmacology, Pharmacy, and Environmental Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Drug Treatment Center Odense, Odense C, Denmark.&#xD;Research Unit for Telepsychiatry and E-Mental Health, Center for Telepsychiatry, Region of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pharmacological treatment of alcohol use disorder in patients with psychotic disorders: A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Neuropharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Neuropharmacol</style></full-title></periodical><edition><style face="normal" font="default" size="100%">20221229</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Dual diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacological agents</style></keyword><keyword><style face="normal" font="default" size="100%">Polypharmacy.</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotic disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Side effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec 29</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1875-6190 (Electronic)&#xD;1570-159X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36582063</style></accession-num><abstract><style face="normal" font="default" size="100%">Patients with psychotic disorders (PD) often have comorbid alcohol use dis- order (AUD), which is typically treated pharmacologically. Up till now, no systematic review has ex- amined the effectiveness and safety of AUD treatment in PD patients. &lt;/P&gt; &lt;P&gt; Objectives: This study aimed to systematically review the literature on (1) the effects of pharmacolog- ical treatments for AUD on drinking outcomes, (2) the side effects of the drugs, and (3) the effects of polypharmacy in patients with comorbid AUD and PD. &lt;/P&gt; &lt;P&gt; Methods: Bibliographic searches were conducted in MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and PsycINFO. At least two reviewers extracted the data, assessed the risk of bi- as, and performed the qualitative synthesis of the collected evidence. &lt;/P&gt; &lt;P&gt; Results: Twelve eligible studies were identified, half being randomized controlled trials (RCTs). Three studies examined disulfiram, nine naltrexone, two acamprosate, and one nalmefene by comparing the effects of treatment to placebo, baseline, or other pharmacological agents. Disulfiram and naltrexone were shown to reduce alcohol intake. Regarding acamprosate, the findings were mixed. Nalmefene decreased alcohol intake. All pharmacological agents appeared safe to use as AUD mono- therapy, but cardiac events were reported when combining naltrexone and disulfiram. Nine studies had a high risk of bias, and three had some other concerns. &lt;/P&gt; &lt;P&gt; Conclusion: The studies provide tentative support for the use of naltrexone and disulfiram in this population, although combinations of pharmacological AUD treatments and other polypharmacy remain unexplored. The studies had high adherence rates that are hardly replicable in real-world settings.</style></abstract><notes><style face="normal" font="default" size="100%">Rosenstand, Niels Jorgen&#xD;Nielsen, Anette Sogaard&#xD;Skot, Lotte&#xD;Anhoj, Simon&#xD;Hojlund, Mikkel&#xD;Nielsen, Dorthe Gruner&#xD;Mellentin, Angelina Isabella&#xD;eng&#xD;United Arab Emirates&#xD;2022/12/31&#xD;Curr Neuropharmacol. 2022 Dec 29. doi: 10.2174/1570159X21666221229160300.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36582063</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2174/1570159X21666221229160300</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>176</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">176</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vainieri, I.</style></author><author><style face="normal" font="default" size="100%">Martin, J.</style></author><author><style face="normal" font="default" size="100%">Rommel, A. S.</style></author><author><style face="normal" font="default" size="100%">Asherson, P.</style></author><author><style face="normal" font="default" size="100%">Banaschewski, T.</style></author><author><style face="normal" font="default" size="100%">Buitelaar, J.</style></author><author><style face="normal" font="default" size="100%">Cormand, B.</style></author><author><style face="normal" font="default" size="100%">Crosbie, J.</style></author><author><style face="normal" font="default" size="100%">Faraone, S. V.</style></author><author><style face="normal" font="default" size="100%">Franke, B.</style></author><author><style face="normal" font="default" size="100%">Loo, S. K.</style></author><author><style face="normal" font="default" size="100%">Miranda, A.</style></author><author><style face="normal" font="default" size="100%">Manor, I.</style></author><author><style face="normal" font="default" size="100%">Oades, R. D.</style></author><author><style face="normal" font="default" size="100%">Purves, K. L.</style></author><author><style face="normal" font="default" size="100%">Ramos-Quiroga, J. A.</style></author><author><style face="normal" font="default" size="100%">Ribases, M.</style></author><author><style face="normal" font="default" size="100%">Roeyers, H.</style></author><author><style face="normal" font="default" size="100%">Rothenberger, A.</style></author><author><style face="normal" font="default" size="100%">Schachar, R.</style></author><author><style face="normal" font="default" size="100%">Sergeant, J.</style></author><author><style face="normal" font="default" size="100%">Steinhausen, H. C.</style></author><author><style face="normal" font="default" size="100%">Vuijk, P. J.</style></author><author><style face="normal" font="default" size="100%">Doyle, A. E.</style></author><author><style face="normal" font="default" size="100%">Kuntsi, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, London, UK.&#xD;MRC Centre for Neuropsychiatric Genetics &amp; Genomics, School of Medicine, Cardiff University, Cardiff, UK.&#xD;Department of Psychiatry &amp; Department of Environmental Medicine, Public Health at the Icahn School of Medicine at Mount Sinai, New York, NY, USA.&#xD;Department of Child and Adolescent Psychiatry, Central Institute of Mental Health and Mannheim Medical Faculty, University of Heidelberg, Heidelberg, Germany.&#xD;Karakter Child and Adolescent Psychiatry University Center, Nijmegen, The Netherlands.&#xD;Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Centre, Nijmegen, The Netherlands.&#xD;Department of Genetics, Microbiology and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain.&#xD;Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.&#xD;Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Catalonia, Spain.&#xD;Institut de Recerca Sant Joan de Deu (IR-SJD), Esplugues de Llobregat, Catalonia, Spain.&#xD;Psychiatry, Neurosciences and Mental Health, The Hospital for Sick Children, University of Toronto, Toronto, Canada.&#xD;Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York, USA.&#xD;Departments of Human Genetics and Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.&#xD;Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior and David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.&#xD;Department of Developmental and Educational Psychology, University of Valencia, Valencia, Spain.&#xD;Geha Mental Health Center, Petah Tikva, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.&#xD;Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, Essen, Germany.&#xD;Department of Psychiatry, Hospital Universitari Vall d&apos;Hebron, Barcelona, Catalonia, Spain.&#xD;Group of Psychiatry, Mental Health and Addictions, Vall d&apos;Hebron Research Institute (VHIR), Barcelona, Catalonia, Spain.&#xD;Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Catalonia, Spain.&#xD;Department of Psychiatry and Forensic Medicine, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain.&#xD;Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain.&#xD;Department of Experimental Clinical and Health Psychology, Ghent University, Gent, Belgium.&#xD;Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Gottingen, Goettingen, Germany.&#xD;Department of Clinical Neuropsychology, Vrije Universiteit, Amsterdam, The Netherlands.&#xD;Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland.&#xD;Clinical Psychology and Epidemiology, Institute of Psychology, University of Basel, Basel, Switzerland.&#xD;Department of Child and Adolescent Psychiatry, University of Southern Denmark, Odense, Denmark.&#xD;Centre of Child and Adolescent Mental Health, Capital Region Psychiatry, Copenhagen, Denmark.&#xD;Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.&#xD;Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Polygenic association between attention-deficit/hyperactivity disorder liability and cognitive impairments</style></title><secondary-title><style face="normal" font="default" size="100%">Psychol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Psychol Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3150-3158</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">14</style></number><edition><style face="normal" font="default" size="100%">20210203</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Attention Deficit Disorder with Hyperactivity/genetics/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">*Cognitive Dysfunction/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">Reaction Time/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Adhd</style></keyword><keyword><style face="normal" font="default" size="100%">attention</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">inhibition</style></keyword><keyword><style face="normal" font="default" size="100%">polygenic risk scores</style></keyword><keyword><style face="normal" font="default" size="100%">reaction time variability</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Cambridge University Press (CUP)</style></publisher><isbn><style face="normal" font="default" size="100%">1469-8978 (Electronic)&#xD;0033-2917 (Print)&#xD;0033-2917 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33531098</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: A recent genome-wide association study (GWAS) identified 12 independent loci significantly associated with attention-deficit/hyperactivity disorder (ADHD). Polygenic risk scores (PRS), derived from the GWAS, can be used to assess genetic overlap between ADHD and other traits. Using ADHD samples from several international sites, we derived PRS for ADHD from the recent GWAS to test whether genetic variants that contribute to ADHD also influence two cognitive functions that show strong association with ADHD: attention regulation and response inhibition, captured by reaction time variability (RTV) and commission errors (CE). METHODS: The discovery GWAS included 19 099 ADHD cases and 34 194 control participants. The combined target sample included 845 people with ADHD (age: 8-40 years). RTV and CE were available from reaction time and response inhibition tasks. ADHD PRS were calculated from the GWAS using a leave-one-study-out approach. Regression analyses were run to investigate whether ADHD PRS were associated with CE and RTV. Results across sites were combined via random effect meta-analyses. RESULTS: When combining the studies in meta-analyses, results were significant for RTV (R(2) = 0.011, beta = 0.088, p = 0.02) but not for CE (R(2) = 0.011, beta = 0.013, p = 0.732). No significant association was found between ADHD PRS and RTV or CE in any sample individually (p &gt; 0.10). CONCLUSIONS: We detected a significant association between PRS for ADHD and RTV (but not CE) in individuals with ADHD, suggesting that common genetic risk variants for ADHD influence attention regulation.</style></abstract><notes><style face="normal" font="default" size="100%">Vainieri, Isabella&#xD;Martin, Joanna&#xD;Rommel, Anna-Sophie&#xD;Asherson, Philip&#xD;Banaschewski, Tobias&#xD;Buitelaar, Jan&#xD;Cormand, Bru&#xD;Crosbie, Jennifer&#xD;Faraone, Stephen V&#xD;Franke, Barbara&#xD;Loo, Sandra K&#xD;Miranda, Ana&#xD;Manor, Iris&#xD;Oades, Robert D&#xD;Purves, Kirstin L&#xD;Ramos-Quiroga, J Antoni&#xD;Ribases, Marta&#xD;Roeyers, Herbert&#xD;Rothenberger, Aribert&#xD;Schachar, Russell&#xD;Sergeant, Joseph&#xD;Steinhausen, Hans-Christoph&#xD;Vuijk, Pieter J&#xD;Doyle, Alysa E&#xD;Kuntsi, Jonna&#xD;eng&#xD;R01 MH062873/MH/NIMH NIH HHS/&#xD;R01 MH081803/MH/NIMH NIH HHS/&#xD;G0300189/Medical Research Council/United Kingdom&#xD;R01 NS054124/NS/NINDS NIH HHS/&#xD;R01 MH116037/MH/NIMH NIH HHS/&#xD;MOP-93696/CIHR/Canada&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2021/02/04&#xD;Psychol Med. 2022 Oct;52(14):3150-3158. doi: 10.1017/S0033291720005218. Epub 2021 Feb 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33531098</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9693667</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S0033291720005218</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>177</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">177</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Madsen, K. B.</style></author><author><style face="normal" font="default" size="100%">Kjeldsen, M. Z.</style></author><author><style face="normal" font="default" size="100%">Petersen, L. V.</style></author><author><style face="normal" font="default" size="100%">Bergink, V.</style></author><author><style face="normal" font="default" size="100%">Skalkidou, A.</style></author><author><style face="normal" font="default" size="100%">Vigod, S. N.</style></author><author><style face="normal" font="default" size="100%">Frokjaer, V. G.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. B.</style></author><author><style face="normal" font="default" size="100%">Maegbaek, M. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research, University of Southern Denmark, Odense, Denmark. tmun@sdu.dk.&#xD;National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark. tmun@sdu.dk.&#xD;National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark.&#xD;Department of Psychiatry, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands.&#xD;Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.&#xD;Department of Women&apos;s and Children&apos;s Health, Uppsala University, Uppsala, Sweden.&#xD;Women&apos;s College Hospital and Women&apos;s College Research Institute, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.&#xD;Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark.&#xD;Neurobiology Research Unit, Copenhagen University Hospital, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark.&#xD;Centre for Integrated Register-based Research, CIRRAU, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Postpartum depression: a developed and validated model predicting individual risk in new mothers</style></title><secondary-title><style face="normal" font="default" size="100%">Transl Psychiatry</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">419</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220930</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antidepressive Agents</style></keyword><keyword><style face="normal" font="default" size="100%">*Depression, Postpartum/diagnosis/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mothers/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 30</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2158-3188 (Electronic)&#xD;2158-3188 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36180471</style></accession-num><abstract><style face="normal" font="default" size="100%">Postpartum depression (PPD) is a serious condition associated with potentially tragic outcomes, and in an ideal world PPDs should be prevented. Risk prediction models have been developed in psychiatry estimating an individual&apos;s probability of developing a specific condition, and recently a few models have also emerged within the field of PPD research, although none are implemented in clinical care. For the present study we aimed to develop and validate a prediction model to assess individualized risk of PPD and provide a tentative template for individualized risk calculation offering opportunities for additional external validation of this tool. Danish population registers served as our data sources and PPD was defined as recorded contact to a psychiatric treatment facility (ICD-10 code DF32-33) or redeemed antidepressant prescriptions (ATC code N06A), resulting in a sample of 6,402 PPD cases (development sample) and 2,379 (validation sample). Candidate predictors covered background information including cohabitating status, age, education, and previous psychiatric episodes in index mother (Core model), additional variables related to pregnancy and childbirth (Extended model), and further health information about the mother and her family (Extended+ model). Results indicated our recalibrated Extended model with 14 variables achieved highest performance with satisfying calibration and discrimination. Previous psychiatric history, maternal age, low education, and hyperemesis gravidarum were the most important predictors. Moving forward, external validation of the model represents the next step, while considering who will benefit from preventive PPD interventions, as well as considering potential consequences from false positive and negative test results, defined through different threshold values.</style></abstract><notes><style face="normal" font="default" size="100%">Munk-Olsen, Trine&#xD;Liu, Xiaoqin&#xD;Madsen, Kathrine Bang&#xD;Kjeldsen, Mette-Marie Zacher&#xD;Petersen, Liselotte Vogdrup&#xD;Bergink, Veerle&#xD;Skalkidou, Alkistis&#xD;Vigod, Simone N&#xD;Frokjaer, Vibe G&#xD;Pedersen, Carsten B&#xD;Maegbaek, Merete L&#xD;eng&#xD;R01MH122869/MH/NIMH NIH HHS/&#xD;891079/MCCC_/Marie Curie/United Kingdom&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/10/01&#xD;Transl Psychiatry. 2022 Sep 30;12(1):419. doi: 10.1038/s41398-022-02190-8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36180471</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">A.S. has earlier served as a consultant for Biogen and Ferring Pharmaceuticals. S.V. receives royalties from UpToDate Inc for authorship of materials related to depression and pregnancy. V.G.F. has served as a consultant for Sage Therapeutics and H. Lundbeck. The rest of the author group declare no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9525696</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41398-022-02190-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>178</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Banaschewski, T.</style></author><author><style face="normal" font="default" size="100%">Bruni, O.</style></author><author><style face="normal" font="default" size="100%">Fuentes, J.</style></author><author><style face="normal" font="default" size="100%">Hill, C. M.</style></author><author><style face="normal" font="default" size="100%">Hvolby, A.</style></author><author><style face="normal" font="default" size="100%">Posserud, M. B.</style></author><author><style face="normal" font="default" size="100%">Schroder, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany. tobias.banaschewski@zi-mannheim.de.&#xD;Department of Developmental and Social Psychology, Sapienza University, Rome, Italy. oliviero.bruni@uniroma1.it.&#xD;Service of Child and Adolescent Psychiatry, Policlinica Gipuzkoa and GAUTENA Autism Society, San Sebastian, Spain.&#xD;School of Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.&#xD;Department of Sleep Medicine, Southampton Children&apos;s Hospital, Southampton, UK.&#xD;Department of Child and Adolescent Psychiatry, Psychiatry in Region of South Denmark, Esbjerg, Denmark.&#xD;Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Medicine, Faculty of Medicine, University of Bergen, Bergen, Norway.&#xD;Department of Child and Adolescent Psychiatry &amp; Excellence Centre for Autism and Neurodevelopmental Disorders STRAS&amp;ND, Strasbourg University Hospitals &amp; University of Strasbourg Medical School, 67000, Strasbourg, France. schroderc@unistra.fr.&#xD;CNRS UPR 3212, Institute for Cellular and Integrative Neurosciences, Strasbourg, France. schroderc@unistra.fr.&#xD;Sleep Disorders Center&amp; International Research Center for ChronoSomnology, Strasbourg, France. schroderc@unistra.fr.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Practice Tools for Screening and Monitoring Insomnia in Children and Adolescents with Autism Spectrum Disorder</style></title><secondary-title><style face="normal" font="default" size="100%">J Autism Dev Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Autism Dev Disord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3758-3768</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">8</style></number><edition><style face="normal" font="default" size="100%">20210831</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mass Screening/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Sleep Initiation and Maintenance Disorders/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Child Adolescent Sleep Insomnia Autism spectrum disorder ASD</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1573-3432 (Electronic)&#xD;0162-3257 (Print)&#xD;0162-3257 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34463899</style></accession-num><abstract><style face="normal" font="default" size="100%">Between 50-80% of children with autism spectrum disorder (ASD) have insomnia, which adversely affects their mental and physical health. However, there is no consensus to-date on suitable tools for insomnia screening and monitoring in daily clinical practice. An expert panel of child neuropsychiatry and sleep specialists, with expertise in children with neurodevelopmental disabilities, recommends: (1) performing insomnia screening of all children with ASD; (2) considering discussion or referral to a sleep specialist when comorbid sleep disorders are suspected. The panel further developed structured, brief screening and monitoring tools to facilitate insomnia screening and management in daily practice, monitor treatment effectiveness and standardize and compare outcomes across clinical settings to improve care and well-being of children with ASD and their families.</style></abstract><notes><style face="normal" font="default" size="100%">Banaschewski, Tobias&#xD;Bruni, Oliviero&#xD;Fuentes, Joaquin&#xD;Hill, Catherine Mary&#xD;Hvolby, Allan&#xD;Posserud, Maj-Britt&#xD;Schroder, Carmen&#xD;eng&#xD;2021/09/01&#xD;J Autism Dev Disord. 2022 Aug;52(8):3758-3768. doi: 10.1007/s10803-021-05236-w. Epub 2021 Aug 31.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34463899</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9296438</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10803-021-05236-w</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>179</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jankovic, I.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author><author><style face="normal" font="default" size="100%">Pedersen, C. B.</style></author><author><style face="normal" font="default" size="100%">Kristensen, B. W.</style></author><author><style face="normal" font="default" size="100%">Schytte, T.</style></author><author><style face="normal" font="default" size="100%">Andersen, T. L.</style></author><author><style face="normal" font="default" size="100%">Langhorn, L.</style></author><author><style face="normal" font="default" size="100%">Graumann, O.</style></author><author><style face="normal" font="default" size="100%">Krone, W.</style></author><author><style face="normal" font="default" size="100%">Hoilund-Carlsen, P. F.</style></author><author><style face="normal" font="default" size="100%">Halle, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurosurgery, Odense University Hospital, J. B. Winslows Vej 4, 5000, Odense C, Denmark. irena.jankovic@live.dk.&#xD;Department of Clinical Research and BRIDGE (Brain Research-Inter Disciplinary Guided Excellence), University of Southern Denmark, Odense, Denmark. irena.jankovic@live.dk.&#xD;Department of Neurosurgery, Odense University Hospital, J. B. Winslows Vej 4, 5000, Odense C, Denmark.&#xD;Department of Clinical Research and BRIDGE (Brain Research-Inter Disciplinary Guided Excellence), University of Southern Denmark, Odense, Denmark.&#xD;Department of Pathology, Odense University Hospital, Odense, Denmark.&#xD;Department of Oncology, Odense University Hospital, Odense, Denmark.&#xD;Department Nuclear Medicine, Odense University Hospital, Odense, Denmark.&#xD;Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.&#xD;Biomedical Laboratory, University of Southern Denmark, Odense, Denmark.&#xD;Department of Radiology, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preclinical cerebral cryoablation in non-tumor bearing pigs</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1977</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220207</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging/*pathology/*surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Neoplasms/diagnostic imaging/pathology/*surgery</style></keyword><keyword><style face="normal" font="default" size="100%">Cryosurgery/*adverse effects/*methods</style></keyword><keyword><style face="normal" font="default" size="100%">Feasibility Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Neuroimaging</style></keyword><keyword><style face="normal" font="default" size="100%">Safety</style></keyword><keyword><style face="normal" font="default" size="100%">Swine</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, X-Ray Computed</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 7</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">2045-2322 (Electronic)&#xD;2045-2322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35132097</style></accession-num><abstract><style face="normal" font="default" size="100%">Patients with brain metastases, the most common intracranial tumor, have an average survival ranging from a few months to 40 months, and new treatment initiatives are needed. Cryoablation is a minimally invasive, well-tolerated, and effective procedure commonly applied for treatment of renal tumors and certain other malignancies. We aimed to examine the clinical usefulness of this procedure in a step-by-step program starting with cerebral cryoablation in healthy pigs. In four terminal and four non-terminal non-tumor bearing pigs, we studied immediate and delayed effects of cerebral cryoablation. Safety was assessed by computed tomography (CT), and clinical observation of behavior, neurological deficits, and wellbeing. Effects were assessed by histological and immuno-histochemical analyses addressing structural and metabolic changes supported by additional magnetic resonance imaging (MRI) and positron emission tomography (PET) in the non-terminal animals. Using CT-guidance, cryoablation probes were successfully inserted without complications, and ice formation could be monitored real-time with CT. No animal developed neurological deficits or signs of discomfort. Histological and immunohistochemical analyses, MRI, and PET revealed profound structural and biological damage within the lesion. MRI and PET revealed no long-term damage to healthy tissue outside the cryoablation zone. Cerebral cryoablation appears to be a feasible, safe, and controllable procedure that can be monitored successfully with CT. The net effect is a dead brain lesion without damage of either nearby or remote healthy structures. Immediate changes are local hemorrhage and edema; delayed effects are perfusion defects, immune system activation, and astrogliosis.</style></abstract><notes><style face="normal" font="default" size="100%">Jankovic, Irena&#xD;Poulsen, Frantz Rom&#xD;Pedersen, Christian Bonde&#xD;Kristensen, Bjarne Winther&#xD;Schytte, Tine&#xD;Andersen, Thomas Lund&#xD;Langhorn, Louise&#xD;Graumann, Ole&#xD;Krone, Willy&#xD;Hoilund-Carlsen, Poul Flemming&#xD;Halle, Bo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/02/09&#xD;Sci Rep. 2022 Feb 7;12(1):1977. doi: 10.1038/s41598-022-05889-2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35132097</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8821607</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41598-022-05889-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>275</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">275</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Madsen, K. B.</style></author><author><style face="normal" font="default" size="100%">Maegbaek, M. L.</style></author><author><style face="normal" font="default" size="100%">Thomsen, N. S.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Eberhard-Gran, M.</style></author><author><style face="normal" font="default" size="100%">Skalkidou, A.</style></author><author><style face="normal" font="default" size="100%">Bergink, V.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Centre for Register-based Research, Business and Social Sciences, Aarhus University, Fuglesangs Alle 26, Building R, Aarhus 8210, Denmark; iPSYCH, the Lundbeck Foundation Initiative for Integrative Psychiatric Research, Denmark. Electronic address: kathrine.bang@econ.au.dk.&#xD;National Centre for Register-based Research, Business and Social Sciences, Aarhus University, Fuglesangs Alle 26, Building R, Aarhus 8210, Denmark; iPSYCH, the Lundbeck Foundation Initiative for Integrative Psychiatric Research, Denmark.&#xD;Norwegian Research Centre for Women&apos;s Health, Women and Children&apos;s Division, Oslo University Hospital, Rikshospitalet, Oslo Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.&#xD;Department of Women&apos;s and Children&apos;s Health, Uppsala University, Sweden.&#xD;Department of Psychiatry and Department of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, NY, USA; Department of Psychiatry, Rotterdam, Erasmus MC, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pregnancy and postpartum psychiatric episodes in fathers: A population-based study on treatment incidence and prevalence</style></title><secondary-title><style face="normal" font="default" size="100%">J Affect Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Affect Disord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">130-135</style></pages><volume><style face="normal" font="default" size="100%">296</style></volume><edition><style face="normal" font="default" size="100%">20210922</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Fathers</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Postpartum Period</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Fathers</style></keyword><keyword><style face="normal" font="default" size="100%">Perinatal psychiatric episodes</style></keyword><keyword><style face="normal" font="default" size="100%">Postpartum depression</style></keyword><keyword><style face="normal" font="default" size="100%">Register-based population study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-2517 (Electronic)&#xD;0165-0327 (Print)&#xD;0165-0327 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34601300</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: For women, the perinatal period confers an increased risk of severe psychiatric disorders, but similar evidence for fathers is lacking. We examined rates of first-time and recurrent psychiatric disorders in men before and after becoming fathers. METHODS: A descriptive prospective study design was applied using information from the Danish National registers. Perinatal psychiatric episodes were assessed as incidence of first-time and prevalence (including recurrence) of recorded in- or outpatient admissions for any mental disorder and redeemed prescriptions for psychotropic medication in fathers to children born from January 1, 1998 until December 31, 2015. RESULTS: We identified 929,415 births and 543,555 unique fathers. Incidence and prevalence proportions for paternal psychiatric in- and outpatient episodes showed an increasing trend over the perinatal period and were marginally higher postpartum compared to pregnancy; e.g., median incidence proportion for inpatient treatment during pregnancy was 0.07 (95% CI: 0.04; 0.07) and 0.10 (95% CI: 0.08; 0.11) postpartum per 1000 births. No difference between the periods was found for incidence of prescriptions for psychotropic medication. Psychiatric disorders in expecting and new fathers were mainly treated in primary care with cumulative incidence of prescriptions for psychotropic medication of 14.56 per 1000 births during the first year of fatherhood. LIMITATIONS: We only capture fathers who actively sought and received treatment, and we consequently underestimate milder psychiatric episodes in expecting and new fathers. CONCLUSION: Becoming a father did not appear to trigger a substantially increased risk of severe psychiatric disorders, as it has been observed for new mothers.</style></abstract><notes><style face="normal" font="default" size="100%">Madsen, Kathrine Bang&#xD;Maegbaek, Merete Lund&#xD;Thomsen, Nete Stubkjaer&#xD;Liu, Xiaoqin&#xD;Eberhard-Gran, Malin&#xD;Skalkidou, Alkistis&#xD;Bergink, Veerle&#xD;Munk-Olsen, Trine&#xD;eng&#xD;R01 MH122869/MH/NIMH NIH HHS/&#xD;Research Support, N.I.H., Extramural&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Netherlands&#xD;2021/10/04&#xD;J Affect Disord. 2022 Jan 1;296:130-135. doi: 10.1016/j.jad.2021.09.056. Epub 2021 Sep 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34601300</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of Competing Interest None</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8595874</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jad.2021.09.056</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>271</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">271</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beck, Iben H.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, Niels</style></author><author><style face="normal" font="default" size="100%">Davidsen, Kirstine A.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, Anne A.</style></author><author><style face="normal" font="default" size="100%">Boye, Henriette</style></author><author><style face="normal" font="default" size="100%">Jensen, Tina K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prenatal and early childhood predictors of intelligence quotient (IQ) in 7-year-old Danish children from the Odense Child Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Public Health</style></full-title></periodical><section><style face="normal" font="default" size="100%">140349482210774</style></section><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">1403-4948&#xD;1651-1905</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/14034948221077463</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>272</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">272</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palm, C. V. B.</style></author><author><style face="normal" font="default" size="100%">Glintborg, D.</style></author><author><style face="normal" font="default" size="100%">Find, L. G.</style></author><author><style face="normal" font="default" size="100%">Larsen, P. V.</style></author><author><style face="normal" font="default" size="100%">Dalgaard, C. M.</style></author><author><style face="normal" font="default" size="100%">Boye, H.</style></author><author><style face="normal" font="default" size="100%">Jensen, T. K.</style></author><author><style face="normal" font="default" size="100%">Dreyer, A. F.</style></author><author><style face="normal" font="default" size="100%">Andersen, M. S.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Endocrinology and Metabolism, Odense University Hospital, Klovervaenget 12C, 5000, Odense, Denmark.&#xD;Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Winslowsparken 19, 3rd floor, 5000, Odense, Denmark.&#xD;Department of Endocrinology and Metabolism, Odense University Hospital, Klovervaenget 12C, 5000, Odense, Denmark. dorte.glintborg@rsyd.dk.&#xD;Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Winslowsparken 19, 3rd floor, 5000, Odense, Denmark. dorte.glintborg@rsyd.dk.&#xD;Department of Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, University of Southern Denmark, J.B. Winslows Vej 16, 5000, Odense, Denmark.&#xD;Mental Health Services in the Region of Southern Denmark, University of Southern Denmark, 5000, Odense, Denmark.&#xD;Odense Child Cohort, Hans Christian Andersen Hospital for Children and Adolescents, Odense University Hospital, Klovervaenget 23C, 5000, Odense, Denmark.&#xD;OPEN Patient Data Explorative Network (OPEN), University of Southern Denmark, J.B. Winslows Vej 9A, 5000, Odense, Denmark.&#xD;Department of Environmental Medicine, Odense University Hospital, J.B. Winslows Vej 17A, 5000, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prenatal Androgen Exposure and Traits of Autism Spectrum Disorder in the Offspring: Odense Child Cohort</style></title><secondary-title><style face="normal" font="default" size="100%">J Autism Dev Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Autism Dev Disord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1053-1065</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20220206</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Androgens</style></keyword><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Testosterone</style></keyword><keyword><style face="normal" font="default" size="100%">*Polycystic Ovary Syndrome/complications</style></keyword><keyword><style face="normal" font="default" size="100%">*Prenatal Exposure Delayed Effects</style></keyword><keyword><style face="normal" font="default" size="100%">Autism spectrum</style></keyword><keyword><style face="normal" font="default" size="100%">Birth cohort</style></keyword><keyword><style face="normal" font="default" size="100%">Prenatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1573-3432 (Electronic)&#xD;0162-3257 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35124780</style></accession-num><abstract><style face="normal" font="default" size="100%">Fetal androgen exposure may be associated with autism spectrum disorder (ASD). We studied 1777 mother-child pairs in the prospective Odense Child Cohort. Prenatal androgen exposure was assessed by maternal 3rd trimester testosterone concentrations, maternal polycystic ovary syndrome (PCOS), and 3 months offspring anogenital distance. ASD traits were assessed at age 3 years with the ASD-symptom scale of the Child Behavior Checklist for ages 1(1/2)-5 years. Maternal testosterone was positively associated with traits of ASD in boys (p &lt; 0.05). Maternal PCOS was associated with increased offspring ASD traits (p = 0.046), but became non-significant after excluding parental psychiatric diagnosis. Offspring anogenital distance was not linked to ASD traits. Higher prevalence of ASD in boys could be linked to higher susceptibility to fetal androgen exposure.</style></abstract><notes><style face="normal" font="default" size="100%">Palm, Camilla V B&#xD;Glintborg, Dorte&#xD;Find, Laura G&#xD;Larsen, Pia V&#xD;Dalgaard, Cilia M&#xD;Boye, Henriette&#xD;Jensen, Tina K&#xD;Dreyer, Anja F&#xD;Andersen, Marianne S&#xD;Bilenberg, Niels&#xD;eng&#xD;2022/02/07&#xD;J Autism Dev Disord. 2023 Mar;53(3):1053-1065. doi: 10.1007/s10803-022-05446-w. Epub 2022 Feb 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35124780</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10803-022-05446-w</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>180</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rajabi, M.</style></author><author><style face="normal" font="default" size="100%">Vafaee, M. S.</style></author><author><style face="normal" font="default" size="100%">Hosseini, L.</style></author><author><style face="normal" font="default" size="100%">Badalzadeh, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.&#xD;Psychiatry Research Unit, Southern Denmark Region, Odense, Denmark.&#xD;Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.&#xD;Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.&#xD;Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.&#xD;Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pretreatment with nicotinamide mononucleotide increases the effect of ischaemic postconditioning on cardioprotection and mitochondrial function following ex vivo myocardial reperfusion injury in aged rats</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Exp Pharmacol Physiol</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">474-482</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220209</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Animals</style></keyword><keyword><style face="normal" font="default" size="100%">*Ischemic Postconditioning/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Mitochondria</style></keyword><keyword><style face="normal" font="default" size="100%">*Myocardial Reperfusion Injury/drug therapy/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Nicotinamide Mononucleotide/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style face="normal" font="default" size="100%">*Reperfusion Injury</style></keyword><keyword><style face="normal" font="default" size="100%">ageing</style></keyword><keyword><style face="normal" font="default" size="100%">ischaemic postconditioning</style></keyword><keyword><style face="normal" font="default" size="100%">mitochondrial function</style></keyword><keyword><style face="normal" font="default" size="100%">nicotinamide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1440-1681 (Electronic)&#xD;0305-1870 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34854121</style></accession-num><abstract><style face="normal" font="default" size="100%">The present study aims to evaluate the combined effect of ischaemic postconditioning (IPostC) and nicotinamide mononucleotide (NMN) on cardioprotection and mitochondrial function in aged rats subjected to myocardial ischaemia-reperfusion (IR) injury. Sixty aged Wistar rats were randomly divided into five groups (n = 12), including sham, control, NMN, IPostC, and NMN + IPostC. Regional ischaemia was induced by 30-min occlusion of the left anterior descending coronary artery (LAD) followed by 60-min reperfusion. IPostC was applied at the onset of reperfusion, by six cycles of 10-s reperfusion/ischaemia. NMN (100 mg/kg) was intraperitoneally injected every other day for 28 days before IR. Myocardial haemodynamics and infarct size (IS) were measured, and the left ventricles samples were harvested to assess cardiac mitochondrial function. The results showed that all treatments reduced lactate dehydrogenase release compared to those of the control group. IPostC alone failed to reduce IS and myocardial function. However, NMN and combined therapy could significantly improve myocardial function and decrease the IS compared to the control animals. Moreover, the effects of combined therapy on the decrease of IS, mitochondrial reactive oxygen species (ROS), and improvement of mitochondrial membrane potential (MMP) were greater than those of stand-alone treatments. These results demonstrated that cardioprotection by combined therapy with NMN + IPostC was superior to individual treatments, and pretreatment of aged rats with NMN was able to correct the failure of IPostC in protecting the hearts of aged rats against IR injury.</style></abstract><notes><style face="normal" font="default" size="100%">Rajabi, Mojgan&#xD;Vafaee, Manouchehr S&#xD;Hosseini, Leila&#xD;Badalzadeh, Reza&#xD;eng&#xD;58284/Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran/&#xD;978686/National Institute for Medical Research Development, Iran (grant number)/&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Australia&#xD;2021/12/03&#xD;Clin Exp Pharmacol Physiol. 2022 Apr;49(4):474-482. doi: 10.1111/1440-1681.13616. Epub 2022 Feb 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34854121</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/1440-1681.13616</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>223</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">223</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hellum, R.</style></author><author><style face="normal" font="default" size="100%">Bilberg, R.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Bischof, G.</style></author><author><style face="normal" font="default" size="100%">Hesse, M.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">The Unit of Clinical Alcohol Research (UCAR), Institute of Clinical Research, University of Southern Denmark, J.B. Winslows vej 18, 5000, Odense C, Denmark.&#xD;The Unit of Clinical Alcohol Research (UCAR), Institute of Clinical Research, University of Southern Denmark, J.B. Winslows vej 18, 5000, Odense C, Denmark. rbilberg@health.sdu.dk.&#xD;Psychiatric Department, Region of Southern Denmark, Odense, Denmark.&#xD;The Department of Psychiatry and Psychotherapy, University of Luebeck, Ratzeburger Allee 160, 23562, Lubeck, Germany.&#xD;Centre for Alcohol and Drug Research, Department of Psychological and Behavioral Sciences, Aarhus University, Artillerivej 90, 2, 2300, Copenhagen S, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Primary Outcome from a cluster-randomized trial of three formats for delivering Community Reinforcement and Family Training (CRAFT) to the significant others of problem drinkers</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Public Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">928</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220510</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alcoholism/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Family Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Medical History Taking</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Acceptance of Health Care</style></keyword><keyword><style face="normal" font="default" size="100%">Reinforcement, Psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Craft</style></keyword><keyword><style face="normal" font="default" size="100%">Community Reinforcement and Family Training</style></keyword><keyword><style face="normal" font="default" size="100%">Concerned significant others</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment engagement</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 10</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-2458 (Electronic)&#xD;1471-2458 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35538465</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Community Reinforcement and Family Training (CRAFT) is an intervention designed to help the concerned significant others (CSOs) of people with alcohol problems who are reluctant to seek treatment. It aims to improve the well-being of CSOs and teach them how to change their behavior in order to positively influence the &quot;identified patient&quot; (IP) to seek treatment. METHODS: The aim of the present pragmatic cluster-randomized trial was to compare the effectiveness of three formats for delivering CRAFT in real life settings: group sessions, individual sessions, and written material only (control group). Eighteen public treatment centers for alcohol use disorders were randomly assigned to deliver CRAFT in one of the three formats as part of their daily clinical routine. CSOs were recruited via pamphlets, general practitioners, and advertisements on social media. Trained clinicians delivered CRAFT in individual and group format, and self-administered CRAFT was limited to handing out a self-help book. The primary outcome was treatment engagement of the IP after three months. RESULTS: A total of 249 CSOs were found to be eligible and randomly assigned to receive CRAFT delivered in group, individual, or self-administered format. The three-month follow-up rate was 60%. At three months follow-up, 29% (n = 32) of the CSOs who received group/individual CRAFT reported that their IP had engaged in treatment. The corresponding rate for the CSOs who received self-administered CRAFT was lower (15%; n = 5) but did not differ significantly from the other group of CSOs (Odds ratio (OR) = 2.27 (95% CI: 0.80, 6.41)). CONCLUSION: We hypothesized that CSOs receiving CRAFT in a group format would improve the most, but although our findings pointed in this direction, the differences were not statistically significant. TRIAL REGISTRATION: Clinical trials.gov ID: NCT03281057 . Registration date:13/09/2017.</style></abstract><notes><style face="normal" font="default" size="100%">Hellum, Rikke&#xD;Bilberg, Randi&#xD;Andersen, Kjeld&#xD;Bischof, Gallus&#xD;Hesse, Morten&#xD;Nielsen, Anette Sogaard&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/05/11&#xD;BMC Public Health. 2022 May 10;22(1):928. doi: 10.1186/s12889-022-13293-8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35538465</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no competing interests.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9087923</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s12889-022-13293-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>202</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">202</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Behrendt, S.</style></author><author><style face="normal" font="default" size="100%">Kuerbis, A.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author><author><style face="normal" font="default" size="100%">Braun-Michl, B.</style></author><author><style face="normal" font="default" size="100%">Bilberg, R.</style></author><author><style face="normal" font="default" size="100%">Bu Hringer, G.</style></author><author><style face="normal" font="default" size="100%">Bogenschutz, M.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">From the Institute of Clinical Psychology and Psychotherapy, Technische Universita t Dresden, Dresden, Germany (GB); IFT Institut fu r Therapieforschung, Mu nchen, Germany (BBM, GB); Unit of Clinical Alcohol Research, Institute of Clinical Research, University of Southern Denmark, and Psychiatric Department, Region of Southern Denmark; OPEN Patient Data Explorative Network, Odense University Hospital; BRIDGE, Brain Research, Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense, Denmark (SB, AM, RB, GB, ASN, KA); Bellevue Hospital Center, New York, NY (MB); Institute for Psychology, University of Southern Denmark, Odense, Denmark (SB); Silberman School of Social Work at Hunter College, New York, NY (AK).</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Prognostic Role of DSM-5 Alcohol Use Disorder Severity and Age of Onset in Treatment Outcome Among Adults Aged 60</style></title><secondary-title><style face="normal" font="default" size="100%">J Addict Med</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">303-309</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age of Onset</style></keyword><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcohol-Related Disorders/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcoholism/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnostic and Statistical Manual of Mental Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May-Jun 01</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Ovid Technologies (Wolters Kluwer Health)</style></publisher><isbn><style face="normal" font="default" size="100%">1935-3227 (Electronic)&#xD;1932-0620 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34282079</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: To investigate among older adults with DSM-5 alcohol use disorder (AUD) the relevance of (1) baseline DSM-5 AUD severity, (2) age of DSM-5 AUD onset, and (3) the interactions of DSM-5 AUD severity*treatment condition and age of DSM-5 AUD onset*treatment condition for the prediction of AUD treatment outcomes. METHODS: The international multicenter RCT &quot;ELDERLY-Study&quot; compared outpatient motivational enhancement therapy (4 sessions) with outpatient motivational enhancement therapy followed by community reinforcement approach for seniors (8 sessions) in adults aged 60+ with DSM-5 AUD. Baseline and 1-, 3-, and 6-month follow-up data from the German and Danish ELDERLY-sites (n = 544) were used (6-month participation rate: 75.9%). DSM-5 AUD diagnoses were obtained using the Mini International Neuropsychiatric Interview and alcohol use using Form 90. Associations between DSM-5 AUD severity and age of onset and AUD treatment outcomes were investigated using multiple logistic regression and generalized linear models. RESULTS: The sample was diverse in AUD severity (severe: 54.9%, moderate: 28.2%, mild: 16.9%) and age of onset (median: 50 years; 12-78 years). Overall, with few exceptions, neither AUD severity, nor age of onset, nor their respective interactions with treatment condition significantly predicted drinking outcomes at the different follow-ups ( P &gt;/= 0.05). CONCLUSIONS: No indication was found for the need to tailor treatment content according to DSM-5 AUD severity and earlier onset in older adults.</style></abstract><notes><style face="normal" font="default" size="100%">Behrendt, Silke&#xD;Kuerbis, Alexis&#xD;Mejldal, Anna&#xD;Braun-Michl, Barbara&#xD;Bilberg, Randi&#xD;Bu Hringer, Gerhard&#xD;Bogenschutz, Michael&#xD;Nielsen, Anette Sogaard&#xD;Andersen, Kjeld&#xD;eng&#xD;Multicenter Study&#xD;2021/07/21&#xD;J Addict Med. 2022 May-Jun 01;16(3):303-309. doi: 10.1097/ADM.0000000000000892.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34282079</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The other authors report no conflicts of interest.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/ADM.0000000000000892</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>203</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">203</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hvingelby, V. S.</style></author><author><style face="normal" font="default" size="100%">Bjarkam, C. R.</style></author><author><style face="normal" font="default" size="100%">Mathiesen, T. I.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author><author><style face="normal" font="default" size="100%">Botker, M. T.</style></author><author><style face="normal" font="default" size="100%">Husted, A.</style></author><author><style face="normal" font="default" size="100%">Korshoej, A. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 165, 8200, Aarhus N, Denmark. au340287@clin.au.dk.&#xD;Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus, Denmark. au340287@clin.au.dk.&#xD;Department of Neurosurgery, Aalborg University Hospital, Aalborg, Denmark.&#xD;Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.&#xD;Department of Neurosurgery, Odense University Hospital, Odense, Denmark.&#xD;Clinical Institute and BRIDGE (Brain Research - Interdisciplinary Guided Excellence), University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 165, 8200, Aarhus N, Denmark.&#xD;Prehospital Emergency Medical Services, Central Denmark Region, Aarhus, Denmark.&#xD;Department of Anaesthesiology, Aarhus Univeristy Hospital, Aarhus, Denmark.&#xD;Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The prognostic significance of biomarkers in cerebrospinal fluid following severe traumatic brain injury: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Neurosurg Rev</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">2547-2564</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220414</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Biomarkers/cerebrospinal fluid</style></keyword><keyword><style face="normal" font="default" size="100%">*Brain Injuries, Traumatic/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrocortisone</style></keyword><keyword><style face="normal" font="default" size="100%">*Interleukin-10</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-8</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarker</style></keyword><keyword><style face="normal" font="default" size="100%">Glasgow Outcome Score</style></keyword><keyword><style face="normal" font="default" size="100%">Severe traumatic brain injury</style></keyword><keyword><style face="normal" font="default" size="100%">Theranostics</style></keyword><keyword><style face="normal" font="default" size="100%">Traumatic brain injury</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1437-2320 (Electronic)&#xD;0344-5607 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35419643</style></accession-num><abstract><style face="normal" font="default" size="100%">After severe traumatic brain injury (sTBI) proteins, neurotrophic factors and inflammatory markers are released into the biofluids. This review and meta-analysis searched the literature for prognostic candidate cerebrospinal fluid markers and their relation to sTBI patient outcome. A systematic search of the literature was carried out across PubMed, EMBASE, PubMed Central (PMC), and Cochrane Central Library. Biomarker concentrations were related to the Glasgow Outcome Scale dichotomized into favorable and unfavorable outcomes. When a biomarker was reported in &gt;/= 3 studies, it was included in meta-analysis. The search returned 1527 articles. After full-text analysis, 54 articles were included, 34 from the search, and 20 from the reference lists. Of 9 biomarkers, 8 were significantly different compared to controls (IL-4, IL-6, IL-8, IL-10, TNFalpha, sFas, BDNF, and cortisol). Of these, 5 were significantly increased in sTBI patients with unfavorable outcome (IL-6, IL-8, IL-10, TNFalpha, and cortisol), compared to patients with favorable outcome. This review demonstrated a correlation between 5 biomarkers and clinical outcome in sTBI patients. The paucity of included studies, however, makes it difficult to extrapolate further on this finding.</style></abstract><notes><style face="normal" font="default" size="100%">Hvingelby, Victor Schwartz&#xD;Bjarkam, Carsten Reidies&#xD;Mathiesen, Tiit Illimar&#xD;Poulsen, Frantz Rom&#xD;Botker, Morten Thingemann&#xD;Husted, Andreas&#xD;Korshoej, Anders Rosendal&#xD;eng&#xD;Meta-Analysis&#xD;Review&#xD;Systematic Review&#xD;Germany&#xD;2022/04/15&#xD;Neurosurg Rev. 2022 Aug;45(4):2547-2564. doi: 10.1007/s10143-022-01786-4. Epub 2022 Apr 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35419643</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10143-022-01786-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Byg, K. E.</style></author><author><style face="normal" font="default" size="100%">Illes, Z.</style></author><author><style face="normal" font="default" size="100%">Sejbaek, T.</style></author><author><style face="normal" font="default" size="100%">Nguyen, N.</style></author><author><style face="normal" font="default" size="100%">Moller, S.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H. H.</style></author><author><style face="normal" font="default" size="100%">Ellingsen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Rheumatology Research Unit, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark; Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark; BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark. Electronic address: keld-erik.byg@rsyd.dk.&#xD;Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark; BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, J.B. Winsloewsvej 21, 5000 Odense, Denmark.&#xD;BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Department of Neurology, South West Jutland University Hospital of Southern Denmark, Finsensgade 35, 6700 Esbjerg, Denmark; Department of Regional Health Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark.&#xD;Department of Radiology, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Open Patient data Explorative Network, Odense University Hospital, J.B. Winsloewsvej 9a, 5000 Odense, Denmark.&#xD;BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark; Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, J.B. Winsloewsvej 21, 5000 Odense, Denmark.&#xD;Rheumatology Research Unit, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense, Denmark; Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 5000 Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A prospective, one-year follow-up study of patients newly diagnosed with neurosarcoidosis</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroimmunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroimmunol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">577913</style></pages><volume><style face="normal" font="default" size="100%">369</style></volume><number><style face="normal" font="default" size="100%">577913</style></number><edition><style face="normal" font="default" size="100%">20220609</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Central Nervous System Diseases/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropsychological Tests</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Sarcoidosis</style></keyword><keyword><style face="normal" font="default" size="100%">Fas</style></keyword><keyword><style face="normal" font="default" size="100%">Mri</style></keyword><keyword><style face="normal" font="default" size="100%">Neurosarcoidosis</style></keyword><keyword><style face="normal" font="default" size="100%">Sdmt</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">mRS</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 15</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1872-8421 (Electronic)&#xD;0165-5728 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35717739</style></accession-num><abstract><style face="normal" font="default" size="100%">METHODS: Twenty patients with newly diagnosed neurosarcoidosis were examined for multiple outcomes in an observational cohort study with 12-month follow-up. RESULTS: The patients&apos; contrast-enhancing lesions on MRI scans reduced during treatment (p &lt; 0.0001). The mean modified Rankin Score improved from 3.0 to 1.8 (p &lt; 0.0001), and 75% of patients experienced clinically important improvement. Patients improved on the Symbol Digit Modalities Test (p &lt; 0.0001) and on SF-36 Physical (p = 0.003) and Mental Component Summary scores (p = 0.03). Proportions of patients with substantial fatigue (75%) and high depression score (35%) were unchanged. CONCLUSIONS: 12-month immunosuppression improved several outcomes, and 75% of patients experienced clinically important improvement.</style></abstract><notes><style face="normal" font="default" size="100%">Byg, Keld-Erik&#xD;Illes, Zsolt&#xD;Sejbaek, Tobias&#xD;Nguyen, Nina&#xD;Moller, Soren&#xD;Lambertsen, Kate L&#xD;Nielsen, Helle H&#xD;Ellingsen, Torkell&#xD;eng&#xD;Observational Study&#xD;Netherlands&#xD;2022/06/20&#xD;J Neuroimmunol. 2022 Aug 15;369:577913. doi: 10.1016/j.jneuroim.2022.577913. Epub 2022 Jun 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35717739</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jneuroim.2022.577913</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>204</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">204</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wulf, M.</style></author><author><style face="normal" font="default" size="100%">Barkovits, K.</style></author><author><style face="normal" font="default" size="100%">Schork, K.</style></author><author><style face="normal" font="default" size="100%">Eisenacher, M.</style></author><author><style face="normal" font="default" size="100%">Riederer, P.</style></author><author><style face="normal" font="default" size="100%">Gerlach, M.</style></author><author><style face="normal" font="default" size="100%">Eggers, B.</style></author><author><style face="normal" font="default" size="100%">Marcus, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medizinisches Proteom-Center, Medical Faculty, Ruhr-University Bochum, 44801 Bochum, Germany.&#xD;Medical Proteome Analysis, Center for Proteindiagnostics (PRODI), Ruhr-University Bochum, 44801 Bochum, Germany.&#xD;Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany.&#xD;Psychiatry Department of Clinical Research, University of Southern Denmark Odense University Hospital, 5000 Odense, Denmark.&#xD;Center of Mental Health, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, University of Wuerzburg, 97070 Wuerzburg, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Proteome of Neuromelanin Granules in Dementia with Lewy Bodies</style></title><secondary-title><style face="normal" font="default" size="100%">Cells</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cells</style></full-title></periodical><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">22</style></number><edition><style face="normal" font="default" size="100%">20221109</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Proteome</style></keyword><keyword><style face="normal" font="default" size="100%">alpha-Synuclein</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">*Lewy Body Disease</style></keyword><keyword><style face="normal" font="default" size="100%">dementia with Lewy bodies</style></keyword><keyword><style face="normal" font="default" size="100%">neurodegeneration</style></keyword><keyword><style face="normal" font="default" size="100%">neuromelanin granules</style></keyword><keyword><style face="normal" font="default" size="100%">stress granules</style></keyword><keyword><style face="normal" font="default" size="100%">substantia nigra pars compacta</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 9</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2073-4409 (Electronic)&#xD;2073-4409 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36428966</style></accession-num><abstract><style face="normal" font="default" size="100%">Neuromelanin granules (NMGs) are organelle-like structures present in the human substantia nigra pars compacta. In addition to neuromelanin, NMGs contain proteins, lipids and metals. As NMG-containing dopaminergic neurons are preferentially lost in Parkinson&apos;s disease and dementia with Lewy bodies (DLB), it is assumed that NMGs may play a role in neurodegenerative processes. Until now, this role is not completely understood and needs further investigation. We therefore set up an exploratory proteomic study to identify differences in the proteomic profile of NMGs from DLB patients (n = 5) compared to healthy controls (CTRL, n = 5). We applied a laser microdissection and mass-spectrometry-based approach, in which we used targeted mass spectrometric experiments for validation. In NMG-surrounding (SN(Surr.)) tissue of DLB patients, we found evidence for ongoing oxidative damage and an impairment of protein degradation. As a potentially disease-related mechanism, we found alpha-synuclein and protein S100A9 to be enriched in NMGs of DLB cases, while the abundance of several ribosomal proteins was significantly decreased. As S100A9 is known to be able to enhance the formation of toxic alpha-synuclein fibrils, this finding points towards an involvement of NMGs in pathogenesis, however the exact role of NMGs as either neuroprotective or neurotoxic needs to be further investigated. Nevertheless, our study provides evidence for an impairment of protein degradation, ongoing oxidative damage and accumulation of potentially neurotoxic protein aggregates to be central mechanisms of neurodegeneration in DLB.</style></abstract><notes><style face="normal" font="default" size="100%">Wulf, Maximilian&#xD;Barkovits, Katalin&#xD;Schork, Karin&#xD;Eisenacher, Martin&#xD;Riederer, Peter&#xD;Gerlach, Manfred&#xD;Eggers, Britta&#xD;Marcus, Katrin&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Switzerland&#xD;2022/11/27&#xD;Cells. 2022 Nov 9;11(22):3538. doi: 10.3390/cells11223538.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36428966</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9688080</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/cells11223538</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>181</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ilieva, M.</style></author><author><style face="normal" font="default" size="100%">Aldana, B. I.</style></author><author><style face="normal" font="default" size="100%">Vinten, K. T.</style></author><author><style face="normal" font="default" size="100%">Hohmann, S.</style></author><author><style face="normal" font="default" size="100%">Woofenden, T. W.</style></author><author><style face="normal" font="default" size="100%">Lukjanska, R.</style></author><author><style face="normal" font="default" size="100%">Waagepetersen, H. S.</style></author><author><style face="normal" font="default" size="100%">Michel, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychiatry, Department of Clinical Research, University of Southern Denmark, Odense, Denmark. mirolyubasi@dcm.aau.dk.&#xD;Psychiatry in the Region of Southern Denmark, Odense University Hospital, Odense, Denmark. mirolyubasi@dcm.aau.dk.&#xD;Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen SV, Denmark. mirolyubasi@dcm.aau.dk.&#xD;Neurometabolism Research Group, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Psychiatry, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Psychiatry in the Region of Southern Denmark, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proteomic phenotype of cerebral organoids derived from autism spectrum disorder patients reveal disrupted energy metabolism, cellular components, and biological processes</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Psychiatry</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">3749-3759</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">20220526</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Organoids</style></keyword><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">Proteome/genetics</style></keyword><keyword><style face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style face="normal" font="default" size="100%">*Biological Phenomena</style></keyword><keyword><style face="normal" font="default" size="100%">Energy Metabolism</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1476-5578 (Electronic)&#xD;1359-4184 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35618886</style></accession-num><abstract><style face="normal" font="default" size="100%">The way in which brain morphology and proteome are remodeled during embryonal development, and how they are linked to the cellular metabolism, could be a key for elucidating the pathological mechanisms of certain neurodevelopmental disorders. Cerebral organoids derived from autism spectrum disorder (ASD) patients were generated to capture critical time-points in the neuronal development, and metabolism and protein expression were investigated. The early stages of development, when neurogenesis commences (day in vitro 39), appeared to be a critical timepoint in pathogenesis. In the first month of development, increased size in ASD-derived organoids were detected in comparison to the controls. The size of the organoids correlates with the number of proliferating cells (Ki-67 positive cells). A significant difference in energy metabolism and proteome phenotype was also observed in ASD organoids at this time point, specifically, prevalence of glycolysis over oxidative phosphorylation, decreased ATP production and mitochondrial respiratory chain activity, differently expressed cell adhesion proteins, cell cycle (spindle formation), cytoskeleton, and several transcription factors. Finally, ASD patients and controls derived organoids were clustered based on a differential expression of ten proteins-heat shock protein 27 (hsp27) phospho Ser 15, Pyk (FAK2), Elk-1, Rac1/cdc42, S6 ribosomal protein phospho Ser 240/Ser 244, Ha-ras, mTOR (FRAP) phospho Ser 2448, PKCalpha, FoxO3a, Src family phospho Tyr 416-at day 39 which could be defined as potential biomarkers and further investigated for potential drug development.</style></abstract><notes><style face="normal" font="default" size="100%">Ilieva, Mirolyuba&#xD;Aldana, Blanca Irene&#xD;Vinten, Kasper Tore&#xD;Hohmann, Sonja&#xD;Woofenden, Thomas William&#xD;Lukjanska, Renate&#xD;Waagepetersen, Helle S&#xD;Michel, Tanja Maria&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/05/27&#xD;Mol Psychiatry. 2022 Sep;27(9):3749-3759. doi: 10.1038/s41380-022-01627-2. Epub 2022 May 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35618886</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41380-022-01627-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>182</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bikic, A.</style></author><author><style face="normal" font="default" size="100%">Smith-Nielsen, J.</style></author><author><style face="normal" font="default" size="100%">Dalsgaard, S.</style></author><author><style face="normal" font="default" size="100%">Swain, J.</style></author><author><style face="normal" font="default" size="100%">Fonagy, P.</style></author><author><style face="normal" font="default" size="100%">Leckman, J. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Child and Adolescent Mental Health Services Southern Jutland, Aabenraa, Region of Southern Denmark, Denmark.&#xD;Department of Regional Health Research, Faculty of Health, University of Southern Denmark, Odense C, Denmark.&#xD;Department of Psychology, Centre for Early Intervention and Family Studies, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Economics and Business, National Centre of Register-Based Research, Aarhus University, Aarhus, Denmark.&#xD;Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Child and Adolescent Psychiatry, Mental Health Services of the Capital Region, Glostrup, Denmark.&#xD;Department of Psychiatry and Behavioral Health, and Psychology, Stony Brook University, Stony Brook, NY, United States of America.&#xD;Department of Clinical, Educational and Health Psychology, University College London, London, United Kingdom.&#xD;Child Study Centre, Yale University School of Medicine, New Haven, Connecticut, United States of America.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protocol for a randomized controlled trial comparing the Circle of Security-parenting (COS-P) with treatment as usual in child mental health services</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS One</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e0265676</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220426</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Conduct Disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">Parent-Child Relations</style></keyword><keyword><style face="normal" font="default" size="100%">Parenting</style></keyword><keyword><style face="normal" font="default" size="100%">Parents/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized Controlled Trials as Topic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/4/26</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)&#xD;1932-6203 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35472058</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The quality of a child&apos;s attachment to its primary caregiver plays an important role for its long-term socioemotional development. While &apos;secure&apos; attachment is associated with better outcomes, &apos;insecure&apos; attachment is associated with a higher risk of externalizing and internalizing symptoms. Children referred to mental health services show much higher rates of insecure attachment than the general population, yet the parent-child relationship is rarely in treatment focus. Attachment quality is closely associated with parental sensitive responsiveness that is target of attachment-based interventions like Circle of Security (COS). COS has shown to improve attachment quality and the well-being of both children and parents. No randomized controlled trials have investigated the effect of COS on parental sensitivity and child psychiatric symptoms in child mental health services. OBJECTIVES: To investigate whether COS-Parenting (COS-P) can increase observed maternal sensitivity and decrease children&apos;s psychiatric symptoms as an add on to treatment as usual (TAU). METHODS: In a randomized controlled parallel superiority trial COS-P is compared with TAU for parents of children referred to child mental health services (n = 186). Families are randomized 2:1 to intervention or control group, if their child is between 3 and 8 years old and scores &gt;/= 93d percentile on both the CBCL total score and the oppositional defiant disorder or conduct disorder subscale. Primary outcome is maternal sensitivity, secondary and exploratory outcomes include, among others, child psychiatric symptoms, parental stress and coping with children&apos;s negative emotions. Outcomes and adverse events are assessed before (T0) and after 10 weeks of treatment (T1) and 6 months later (T2). Regression analysis and /or ANOVA will be used for all outcomes. PERSPECTIVES: Targeting the parent-child relation has the potential to reduce psychiatric symptoms in children. This trial will provide valuable information if attachment-based interventions like COS-P can enhance treatment as usual in child mental health services. TRAIL REGISTRATION: ClinicalTrials.gov Identifier: NCT03578016.</style></abstract><notes><style face="normal" font="default" size="100%">Bikic, Aida&#xD;Smith-Nielsen, Johanne&#xD;Dalsgaard, Soren&#xD;Swain, James&#xD;Fonagy, Peter&#xD;Leckman, James F&#xD;eng&#xD;R01 DA047336/DA/NIDA NIH HHS/&#xD;R61 DA053688/DA/NIDA NIH HHS/&#xD;RC2 MD004767/MD/NIMHD NIH HHS/&#xD;Clinical Trial Protocol&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/04/27&#xD;PLoS One. 2022 Apr 26;17(4):e0265676. doi: 10.1371/journal.pone.0265676. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35472058</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">JSN is a Circle of Security-Parenting (COS-P) trainer and a certified COS-P fidelity coach. She provides COS-P trainings for professionals in Denmark with fees paid by Circle of Security International. This does not alter the authors&apos; adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9041756</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0265676</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>278</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">278</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trinh, N. T. H.</style></author><author><style face="normal" font="default" size="100%">Semark, B. D.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author><author><style face="normal" font="default" size="100%">Liu, X.</style></author><author><style face="normal" font="default" size="100%">Ro, O.</style></author><author><style face="normal" font="default" size="100%">Bulik, C. M.</style></author><author><style face="normal" font="default" size="100%">Torgersen, L.</style></author><author><style face="normal" font="default" size="100%">Lupattelli, A.</style></author><author><style face="normal" font="default" size="100%">Petersen, L. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.&#xD;NCRR-The National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;CIRRAU-Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Regional Department for Eating Disorders, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.&#xD;Division of Mental Health and Addiction, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.&#xD;UNC Center of Excellence for Eating Disorders, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.&#xD;Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.&#xD;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Psychiatric visits during the postpartum year in women with eating disorders who continue or discontinue antidepressant treatment in pregnancy</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Eat Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Int J Eat Disord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">582-594</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20221216</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Postpartum Period</style></keyword><keyword><style face="normal" font="default" size="100%">Antidepressive Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Anxiety Disorders/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Anxiety/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Feeding and Eating Disorders/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">antidepressant</style></keyword><keyword><style face="normal" font="default" size="100%">eating disorders</style></keyword><keyword><style face="normal" font="default" size="100%">postpartum</style></keyword><keyword><style face="normal" font="default" size="100%">preventative effect</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1098-108X (Electronic)&#xD;0276-3478 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36524675</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To determine the association between continued antidepressant use in pregnancy and postpartum psychiatric visits for eating (ED) or mood/anxiety disorders in women with preexisting ED. METHOD: Using Danish health registry data (1998-2015), we identified 3529 pregnancies in women with ED prepregnancy: (i) 564 with continued antidepressant use before and during pregnancy; (ii) 778 with discontinued antidepressants before pregnancy; (iii) 2137 unexposed. Outpatient and inpatient postpartum visits for an ED or a mood/anxiety disorder constituted the outcome measures. We estimated hazard ratios (HRs) and 95% confidence intervals (CI) using Cox regression with inverse probability of treatment weighting, and performed stratified analyses by antidepressant prescription filling in the first 3 months postpartum. RESULTS: The weighted cumulative incidence for an ED visit at end of follow-up was 4.5% (continued) and 4.8% (discontinued). We found no association between continued antidepressant and postpartum ED visit, relative to discontinued (HR: 0.89, 95% CI: 0.52-1.52). The HR for postpartum mood/anxiety disorder visit was 1.27 (95% CI: 0.68-2.36) with continued antidepressants versus discontinued but decreased if more than two antidepressant prescriptions were refilled. Continued antidepressant use was associated with a 57% reduced likelihood of a postpartum ED visit versus discontinued use in pregnancies with antidepressant prescription refills in the early postpartum. CONCLUSION: Among women with preexisting ED, there was no association between continued antidepressant use during pregnancy and the likelihood of postpartum psychiatric visits, relative to discontinued antidepressants before pregnancy. Continuation of treatment into the early postpartum is associated with reduced likelihood of postpartum ED visit. PUBLIC SIGNIFICANCE: Based on data from the Danish registries, we identified 3529 pregnancies among women with preexisting eating disorders before pregnancy. Women with continued antidepressant treatment both before and during pregnancy did not have a lower probability of having postpartum psychiatric visits for an eating disorder or for mood/anxiety disorders (often coexisting with eating disorders), relative to those who discontinued antidepressants before pregnancy. Further continuation of antidepressant treatment into the early postpartum is associated with improved maternal postpartum outcomes. However, residual confounding by disease severity limits confidence in this conclusion.</style></abstract><notes><style face="normal" font="default" size="100%">Trinh, Nhung T H&#xD;Semark, Birgitte Dige&#xD;Munk-Olsen, Trine&#xD;Liu, Xiaoqin&#xD;Ro, Oyvind&#xD;Bulik, Cynthia M&#xD;Torgersen, Leila&#xD;Lupattelli, Angela&#xD;Petersen, Liselotte Vogdrup&#xD;eng&#xD;288696/Norges Forskningsrad/&#xD;R01MH118278/MH/NIMH NIH HHS/&#xD;R01MH119084/MH/NIMH NIH HHS/&#xD;R01MH124871/MH/NIMH NIH HHS/&#xD;R01MH120170/MH/NIMH NIH HHS/&#xD;Brain and Behavior Research Foundation Distinguished Investigator Grant/&#xD;538-2013-8864/Swedish Research Council/&#xD;R276-2018-4581/Lundbeck Foundation/&#xD;891079/Marie Sklodowska-Curie grant/&#xD;2022/12/17&#xD;Int J Eat Disord. 2023 Mar;56(3):582-594. doi: 10.1002/eat.23877. Epub 2022 Dec 16.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36524675</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/eat.23877</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>183</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">183</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rohde, C.</style></author><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Gasse, C.</style></author><author><style face="normal" font="default" size="100%">Hauser, A. S.</style></author><author><style face="normal" font="default" size="100%">Petersen, L. V.</style></author><author><style face="normal" font="default" size="100%">Christensen, R. H.</style></author><author><style face="normal" font="default" size="100%">Benros, M. E.</style></author><author><style face="normal" font="default" size="100%">Hallas, J.</style></author><author><style face="normal" font="default" size="100%">Mors, O.</style></author><author><style face="normal" font="default" size="100%">Kohler-Forsberg, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.&#xD;Clinical Pharmacology, Pharmacy, and Environmental Medicine, University of Southern Denmark, Odense, Denmark; Department of Psychiatry Aabenraa, Mental Health Services Region of Southern Denmark, Aabenraa, Denmark.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark; Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.&#xD;Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.&#xD;Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark; National Centre for Register-Based Research (NCRR), Aarhus University, Aarhus, Denmark.&#xD;CORE, Copenhagen, Denmark.&#xD;Clinical Pharmacology, Pharmacy, and Environmental Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark; Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark. Electronic address: olekoehler@clin.au.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study</style></title><secondary-title><style face="normal" font="default" size="100%">Schizophr Res</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">268-276</style></pages><volume><style face="normal" font="default" size="100%">246</style></volume><edition><style face="normal" font="default" size="100%">20220717</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antidepressive Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotropic Drugs/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/diagnosis/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Antidepressant</style></keyword><keyword><style face="normal" font="default" size="100%">Antipsychotic</style></keyword><keyword><style face="normal" font="default" size="100%">Pre-diagnostic</style></keyword><keyword><style face="normal" font="default" size="100%">Prodromal</style></keyword><keyword><style face="normal" font="default" size="100%">Schizophrenia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1573-2509 (Electronic)&#xD;0920-9964 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35858504</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Many patients with schizophrenia experience psychiatric symptoms long before being diagnosed. We investigated patterns of pre-diagnostic psychopharmacological treatment in individuals diagnosed with first-episode schizophrenia during the last two decades. DESIGN: Using Danish nationwide healthcare registers, we identified all individuals aged &gt;/=10 years registered with their first ICD-10 schizophrenia diagnosis between January 1999 and March 2019. For each calendar year from 1999 to 2019, we calculated the proportion of patients - among those having received their first schizophrenia diagnosis in the respective calendar year - who redeemed prescriptions for various psychotropics in the two years preceding the schizophrenia diagnosis. We calculated proportions of all pre-diagnostic prescriptions since 1995 for a sub-population diagnosed 2011-2019 and for an age- and sex-matched reference group without schizophrenia. RESULTS: Among 33,361 individuals with schizophrenia (58 % males), the schizophrenia incidence rate was stable during the study period but the mean age at diagnosis decreased by &gt;10 years. In the two pre-diagnostic years, 69 % received psychopharmacological treatment (52 % antipsychotics, 40 % antidepressants). This was stable between 1999 and 2019. Among 14,425 individuals diagnosed 2011-2019, psychotropic drug use was observed among 14-20 % between 24 and 10 years before the diagnosis, being four times higher than the reference group. Particularly antipsychotic and antidepressant drug use increased steadily during the ten pre-diagnostic years. CONCLUSIONS: Pre-diagnostic psychotropic drug use in schizophrenia was frequent but stable between 1999 and 2019 despite an earlier identification of schizophrenia patients. Our findings emphasize the continued importance of thorough diagnostic interviews, particularly among patients in need of antipsychotic treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Rohde, Christopher&#xD;Hojlund, Mikkel&#xD;Gasse, Christiane&#xD;Hauser, Alexander S&#xD;Petersen, Liselotte V&#xD;Christensen, Rune H&#xD;Benros, Michael E&#xD;Hallas, Jesper&#xD;Mors, Ole&#xD;Kohler-Forsberg, Ole&#xD;eng&#xD;Netherlands&#xD;2022/07/21&#xD;Schizophr Res. 2022 Aug;246:268-276. doi: 10.1016/j.schres.2022.06.034. Epub 2022 Jul 17.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35858504</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.schres.2022.06.034</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>184</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duarte-Andrade, F. F.</style></author><author><style face="normal" font="default" size="100%">Pereira, Tdsf</style></author><author><style face="normal" font="default" size="100%">Vitorio, J. G.</style></author><author><style face="normal" font="default" size="100%">Diniz, M. G.</style></author><author><style face="normal" font="default" size="100%">Amorim, L. S. D.</style></author><author><style face="normal" font="default" size="100%">Nawrocki, A.</style></author><author><style face="normal" font="default" size="100%">Felicori, L. F.</style></author><author><style face="normal" font="default" size="100%">De Marco, L.</style></author><author><style face="normal" font="default" size="100%">Gomes, C. C.</style></author><author><style face="normal" font="default" size="100%">Larsen, M. R.</style></author><author><style face="normal" font="default" size="100%">Melo-Braga, M. N.</style></author><author><style face="normal" font="default" size="100%">Gomez, R. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Oral Surgery and Pathology, School of Dentistry, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.&#xD;Department of Pathology, Biological Sciences Institute, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.&#xD;Department of Biochemistry and Molecular Biology, University of Southern Denmark (SDU), Odense, Denmark.&#xD;Department of Biochemistry and Immunology, Biological Sciences Institute, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.&#xD;Department of Surgery, School of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantitative proteomic study reveals differential expression of matricellular proteins between fibrous dysplasia and cemento-ossifying fibroma pathogenesis</style></title><secondary-title><style face="normal" font="default" size="100%">J Oral Pathol Med</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">405-412</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220307</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Cementoma/diagnosis/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis, Differential</style></keyword><keyword><style face="normal" font="default" size="100%">*Fibroma, Ossifying/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Fibrous Dysplasia of Bone/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style face="normal" font="default" size="100%">bone tumors</style></keyword><keyword><style face="normal" font="default" size="100%">fibro-osseous lesions</style></keyword><keyword><style face="normal" font="default" size="100%">fibrous dysplasia</style></keyword><keyword><style face="normal" font="default" size="100%">ossifying fibroma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1600-0714 (Electronic)&#xD;0904-2512 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35103997</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Fibrous dysplasia (FD) and cemento-ossifying fibroma (COF) are the most common gnathic fibro-osseous lesions. These diseases exhibit remarkable overlap of several clinicopathological aspects, and differential diagnosis depends on the combination of histopathological, radiographic, and clinical aspects. Their molecular landscape remains poorly characterized, and herein, we assessed their proteomic and phosphoproteomic profiles. METHODS: The quantitative differences in protein profile of FD and COF were assessed by proteomic and phosphoproteomic analyses of formalin-fixed paraffin-embedded tissue samples. Pathway enrichment analyses with differentially regulated proteins were performed. RESULTS: FD and COF exhibited differential regulation of pathways related to extracellular matrix organization, cell adhesion, and platelet and erythrocytes activities. Additionally, these lesions demonstrated distinct abundance of proteins involved in osteoblastic differentiation and tumorigenesis and differential abundance of phosphorylation of Ser61 of Yes-associated protein 1 (YAP1). CONCLUSIONS: In summary, despite the morphological similarity between these diseases, our results demonstrated that COF and DF present numerous quantitative differences in their proteomic profiles. These findings suggest that these fibro-osseous lesions trigger distinct molecular mechanisms during their pathogenesis. Moreover, some proteins identified in our analysis could serve as potential biomarkers for differential diagnosis of these diseases after further validation.</style></abstract><notes><style face="normal" font="default" size="100%">Duarte-Andrade, Filipe Fideles&#xD;Pereira, Thais Dos Santos Fontes&#xD;Vitorio, Jessica Gardone&#xD;Diniz, Marina Goncalves&#xD;Amorim, Larissa Stefhanne Damasceno&#xD;Nawrocki, Arkadiusz&#xD;Felicori, Liza Figueiredo&#xD;De Marco, Luiz&#xD;Gomes, Carolina Cavalieri&#xD;Larsen, Martin R&#xD;Melo-Braga, Marcella Nunes&#xD;Gomez, Ricardo Santiago&#xD;eng&#xD;Fundacao de Amparo a Pesquisa do Estado de Minas Gerais/&#xD;VILLUM Center for Bioanalytical Sciences at the University of Southern Denmark/&#xD;001/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/&#xD;Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/&#xD;Denmark&#xD;2022/02/02&#xD;J Oral Pathol Med. 2022 Apr;51(4):405-412. doi: 10.1111/jop.13282. Epub 2022 Mar 7.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35103997</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jop.13282</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lund, L. C.</style></author><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Henriksen, D. P.</style></author><author><style face="normal" font="default" size="100%">Hallas, J.</style></author><author><style face="normal" font="default" size="100%">Kristensen, K. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RE: Gout and sodium-glucose cotransporter-2 inhibitors</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacoepidemiol Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmacoepidemiol Drug Saf</style></full-title></periodical><pages><style face="normal" font="default" size="100%">114-115</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20211114</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Diabetes Mellitus, Type 2/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose</style></keyword><keyword><style face="normal" font="default" size="100%">*Gout/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Hypoglycemic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Sodium</style></keyword><keyword><style face="normal" font="default" size="100%">*Sodium-Glucose Transporter 2 Inhibitors/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1099-1557 (Electronic)&#xD;1053-8569 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34729863</style></accession-num><notes><style face="normal" font="default" size="100%">Lund, Lars Christian&#xD;Hojlund, Mikkel&#xD;Henriksen, Daniel Pilsgaard&#xD;Hallas, Jesper&#xD;Kristensen, Kasper Bruun&#xD;eng&#xD;Comment&#xD;Letter&#xD;England&#xD;2021/11/04&#xD;Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):114-115. doi: 10.1002/pds.5380. Epub 2021 Nov 14.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34729863</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/pds.5380</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>185</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nielsen, R. E.</style></author><author><style face="normal" font="default" size="100%">Grontved, S.</style></author><author><style face="normal" font="default" size="100%">Lolk, A.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Valentin, J. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Aalborg University Hospital - Psychiatry, Aalborg, Denmark.&#xD;Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Department of Mental Health, Odense, Region of Southern Denmark, Denmark.&#xD;Danish Center for Clinical Health Services Research (DACS), Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer s dementia</style></title><secondary-title><style face="normal" font="default" size="100%">Medicine (Baltimore)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medicine (Baltimore)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e31625</style></pages><volume><style face="normal" font="default" size="100%">101</style></volume><number><style face="normal" font="default" size="100%">45</style></number><keywords><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Rivastigmine/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Donepezil/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Galantamine/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/drug therapy/chemically induced</style></keyword><keyword><style face="normal" font="default" size="100%">Indans/therapeutic use/pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylcarbamates/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Piperidines/adverse effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 11</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Ovid Technologies (Wolters Kluwer Health)</style></publisher><isbn><style face="normal" font="default" size="100%">1536-5964 (Electronic)&#xD;0025-7974 (Print)&#xD;0025-7974 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36397447</style></accession-num><abstract><style face="normal" font="default" size="100%">To examine the real-world effects of the cholinesterase inhibitors (AChEI) on all-cause mortality. A nationwide, retrospective cohort study. Participants were diagnosed with incident AD in Denmark from January 1, 2000 to December 31, 2011 with follow-up until December 31, 2012. A total of 36,513 participants were included in the current study with 22,063 deaths during 132,426 person-years of follow-up. At baseline, patients not treated with AChEI (n = 28,755 [9961 males (35%)]) had a mean age +/- standard deviation (SD) of 80.33 +/- 7.98 years (78.97 +/- 8.26 for males and 81.04 +/- 7.98 for females), as compared to 79.95 +/- 7.67 (78.87 +/- 7.61 for males and 80.61 +/- 7.63 for females) in the group exposed at baseline. Patients treated with AChEI had a beneficial hazard ratio (HR) of 0.69, 95% confidence interval (CI) (0.67-0.71) for all-cause mortality as compared to patients not treated, with donepezil (HR 0.80, 95% CI [0.77-0.82]) and galantamine (HR 0.93,95% CI [0.89-0.97]) having beneficial effects on mortality rate as compared to non-treatment, whereas rivastigmine (HR 0.99, 95% CI [0.95-1.03]) was associated with a mortality rate comparable to non-treatment with AChEI. Patients were primarily exposed to donepezil (65.8%) with rivastigmine (19.8%) and galantamine (14.4%) being used less often. These findings underscore the effect of AChEI on not only reducing speed of cognitive decline but also directly prolonging life, which could result in changes in treatment recommendation for when to stop treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Nielsen, Rene Ernst&#xD;Grontved, Simon&#xD;Lolk, Annette&#xD;Andersen, Kjeld&#xD;Valentin, Jan B&#xD;eng&#xD;2022/11/19&#xD;Medicine (Baltimore). 2022 Nov 11;101(45):e31625. doi: 10.1097/MD.0000000000031625.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36397447</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9666173</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/MD.0000000000031625</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>265</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">265</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Konieczna, Agnieszka</style></author><author><style face="normal" font="default" size="100%">Jakobsen, Sarah Grube</style></author><author><style face="normal" font="default" size="100%">Larsen, Christina Petrea</style></author><author><style face="normal" font="default" size="100%">Christiansen, Erik</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Recession and risk of suicide in Denmark during the 2009 global financial crisis: an ecological register-based study</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Public Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">584-592</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">5</style></number><section><style face="normal" font="default" size="100%">584</style></section><dates><year><style face="normal" font="default" size="100%">2021</style></year></dates><isbn><style face="normal" font="default" size="100%">1403-4948&#xD;1651-1905</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/14034948211013270</style></electronic-resource-num></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>186</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stryhn, L.</style></author><author><style face="normal" font="default" size="100%">Larsen, M. B.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author><author><style face="normal" font="default" size="100%">Sibbersen, C.</style></author><author><style face="normal" font="default" size="100%">Nielsen, D. G.</style></author><author><style face="normal" font="default" size="100%">Nielsen, B.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Stenager, E.</style></author><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research, Unit for Clinical Alcohol Research, Unit for Psychiatric Research, University of Southern Denmark, Odense, Denmark.&#xD;Unit for Psychiatric Research, Institute of Regional Health Services Research, University of Southern Denmark, Aabenraa, Denmark.&#xD;Psychiatric Research Academy, Odense, Denmark.&#xD;Department of Clinical Research, Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Relapse prevention for alcohol use disorders: combined acamprosate and cue exposure therapy as aftercare</style></title><secondary-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">394-402</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">20211008</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acamprosate/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Aftercare</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcoholism/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Cues</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Implosive Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Secondary Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol use disorders</style></keyword><keyword><style face="normal" font="default" size="100%">acamprosate</style></keyword><keyword><style face="normal" font="default" size="100%">craving</style></keyword><keyword><style face="normal" font="default" size="100%">cue exposure therapy</style></keyword><keyword><style face="normal" font="default" size="100%">relapse prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Informa UK Limited</style></publisher><isbn><style face="normal" font="default" size="100%">1502-4725 (Electronic)&#xD;0803-9488 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34622734</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: Many patients with alcohol use disorders are challenged by cravings leading to repeated relapses. Both cue exposure therapy (CET) and acamprosate target alcohol cravings and are often combined (CET + acamprosate). The main aim of this study was to investigate whether aftercare treatment consisting of CET combined with acamprosate is equivalent to (A) CET as monotherapy, (B) aftercare as usual (AAU) as monotherapy or (C) AAU combined with acamprosate. METHODS: Patients were randomized to receive either CET with urge-specific coping skills (USCS) as aftercare or AAU. Acamprosate prescription data were extracted from patient case records. Alcohol consumption, cravings, and USCS were assessed at pre-aftercare, post-aftercare, and 6-month follow-up. RESULTS: Overall, patients increased their alcohol consumption during and following aftercare treatment, thereby relapsing despite any treatment. However, CET + acamprosate achieved greater abstinence compared to AAU + acamprosate at follow-up (p=.047). CET + acamprosate also reduced number of drinking days (p=.020) and number of days with excessive drinking (p=.020) at post-aftercare, when compared to AAU monotherapy. CET monotherapy increased sensible drinking at post-aftercare compared to AAU monotherapy (p=.045) and AAU + acamprosate (p=.047). Only CET monotherapy showed improvement in cravings, when compared to AAU at follow-up (mean urge level: p=.032; peak urge level: p=.014). CONCLUSION: The study showed that CET both as monotherapy and combined with acamprosate was superior to AAU monotherapy and AAU + acamprosate in reducing alcohol consumption. Only CET + acamprosate was capable of reducing alcohol consumption in the longer term, indicating that anti-craving medication may not impede CET from exerting an effect on alcohol consumption. Trial registration: ClinicalTrials.gov ID: NCT02298751 (24/11-2014).</style></abstract><notes><style face="normal" font="default" size="100%">Stryhn, Lene&#xD;Larsen, Mathias Bach&#xD;Mejldal, Anna&#xD;Sibbersen, Christian&#xD;Nielsen, Dorthe Gruner&#xD;Nielsen, Bent&#xD;Nielsen, Anette Sogaard&#xD;Stenager, Elsebeth&#xD;Mellentin, Angelina Isabella&#xD;eng&#xD;Randomized Controlled Trial&#xD;England&#xD;2021/10/09&#xD;Nord J Psychiatry. 2022 Jul;76(5):394-402. doi: 10.1080/08039488.2021.1985169. Epub 2021 Oct 8.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34622734</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08039488.2021.1985169</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>205</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">205</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kraplin, A.</style></author><author><style face="normal" font="default" size="100%">Joshanloo, M.</style></author><author><style face="normal" font="default" size="100%">Wolff, M.</style></author><author><style face="normal" font="default" size="100%">Kronke, K. M.</style></author><author><style face="normal" font="default" size="100%">Goschke, T.</style></author><author><style face="normal" font="default" size="100%">Buhringer, G.</style></author><author><style face="normal" font="default" size="100%">Smolka, M. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Work Group Addictive Behaviors, Risk Analysis and Risk Management, Faculty of Psychology, Technische Universitat Dresden, Chemnitzer Strasse 46, D-01187, Dresden, Germany. anja.kraeplin@tu-dresden.de.&#xD;Department of Psychology, Keimyung University, Daegu, South Korea.&#xD;Work Group Addictive Behaviors, Risk Analysis and Risk Management, Faculty of Psychology, Technische Universitat Dresden, Chemnitzer Strasse 46, D-01187, Dresden, Germany.&#xD;Department of Psychiatry, Technische Universitat Dresden, Dresden, Germany.&#xD;MIND Foundation, Berlin, Germany.&#xD;Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charite Mitte, Berlin, Germany.&#xD;IFT Institut fur Therapieforschung, Munich, Germany.&#xD;Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The relationship between executive functioning and addictive behavior: new insights from a longitudinal community study</style></title><secondary-title><style face="normal" font="default" size="100%">Psychopharmacology (Berl)</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">3507-3524</style></pages><volume><style face="normal" font="default" size="100%">239</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">20221003</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Behavior, Addictive</style></keyword><keyword><style face="normal" font="default" size="100%">*Executive Function</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Problem Solving</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Behavioral addictions</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive control</style></keyword><keyword><style face="normal" font="default" size="100%">Executive functions</style></keyword><keyword><style face="normal" font="default" size="100%">Self-control</style></keyword><keyword><style face="normal" font="default" size="100%">Substance use disorders</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1432-2072 (Electronic)&#xD;0033-3158 (Print)&#xD;0033-3158 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36190537</style></accession-num><abstract><style face="normal" font="default" size="100%">RATIONALE: Although there is evidence that impaired executive functioning plays a role in addictive behavior, the longitudinal relationship between the two remains relatively unknown. OBJECTIVES: In a prospective-longitudinal community study, we tested the hypothesis that lower executive functioning is associated with more addictive behavior at one point in time and over time. METHODS: Three hundred and thirty-eight individuals (19-27 years, 59% female) from a random community sample were recruited into three groups: addictive disorders related to substances (n = 100) or to behaviors (n = 118), or healthy controls (n = 120). At baseline, participants completed nine executive function tasks from which a latent variable of general executive functioning (GEF) was derived. Addictive behavior (i.e., quantity and frequency of use, and number of DSM-5 criteria met) were assessed using standardized clinical interviews at baseline and three annual follow-ups. The trajectories of addictive behaviors were examined using latent growth curve modeling. RESULTS: At baseline, we found weak to no evidence of an associations between GEF and addictive behavior. We found evidence for an association between a lower GEF at baseline and a higher increase in the quantity of use and a smaller decrease in frequency of use over time, but no evidence for an association with an increase in the number of DSM-5 criteria met. CONCLUSIONS: Lower EFs appear to lead to a continuing loss of control over use, whereas addictive disorders may develop secondarily after a long period of risky use. Previous etiological models assuming lower EF as a direct vulnerability factor for addictive disorders need to be refined.</style></abstract><notes><style face="normal" font="default" size="100%">Kraplin, Anja&#xD;Joshanloo, Mohsen&#xD;Wolff, Max&#xD;Kronke, Klaus-Martin&#xD;Goschke, Thomas&#xD;Buhringer, Gerhard&#xD;Smolka, Michael N&#xD;eng&#xD;178833530/Deutsche Forschungsgemeinschaft/&#xD;Germany&#xD;2022/10/04&#xD;Psychopharmacology (Berl). 2022 Nov;239(11):3507-3524. doi: 10.1007/s00213-022-06224-3. Epub 2022 Oct 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36190537</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Anja Kraplin&apos;s salary is partly funded by an unrestricted research grant from the Federal Ministry of Economic Affairs and Climate Action as part of the evaluation of the Gaming Ordinance. Mohsen Joshanloo, Max Wolff, Klaus-Martin Kronke, Thomas Goschke, and Michael N. Smolka have no conflicts of interest to declare. Gerhard Buhringer received unrestricted grants for gambling research activities from various public and commercial gambling providers and regulatory agencies. He is a member of the &apos;Dusseldorfer Kreis&apos; (a group of key stakeholders from public and private gambling providers, research and the support system).</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9584881</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00213-022-06224-3</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>187</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">187</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khodaii, J.</style></author><author><style face="normal" font="default" size="100%">Araj-Khodaei, M.</style></author><author><style face="normal" font="default" size="100%">Vafaee, M. S.</style></author><author><style face="normal" font="default" size="100%">Wong, D. F.</style></author><author><style face="normal" font="default" size="100%">Gjedde, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Mechanical Engineering, Amirkabir University of Technology, Tehran, Iran.&#xD;Research Center for Integrative Medicine in Aging, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.&#xD;BRIDGE (Brain Research Inter-Disciplinary Guided Excellence), Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Research Unit for Psychiatry, Southern Region, University of Southern Denmark, Odense, Denmark.&#xD;Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.&#xD;Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri.&#xD;BRIDGE (Brain Research Inter-Disciplinary Guided Excellence), Department of Clinical Research, University of Southern Denmark, Odense, Denmark; albert.gjedde@clin.au.dk.&#xD;Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Panum Institute, Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark; and.&#xD;Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots</style></title><secondary-title><style face="normal" font="default" size="100%">J Nucl Med</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">294-301</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20210604</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Brain/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Linear Models</style></keyword><keyword><style face="normal" font="default" size="100%">Positron-Emission Tomography/methods</style></keyword><keyword><style face="normal" font="default" size="100%">*Radiopharmaceuticals/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Tomography, X-Ray Computed</style></keyword><keyword><style face="normal" font="default" size="100%">Lassen plots</style></keyword><keyword><style face="normal" font="default" size="100%">Pet</style></keyword><keyword><style face="normal" font="default" size="100%">binding potential</style></keyword><keyword><style face="normal" font="default" size="100%">inhibition plot</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Society of Nuclear Medicine</style></publisher><isbn><style face="normal" font="default" size="100%">1535-5667 (Electronic)&#xD;0161-5505 (Print)&#xD;0161-5505 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34088774</style></accession-num><abstract><style face="normal" font="default" size="100%">We derived three widely used linearizations from the definition of receptor availability in molecular imaging with positron emission tomography (PET). The purpose of the present research was to determine the convergence of the results of the 3 methods in terms of 3 parameters-occupancy (s), distribution volume of the nondisplaceable reference binding compartment (V(ND)), and nondisplaceable reference binding potential (BP(ND)) of the radioligand-in the absence of a gold standard. We tested 104 cases culled from the literature and calculated the goodness of fit of the least-squares and Deming II methods of linear regression when applied to the determination of s, V(ND), and BP(ND) using the goodness-of-fit parameters R(2), coefficient of variation (root-mean-square error [RMSE]), and the infinity norm ( ||X ||(infinity)) with both regression methods. We observed superior convergence among the values of s, V(ND), and BP(ND) for the inhibition and occupancy plots. The inhibition plot emerged as the plot with a slightly higher degree of convergence (based on R(2), RMSE, and ||X ||(infinity) value). With two regression methods (the least-squares method [LSM] and the Deming II [DM] method), the estimated values of s, V(ND), and BP(ND) generally converged. The inhibition and occupancy plots yielded the best fits to the data, according to the goodness-of-fit parameters, due primarily to absence of commingling of the dependent and independent variables tested with the saturation (original Lassen) plot. In the presence of noise, the inhibition and occupancy plots yielded higher convergences.</style></abstract><notes><style face="normal" font="default" size="100%">Khodaii, Javad&#xD;Araj-Khodaei, Mostafa&#xD;Vafaee, Manouchehr S&#xD;Wong, Dean F&#xD;Gjedde, Albert&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2021/06/06&#xD;J Nucl Med. 2022 Feb;63(2):294-301. doi: 10.2967/jnumed.117.204453. Epub 2021 Jun 4.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34088774</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC8805780</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2967/jnumed.117.204453</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>247</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">247</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmidt, S. I.</style></author><author><style face="normal" font="default" size="100%">Blaabjerg, M.</style></author><author><style face="normal" font="default" size="100%">Freude, K.</style></author><author><style face="normal" font="default" size="100%">Meyer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, DK-5000 Odense, Denmark.&#xD;Department of Neurology, Odense University Hospital, DK-5000 Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark.&#xD;BRIDGE-Brain Research Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark.&#xD;Section for Pathobiological Sciences, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1870 Frederiksberg, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">RhoA Signaling in Neurodegenerative Diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Cells</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cells</style></full-title></periodical><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">20220501</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Huntington Disease/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Neurodegenerative Diseases/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Neurons/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Parkinson Disease/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Signal Transduction/physiology</style></keyword><keyword><style face="normal" font="default" size="100%">rhoA GTP-Binding Protein/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">Huntington&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">Parkinson&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">Ras homolog gene family member A (RhoA)</style></keyword><keyword><style face="normal" font="default" size="100%">Rho-associated coiled-coil-containing kinase (ROCK)</style></keyword><keyword><style face="normal" font="default" size="100%">amyotrophic lateral sclerosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May 1</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2073-4409 (Electronic)&#xD;2073-4409 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35563826</style></accession-num><abstract><style face="normal" font="default" size="100%">Ras homolog gene family member A (RhoA) is a small GTPase of the Rho family involved in regulating multiple signal transduction pathways that influence a diverse range of cellular functions. RhoA and many of its downstream effector proteins are highly expressed in the nervous system, implying an important role for RhoA signaling in neurons and glial cells. Indeed, emerging evidence points toward a role of aberrant RhoA signaling in neurodegenerative diseases such as Parkinson&apos;s disease, Alzheimer&apos;s disease, Huntington&apos;s disease, and amyotrophic lateral sclerosis. In this review, we summarize the current knowledge of RhoA regulation and downstream cellular functions with an emphasis on the role of RhoA signaling in neurodegenerative diseases and the therapeutic potential of RhoA inhibition in neurodegeneration.</style></abstract><notes><style face="normal" font="default" size="100%">Schmidt, Sissel Ida&#xD;Blaabjerg, Morten&#xD;Freude, Kristine&#xD;Meyer, Morten&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;Switzerland&#xD;2022/05/15&#xD;Cells. 2022 May 1;11(9):1520. doi: 10.3390/cells11091520.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35563826</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9103838</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/cells11091520</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>290</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">290</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kildegaard, H.</style></author><author><style face="normal" font="default" size="100%">Lund, L. C.</style></author><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Stensballe, L. G.</style></author><author><style face="normal" font="default" size="100%">Pottegard, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, DK-5000 Odense C, Denmark hckildegaard@health.sdu.dk.&#xD;Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, DK-5000 Odense C, Denmark.&#xD;Department of Paediatrics and Adolescent Medicine, The Juliane Marie Centre, Rigshospitalet, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e068898</style></pages><volume><style face="normal" font="default" size="100%">377</style></volume><edition><style face="normal" font="default" size="100%">20220411</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style face="normal" font="default" size="100%">*COVID-19/complications/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">COVID-19 Vaccines/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Myocarditis/epidemiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style face="normal" font="default" size="100%">Systemic Inflammatory Response Syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines, Synthetic</style></keyword><keyword><style face="normal" font="default" size="100%">mRNA Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr 11</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1756-1833 (Electronic)&#xD;0959-8138 (Print)&#xD;0959-8138 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35410884</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To assess the risk of acute and post-acute adverse events after SARS-CoV-2 infection in children and adolescents in Denmark and to evaluate the real world effectiveness of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) among adolescents. DESIGN: Cohort study. SETTING: Nationwide Danish healthcare registers. PARTICIPANTS: All Danish people younger than 18 years who were either tested for SARS-CoV-2 using reverse transcriptase polymerase chain reaction (RT-PCR) or vaccinated with BNT162b2 to 1 October 2021. MAIN OUTCOME MEASURES: Risk of hospital admissions (any hospital contact of &gt;/=12 hours); intensive care unit (ICU) admissions; serious complications, including multisystem inflammatory syndrome in children (MIS-C), myocarditis, and neuroimmune disorders; and initiating drug treatment and health service use up to six months after being tested. Vaccine effectiveness in vaccine recipients compared with unvaccinated peers was evaluated as one minus the risk ratio at 20 days after the first dose and 60 days after the second dose. RESULTS: Of 991 682 children and adolescents tested for SARS-CoV-2 using RT-PCR in Denmark, 74 611 (7.5%) were positive. The risk of hospital admission with any variant for &gt;/=12 hours was 0.49% (95% confidence interval 0.44% to 0.54%; 361/74 350), and 0.01% (0.01% to 0.03%; 10/73 187) of participants were admitted to an ICU within 30 days of testing positive. The risk of MIS-C within two months of SARS-CoV-2 infection was 0.05% (0.03% to 0.06%; 32/70 666), whereas no participants had myocarditis outside of MIS-C or encephalitis and fewer than five had Guillain-Barre syndrome. In the post-acute phase (1-6 months after infection), participants who tested positive for SARS-CoV-2 showed a 1.08-fold (95% confidence interval 1.06-fold to 1.10-fold) increase in rate of contacts with general practitioners compared with a reference cohort sampled among all children tested for SARS-CoV-2 during the study period. Overall, 278 649 adolescents received BNT162b2. Compared with unvaccinated adolescents, the estimated vaccine effectiveness among 229 799 adolescents vaccinated with one dose was 62% (95% confidence interval 59% to 65%) after 20 days, and among 175 176 vaccinated with two doses was 93% (92% to 94%) after 60 days during a period when delta was the dominant variant. CONCLUSIONS: The absolute risks of adverse events after SARS-CoV-2 infection were generally low in Danish children and adolescents, although MIS-C occurred in 0.05% (32/70 666) of participants with RT-PCR confirmed SARS-CoV-2 infection. In adjusted analyses, rates of general practitioner visits were slightly increased in SARS-CoV-2 positive children and adolescents, which could indicate persisting symptoms. BNT162b2 appeared to be effective in reducing the risk of SARS-CoV-2 infection with the delta variant in adolescents.</style></abstract><notes><style face="normal" font="default" size="100%">Kildegaard, Helene&#xD;Lund, Lars Christian&#xD;Hojlund, Mikkel&#xD;Stensballe, Lone Graff&#xD;Pottegard, Anton&#xD;eng&#xD;England&#xD;2022/04/13&#xD;BMJ. 2022 Apr 11;377:e068898. doi: 10.1136/bmj-2021-068898.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35410884</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: AP reports funds paid to his institution for participation in research projects funded by Alcon, Almirall, Astellas, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Servier, and LEO Pharma, outside the current work. LCL reports funds paid to his institution for participation in research projects funded by Menarini Pharmaceuticals and LEO Pharma, outside the current work.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8995669</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmj-2021-068898</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>299</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">299</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fahrenholtz, I. L.</style></author><author><style face="normal" font="default" size="100%">Melin, A. K.</style></author><author><style face="normal" font="default" size="100%">Wasserfurth, P.</style></author><author><style face="normal" font="default" size="100%">Stenling, A.</style></author><author><style face="normal" font="default" size="100%">Logue, D.</style></author><author><style face="normal" font="default" size="100%">Garthe, I.</style></author><author><style face="normal" font="default" size="100%">Koehler, K.</style></author><author><style face="normal" font="default" size="100%">Grafnings, M.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Madigan, S.</style></author><author><style face="normal" font="default" size="100%">Torstveit, M. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Sport Science and Physical Education, University of Agder, Kristiansand, Norway.&#xD;Department of Sport Science, Linnaeus University, Kalmar, Vaxjo, Sweden.&#xD;Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany.&#xD;Department of Psychology, Umea University, Umea, Sweden.&#xD;Sport Ireland Institute, National Sports Campus, Dublin, Ireland.&#xD;The Norwegian Olympic and Paralympic Committee and Confederation of Sport, Oslo, Norway.&#xD;Department of Medical Science, Dalarna University, Falun, Sweden.&#xD;Centre for Telepsychiatry, Mental Health Services in the Region of Southern Denmark, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk of Low Energy Availability, Disordered Eating, Exercise Addiction, and Food Intolerances in Female Endurance Athletes</style></title><secondary-title><style face="normal" font="default" size="100%">Front Sports Act Living</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Sports Act Living</style></full-title></periodical><pages><style face="normal" font="default" size="100%">869594</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><edition><style face="normal" font="default" size="100%">20220503</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Low Energy Availability in Females Questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">Relative Energy Deficiency in Sport (RED-S)</style></keyword><keyword><style face="normal" font="default" size="100%">compulsive exercise</style></keyword><keyword><style face="normal" font="default" size="100%">eating disorder</style></keyword><keyword><style face="normal" font="default" size="100%">endurance training</style></keyword><keyword><style face="normal" font="default" size="100%">restrictive eating behavior</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">2624-9367 (Electronic)&#xD;2624-9367 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35592590</style></accession-num><abstract><style face="normal" font="default" size="100%">Relative energy deficiency in sport (RED-S) is a complex syndrome describing health and performance consequences of low energy availability (LEA) and is common among female endurance athletes. Various underlying causes of LEA have been reported, including disordered eating behavior (DE), but studies investigating the association with exercise addiction and food intolerances are lacking. Therefore, the aim of this cross-sectional study was to investigate the association between DE, exercise addiction and food intolerances in athletes at risk of LEA compared to those with low risk. Female endurance athletes, 18-35 years, training &gt;/=5 times/week were recruited in Norway, Sweden, Ireland, and Germany. Participants completed an online-survey comprising the LEA in Females Questionnaire (LEAF-Q), Exercise Addiction Inventory (EAI), Eating Disorder Examination Questionnaire (EDE-Q), and questions regarding food intolerances. Of the 202 participants who met the inclusion criteria and completed the online survey, 65% were at risk of LEA, 23% were at risk of exercise addiction, and 21% had DE. Athletes at risk of LEA had higher EDE-Q and EAI scores compared to athletes with low risk. EAI score remained higher in athletes with risk of LEA after excluding athletes with DE. Athletes at risk of LEA did not report more food intolerances (17 vs. 10%, P = 0.198), but were more frequently reported by athletes with DE (28 vs. 11%, P = 0.004). In conclusion, these athletes had a high risk of LEA, exercise addiction, and DE. Exercise addiction should be considered as an additional risk factor in the prevention, early detection, and targeted treatment of RED-S among female endurance athletes.</style></abstract><notes><style face="normal" font="default" size="100%">Fahrenholtz, Ida Lysdahl&#xD;Melin, Anna Katarina&#xD;Wasserfurth, Paulina&#xD;Stenling, Andreas&#xD;Logue, Danielle&#xD;Garthe, Ina&#xD;Koehler, Karsten&#xD;Grafnings, Maria&#xD;Lichtenstein, Mia Beck&#xD;Madigan, Sharon&#xD;Torstveit, Monica Klungland&#xD;eng&#xD;Switzerland&#xD;2022/05/21&#xD;Front Sports Act Living. 2022 May 3;4:869594. doi: 10.3389/fspor.2022.869594. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35592590</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9110838</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fspor.2022.869594</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>263</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">263</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jakobsen, S. G.</style></author><author><style face="normal" font="default" size="100%">Larsen, C. P.</style></author><author><style face="normal" font="default" size="100%">Stenager, E.</style></author><author><style face="normal" font="default" size="100%">Christiansen, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Suicide Research, Odense, Denmark.&#xD;Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.&#xD;Unit for Psychiatric Research, Department of Regional Health Services Research, University of Southern Denmark, Aabenraa, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk of repeated suicide attempt after redeeming prescriptions for antidepressants: a register-based study in Denmark</style></title><secondary-title><style face="normal" font="default" size="100%">Psychol Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Psychol Med</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-8</style></pages><edition><style face="normal" font="default" size="100%">20220831</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antidepressive agents</style></keyword><keyword><style face="normal" font="default" size="100%">attempted</style></keyword><keyword><style face="normal" font="default" size="100%">psychopharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">registries</style></keyword><keyword><style face="normal" font="default" size="100%">risk factors</style></keyword><keyword><style face="normal" font="default" size="100%">suicide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 31</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1469-8978 (Electronic)&#xD;0033-2917 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36043363</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: It remains unclear how SSRIs and other antidepressants are associated with the risk of repeated suicide attempts. We aimed to analyse the association between redeemed antidepressant prescriptions and the risk of repeated suicide attempts, hypothesising that antidepressant treatment is associated with increased risk of repeated suicide attempts. METHODS: The study was based on Danish register data and a validated cohort of 1842 suicide attempts. We used three Cox regression models (crude, adjusted and propensity score matched) to analyse the data; these models included both static and dynamic time-dependent factors. RESULTS: 1842 individuals attempted suicide in the study period, with a total of 210 repeated attempts. Individuals redeeming antidepressant prescriptions were more likely to repeat a suicide attempt. All crude models showed all antidepressants to be significant risk factors (HR around 1.39), whereas all adjusted models showed all antidepressants to be insignificant risk factors. CONCLUSION: We found no significant increased risk of repeated suicide attempts in individuals redeeming a prescription for any antidepressant (or only SSRIs) when considering the individuals&apos; baseline risk of repetition. This study is based on validated suicide attempts, register data, and strong epidemiology designs, but it still has some limitations, and the results should be replicated and confirmed in other studies.</style></abstract><notes><style face="normal" font="default" size="100%">Jakobsen, Sarah Grube&#xD;Larsen, Christina Petrea&#xD;Stenager, Elsebeth&#xD;Christiansen, Erik&#xD;eng&#xD;England&#xD;2022/09/01&#xD;Psychol Med. 2022 Aug 31:1-8. doi: 10.1017/S0033291722002719.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36043363</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S0033291722002719</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>188</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mellentin, A. I.</style></author><author><style face="normal" font="default" size="100%">Nielsen, D. G.</style></author><author><style face="normal" font="default" size="100%">Skot, L.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author><author><style face="normal" font="default" size="100%">Guala, M. M.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Wesselhoeft, R.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit for Clinical Alcohol Research, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Research Unit for Telepsychiatry and E-Mental Health, Center for Telepsychiatry, Region of Southern Denmark, Odense C, Denmark.&#xD;Brain Research-Inter-Disciplinary Guided Excellence (BRIDGE), Department of Clinical Research, University of Southern Denmark, Odense C, Denmark.&#xD;Center for Eating Disorders, Odense University Hospital, Odense C, Denmark.&#xD;Research Unit for Medical Endocrinology, Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark.&#xD;Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense C, Denmark.&#xD;Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, Odense C, Denmark.&#xD;Open Patient data Explorative Network, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk of somatic diseases in patients with eating disorders: the role of comorbid substance use disorders</style></title><secondary-title><style face="normal" font="default" size="100%">Epidemiol Psychiatr Sci</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">e73</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">e73</style></number><edition><style face="normal" font="default" size="100%">20221017</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Comorbidity</style></keyword><keyword><style face="normal" font="default" size="100%">*Feeding and Eating Disorders/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Substance-Related Disorders/complications</style></keyword><keyword><style face="normal" font="default" size="100%">Alcohol abuse</style></keyword><keyword><style face="normal" font="default" size="100%">common mental disorders</style></keyword><keyword><style face="normal" font="default" size="100%">health outcomes</style></keyword><keyword><style face="normal" font="default" size="100%">prospective study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 17</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Cambridge University Press (CUP)</style></publisher><isbn><style face="normal" font="default" size="100%">2045-7979 (Electronic)&#xD;2045-7960 (Print)&#xD;2045-7960 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36245431</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: Eating disorders (EDs) and substance use disorders (SUDs) often co-occur, and both involve somatic diseases. So far, no study has considered whether comorbid SUDs may impact somatic disease risk in patients with EDs. Therefore, this study aimed to examine the impact of comorbid SUDs on the risk of 11 somatic disease categories in patients with anorexia nervosa (AN), bulimia nervosa (BN) and unspecified eating disorder (USED) compared to matched controls. METHODS: A retrospective cohort study was conducted using Danish nationwide registries. The study population included 20 759 patients with EDs and 83 036 controls matched on month and year of birth, sex and ethnicity. Hazard ratios (HRs) were calculated to compare the risk of being diagnosed with a somatic disease (within 11 categories defined by the ICD-10) following first ED diagnosis (index date) between ED patients and controls both with and without SUDs (alcohol, cannabis or hard drugs). RESULTS: The ED cohort and matched controls were followed for 227 538 and 939 628 person-years, respectively. For ED patients with SUDs, the risk pattern for being diagnosed with different somatic diseases (relative to controls without SUDs) varied according to type of ED and SUD [adjusted HRs ranged from 0.95 (99% CI = 0.57; 1.59) to 4.17 (2.68, 6.47)]. The risk estimates observed among ED patients with SUDs were generally higher than those observed among ED patients without SUDs [adjusted HRs ranged from 1.08 (99% CI = 0.95, 1.22) to 2.56 (2.31, 2.84)]. Abuse of alcohol only had a non-synergistic effect on six disease categories in AN patients and five in BN and USED patients. Abuse of cannabis (with/without alcohol) had a non-synergistic effect on five disease categories in AN and BN patients and two in USED patients. Abuse of hard drugs (with/without alcohol or cannabis) had a non-synergistic effect on nine disease categories in AN patients, eight in BN patients and seven in USED patients. CONCLUSIONS: The present study documents non-synergistic but not synergistic harmful somatic consequences of SUDs among patients with different EDs, with AN and hard drugs being the most predominant factors. Hence, EDs and SUDs did not interact and result in greater somatic disease risk than that caused by the independent effects. Since EDs and SUDs have independent effects on many somatic diseases, it is important to monitor and treat ED patients for SUD comorbidity to prevent exacerbated physical damage in this vulnerable population.</style></abstract><notes><style face="normal" font="default" size="100%">Mellentin, A I&#xD;Nielsen, D G&#xD;Skot, L&#xD;Stoving, R K&#xD;Guala, M M&#xD;Nielsen, A S&#xD;Wesselhoeft, R&#xD;Mejldal, A&#xD;eng&#xD;England&#xD;2022/10/18&#xD;Epidemiol Psychiatr Sci. 2022 Oct 17;31:e73. doi: 10.1017/S204579602200052X.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36245431</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9583632</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S204579602200052X</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>255</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">255</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knudsen, L. V.</style></author><author><style face="normal" font="default" size="100%">Gazerani, P.</style></author><author><style face="normal" font="default" size="100%">Duan, Y.</style></author><author><style face="normal" font="default" size="100%">Michel, T. M.</style></author><author><style face="normal" font="default" size="100%">Vafaee, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit for Psychiatry, Odense University Hospital, Odense, Denmark.&#xD;Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark.&#xD;Department of Life Sciences and Health, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, 0130, Norway.&#xD;Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.&#xD;Tiantan Image Research Center, China National Clinical Research Center for Neurological Diseases, Beijing, China.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of multimodal MRI in mild cognitive impairment and Alzheimer&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">J Neuroimaging</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Neuroimaging</style></full-title></periodical><pages><style face="normal" font="default" size="100%">148-157</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20211109</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Alzheimer Disease/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Brain/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">*Cognitive Dysfunction/diagnostic imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Diffusion Tensor Imaging</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Magnetic Resonance Imaging/methods</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">clinical assessment</style></keyword><keyword><style face="normal" font="default" size="100%">magnetic resonance imaging</style></keyword><keyword><style face="normal" font="default" size="100%">mild cognitive impairment</style></keyword><keyword><style face="normal" font="default" size="100%">support vector machine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1552-6569 (Electronic)&#xD;1051-2284 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34752671</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND AND PURPOSE: Mild cognitive impairment (MCI) is a prodromal stage of Alzheimer&apos;s disease (AD), where neurodegeneration is not as considerable, thereby potentially increasing the effect of treatments. Therefore, highly sensitive and specific classification of subjects with MCI is necessary, where various MRI modalities have displayed promise. METHODS: Structural, diffusion, and resting-state (RS) functional MRI analyses were performed on the AD (n = 26), MCI (n = 5), and healthy control (HC) (n = 14) group. Structural analysis was performed via voxel-based morphometry (VBM) and volumetric subcortical segmentation analysis. Fractional anisotropy and mean diffusivity were estimated during the diffusion analysis. RS analysis investigated seed-based functional connectivity. Classification via support vector machine was performed to evaluate which MRI modality most accurately differentiated the groups. Multiple linear regression was conducted to evaluate the MRI modalities correlation with clinical assessment scores. RESULTS: Classification of MCI and HC displayed highest accuracy based on diffusion MRI, which besides demonstrated high correlation with clinical scores. Classification was equally accurate in AD, when using VBM or diffusion tensor imaging measures. Yet, more variance was explained by VBM measures in the clinical assessment scores of the AD group. CONCLUSIONS: This study highlights the potential of diffusion MRI in differentiating MCI from HC and AD. However, the results need to be interpreted with caution as sample size and artifacts in the MRI data probably influenced the results.</style></abstract><notes><style face="normal" font="default" size="100%">Knudsen, Laust Vind&#xD;Gazerani, Parisa&#xD;Duan, Yunyun&#xD;Michel, Tanja Maria&#xD;Vafaee, Manouchehr Seyedi&#xD;eng&#xD;2021/11/10&#xD;J Neuroimaging. 2022 Jan;32(1):148-157. doi: 10.1111/jon.12940. Epub 2021 Nov 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34752671</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jon.12940</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>189</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Griepke, S.</style></author><author><style face="normal" font="default" size="100%">Grupe, E.</style></author><author><style face="normal" font="default" size="100%">Lindholt, J. S.</style></author><author><style face="normal" font="default" size="100%">Fuglsang, E. H.</style></author><author><style face="normal" font="default" size="100%">Steffensen, L. B.</style></author><author><style face="normal" font="default" size="100%">Beck, H. C.</style></author><author><style face="normal" font="default" size="100%">Larsen, M. D.</style></author><author><style face="normal" font="default" size="100%">Bang-Moller, S. K.</style></author><author><style face="normal" font="default" size="100%">Overgaard, M.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, L. M.</style></author><author><style face="normal" font="default" size="100%">Lambertsen, K. L.</style></author><author><style face="normal" font="default" size="100%">Stubbe, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Elite Research Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, Odense, Denmark.&#xD;Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.&#xD;Department of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Neurology, Odense University Hospital, Odense, Denmark.&#xD;BRIDGE-Brain Research-Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Selective inhibition of soluble tumor necrosis factor signaling reduces abdominal aortic aneurysm progression</style></title><secondary-title><style face="normal" font="default" size="100%">Front Cardiovasc Med</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">942342</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><edition><style face="normal" font="default" size="100%">20220916</style></edition><keywords><keyword><style face="normal" font="default" size="100%">abdominal aortic aneurysm</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">translational research</style></keyword><keyword><style face="normal" font="default" size="100%">tumor necrosis factor inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">vascular inflammation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/9/16</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2297-055X (Print)&#xD;2297-055X (Electronic)&#xD;2297-055X (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36186984</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Tumor necrosis factor (TNF) is pathologically elevated in human abdominal aortic aneurysms (AAA). Non-selective TNF inhibition-based therapeutics are approved for human use but have been linked to several side effects. Compounds that target the proinflammatory soluble form of TNF (solTNF) but preserve the immunomodulatory capabilities of the transmembrane form of TNF (tmTNF) may prevent these side effects. We hypothesize that inhibition of solTNF signaling prevents AAA expansion. METHODS: The effect of the selective solTNF inhibitor, XPro1595, and the non-selective TNF inhibitor, Etanercept (ETN) was examined in porcine pancreatic elastase (PPE) induced AAA mice, and findings with XPro1595 was confirmed in angiotensin II (ANGII) induced AAA in hyperlipidemic apolipoprotein E (Apoe) (-/-) mice. RESULTS: XPro1595 treatment significantly reduced AAA expansion in both models, and a similar trend (p = 0.06) was observed in PPE-induced AAA in ETN-treated mice. In the PPE aneurysm wall, XPro1595 improved elastin integrity scores. In aneurysms, mean TNFR1 levels reduced non-significantly (p = 0.07) by 50% after TNF inhibition, but the histological location in murine AAAs was unaffected and similar to that in human AAAs. Semi-quantification of infiltrating leucocytes, macrophages, T-cells, and neutrophils in the aneurysm wall were unaffected by TNF inhibition. XPro1595 increased systemic TNF levels, while ETN increased systemic IL-10 levels. In ANGII-induced AAA mice, XPro1595 increased systemic TNF and IL-5 levels. In early AAA development, proteomic analyses revealed that XPro1595 significantly upregulated ontology terms including &quot;platelet aggregation&quot; and &quot;coagulation&quot; related to the fibrinogen complex, from which several proteins were among the top regulated proteins. Downregulated ontology terms were associated with metabolic processes. CONCLUSION: In conclusion, selective inhibition of solTNF signaling reduced aneurysm expansion in mice, supporting its potential as an attractive treatment option for AAA patients.</style></abstract><notes><style face="normal" font="default" size="100%">Griepke, Silke&#xD;Grupe, Emilie&#xD;Lindholt, Jes Sanddal&#xD;Fuglsang, Elizabeth Hvitfeldt&#xD;Steffensen, Lasse Bach&#xD;Beck, Hans Christian&#xD;Larsen, Mia Dupont&#xD;Bang-Moller, Sissel Karoline&#xD;Overgaard, Martin&#xD;Rasmussen, Lars Melholt&#xD;Lambertsen, Kate Lykke&#xD;Stubbe, Jane&#xD;eng&#xD;Switzerland&#xD;2022/10/04&#xD;Front Cardiovasc Med. 2022 Sep 16;9:942342. doi: 10.3389/fcvm.2022.942342. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36186984</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9523116</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fcvm.2022.942342</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>280</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">280</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koskela, M.</style></author><author><style face="normal" font="default" size="100%">Jokiranta-Olkoniemi, E.</style></author><author><style face="normal" font="default" size="100%">Luntamo, T.</style></author><author><style face="normal" font="default" size="100%">Suominen, A.</style></author><author><style face="normal" font="default" size="100%">Sourander, A.</style></author><author><style face="normal" font="default" size="100%">Steinhausen, H. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Child Psychiatry, University of Turku, Turku, Finland. miikosy@utu.fi.&#xD;Department of Child Psychiatry, Turku University Hospital, Turku, Finland. miikosy@utu.fi.&#xD;INVEST Research Flagship Center, University of Turku, Turku, Finland. miikosy@utu.fi.&#xD;Research Centre for Child Psychiatry, Faculty of Medicine, University of Turku, Turku, Finland. miikosy@utu.fi.&#xD;Department of Child Psychiatry, University of Turku, Turku, Finland.&#xD;Department of Child Psychiatry, Turku University Hospital, Turku, Finland.&#xD;INVEST Research Flagship Center, University of Turku, Turku, Finland.&#xD;Unit of Psychology, Faculty of Education, University of Oulu, Oulu, Finland.&#xD;Department of Child and Adolescent Psychiatry, Psychiatric University Clinic, Zurich, Switzerland.&#xD;Clinical Psychology and Epidemiology, Department of Psychology, University of Basel, Basel, Switzerland.&#xD;Department of Child and Adolescent Psychiatry, University of Southern Denmark, Odense, Denmark.&#xD;Child and Adolescent Mental Health Centre, Capital Region Psychiatry, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Selective mutism and the risk of mental and neurodevelopmental disorders among siblings</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></full-title></periodical><edition><style face="normal" font="default" size="100%">20221123</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Family clustering</style></keyword><keyword><style face="normal" font="default" size="100%">Mental disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Selective mutism</style></keyword><keyword><style face="normal" font="default" size="100%">Sibling study</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov 23</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1435-165X (Electronic)&#xD;1018-8827 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36422730</style></accession-num><abstract><style face="normal" font="default" size="100%">The siblings of children with mental disorders are more likely to experience mental health issues themselves, but there has been a lack of sibling studies on selective mutism (SM). The aim of this population-based study was to use national registers to examine associations between children with SM and diagnoses of various mental disorder in their siblings. All singleton children born in Finland from 1987 to 2009, and diagnosed with SM from 1998 to 2012, were identified from national health registers and matched with four controls by age and sex. Their biological siblings and parents were identified using national registries and the diagnostic information on the siblings of the subjects and controls was obtained. The final analyses comprised 658 children with SM and their 1661 siblings and 2092 controls with 4120 siblings. The analyses were conducted using generalized estimating equations. Mental disorders were more common among the siblings of the children with SM than among the siblings of the controls. The strongest associations were observed for childhood emotional disorders and autism spectrum disorders after the data were adjusted for covariates and comorbid diagnoses among SM subjects. The final model showed associations between SM and a wide range of disorders in siblings, with strongest associations with disorders that usually have their onset during childhood. Our finding showed that SM clustered with other mental disorders in siblings and this requires further research, especially the association between SM and autism spectrum disorders. Strong associations with childhood onset disorders may indicate shared etiologies.</style></abstract><notes><style face="normal" font="default" size="100%">Koskela, Miina&#xD;Jokiranta-Olkoniemi, Elina&#xD;Luntamo, Terhi&#xD;Suominen, Auli&#xD;Sourander, Andre&#xD;Steinhausen, Hans-Christoph&#xD;eng&#xD;320162/Academy of Finland/&#xD;308552/Academy of Finland/&#xD;303581/Strategic Research Council/&#xD;Germany&#xD;2022/11/25&#xD;Eur Child Adolesc Psychiatry. 2022 Nov 23. doi: 10.1007/s00787-022-02114-3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36422730</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00787-022-02114-3</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>190</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shakeshaft, A.</style></author><author><style face="normal" font="default" size="100%">Panjwani, N.</style></author><author><style face="normal" font="default" size="100%">Collingwood, A.</style></author><author><style face="normal" font="default" size="100%">Crudgington, H.</style></author><author><style face="normal" font="default" size="100%">Hall, A.</style></author><author><style face="normal" font="default" size="100%">Andrade, D. M.</style></author><author><style face="normal" font="default" size="100%">Beier, C. P.</style></author><author><style face="normal" font="default" size="100%">Fong, C. Y.</style></author><author><style face="normal" font="default" size="100%">Gardella, E.</style></author><author><style face="normal" font="default" size="100%">Gesche, J.</style></author><author><style face="normal" font="default" size="100%">Greenberg, D. A.</style></author><author><style face="normal" font="default" size="100%">Hamandi, K.</style></author><author><style face="normal" font="default" size="100%">Koht, J.</style></author><author><style face="normal" font="default" size="100%">Lim, K. S.</style></author><author><style face="normal" font="default" size="100%">Moller, R. S.</style></author><author><style face="normal" font="default" size="100%">Ng, C. C.</style></author><author><style face="normal" font="default" size="100%">Orsini, A.</style></author><author><style face="normal" font="default" size="100%">Rees, M. I.</style></author><author><style face="normal" font="default" size="100%">Rubboli, G.</style></author><author><style face="normal" font="default" size="100%">Selmer, K. K.</style></author><author><style face="normal" font="default" size="100%">Striano, P.</style></author><author><style face="normal" font="default" size="100%">Syvertsen, M.</style></author><author><style face="normal" font="default" size="100%">Thomas, R. H.</style></author><author><style face="normal" font="default" size="100%">Zarubova, J.</style></author><author><style face="normal" font="default" size="100%">Richardson, M. P.</style></author><author><style face="normal" font="default" size="100%">Strug, L. J.</style></author><author><style face="normal" font="default" size="100%">Pal, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Basic and Clinical Neurosciences, Maurice Wohl Clinical Neurosciences Institute, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, 5 Cutcombe Road, London, SE5 9RX, UK.&#xD;MRC Centre for Neurodevelopmental Disorders, King&apos;s College London, London, UK.&#xD;Program in Genetics and Genome Biology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada.&#xD;Adult Epilepsy Genetics Program, Krembil Research Institute, University of Toronto, Toronto, Canada.&#xD;Odense University Hospital, Odense, Denmark.&#xD;Division of Paediatric Neurology, Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.&#xD;Danish Epilepsy Centre, Dianalund, Denmark.&#xD;Nationwide Children&apos;s Hospital, Columbus, OH, USA.&#xD;Cardiff and Vale University Health Board, Cardiff, UK.&#xD;Department of Neurology, Oslo University Hospital, Oslo, Norway.&#xD;Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.&#xD;Department of Regional Health Services, University of Southern Denmark, Odense, Denmark.&#xD;Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia.&#xD;Department of Clinical and Experimental Medicine, Pisa University Hospital, Pisa, Italy.&#xD;Neurology Research Group, Swansea University Medical School, Swansea, UK.&#xD;University of Copenhagen, Copenhagen, Denmark.&#xD;Division of Clinical Neuroscience, Department of Research and Innovation, Oslo University Hospital, Oslo, Norway.&#xD;National Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.&#xD;IRCCS Istituto &apos;G. Gaslini&apos;, Genoa, Italy.&#xD;University of Genova, Genoa, Italy.&#xD;Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway.&#xD;Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.&#xD;Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.&#xD;Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.&#xD;King&apos;s College Hospital, London, UK.&#xD;Program in Genetics and Genome Biology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada. Lisa.Strug@utoronto.ca.&#xD;Departments of Statistical Sciences and Computer Science and Division of Biostatistics, The University of Toronto, Toronto, Canada. Lisa.Strug@utoronto.ca.&#xD;Department of Basic and Clinical Neurosciences, Maurice Wohl Clinical Neurosciences Institute, Institute of Psychiatry, Psychology and Neuroscience, King&apos;s College London, 5 Cutcombe Road, London, SE5 9RX, UK. deb.pal@kcl.ac.uk.&#xD;MRC Centre for Neurodevelopmental Disorders, King&apos;s College London, London, UK. deb.pal@kcl.ac.uk.&#xD;King&apos;s College Hospital, London, UK. deb.pal@kcl.ac.uk.&#xD;Evelina London Children&apos;s Hospital, London, UK. deb.pal@kcl.ac.uk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sex-specific disease modifiers in juvenile myoclonic epilepsy</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">2785</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20220221</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Epilepsies, Myoclonic</style></keyword><keyword><style face="normal" font="default" size="100%">Epilepsy, Absence</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">*Myoclonic Epilepsy, Juvenile/drug therapy/epidemiology/etiology/physiopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Photosensitivity Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Seizures</style></keyword><keyword><style face="normal" font="default" size="100%">*Sex Characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb 21</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">2045-2322 (Electronic)&#xD;2045-2322 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35190554</style></accession-num><abstract><style face="normal" font="default" size="100%">Juvenile myoclonic epilepsy (JME) is a common idiopathic generalised epilepsy with variable seizure prognosis and sex differences in disease presentation. Here, we investigate the combined epidemiology of sex, seizure types and precipitants, and their influence on prognosis in JME, through cross-sectional data collected by The Biology of Juvenile Myoclonic Epilepsy (BIOJUME) consortium. 765 individuals met strict inclusion criteria for JME (female:male, 1.8:1). 59% of females and 50% of males reported triggered seizures, and in females only, this was associated with experiencing absence seizures (OR = 2.0, p &lt; 0.001). Absence seizures significantly predicted drug resistance in both males (OR = 3.0, p = 0.001) and females (OR = 3.0, p &lt; 0.001) in univariate analysis. In multivariable analysis in females, catamenial seizures (OR = 14.7, p = 0.001), absence seizures (OR = 6.0, p &lt; 0.001) and stress-precipitated seizures (OR = 5.3, p = 0.02) were associated with drug resistance, while a photoparoxysmal response predicted seizure freedom (OR = 0.47, p = 0.03). Females with both absence seizures and stress-related precipitants constitute the prognostic subgroup in JME with the highest prevalence of drug resistance (49%) compared to females with neither (15%) and males (29%), highlighting the unmet need for effective, targeted interventions for this subgroup. We propose a new prognostic stratification for JME and suggest a role for circuit-based risk of seizure control as an avenue for further investigation.</style></abstract><notes><style face="normal" font="default" size="100%">Shakeshaft, Amy&#xD;Panjwani, Naim&#xD;Collingwood, Amber&#xD;Crudgington, Holly&#xD;Hall, Anna&#xD;Andrade, Danielle M&#xD;Beier, Christoph P&#xD;Fong, Choong Yi&#xD;Gardella, Elena&#xD;Gesche, Joanna&#xD;Greenberg, David A&#xD;Hamandi, Khalid&#xD;Koht, Jeanette&#xD;Lim, Kheng Seang&#xD;Moller, Rikke S&#xD;Ng, Ching Ching&#xD;Orsini, Alessandro&#xD;Rees, Mark I&#xD;Rubboli, Guido&#xD;Selmer, Kaja K&#xD;Striano, Pasquale&#xD;Syvertsen, Marte&#xD;Thomas, Rhys H&#xD;Zarubova, Jana&#xD;Richardson, Mark P&#xD;Strug, Lisa J&#xD;Pal, Deb K&#xD;eng&#xD;201503MOP-342469/CIHR/Canada&#xD;MR/N026063/1/Medical Research Council, Centre for Neurodevelopmental Disorders/&#xD;MR/K013998/1/MRC_/Medical Research Council/United Kingdom&#xD;201809FDN-407295/CIHR/Canada&#xD;MR/N026063/1/MRC_/Medical Research Council/United Kingdom&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/02/23&#xD;Sci Rep. 2022 Feb 21;12(1):2785. doi: 10.1038/s41598-022-06324-2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35190554</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">AS, NP, AC, HC, AH, CPB, CYF, EG, JG, DAG, KH, JK, KSL, RSM, CCN, AO, MIR, GR, JZ, MPR, LJS and DKP report no conflicts of interest. DA reports a grant and honoraria from Biocodex, honoraria from Eisai, royalties from UpToDate and grants from Ontario Brain Institute, McLaughlin Foundation and Dravet Syndrome Foundation, outside the present work. KKS reports a travel grant from UCB Nordic outside the present work. PS reports grants from Proveca and personal fees from Kolfarma, outside the present work. MS reports honoraria from Eisai. RHT reports honoraria from Sanofi, Eisai, GW Pharma, UCB Pharma, Zogenix, Arvelle and Bial and meeting support from LivaNova and Novartis outside the present work.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8861057</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41598-022-06324-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>284</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">284</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moeller, S. B.</style></author><author><style face="normal" font="default" size="100%">Juul, S.</style></author><author><style face="normal" font="default" size="100%">Arendt, I. T. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychology, University of Southern Denmark, Denmark.&#xD;Mental Health Services, Capital Region of Denmark.&#xD;Department of Psychology, University of Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Short Version of the Metacognitive Anger Processing Scale (MAP-SV) - initial psychometric testing</style></title><secondary-title><style face="normal" font="default" size="100%">Behav Cogn Psychother</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Behav Cogn Psychother</style></full-title></periodical><pages><style face="normal" font="default" size="100%">117-121</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20210603</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Anger</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Metacognition</style></keyword><keyword><style face="normal" font="default" size="100%">Psychometrics</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">assessment tool</style></keyword><keyword><style face="normal" font="default" size="100%">metacognitive anger processing</style></keyword><keyword><style face="normal" font="default" size="100%">metacognitive beliefs</style></keyword><keyword><style face="normal" font="default" size="100%">rumination</style></keyword><keyword><style face="normal" font="default" size="100%">short version</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1469-1833 (Electronic)&#xD;1352-4658 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34078508</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The 26-item version of the Metacognitive Anger Processing Scale (MAP) has shown good psychometric properties in previous studies. However, there is a need for a shorter version of the scale. AIMS: The aim of the present study is to psychometrically evaluate the 9-item Metacognitive Anger Processing Scale - Short Version (MAP-SV) in comparison with the original, 26-item version. METHOD: The 26-item MAP includes three subscales: rumination, positive beliefs and negative beliefs. Three items from each subscale were selected based on clinical validity to constitute the 9-item MAP-SV. A previous sample used for validation of the 26-item MAP was used for clinimetric testing. The sample included psychiatric patients (n = 88) and male forensic inpatients (n = 54). The MAP-SV was assessed according to scalability, convergent validity with general metacognition, and concurrent validity with anger measures. RESULTS: The scalability of the 9-item MAP-SV was comparable to that of the original 26-item MAP in most psychometric tests. The Loevinger&apos;s coefficient of homogeneity for the total score of the MAP-SV items was 0.29 for the combined sample compared with 0.36 in the original MAP, indicating close to acceptable scalability. The alpha coefficient for the MAP-SV total score was 0.79. For the combined sample, Pearson inter-correlations between the subscales of the MAP-SV were highly correlated with the MAP-SV total score (ranging from .66 to .84). CONCLUSIONS: The 9-item MAP-SV showed good psychometric properties and can be used as a reliable tool for assessing self-reported metacognitive anger processing.</style></abstract><notes><style face="normal" font="default" size="100%">Moeller, Stine Bjerrum&#xD;Juul, Sophie&#xD;Arendt, Ida-Marie T P&#xD;eng&#xD;2021/06/04&#xD;Behav Cogn Psychother. 2022 Jan;50(1):117-121. doi: 10.1017/S1352465821000199. Epub 2021 Jun 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34078508</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S1352465821000199</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>105</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vitger, T.</style></author><author><style face="normal" font="default" size="100%">Hjorthoj, C.</style></author><author><style face="normal" font="default" size="100%">Austin, S. F.</style></author><author><style face="normal" font="default" size="100%">Petersen, L.</style></author><author><style face="normal" font="default" size="100%">Tonder, E. S.</style></author><author><style face="normal" font="default" size="100%">Nordentoft, M.</style></author><author><style face="normal" font="default" size="100%">Korsbek, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Competence Center for Rehabilitation and Recovery, Mental Health Center Ballerup, Mental Health Services in the Capital Region of Denmark, Ballerup, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Copenhagen Research Center for Mental Health - CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.&#xD;Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.&#xD;Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark.&#xD;The Mental Health Services of Zealand, Slagelse, Denmark.&#xD;The Mental Health Centre Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Smartphone App to Promote Patient Activation and Support Shared Decision-making in People With a Diagnosis of Schizophrenia in Outpatient Treatment Settings (Momentum Trial): Randomized Controlled Assessor-Blinded Trial</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Internet Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Med Internet Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e40292</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">20221026</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Patient Participation</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/diagnosis/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Mobile Applications</style></keyword><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Decision Making</style></keyword><keyword><style face="normal" font="default" size="100%">digital intervention</style></keyword><keyword><style face="normal" font="default" size="100%">early intervention</style></keyword><keyword><style face="normal" font="default" size="100%">mHealth</style></keyword><keyword><style face="normal" font="default" size="100%">mobile health</style></keyword><keyword><style face="normal" font="default" size="100%">mobile phone</style></keyword><keyword><style face="normal" font="default" size="100%">patient activation</style></keyword><keyword><style face="normal" font="default" size="100%">randomized clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">schizotypal</style></keyword><keyword><style face="normal" font="default" size="100%">shared decision-making</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct 26</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">JMIR Publications Inc.</style></publisher><isbn><style face="normal" font="default" size="100%">1438-8871 (Electronic)&#xD;1439-4456 (Print)&#xD;1438-8871 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36287604</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Shared decision-making (SDM) is a process aimed at facilitating patient-centered care by ensuring that the patient and provider are actively involved in treatment decisions. In mental health care, SDM has been advocated as a means for the patient to gain or regain control and responsibility over their life and recovery process. To support the process of patient-centered care and SDM, digital tools may have advantages in terms of accessibility, structure, and reminders. OBJECTIVE: In this randomized controlled trial, we aimed to investigate the effect of a digital tool to support patient activation and SDM. METHODS: The trial was designed as a randomized, assessor-blinded, 2-armed, parallel-group multicenter trial investigating the use of a digital SDM intervention for 6 months compared with treatment as usual. Participants with a diagnosis of schizophrenia, schizotypal or delusional disorder were recruited from 9 outpatient treatment sites in the Capital Region of Denmark. The primary outcome was the self-reported level of activation at the postintervention time point. The secondary outcomes included self-efficacy, hope, working alliance, satisfaction, preparedness for treatment consultation, symptom severity, and level of functioning. Explorative outcomes on the effect of the intervention at the midintervention time point along with objective data on the use of the digital tool were collected. RESULTS: In total, 194 participants were included. The intention-to-treat analysis revealed a statistically significant effect favoring the intervention group on patient activation (mean difference 4.39, 95% CI 0.99-7.79; Cohen d=0.33; P=.01), confidence in communicating with one&apos;s provider (mean difference 1.85, 95% CI 0.01-3.69; Cohen d=0.24; P=.05), and feeling prepared for decision-making (mean difference 5.12, 95% CI 0.16-10.08; Cohen d=0.27; P=.04). We found no effect of the digital SDM tool on treatment satisfaction, hope, self-efficacy, working alliance, severity of symptoms, level of functioning, use of antipsychotic medicine, and number or length of psychiatric hospital admissions. CONCLUSIONS: This trial showed a significant effect of a digital SDM tool on the subjective level of patient activation, confidence in communicating with one&apos;s provider, and feeling prepared for decision-making at the postintervention time point. The effect size was smaller than the 0.42 effect size that we had anticipated and sampled for. The trial contributes to the evidence on how digital tools may support patient-centered care and SDM in mental health care. TRIAL REGISTRATION: ClinicalTrials.gov NCT03554655; https://clinicaltrials.gov/ct2/show/NCT03554655. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-doi: 10.1186/s12888-019-2143-2.</style></abstract><notes><style face="normal" font="default" size="100%">Vitger, Tobias&#xD;Hjorthoj, Carsten&#xD;Austin, Stephen F&#xD;Petersen, Lone&#xD;Tonder, Esben Sandvik&#xD;Nordentoft, Merete&#xD;Korsbek, Lisa&#xD;eng&#xD;Multicenter Study&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Canada&#xD;2022/10/27&#xD;J Med Internet Res. 2022 Oct 26;24(10):e40292. doi: 10.2196/40292.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36287604</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflicts of Interest: None declared.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9647453</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.2196/40292</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>248</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">248</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spitz, A.</style></author><author><style face="normal" font="default" size="100%">Aebi, M.</style></author><author><style face="normal" font="default" size="100%">Metzke, C. W.</style></author><author><style face="normal" font="default" size="100%">Walitza, S.</style></author><author><style face="normal" font="default" size="100%">Steinhausen, H. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital, Zurich, Switzerland; Clinical Psychology and Epidemiology, Institute of Psychology, University of Basel, Switzerland.&#xD;Research &amp; Development, Corrections and Rehabilitation, Department of Justice and Home Affairs, Canton of Zurich, Switzerland.&#xD;Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital, Zurich, Switzerland.&#xD;Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital, Zurich, Switzerland; Clinical Psychology and Epidemiology, Institute of Psychology, University of Basel, Switzerland; Department of Child and Adolescent Psychiatry, University of Southern Denmark, Odense, Denmark; Child and Adolescent Mental Health Centre, Capital Region Psychiatry, Copenhagen, Denmark. Electronic address: hc.steinhausen@kjpd.uzh.ch.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Stability and change in a predictive model of emotional and behavioural problems from early adolescence to middle adulthood</style></title><secondary-title><style face="normal" font="default" size="100%">J Psychiatr Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Psychiatr Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">8-16</style></pages><volume><style face="normal" font="default" size="100%">151</style></volume><edition><style face="normal" font="default" size="100%">20220324</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adaptation, Psychological</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Emotions</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Longitudinal Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Problem Behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Self Concept</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescence</style></keyword><keyword><style face="normal" font="default" size="100%">Adulthood</style></keyword><keyword><style face="normal" font="default" size="100%">Behavioural problems</style></keyword><keyword><style face="normal" font="default" size="100%">Coping</style></keyword><keyword><style face="normal" font="default" size="100%">Life-events</style></keyword><keyword><style face="normal" font="default" size="100%">Self-esteem</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1879-1379 (Electronic)&#xD;0022-3956 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35427875</style></accession-num><abstract><style face="normal" font="default" size="100%">The impact of negative life events, self-esteem, and coping behaviour are considered to be contributing factors in the development of emotional and behavioural problems. Differences in the predictive value of these three factors on emotional and behavioural problems from adolescence to adulthood have not yet been studied. Multiple linear regressions separate for the two sexes were used to assess whether the impact of negative life-events, self-esteem, and coping behaviour predicted emotional and behavioural problems at four discrete measurement points from early adolescence to middle adulthood in a cohort of N = 366 participants from a Swiss longitudinal community study. Mostly irrespective of sex, negative life-events and low self-esteem were significant predictors of internalizing problems, externalizing problems and total problem scores in adolescence as well as in adulthood. The explained variance in the model increased steadily from early adolescence to middle adulthood. While the impact of negative life-events was on the same level across all measurements until adulthood, the contribution of self-esteem increased steadily. There was a significant association, particularly in adolescent males, between avoidant coping and emotional and behavioural problems. The cross-sectional findings from this community study reflect long-term robust patterns in the associations of negative life-events, self-esteem, and avoidant coping with emotional and behavioural problems from adolescence to adulthood. Clinically, the three constructs represent actionable targets for optimizing assessment and intervention strategies across the adolescent life-span.</style></abstract><notes><style face="normal" font="default" size="100%">Spitz, Andrea&#xD;Aebi, Marcel&#xD;Metzke, Christa Winkler&#xD;Walitza, Susanne&#xD;Steinhausen, Hans-Christoph&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/04/16&#xD;J Psychiatr Res. 2022 Jul;151:8-16. doi: 10.1016/j.jpsychires.2022.03.029. Epub 2022 Mar 24.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35427875</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jpsychires.2022.03.029</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>191</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ejlersen, M.</style></author><author><style face="normal" font="default" size="100%">Ilieva, M.</style></author><author><style face="normal" font="default" size="100%">Michel, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Health Sciences, University of Southern Denmark, J.B. Winslows Vej 19.3, 5000, Odense, Denmark.&#xD;Research Unit of the Department of Psychiatry, University Hospital of Southern Denmark, J.B. Winslows Vej 20, 5000, Odense, Denmark.&#xD;Faculty of Health Sciences, University of Southern Denmark, J.B. Winslows Vej 19.3, 5000, Odense, Denmark. Tanja.michel@rsyd.dk.&#xD;Research Unit of the Department of Psychiatry, University Hospital of Southern Denmark, J.B. Winslows Vej 20, 5000, Odense, Denmark. Tanja.michel@rsyd.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Superoxide dismutase isozymes in cerebral organoids from autism spectrum disorder patients</style></title><secondary-title><style face="normal" font="default" size="100%">J Neural Transm (Vienna)</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">617-626</style></pages><volume><style face="normal" font="default" size="100%">129</style></volume><number><style face="normal" font="default" size="100%">5-6</style></number><edition><style face="normal" font="default" size="100%">20220309</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Isoenzymes</style></keyword><keyword><style face="normal" font="default" size="100%">*Organoids/enzymology</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style face="normal" font="default" size="100%">*Superoxide Dismutase/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">*Superoxide Dismutase-1/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Autism spectrum disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Cerebral organoids</style></keyword><keyword><style face="normal" font="default" size="100%">Superoxide dismutase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1435-1463 (Electronic)&#xD;0300-9564 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35266053</style></accession-num><abstract><style face="normal" font="default" size="100%">Autism spectrum disorder is a pervasive neurodevelopmental disorder with a substantial contribution to the global disease burden. Despite intensive research efforts, the aetiopathogenesis remains unclear. The Janus-faced antioxidant enzymes superoxide dismutase 1-3 have been implicated in initiating oxidative stress and as such may constitute a potential therapeutic target. However, no measurement has been taken in human autistic brain samples. The aim of this study is to measure superoxide dismutase 1-3 in autistic cerebral organoids as an in vitro model of human foetal neurodevelopment. Whole brain organoids were created from induced pluripotent stem cells from healthy individuals (n = 5) and individuals suffering from autism (n = 4). Using Pierce bicinchoninic acid and enzyme-linked immunosorbent assays, the protein and superoxide dismutase 1, 2, and 3 concentrations were quantified in the cerebral organoids at days 22, 32, and 42. Measurements were normalized to the protein concentration. Results represented using medians and interquartile ranges. Using Wilcoxon matched-pairs signed-rank test, an abrupt rise in the superoxide dismutase concentration was observed at day 32 and onwards. Using Wilcoxon rank-sum test, no differences were observed between healthy (SOD1: 35.56 ng/mL +/- 3.46; SOD2: 2435.80 ng/mL +/- 1327.00; SOD3: 1854.88 ng/mL +/- 867.94) and autistic (SOD1: 32.85 ng/mL +/- 5.26; SOD2: 2717.80 ng/mL +/- 1889.10; SOD3: 1690.18 ng/mL +/- 615.49) organoids. Cerebral organoids recapitulate many aspects of human neurodevelopment, but the diffusion restriction may render efforts in modelling differences in oxidative stress futile due to the intrinsic hypoxia and central necrosis.</style></abstract><notes><style face="normal" font="default" size="100%">Ejlersen, Morten&#xD;Ilieva, Mirolyuba&#xD;Michel, Tanja Maria&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Austria&#xD;2022/03/11&#xD;J Neural Transm (Vienna). 2022 Jun;129(5-6):617-626. doi: 10.1007/s00702-022-02472-x. Epub 2022 Mar 9.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35266053</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00702-022-02472-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>192</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">192</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wolf, R. T.</style></author><author><style face="normal" font="default" size="100%">Puggaard, L. B.</style></author><author><style face="normal" font="default" size="100%">Pedersen, M. M. A.</style></author><author><style face="normal" font="default" size="100%">Pagsberg, A. K.</style></author><author><style face="normal" font="default" size="100%">Silverman, W. K.</style></author><author><style face="normal" font="default" size="100%">Correll, C. U.</style></author><author><style face="normal" font="default" size="100%">Plessen, K. J.</style></author><author><style face="normal" font="default" size="100%">Neumer, S. P.</style></author><author><style face="normal" font="default" size="100%">Gyrd-Hansen, D.</style></author><author><style face="normal" font="default" size="100%">Thastum, M.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Thomsen, P. H.</style></author><author><style face="normal" font="default" size="100%">Jeppesen, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Child and Adolescent Mental Health Centre, Mental Health Services - Capital Region of Denmark, Copenhagen, Denmark. rasmus.trap.wolf@regionh.dk.&#xD;Danish Centre for Health Economics, Department of Public Health, University of Southern Denmark, Odense, Denmark. rasmus.trap.wolf@regionh.dk.&#xD;Child and Adolescent Mental Health Centre, Mental Health Services - Capital Region of Denmark, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Anxiety and Mood Disorders Program, Yale Child Study Center, School of Medicine, Yale University, New Haven, CT, USA.&#xD;Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine At Hofstra/Northwell, Hempstead, NY, USA.&#xD;Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA.&#xD;Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA.&#xD;Department of Child and Adolescent Psychiatry, Charite Universitatsmedizin, Berlin, Germany.&#xD;Division of Child and Adolescent Psychiatry, Department of Psychiatry, Lausanne University Hospital CHUV, Lausanne, Switzerland.&#xD;Centre for Child and Adolescent Mental Health, Oslo, Norway.&#xD;Centre for Child and Youth Mental Health and Child Welfare, The Arctic University of Norway, North Norway (RKBU North), Tromso, Norway.&#xD;Danish Centre for Health Economics, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Centre for the Psychological Treatment of Children and Adolescents, Department of Psychology and Behavioural Sciences, Aarhus BSS, Aarhus University, Aarhus, Denmark.&#xD;Department for Child and Adolescent Psychiatry, Mental Health Services in the Region of Southern Denmark, Copenhagen, Denmark.&#xD;University of Southern Denmark, Odense, Denmark.&#xD;Research Center At Department for Child- and Adolescent Psychiatry, Aarhus University Hospital, Skejby, Denmark.&#xD;Institute of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Systematic identification and stratification of help-seeking school-aged youth with mental health problems: a novel approach to stage-based stepped-care</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">781-793</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">20210118</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Anxiety Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Disorders/diagnosis/epidemiology/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Mental Health</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Health Services</style></keyword><keyword><style face="normal" font="default" size="100%">*Psychotic Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Schools</style></keyword><keyword><style face="normal" font="default" size="100%">Children and adolescents</style></keyword><keyword><style face="normal" font="default" size="100%">Mental health problems</style></keyword><keyword><style face="normal" font="default" size="100%">Mental health services</style></keyword><keyword><style face="normal" font="default" size="100%">Stage-based stepped-care</style></keyword><keyword><style face="normal" font="default" size="100%">Visitation</style></keyword><keyword><style face="normal" font="default" size="100%">Youth</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">May</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1435-165X (Electronic)&#xD;1018-8827 (Print)&#xD;1018-8827 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33459884</style></accession-num><abstract><style face="normal" font="default" size="100%">We investigated whether a novel visitation model for school-aged youth with mental health problems based on a stage-based stepped-care approach facilitated a systematic identification and stratification process without problems with equity in access. The visitation model was developed within the context of evaluating a new transdiagnostic early treatment for youth with anxiety, depressive symptoms, and/or behavioural problems. The model aimed to identify youth with mental health problems requiring an intervention, and to stratify the youth into three groups with increasing severity of problems. This was accomplished using a two-phase stratification process involving a web-based assessment and a semi-structured psychopathological interview of the youth and parents. To assess problems with inequity in access, individual-level socioeconomic data were obtained from national registers with data on both the youth participating in the visitation and the background population. Altogether, 573 youth and their parents took part in the visitation process. Seventy-five (13%) youth had mental health problems below the intervention threshold, 396 (69%) were deemed eligible for the early treatment, and 52 (9%) had symptoms of severe mental health problems. Fifty (9%) youth were excluded for other reasons. Eighty percent of the 396 youth eligible for early treatment fulfilled criteria of a mental disorder. The severity of mental health problems highlights the urgent need for a systematic approach. Potential problems in reaching youth of less resourceful parents, and older youth were identified. These findings can help ensure that actions are taken to avoid equity problems in future mental health care implementations.</style></abstract><notes><style face="normal" font="default" size="100%">Wolf, Rasmus Trap&#xD;Puggaard, Louise Berg&#xD;Pedersen, Mette Maria Agner&#xD;Pagsberg, Anne Katrine&#xD;Silverman, Wendy K&#xD;Correll, Christoph U&#xD;Plessen, Kerstin Jessica&#xD;Neumer, Simon-Peter&#xD;Gyrd-Hansen, Dorte&#xD;Thastum, Mikael&#xD;Bilenberg, Niels&#xD;Thomsen, Per Hove&#xD;Jeppesen, Pia&#xD;eng&#xD;-/TrygFonden (DK)/&#xD;-/Lundbeckfonden (DK)/&#xD;TrygFonden (DK)/&#xD;Lundbeckfonden (DK)/&#xD;Germany&#xD;2021/01/19&#xD;Eur Child Adolesc Psychiatry. 2022 May;31(5):781-793. doi: 10.1007/s00787-021-01718-5. Epub 2021 Jan 18.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33459884</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">RTW, LBP, MMAP, AKP, WKS, KJP, SPN, DGH, MT, NB, PHT and PJ declare that they have no conflict of interest. CUC has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&amp;J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9142415</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00787-021-01718-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>298</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">298</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Linnet, J.</style></author><author><style face="normal" font="default" size="100%">Jensen, E. S.</style></author><author><style face="normal" font="default" size="100%">Runge, E.</style></author><author><style face="normal" font="default" size="100%">Hansen, M. B.</style></author><author><style face="normal" font="default" size="100%">Hertz, S. P. T.</style></author><author><style face="normal" font="default" size="100%">Mathiasen, K.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Telepsychiatry, Mental Health Services in the Region of Southern Denmark, Denmark.&#xD;Clinic on Gambling- and Binge Eating Disorder, Department of Occupational and Environmental Medicine, Odense University Hospital, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Text based internet intervention of Binge Eating Disorder (BED): Words per message is associated with treatment adherence</style></title><secondary-title><style face="normal" font="default" size="100%">Internet Interv</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Internet Interv</style></full-title></periodical><pages><style face="normal" font="default" size="100%">100538</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><edition><style face="normal" font="default" size="100%">20220413</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Binge-Eating Disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Cognitive behavioral therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Internet-based intervention</style></keyword><keyword><style face="normal" font="default" size="100%">Sensitivity and specificity</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment adherence and compliance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2214-7829 (Electronic)&#xD;2214-7829 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35480237</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Some evidence suggests that in internet-based cognitive behavioral therapy (iCBT) the likelihood of adherence is increased when patients write longer messages to the therapist in the program. This association has not previously been investigated in iCBT for Binge Eating Disorder (BED). OBJECTIVE: In this study, we hypothesized that the number of words written by patients with mild to moderate BED was associated with increased likelihood of treatment completion in a text-based iCBT program. MATERIAL AND METHODS: We compared 143 BED patients (92 completers and 51 non-completers) on the number of messages and words written to their therapist during the treatment. RESULTS: Completers wrote significantly more words per message (words/message) than non-completers. The results remained significant after controlling for gender, age, educational level, marital status, children, source of income and intake measures of BED, BMI and depression symptoms (Wald = 14.48, p &lt; .001). The odds ratio of completion increased by 1.5% for each additional word patients wrote per message (OR = 1.015). The model showed a 72.4% classification accuracy, and an optimal cut-off point of 68.99 words/message for differentiating completers and non-completers. The model accurately identified 80.9% of completers (sensitivity) and 54.9% of non-completers (specificity). CONCLUSIONS: The number of words/message patients write may have important implications for ascertaining likelihood of adherence and improving adherence rates. From a clinical perspective, therapists should encourage patients to use the option of writing messages to the therapist. Words/message may prove to be a transdiagnostic predictor of treatment adherence in text based iCBT.</style></abstract><notes><style face="normal" font="default" size="100%">Linnet, Jakob&#xD;Jensen, Esben Skov&#xD;Runge, Eik&#xD;Hansen, Marina Bohn&#xD;Hertz, Soren Peter Thygesen&#xD;Mathiasen, Kim&#xD;Lichtenstein, Mia Beck&#xD;eng&#xD;Netherlands&#xD;2022/04/29&#xD;Internet Interv. 2022 Apr 13;28:100538. doi: 10.1016/j.invent.2022.100538. eCollection 2022 Apr.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35480237</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9035730</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.invent.2022.100538</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>218</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">218</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fusaroli, R.</style></author><author><style face="normal" font="default" size="100%">Grossman, R.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Cantio, C.</style></author><author><style face="normal" font="default" size="100%">Jepsen, J. R. M.</style></author><author><style face="normal" font="default" size="100%">Weed, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Linguistics, Cognitive Science and Semiotics, School of Communication and Culture, Aarhus University, Aarhus, Denmark.&#xD;Interacting Minds Center, School of Culture and Society, Aarhus University, Aarhus, Denmark.&#xD;Linguistic Data Consortium, University of Pennsylvania, Philadelphia, Pennsylvania, USA.&#xD;Department of Communication Sciences and Disorders, Emerson College, Boston, Massachusetts, USA.&#xD;Child and Youth Psychiatry, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychology, University of Southern Denmark, Odense, Denmark.&#xD;Child and Adolescent Mental Health Centre, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark.&#xD;Center for Neuropsychiatric Schizophrenia Research and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Toward a cumulative science of vocal markers of autism: A cross-linguistic meta-analysis-based investigation of acoustic markers in American and Danish autistic children</style></title><secondary-title><style face="normal" font="default" size="100%">Autism Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Autism Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">653-664</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20211226</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acoustics</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">*Autistic Disorder</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Language</style></keyword><keyword><style face="normal" font="default" size="100%">Linguistics</style></keyword><keyword><style face="normal" font="default" size="100%">autism spectrum disorder</style></keyword><keyword><style face="normal" font="default" size="100%">cross-linguistic</style></keyword><keyword><style face="normal" font="default" size="100%">speech</style></keyword><keyword><style face="normal" font="default" size="100%">voice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1939-3806 (Electronic)&#xD;1939-3806 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34957701</style></accession-num><abstract><style face="normal" font="default" size="100%">Acoustic atypicalities in speech production are argued to be potential markers of clinical features in autism spectrum disorder (ASD). A recent meta-analysis highlighted shortcomings in the field, in particular small sample sizes and study heterogeneity. We showcase a cumulative (i.e., explicitly building on previous studies both conceptually and statistically) yet self-correcting (i.e., critically assessing the impact of cumulative statistical techniques) approach to prosody in ASD to overcome these issues. We relied on the recommendations contained in the meta-analysis to build and analyze a cross-linguistic corpus of multiple speech productions in 77 autistic and 72 neurotypical children and adolescents (&gt;1000 recordings in Danish and US English). We used meta-analytically informed and skeptical priors, with informed priors leading to more generalizable inference. We replicated findings of a minimal cross-linguistically reliable distinctive acoustic profile for ASD (higher pitch and longer pauses) with moderate effect sizes. We identified novel reliable differences between the two groups for normalized amplitude quotient, maxima dispersion quotient, and creakiness. However, the differences were small, and there is likely no one acoustic profile characterizing all autistic individuals. We identified reliable relations of acoustic features with individual differences (age, gender), and clinical features (speech rate and ADOS sub-scores). Besides cumulatively building our understanding of acoustic atypicalities in ASD, the study shows how to use systematic reviews and meta-analyses to guide the design and analysis of follow-up studies. We indicate future directions: larger and more diverse cross-linguistic datasets, focus on heterogeneity, self-critical cumulative approaches, and open science. LAY SUMMARY: Autistic individuals are reported to speak in distinctive ways. Distinctive vocal production can affect social interactions and social development and could represent a noninvasive way to support the assessment of autism spectrum disorder (ASD). We systematically checked whether acoustic atypicalities highlighted in previous articles could be actually found across multiple recordings and two languages. We find a minimal acoustic profile of ASD: higher pitch, longer pauses, increased hoarseness and creakiness of the voice. However, there is much individual variability (by age, sex, language, and clinical characteristics). This suggests that the search for one common &quot;autistic voice&quot; might be naive and more fine-grained approaches are needed.</style></abstract><notes><style face="normal" font="default" size="100%">Fusaroli, Riccardo&#xD;Grossman, Ruth&#xD;Bilenberg, Niels&#xD;Cantio, Cathriona&#xD;Jepsen, Jens Richardt Mollegaard&#xD;Weed, Ethan&#xD;eng&#xD;Meta-Analysis&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2021/12/28&#xD;Autism Res. 2022 Apr;15(4):653-664. doi: 10.1002/aur.2661. Epub 2021 Dec 26.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34957701</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/aur.2661</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>206</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">206</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Asmussen, J.</style></author><author><style face="normal" font="default" size="100%">Skovgaard, A. M.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit of Child and Adolescent Mental Health, Department of Clinical Research, University of Southern Denmark, J.B Winslows Vej 16, indgang 228, 5000, Odense C, Denmark. jette.asmussen@rsyd.dk.&#xD;Faculty of Health Sciences, National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.&#xD;Research Unit of Child and Adolescent Psychiatry Odense, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trajectories of dysregulation in preschool age</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">313-324</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20210101</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">*Child Behavior Disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">*Depression, Postpartum</style></keyword><keyword><style face="normal" font="default" size="100%">Emotions</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Mothers</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Psychopathology</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Cbcl1(1/2)-5</style></keyword><keyword><style face="normal" font="default" size="100%">Dysregulation</style></keyword><keyword><style face="normal" font="default" size="100%">PPD (maternal postpartum depression)</style></keyword><keyword><style face="normal" font="default" size="100%">Preschool</style></keyword><keyword><style face="normal" font="default" size="100%">Trajectory</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1435-165X (Electronic)&#xD;1018-8827 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">33386524</style></accession-num><abstract><style face="normal" font="default" size="100%">Dysregulation of emotions, behaviour and attention is involved in several areas of childhood psychopathology, but knowledge about early developmental trajectories remains scarce. This study aims to explore continuity and associations of dysregulation in preschool age. Dysregulation was measured at age 2(1/2) years and again at 5 years in a community-based birth cohort of 1099 children using the Child Behavior Checklist, preschool version (CBCL1(1/2)-5), answered by mothers. Based on the Dysregulation Profile (CBCL-DP) score, we defined four trajectory groups, using the 75th percentile from the Danish norm material as a cut-off. Associations between the four CBCL-DP trajectory groups and potential covariates, including child, parental and family factors, were analysed using univariate and multiple multinomial logistic regression. Nearly half (54%) of the children showed persistent low scores of CBCL-DP, 17% displayed continuing dysregulation problems, 13% had problems that increased from 2(1/2) years to 5 years, whereas 16% of the children showed reduced problems across preschool age. Persistent dysregulation was associated with maternal postpartum depressive symptoms RRR = 2.20 (95% CI 1.29-3.75), low maternal educational level RRR = 1.69 (95% CI 1.08-2.66), and mothers&apos; smoking during pregnancy RRR = 2.87 (95% CI 1.09-7.55). Persistent problems of emotional, behavioural and attention regulation in children aged 2(1/2) years to 5 years is influenced by maternal educational level and post-partum depression symptoms. The study draws clinical attention to early symptoms of dysregulation and to the importance of addressing the specific needs of mentally vulnerable parents in intervention planning.</style></abstract><notes><style face="normal" font="default" size="100%">Asmussen, Jette&#xD;Skovgaard, Anne Mette&#xD;Bilenberg, Niels&#xD;eng&#xD;Germany&#xD;2021/01/03&#xD;Eur Child Adolesc Psychiatry. 2022 Feb;31(2):313-324. doi: 10.1007/s00787-020-01689-z. Epub 2021 Jan 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33386524</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00787-020-01689-z</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>256</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author><author><style face="normal" font="default" size="100%">Askgaard, G.</style></author><author><style face="normal" font="default" size="100%">Thiele, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research Unit of Alcohol Research, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, Zealand University Hospital, Koge, Denmark; Center for Clinical Research and Prevention, Frederiksberg University Hospital, Copenhagen, Denmark.&#xD;Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: Maja.thiele@rsyd.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of alcohol use disorder in patients with liver disease</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Opin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Curr Opin Pharmacol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">145-151</style></pages><volume><style face="normal" font="default" size="100%">62</style></volume><edition><style face="normal" font="default" size="100%">20220106</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Acamprosate/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcohol Deterrents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Alcoholism/complications/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Liver Diseases/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Naltrexone/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Narcotic Antagonists/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1471-4973 (Electronic)&#xD;1471-4892 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34999372</style></accession-num><abstract><style face="normal" font="default" size="100%">Alcohol contributes to more than 5% of global mortality, and causes more than half of all liver-related deaths. The Alcohol Use Disorders Identification Test (AUDIT) can be used to detect those patients with hazardous drinking and alcohol dependence who will benefit from psychosocial and pharmacological alcohol treatment. Psychosocial treatments range from brief interventions and cognitive behavioral therapy, to experimental neuropsychological treatments. Psychosocial intervention can be combined with acamprosate or naltrexone as first line pharmacological treatments. For patients with liver disease, abstinence increases survival and is therefore an important treatment goal. Acamprosate is a good choice, as it prevents relapse to drinking with a number needed to treat of 12. There are no reports indicating high risks of liver toxicity for acamprosate or naltrexone, but evidence is scarce. We recommend vigorous screening for alcohol use disorder in liver disease patients, followed by psychosocial intervention and complemented by pharmaceutical therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Nielsen, Anette Sogaard&#xD;Askgaard, Gro&#xD;Thiele, Maja&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Review&#xD;England&#xD;2022/01/10&#xD;Curr Opin Pharmacol. 2022 Feb;62:145-151. doi: 10.1016/j.coph.2021.11.012. Epub 2022 Jan 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34999372</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Conflict of interest statement Nothing declared.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.coph.2021.11.012</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>283</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">283</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moeller, S. B.</style></author><author><style face="normal" font="default" size="100%">Gbyl, K.</style></author><author><style face="normal" font="default" size="100%">Hjorthoj, C.</style></author><author><style face="normal" font="default" size="100%">Andreasen, M.</style></author><author><style face="normal" font="default" size="100%">Austin, S. F.</style></author><author><style face="normal" font="default" size="100%">Buchholtz, P. E.</style></author><author><style face="normal" font="default" size="100%">Fonss, L.</style></author><author><style face="normal" font="default" size="100%">Hjerrild, S.</style></author><author><style face="normal" font="default" size="100%">Hogervorst, L.</style></author><author><style face="normal" font="default" size="100%">Jorgensen, M. B.</style></author><author><style face="normal" font="default" size="100%">Ladegaard, N.</style></author><author><style face="normal" font="default" size="100%">Martiny, K.</style></author><author><style face="normal" font="default" size="100%">Meile, J.</style></author><author><style face="normal" font="default" size="100%">Packness, A.</style></author><author><style face="normal" font="default" size="100%">Sigaard, K. R.</style></author><author><style face="normal" font="default" size="100%">Straarup, K.</style></author><author><style face="normal" font="default" size="100%">Straszek, S. P. V.</style></author><author><style face="normal" font="default" size="100%">Soerensen, C. H.</style></author><author><style face="normal" font="default" size="100%">Welcher, B.</style></author><author><style face="normal" font="default" size="100%">Videbech, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Psychotherapy Research Unit, Mental Health Centre Stolpegaard, Capital Region Psychiatry, Gentofte, Denmark.&#xD;Department of Psychology, University of Southern Denmark, Odense, Denmark.&#xD;Center for Neuropsychiatric Depression Research (CNDR), Psychiatric Center Glostrup, Capital Region Psychiatry, Glostrup, Denmark.&#xD;Copenhagen Research Center for Mental Health - Core, Mental Health Center Copenhagen, Section of Epidemiology, Department of Public Health, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.&#xD;Department of Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark.&#xD;Psychiatric Research Unit, Psychiatry Region Zealand, Department of Psychology, University of Southern Denmark, Slagelse, Denmark.&#xD;Department for Affective Disorders, Aarhus University Hospital, Aarhus N, Denmark.&#xD;NA, Copenhagen, Denmark.&#xD;Mental Health Center Copenhagen, Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Psychiatric Centre Copenhagen and Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.&#xD;Sydhavnens Medical Clinic, Kobenhavn, Denmark.&#xD;Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark.&#xD;Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;The Royal Danish Library, Aarhus University Library, Health Sciences, Aarhus, Denmark.&#xD;Mood Disorder Clinic, Aarhus University Hospital, Skejby, Denmark.&#xD;Research and Treatment Program for Bipolar Disorder, Psychiatry, Aalborg University Hospital, Aalborg, Denmark.&#xD;Department of Psychiatry, University Clinic, Odense, Denmark.&#xD;Mental health Center Psychiatry Vest, Region Zealand Psychiatry, Slagelse, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of difficult-to-treat depression - clinical guideline for selected interventions</style></title><secondary-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nord J Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">177-188</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">3</style></number><edition><style face="normal" font="default" size="100%">20210828</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Antidepressive Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Cognitive Behavioral Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Depression/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Psychotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical guideline</style></keyword><keyword><style face="normal" font="default" size="100%">affective disorders</style></keyword><keyword><style face="normal" font="default" size="100%">persistent depressive disorder</style></keyword><keyword><style face="normal" font="default" size="100%">refractory depression</style></keyword><keyword><style face="normal" font="default" size="100%">treatment-resistant depression</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1502-4725 (Electronic)&#xD;0803-9488 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34455900</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Difficult-to-treat-depression (DTD) is a clinical challenge. The interventions that are well-established for DTD are not suitable or effective for all the patients. Therefore, more treatment options are highly warranted. We formulated an evidence-based guideline concerning six interventions not well-established for DTD in Denmark. METHODS: Selected review questions were formulated according to the PICO principle with specific definitions of the patient population (P), the intervention (I), the comparison (C), and the outcomes of interest (O), and systematic literature searches were performed stepwise for each review question to identify relevant systematic reviews/meta-analyses, and randomized controlled trials. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used to assess the methodological quality of the included studies. Clinical recommendations were formulated based on the evidence, the risk-benefit ratio, and perceived patient preferences. RESULTS: We found sufficient evidence for a weak recommendation of repetitive transcranial magnetic stimulation (rTMS) and cognitive behavioural analysis system of psychotherapy (CBASP). The use of bright light therapy in DTD was not sufficiently supported by the evidence, but should be considered as good clinical practice. The interventions should be considered in addition to ongoing antidepressant treatment. We did not find sufficient evidence to recommend intravenous ketamine/esketamine, rumination-focused psychotherapy, or cognitive remediation to patients with DTD. CONCLUSION: The evidence supported two of the six reviewed interventions, however it was generally weak which emphasizes the need for more good quality studies. This guideline does not cover all treatment options and should be regarded as a supplement to relevant DTD-guidelines.</style></abstract><notes><style face="normal" font="default" size="100%">Moeller, Stine Bjerrum&#xD;Gbyl, Krzysztof&#xD;Hjorthoj, Carsten&#xD;Andreasen, Maike&#xD;Austin, Stephen F&#xD;Buchholtz, Poul Erik&#xD;Fonss, Line&#xD;Hjerrild, Simon&#xD;Hogervorst, Lise&#xD;Jorgensen, Martin Balslev&#xD;Ladegaard, Nicolai&#xD;Martiny, Klaus&#xD;Meile, Jonas&#xD;Packness, Aake&#xD;Sigaard, Karen Rodriguez&#xD;Straarup, Krista&#xD;Straszek, Sune P V&#xD;Soerensen, Claus Havregaard&#xD;Welcher, Birgitte&#xD;Videbech, Poul&#xD;eng&#xD;Practice Guideline&#xD;England&#xD;2021/08/31&#xD;Nord J Psychiatry. 2022 Apr;76(3):177-188. doi: 10.1080/08039488.2021.1952303. Epub 2021 Aug 28.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34455900</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08039488.2021.1952303</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>261</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sorensen, A. M. S.</style></author><author><style face="normal" font="default" size="100%">Wesselhoeft, R.</style></author><author><style face="normal" font="default" size="100%">Andersen, J. H.</style></author><author><style face="normal" font="default" size="100%">Reutfors, J.</style></author><author><style face="normal" font="default" size="100%">Cesta, C. E.</style></author><author><style face="normal" font="default" size="100%">Furu, K.</style></author><author><style face="normal" font="default" size="100%">Hartz, I.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, 2400, Copenhagen, NV, Denmark.&#xD;Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, JB Winslowsvej 19, 5000, Odense C, Denmark.&#xD;Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, 5000, Odense C, Denmark.&#xD;Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.&#xD;Department of Chronic Diseases and Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.&#xD;Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.&#xD;Innlandet Hospital Trust, Brumunddal, Norway.&#xD;Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, JB Winslowsvej 19, 5000, Odense C, Denmark. lorasmussen@health.sdu.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Eur Child Adolesc Psychiatry</style></full-title></periodical><edition><style face="normal" font="default" size="100%">20220713</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adhd</style></keyword><keyword><style face="normal" font="default" size="100%">Adolescents</style></keyword><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Drug utilization</style></keyword><keyword><style face="normal" font="default" size="100%">Scandinavia</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul 13</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1435-165X (Electronic)&#xD;1018-8827 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35831669</style></accession-num><abstract><style face="normal" font="default" size="100%">The objective of the study was to compare the use of attention deficit hyperactivity disorder (ADHD) medication among children and adolescents in Scandinavia 2010-2020. Using aggregated prescription data for individuals aged 5-19 years, we calculated annual prevalence proportions of ADHD medication (users/1000 inhabitants) for each country, overall and stratified by age and sex. Overall, use of ADHD medication increased during 2010-2020 in all countries. The increase was pronounced in Sweden reaching 35 users/1000 inhabitants in 2020 (119% increase), whereas it reached 22/1000 in Denmark and Norway (equivalent to a 38% and 16% increase, respectively). Methylphenidate was the most frequently used drug and Sweden had the highest use reaching 25/1000 in 2020 compared to 16/1000 and 18/1000 in Denmark and Norway, respectively. Lisdexamfetamine use increased steadily and was also highest in Sweden (13/1000 in 2020). In 2020, atomoxetine use was higher in Sweden (4.6/1000) and Denmark (4.5/1000) compared to Norway (2.2/1000). From 2015, use of guanfacine increased in Sweden reaching 4.4/1000 in 2020 but remained low in Denmark (0.4/1000) and Norway (0.7/1000). Use of dexamphetamine was low (ranging from 0.47 to 0.75/1000 in 2020) in the three countries. ADHD medication use was highest in Sweden across all age groups. In all countries, the prevalence was higher in males compared to females. In conclusion, use of ADHD medication among children and adolescents in Scandinavia is increasing. The prevalence of use is higher in Sweden for all drug groups compared to Norway and Denmark.</style></abstract><notes><style face="normal" font="default" size="100%">Sorensen, Anne Mette Skov&#xD;Wesselhoeft, Rikke&#xD;Andersen, Jacob Harbo&#xD;Reutfors, Johan&#xD;Cesta, Carolyn E&#xD;Furu, Kari&#xD;Hartz, Ingeborg&#xD;Rasmussen, Lotte&#xD;eng&#xD;Germany&#xD;2022/07/14&#xD;Eur Child Adolesc Psychiatry. 2022 Jul 13. doi: 10.1007/s00787-022-02034-2.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35831669</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00787-022-02034-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>207</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">207</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frandsen, C. L. B.</style></author><author><style face="normal" font="default" size="100%">Jensen, A.</style></author><author><style face="normal" font="default" size="100%">Poulsen, F. R.</style></author><author><style face="normal" font="default" size="100%">Moller, M.</style></author><author><style face="normal" font="default" size="100%">Lindquist, S.</style></author><author><style face="normal" font="default" size="100%">Albieri, V.</style></author><author><style face="normal" font="default" size="100%">Nohr, B.</style></author><author><style face="normal" font="default" size="100%">Kjaer, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Lifestyle, Reproduction and Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark.&#xD;Department of Obstetrics and Gynecology, Copenhagen University Hospital Herlev, Copenhagen, Denmark.&#xD;Department of Neurosurgery, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research and Bridge (Brain Research Inter Disciplinary Guided Excellence), University of Southern Denmark, Odense, Denmark.&#xD;Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.&#xD;Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark.&#xD;Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. susanne@cancer.dk.&#xD;Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. susanne@cancer.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tumors of the central nervous system among women treated with fertility drugs: a population-based cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Causes Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cancer Causes Control</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1285-1293</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">20220727</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Central Nervous System Neoplasms/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Fertility Agents/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Infertility, Female/drug therapy/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">*Meningeal Neoplasms</style></keyword><keyword><style face="normal" font="default" size="100%">*Meningioma</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Central nervous system neoplasms</style></keyword><keyword><style face="normal" font="default" size="100%">Fertility agents</style></keyword><keyword><style face="normal" font="default" size="100%">Glioma</style></keyword><keyword><style face="normal" font="default" size="100%">Infertility</style></keyword><keyword><style face="normal" font="default" size="100%">Meningioma</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1573-7225 (Electronic)&#xD;0957-5243 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35895242</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: To investigate the association between fertility drugs and tumors of the central nervous system (CNS). METHODS: This cohort study was based on The Danish Infertility Cohort and included 148,016 infertile women living in Denmark (1995-2017). The study cohort was linked to national registers to obtain information on use of specific fertility drugs, cancer diagnoses, covariates, emigration, and vital status. Cox proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for all CNS tumors and separately for gliomas, meningiomas and diverse benign tumors of the brain and other parts of the CNS. RESULTS: During a median 11.3 years of follow-up, 328 women were diagnosed with CNS tumors. No marked associations were observed between use of the fertility drugs clomiphene citrate, gonadotropins, gonadotropin-releasing hormone receptor modulators and progesterone and CNS tumors. However, use of human chorionic gonadotropin was associated with a decreased rate of meningiomas (HR 0.49 95% CI 0.28-0.87). No clear associations with CNS tumors were observed according to time since first use or cumulative dose for any of the fertility drugs. CONCLUSION: No associations between use of most types of fertility drugs and CNS tumors were observed. However, our findings only apply to premenopausal women and additional studies with longer follow-up time are necessary.</style></abstract><notes><style face="normal" font="default" size="100%">Frandsen, Clarissa L B&#xD;Jensen, Allan&#xD;Poulsen, Frantz R&#xD;Moller, Maria&#xD;Lindquist, Sofie&#xD;Albieri, Vanna&#xD;Nohr, Bugge&#xD;Kjaer, Susanne K&#xD;eng&#xD;internal grant/Kraeftens Bekaempelse/&#xD;Netherlands&#xD;2022/07/28&#xD;Cancer Causes Control. 2022 Oct;33(10):1285-1293. doi: 10.1007/s10552-022-01610-w. Epub 2022 Jul 27.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35895242</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10552-022-01610-w</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>208</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">208</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sorensen, M. D.</style></author><author><style face="normal" font="default" size="100%">Kristensen, B. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.&#xD;Department of Clinical Medicine and Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tumour-associated CD204(+) microglia/macrophages accumulate in perivascular and perinecrotic niches and correlate with an interleukin-6-enriched inflammatory profile in glioblastoma</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropathol Appl Neurobiol</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">e12772</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">2</style></number><edition><style face="normal" font="default" size="100%">20220105</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers, Tumor/metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Brain Neoplasms/*metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Glioblastoma/*metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Immunohistochemistry</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation/*metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Interleukin-6/*metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Macrophages/*metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Microglia/*metabolism/pathology</style></keyword><keyword><style face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style face="normal" font="default" size="100%">Tumor Microenvironment</style></keyword><keyword><style face="normal" font="default" size="100%">Cd204</style></keyword><keyword><style face="normal" font="default" size="100%">glioblastoma</style></keyword><keyword><style face="normal" font="default" size="100%">immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">interleukin-6</style></keyword><keyword><style face="normal" font="default" size="100%">macrophage</style></keyword><keyword><style face="normal" font="default" size="100%">microglia</style></keyword><keyword><style face="normal" font="default" size="100%">nanostring</style></keyword><keyword><style face="normal" font="default" size="100%">tumour microenvironment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Feb</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1365-2990 (Electronic)&#xD;0305-1846 (Print)&#xD;0305-1846 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34713474</style></accession-num><abstract><style face="normal" font="default" size="100%">AIMS: Glioblastomas are heterogeneous tumours with a rich tumour microenvironment particularly comprised of tumour-associated microglia/macrophages (TAMs), but also containing a population of dedifferentiated/stem-like glioblastoma cells. Both cell populations contribute to tumour aggressiveness and immune evasion through the actions of various signalling molecules. The scavenger and pattern recognition receptor CD204 is associated with a pro-tumourigenic phenotype of TAMs and has a negative prognostic value. Our objective was to investigate the possible interaction between TAMs and dedifferentiated glioblastoma cells and characterise the myeloid phenotype of CD204-enriched glioblastomas. METHODS: Double immunohistochemistry and cell counting was performed on eight glioblastoma samples to estimate the expression and interaction level between dedifferentiated/stem-like tumour cells and TAMs. Using the NanoString technology, myeloid transcriptome profiling was performed on 46 glioblastomas, which had been selected based on their protein expression levels of CD204 and ionised calcium-binding adaptor molecule-1 (IBA1). The results were validated by immunohistochemistry and in silico gene expression analyses. RESULTS: TAMs especially CD204(+) TAMs accumulated in perivascular and perinecrotic niches in close proximity to podoplanin(+) glioblastoma cells. Gene profiling revealed that CD204-enriched glioblastoma has a unique signature with upregulation of genes related to hypoxia, angiogenesis and invasion, including interleukin-6. The gene signature favoured a poor prognosis in patients with glioblastoma. CONCLUSIONS: This is the first study to characterise the role of CD204 in the myeloid microenvironment of glioblastoma. Our results support the unfavourable prognostic impact of CD204 and suggest that CD204 and interleukin-6 could serve as targets for re-education of TAMs and potentiation of current anti-glioma therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Sorensen, Mia D&#xD;Kristensen, Bjarne W&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2021/10/30&#xD;Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12772. doi: 10.1111/nan.12772. Epub 2022 Jan 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34713474</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Both authors declare that they have no conflicts of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9306597</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/nan.12772</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>288</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">288</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Correll, C. U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services Region of Southern Denmark, Aabenraa, Denmark.&#xD;Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.&#xD;Department of Psychiatry, Glen Oaks, Zucker Hillside Hospital, New York, NY, USA.&#xD;Child and Adolescent Psychiatry, Charite Universitatsmedizin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Opin Investig Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Opin Investig Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1279-1290</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">12</style></number><edition><style face="normal" font="default" size="100%">20221222</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Pyrans/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Serotonin 5-HT1 Receptor Agonists/pharmacology/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Antipsychotic agents</style></keyword><keyword><style face="normal" font="default" size="100%">Sep-363856</style></keyword><keyword><style face="normal" font="default" size="100%">Taar1</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">review</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">trace amine-associated receptor 1 agonist</style></keyword><keyword><style face="normal" font="default" size="100%">ulotaront</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Dec</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1744-7658 (Electronic)&#xD;1354-3784 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36533396</style></accession-num><abstract><style face="normal" font="default" size="100%">INTRODUCTION: Current antipsychotics are postsynaptic dopamine-2(D(2)) receptor blockers, which often, but not always, effectively improve acute psychotic symptoms and prevent relapse in schizophrenia and other severe mental disorders, but are associated with various side effects, including parkinsonism, akathisia, sedation/somnolence, and cardiometabolic alterations. Furthermore, the efficacy of current antipsychotics for negative and cognitive symptoms in schizophrenia is limited. Ulotaront is a novel trace-amine-associated receptor-1(TAAR1) agonist with serotonin-1A receptor agonist activity, and without postsynaptic D2-receptor antagonism. Phase 2 clinical data for ulotaront in patients with acutely exacerbated schizophrenia are promising regarding the potential improvement in positive, negative, and depressive symptoms. AREAS COVERED: An overview of the pharmacokinetic and pharmacodynamic properties of ulotaront is given. Summary of clinical efficacy and safety/tolerability from Phase 1/2-trials, and of ongoing Phase 3-trials, is also given. EXPERT OPINION: Ulotaront is a promising agent for the treatment of schizophrenia with an apparent benign safety profile, which might provide a much-needed new and different treatment option for various domains of schizophrenia. Data from larger Phase 3-trials, including for relapse prevention, schizophrenia subdomains, and in adolescents, are awaited. If ongoing Phase 3-trials in adults are successful, further research on combination regimens with existing antipsychotics, and in treatment-resistant schizophrenia as well as in mood disorders would be desirable.</style></abstract><notes><style face="normal" font="default" size="100%">Hojlund, Mikkel&#xD;Correll, Christoph U&#xD;eng&#xD;England&#xD;2022/12/20&#xD;Expert Opin Investig Drugs. 2022 Dec;31(12):1279-1290. doi: 10.1080/13543784.2022.2158811. Epub 2022 Dec 22.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36533396</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/13543784.2022.2158811</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>209</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">209</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lindhardt, L.</style></author><author><style face="normal" font="default" size="100%">Nilsson, L. S.</style></author><author><style face="normal" font="default" size="100%">Munk-Jorgensen, P.</style></author><author><style face="normal" font="default" size="100%">Mortensen, O. S.</style></author><author><style face="normal" font="default" size="100%">Simonsen, E.</style></author><author><style face="normal" font="default" size="100%">Nordgaard, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Early Psychosis Intervention Center, Mental Health Services East, Psychiatry Region Zealand, Roskilde, Denmark.&#xD;Mental Health Center Amager, Mental Health Services Capital Region of Denmark, Copenhagen, Denmark.&#xD;Psychiatric Research Academy, Region of Southern Denmark, Odense, Denmark.&#xD;Department of Occupational and Social Medicine, Holbaek Hospital, Holbaek, Denmark.&#xD;Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Mental Health Services East, Copenhagen University Hospital, Psychiatry Region Zealand, Roskilde, Denmark.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Unrecognized schizophrenia spectrum and other mental disorders in youth disconnected from education and work-life</style></title><secondary-title><style face="normal" font="default" size="100%">Front Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Front Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1015616</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><edition><style face="normal" font="default" size="100%">20221026</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Neet</style></keyword><keyword><style face="normal" font="default" size="100%">psychopathology</style></keyword><keyword><style face="normal" font="default" size="100%">psychosis</style></keyword><keyword><style face="normal" font="default" size="100%">schizophrenia spectrum disorder</style></keyword><keyword><style face="normal" font="default" size="100%">social disconnection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">2022/10/26</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Frontiers Media SA</style></publisher><isbn><style face="normal" font="default" size="100%">1664-0640 (Print)&#xD;1664-0640 (Electronic)&#xD;1664-0640 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36386963</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Schizophrenia spectrum disorders typically emerge during adolescence or early adulthood. Often the symptomatology is vague initially, while a marked functional decline and social withdrawal can be seen. A group of young people with such social and functional impairments is the so-called &quot;Not in Education, Employment or Training&quot; (NEET), i.e., a youth population that is socially disconnected from education and work-life. Despite the NEET group&apos;s disconnection from important parts of social life and a rising concern of an intersection with mental health problems, a psychopathological perspective on the problems experienced by this group remains underexplored. AIM: To examine a NEET sample for psychopathology and if relevant allocate psychiatric diagnoses. METHODS: We performed an interview study comprising 40 participants from youth job-counseling services. All underwent a comprehensive psychiatric evaluation. Inclusion criteria were 18-29 years of age and a welfare benefit history of minimum 6 months. RESULTS: Diagnostic criteria of any mental disorder were fulfilled by 95% of the sample; half of whom were diagnosed with a schizophrenia spectrum disorder. The participants with schizophrenia spectrum disorders had lower global functioning, were more often in contact with the mental health services and had higher PANSS and Examination of Anomalous Self-Experiences (EASE) scores compared to those with non-schizophrenia spectrum disorders. The participants fulfilling the criteria for schizophrenia spectrum disorders had lower EASE and PANSS scores than usually reported in the literature, suggesting more &quot;symptom-poor&quot; presentations. CONCLUSION: Psychiatric illness and particularly schizophrenia spectrum disorders affecting social interaction and the ability to take part in educational and work-life were grossly overrepresented in the NEET sample. Our findings suggest that pronounced social disconnection in youth in and of itself should lead to suspect the presence of a severe mental disorder.</style></abstract><notes><style face="normal" font="default" size="100%">Lindhardt, Line&#xD;Nilsson, Lars Siersbaek&#xD;Munk-Jorgensen, Povl&#xD;Mortensen, Ole Steen&#xD;Simonsen, Erik&#xD;Nordgaard, Julie&#xD;eng&#xD;Switzerland&#xD;2022/11/18&#xD;Front Psychiatry. 2022 Oct 26;13:1015616. doi: 10.3389/fpsyt.2022.1015616. eCollection 2022.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36386963</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9645021</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fpsyt.2022.1015616</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>210</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">210</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Wagner, C. B.</style></author><author><style face="normal" font="default" size="100%">Wesselhoeft, R.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Fink-Jensen, A.</style></author><author><style face="normal" font="default" size="100%">Hallas, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark.&#xD;Mental Health Center Glostrup, Copenhagen University Hospital, Mental Health Services CPH, Copenhagen, Denmark.&#xD;Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Odense - University Clinic, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Research Unit of Psychiatry, Department of Clinical Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Psychiatric Centre Copenhagen, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark.&#xD;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Basic Clin Pharmacol Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Basic Clin Pharmacol Toxicol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">501-512</style></pages><volume><style face="normal" font="default" size="100%">130</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220215</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Cardiovascular Diseases/chemically induced/complications/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorprothixene/therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Diabetes Mellitus, Type 2/chemically induced/drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">*Myocardial Infarction/chemically induced/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Quetiapine Fumarate/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">antipsychotic agents</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular diseases</style></keyword><keyword><style face="normal" font="default" size="100%">chlorprothixene</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">pharmacoepidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine fumarate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Apr</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1742-7843 (Electronic)&#xD;1742-7835 (Print)&#xD;1742-7835 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35122399</style></accession-num><abstract><style face="normal" font="default" size="100%">Chlorprothixene is commonly used off-label in low doses for sedative-hypnotic purposes although it might carry a risk of cardiometabolic adverse events due to its pharmacodynamic profile. We investigated the risk of diabetes and major adverse cardiovascular events (MACE) with use of low-dose chlorprothixene, compared with use of low-dose quetiapine in a nationwide cohort study, including all new users of low-dose chlorprothixene (n = 81 328) and low-dose quetiapine (n = 91 163) in Denmark 2000-2017. Main outcomes were diabetes and MACE (myocardial infarction, stroke and death from cardiovascular causes). The association between cumulative dose of chlorprothixene and the outcomes was tested in a case-control analysis. Low-dose chlorprothixene use was associated with increased risk of diabetes (intention-to-treat [ITT]-hazard ratio [HR]: 1.16; 95% CI: 1.08-1.25), compared with low-dose quetiapine use. This association strengthened when follow-up was restricted to time on treatment (as-treated [AT]-HR: 1.34; 95% CI: 1.14-1.56). Low-dose chlorprothixene use was also associated with increased risk of MACE (ITT-HR: 1.12; 95% CI: 1.04-1.21) and stroke (ITT-HR: 1.21; 95% CI: 1.06-1.37) but not with myocardial infarction (ITT-HR: 1.11; 95% CI: 0.95-1.30) nor death from cardiovascular causes (ITT-HR: 1.07; 95% CI: 0.96-1.20). Cumulative dose of chlorprothixene &gt;/=6000 mg was associated with increased risk of diabetes (OR: 1.15-1.63; test for trend: p &lt; 0.001), whereas cumulative dose of chlorprothixene &gt;/=1500 mg was associated with increased risk of MACE (OR: 1.10-1.85; test for trend: p &lt; 0.001). In conclusion, low-dose chlorprothixene use is associated with increased risk of cardiometabolic adverse events compared with low-dose quetiapine use.</style></abstract><notes><style face="normal" font="default" size="100%">Hojlund, Mikkel&#xD;Wagner, Christina Blanner&#xD;Wesselhoeft, Rikke&#xD;Andersen, Kjeld&#xD;Fink-Jensen, Anders&#xD;Hallas, Jesper&#xD;eng&#xD;A2957/Mental Health Services in the Region of Southern Denmark/&#xD;England&#xD;2022/02/06&#xD;Basic Clin Pharmacol Toxicol. 2022 Apr;130(4):501-512. doi: 10.1111/bcpt.13711. Epub 2022 Feb 15.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35122399</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">The authors have no conflict of interest to declare.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9303779</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/bcpt.13711</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>211</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">211</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Andersen, K.</style></author><author><style face="normal" font="default" size="100%">Ernst, M. T.</style></author><author><style face="normal" font="default" size="100%">Correll, C. U.</style></author><author><style face="normal" font="default" size="100%">Hallas, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark.&#xD;Department of Clinical Research, Psychiatry, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA.&#xD;Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.&#xD;Department of Child and Adolescent Psychiatry, Charite Universitatsmedizin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">World Psychiatry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World Psychiatry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">444-451</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Low-dose quetiapine</style></keyword><keyword><style face="normal" font="default" size="100%">anxiolytic or hypnotic use</style></keyword><keyword><style face="normal" font="default" size="100%">cardiovascular safety</style></keyword><keyword><style face="normal" font="default" size="100%">death from cardiovascular causes</style></keyword><keyword><style face="normal" font="default" size="100%">major adverse cardiovascular events</style></keyword><keyword><style face="normal" font="default" size="100%">off-label use</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1723-8617 (Print)&#xD;2051-5545 (Electronic)&#xD;1723-8617 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36073694</style></accession-num><abstract><style face="normal" font="default" size="100%">At standard doses used for schizophrenia or bipolar disorder, quetiapine has been associated with weight gain and increased levels of triglycerides, to-tal cholesterol and low-density lipoprotein (LDL) cholesterol, which are risk factors for cardiovascular morbidity and mortality. However, this drug is also commonly used off-label at low doses for anxiolytic or hypnotic purposes, and its cardiovascular safety at these doses is unknown. We aimed to assess the risk of major adverse cardiovascular events with use of low-dose quetiapine compared to use of Z-drug hypnotics in a nationwide, active comparator-controlled cohort study. The cohort included new users of either drugs in Denmark from 2003 to 2017, aged 18-85 years, without history of ischemic stroke, myocardial infarction, cancer, and severe mental illness. The main outcome was the occurrence of major adverse cardiovascular events, defined as non-fatal myocardial infarction or ischemic stroke, or death from cardiovascular causes. Selective serotonin reuptake inhibitors (SSRIs) were used as an alternative comparator in sensitivity analyses. Altogether, we compared 60,566 low-dose quetiapine users with 454,567 Z-drug users, followed for 890,198 person-years in intent-to-treat analysis, and 330,334 person-years in as-treated analysis. In intention-to-treat analysis, low-dose quetiapine was associated with an increased risk of major adverse cardiovascular events (adjusted hazard ratio, aHR=1.13, 95% CI: 1.02-1.24, p=0.014) and cardiovascular death (aHR=1.26, 95% CI: 1.11-1.43, p&lt;0.001). In as-treated analysis, continuous low-dose quetiapine use was associated with increased risk of major adverse cardiovascular events (aHR=1.52, 95% CI: 1.35-1.70, p&lt;0.001), non-fatal ischemic stroke (aHR=1.37, 95% CI: 1.13-1.68, p=0.002) and cardiovascular death (aHR=1.90, 95% CI: 1.64-2.19, p&lt;0.001). The risk of major adverse cardiovascular events was greater in women (aHR=1.28, p=0.02) and those aged &gt;/=65 years at initiation (aHR=1.24, p&lt;0.001). Compared to SSRIs, low-dose quetiapine use was associated with an increased risk of major adverse cardiovascular events (aHR=1.42, p&lt;0.001), non-fatal ischemic stroke (aHR=1.27, p=0.0028) and cardiovascular death (aHR=1.72, p&lt;0.001). So, we conclude that the use of low-dose quetiapine is associated with an increased risk of major adverse cardiovascular events, especially in women and the elderly. On the basis of these findings, we suggest that use of off-label low-dose quetiapine for sedative or hypnotic purposes should be discouraged.</style></abstract><notes><style face="normal" font="default" size="100%">Hojlund, Mikkel&#xD;Andersen, Kjeld&#xD;Ernst, Martin T&#xD;Correll, Christoph U&#xD;Hallas, Jesper&#xD;eng&#xD;Italy&#xD;2022/09/09&#xD;World Psychiatry. 2022 Oct;21(3):444-451. doi: 10.1002/wps.21010.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36073694</style></url></related-urls></urls><custom2><style face="normal" font="default" size="100%">PMC9453914</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/wps.21010</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>212</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">212</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Linkhorst, T.</style></author><author><style face="normal" font="default" size="100%">Birkeland, S. F.</style></author><author><style face="normal" font="default" size="100%">Gildberg, F. A.</style></author><author><style face="normal" font="default" size="100%">Mainz, J.</style></author><author><style face="normal" font="default" size="100%">Torp-Pedersen, C.</style></author><author><style face="normal" font="default" size="100%">Boggild, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Odense University Hospital, Region of Southern Denmark, 5000 Odense, Denmark; Forensic Mental Health Research Unit Middelfart, Department of Regional Health Research, University of Southern Denmark, 5500 Middelfart, Denmark.&#xD;Odense University Hospital, Region of Southern Denmark, 5000 Odense, Denmark. Electronic address: sbirkeland@health.sdu.dk.&#xD;Forensic Mental Health Research Unit Middelfart, Department of Regional Health Research, University of Southern Denmark, 5500 Middelfart, Denmark; Department of Psychiatry, Middelfart, Mental Health Services, Region of Southern Denmark, 5500 Middelfart, Denmark. Electronic address: frederik.alkier.gildberg@rsyd.dk.&#xD;Department of Psychiatry, North Denmark Region, 9000 Aalborg, Denmark; Danish Center for Clinical Health Services Research (DACS), Aalborg University Hospital, Aalborg University, 9000 Aalborg, Denmark; Department of Community Mental Health, University of Haifa, Mount Carmel, Haifa, Israel; DaCHE, University of Southern Denmark, 5000 Odense, Denmark. Electronic address: jan.mainz@rn.dk.&#xD;Department of Cardiology, Aalborg University Hospital, 9000 Aalborg, Denmark; Department of Cardiology, Nordsjaellands Hospital, 3400 Hillerod, Denmark; Department of Public Health, University of Copenhagen, 2100 Copenhagen, Denmark. Electronic address: ctp@heart.dk.&#xD;Public Health and Epidemiology, Department of Health Science and Technology, Aalborg University, 9220 Aalborg, E, Denmark; Unit of Clinical Biostatistics, Aalborg University Hospital, 9000 Aalborg, Denmark. Electronic address: boggild@hst.aau.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of the least intrusive coercion at Danish psychiatric wards: A register-based cohort study of 131,632 first and subsequent coercive episodes within 35,812 admissions</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Law Psychiatry</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">101838</style></pages><volume><style face="normal" font="default" size="100%">85</style></volume><number><style face="normal" font="default" size="100%">101838</style></number><edition><style face="normal" font="default" size="100%">20221005</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Psychiatric Department, Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Coercion</style></keyword><keyword><style face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style face="normal" font="default" size="100%">*Mental Disorders/therapy/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Restraint, Physical/psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">Hospitals, Psychiatric</style></keyword><keyword><style face="normal" font="default" size="100%">Mental disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Psychiatry</style></keyword><keyword><style face="normal" font="default" size="100%">Restraint, physical</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov-Dec</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Elsevier BV</style></publisher><isbn><style face="normal" font="default" size="100%">1873-6386 (Electronic)&#xD;0160-2527 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36208564</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVE: Psychiatric legislation in Denmark implies a principle of using the least intrusive types of coercion first. The intrusiveness is not universally agreed upon. We examined the order in which coercive measures during admission were used, implying that the first used should be less intrusive than the following types. METHODS: For coercive episodes reported to the national administrative register for the period 2011-16, the order of 12 legal coercive interventions during each admission was examined. Comparing with mechanical restraint, the odds ratio (OR) and confidence interval (95%CI) of being first or subsequent used types were estimated using conditioned (96,611 episodes) and unconditioned (131,632 episodes) logistic regression models, stratified on sex. RESULTS: Totally 17,796 patients aged 18+ were subjected to at least one coercive episode. The median time between admission and the first episode was 4 days in men and 6 for women. For females, involuntary detention, forced feeding, coercive treatment of somatic disorder, locking of doors and close observations in females were used before mechanical restraint, and forced follow-up, involuntary electro convulsive therapy (ECT), forced treatment, use of gloves and straps, physical restraint and forced intramuscular medication was used later. In men, only involuntary detention was used before mechanical restraint, while involuntary ECT, close observations, administration of drugs, use of gloves and straps, physical restraint and forced intramuscular medication was used after mechanical restraint. CONCLUSION: The order of used coercive measures is not consistent with the international ranking of the least intrusive types, especially in men and in younger adults.</style></abstract><notes><style face="normal" font="default" size="100%">Linkhorst, Thea&#xD;Birkeland, Soren Fryd&#xD;Gildberg, Frederik Alkier&#xD;Mainz, Jan&#xD;Torp-Pedersen, Christian&#xD;Boggild, Henrik&#xD;eng&#xD;Netherlands&#xD;2022/10/09&#xD;Int J Law Psychiatry. 2022 Nov-Dec;85:101838. doi: 10.1016/j.ijlp.2022.101838. Epub 2022 Oct 5.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36208564</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of interests None.</style></custom1><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijlp.2022.101838</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>213</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">213</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Winkler, L. A.</style></author><author><style face="normal" font="default" size="100%">Arnfred, S. M. H.</style></author><author><style face="normal" font="default" size="100%">Larsen, P. V.</style></author><author><style face="normal" font="default" size="100%">Roder, M. E.</style></author><author><style face="normal" font="default" size="100%">Gudex, C.</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, M. B.</style></author><author><style face="normal" font="default" size="100%">Adair, C. E.</style></author><author><style face="normal" font="default" size="100%">Clausen, L.</style></author><author><style face="normal" font="default" size="100%">Sjogren, J. M.</style></author><author><style face="normal" font="default" size="100%">Stoving, R. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nutrition Clinic, Endocrine Research Center, Center for Eating Disorders, Odense University Hospital, Psychiatric Services in the Region of Southern Denmark, Odense, Denmark. laurawinkler@dadlnet.dk.&#xD;Child and Adolescent Psychiatry, Odense University Hospital, 5000, Odense C, Denmark. laurawinkler@dadlnet.dk.&#xD;Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.&#xD;Psychiatry West, Slagelse, Region Zealand Mental Health Service, Slagelse, Denmark.&#xD;Mental Health Services in the Region Southern Denmark, Odense, Denmark.&#xD;Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;OPEN-Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.&#xD;Centre for Telepsychiatry, Department of Clinical Research, Region of Southern Denmark, University of Southern Denmark, Odense, Denmark.&#xD;Departments of Community Health Sciences and Psychiatry, Faculty of Medicine, University of Calgary, Health Sciences Centre Calgary, Calgary, Canada.&#xD;Institute of Clinical Medicine, Child and Adolescent Psychiatry, Risskov, Denmark.&#xD;Institute of Clinical Medicine, Psychiatric Center Ballerup of Capital Region of Denmark, Ballerup, Denmark.&#xD;Copenhagen University, Copenhagen, Denmark.&#xD;Nutrition Clinic, Endocrine Research Center, Center for Eating Disorders, Odense University Hospital, Psychiatric Services in the Region of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Validating the Danish version of the Eating Disorder Quality of Life Scale (EDQLS) in anorexia nervosa</style></title><secondary-title><style face="normal" font="default" size="100%">Eat Weight Disord</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1717-1728</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">5</style></number><edition><style face="normal" font="default" size="100%">20220103</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Anorexia Nervosa/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">*Feeding and Eating Disorders/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Psychometrics</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of Life</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default" size="100%">Young Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Anorexia nervosa</style></keyword><keyword><style face="normal" font="default" size="100%">Eating disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Questionnaire</style></keyword><keyword><style face="normal" font="default" size="100%">Survey</style></keyword><keyword><style face="normal" font="default" size="100%">Validation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Springer Science and Business Media LLC</style></publisher><isbn><style face="normal" font="default" size="100%">1590-1262 (Electronic)&#xD;1124-4909 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">34978053</style></accession-num><abstract><style face="normal" font="default" size="100%">PURPOSE: The aim of this study was to explore the factor structure of the Danish translation of the eating disorder quality of life scale and evaluate the internal reliability and convergent validity of the scale in a Danish cohort of women with AN. METHODS: The total sample comprised 211 patients diagnosed with anorexia nervosa age 13-40 years. Patients completed questionnaires assessing eating disorder psychopathology, physical and social functioning, and well-being. RESULTS: Factor analyses were not able to support the current division of the scale into 12 factors. We found excellent internal consistency of the eating disorder quality-of-life scale total score. We found relevant associations between quality of life and pre-determined variables. CONCLUSION: This study supports the use of the total score of the eating disorder quality of life scale in assessing quality of life in patients with anorexia nervosa. However, future studies should explore the factor structure of the scale further. LEVEL OF EVIDENCE: III: Evidence obtained from cohort or case-control analytic studies.</style></abstract><notes><style face="normal" font="default" size="100%">Winkler, Laura Al-Dakhiel&#xD;Arnfred, Sidse Marie Hemmingsen&#xD;Larsen, Pia Veldt&#xD;Roder, Michael Ejnar&#xD;Gudex, Claire&#xD;Lichtenstein, Mia Beck&#xD;Adair, Carol E&#xD;Clausen, Loa&#xD;Sjogren, Jan Magnus&#xD;Stoving, Rene Klinkby&#xD;eng&#xD;5240 A/Jascha Fonden/&#xD;Germany&#xD;2022/01/04&#xD;Eat Weight Disord. 2022 Jun;27(5):1717-1728. doi: 10.1007/s40519-021-01310-5. Epub 2022 Jan 3.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34978053</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s40519-021-01310-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>286</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">286</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nielsen, C. M.</style></author><author><style face="normal" font="default" size="100%">Kolbaek, P.</style></author><author><style face="normal" font="default" size="100%">Dines, D.</style></author><author><style face="normal" font="default" size="100%">Pedersen, M. L.</style></author><author><style face="normal" font="default" size="100%">Danielsen, A. A.</style></author><author><style face="normal" font="default" size="100%">Holmgard, C.</style></author><author><style face="normal" font="default" size="100%">Wissing, S.</style></author><author><style face="normal" font="default" size="100%">Esbol, A. M.</style></author><author><style face="normal" font="default" size="100%">Fuglsang, N. F. B.</style></author><author><style face="normal" font="default" size="100%">Nguyen, T. D.</style></author><author><style face="normal" font="default" size="100%">Mors, O.</style></author><author><style face="normal" font="default" size="100%">Opler, M.</style></author><author><style face="normal" font="default" size="100%">Correll, C. U.</style></author><author><style face="normal" font="default" size="100%">Ostergaard, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Psychosis Research Unit, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.&#xD;Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.&#xD;Department of Affective Disorders, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.&#xD;Department of Psychosis, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.&#xD;Department of Forensic Psychiatry, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.&#xD;Department of Public Health, Aarhus University, Aarhus, Denmark.&#xD;MedAvante-ProPhase Inc., New York, NY, USA.&#xD;Department of Psychiatry, New York University School of Medicine, New York, USA.&#xD;Division of Psychiatry Research, The Zucker Hillside Hospital, New York, NY, USA.&#xD;Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, NY, USA.&#xD;Department of Child and Adolescent Psychiatry and Psychotherapy, Charite Universitatsmedizin, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia</style></title><secondary-title><style face="normal" font="default" size="100%">J Psychopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">J Psychopharmacol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1208-1217</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">11</style></number><edition><style face="normal" font="default" size="100%">20221021</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">Female</style></keyword><keyword><style face="normal" font="default" size="100%">*Schizophrenia/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Schizophrenic Psychology</style></keyword><keyword><style face="normal" font="default" size="100%">Psychiatric Status Rating Scales</style></keyword><keyword><style face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Psychometrics</style></keyword><keyword><style face="normal" font="default" size="100%">Schizophrenia</style></keyword><keyword><style face="normal" font="default" size="100%">antipsychotic agents</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Nov</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1461-7285 (Electronic)&#xD;0269-8811 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36268705</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: The six-item Positive and Negative Syndrome Scale (PANSS-6) is a measure of the severity of core symptoms of schizophrenia, which can be administered via the brief Simplified Negative and Positive Symptoms Interview (SNAPSI). A recent study has confirmed the validity of PANSS-6 ratings as derived by SNAPSI (PANSS-6(SNAPSI)) among inpatients with schizophrenia. AIMS: We aimed to test the validity of PANSS-6(SNAPSI) among outpatients with schizophrenia using PANSS-6 ratings extracted from the 30-item PANSS-30 as derived by the Structured Clinical Interview for the Positive and Negative Syndrome Scale (PANSS-6(SCI-PANSS)) as a gold standard reference. METHODS: PANSS-6(SNAPSI) and PANSS-6(SCI-PANSS) ratings were obtained at two time points by independent raters with established inter-rater reliability. Agreement between PANSS-6(SNAPSI) and PANSS-6(SCI-PANSS) ratings was estimated via intra-class coefficients (ICCs) and responsiveness over time was quantified using Spearman&apos;s rank correlation coefficients. Post hoc &quot;leave-one-out&quot; analyses were carried out, in which each rater in turn was excluded from the ICC calculations. RESULTS: Seventy-three outpatients with schizophrenia participated in the study (mean age: 38.3 years; 56% males). The ICC for PANSS-6(SNAPSI) versus PANSS-6(SCI-PANSS) was 0.67 [95%CI = 0.56-0.76] and the Spearman&apos;s rank correlation coefficient for responsiveness was 0.40 (p = 0.004). When data from a specific outlying rater were excluded, the ICC for PANSS-6(SNAPSI) versus PANSS-6(SCI-PANSS) was 0.75 [95% CI = 0.63-0.83] and the Spearman&apos;s rank correlation coefficient for responsiveness was 0.55 (p = 0.018). CONCLUSIONS: We found PANSS-6(SNAPSI) ratings to have acceptable clinical validity, suggesting that PANSS-6(SNAPSI) can be used for both inpatients and outpatients with schizophrenia.</style></abstract><notes><style face="normal" font="default" size="100%">Nielsen, Cecilie Marie&#xD;Kolbaek, Pernille&#xD;Dines, David&#xD;Pedersen, Martin Locht&#xD;Danielsen, Andreas Aalkjaer&#xD;Holmgard, Camilla&#xD;Wissing, Sanne&#xD;Esbol, Anne-Mette&#xD;Fuglsang, Nina Friis Bak&#xD;Nguyen, Tuan Dang&#xD;Mors, Ole&#xD;Opler, Mark&#xD;Correll, Christoph U&#xD;Ostergaard, Soren Dinesen&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/10/22&#xD;J Psychopharmacol. 2022 Nov;36(11):1208-1217. doi: 10.1177/02698811221131992. Epub 2022 Oct 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36268705</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/02698811221131992</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>214</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">214</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andersen, T. E.</style></author><author><style face="normal" font="default" size="100%">Ravn, S. L.</style></author><author><style face="normal" font="default" size="100%">Mejldal, A.</style></author><author><style face="normal" font="default" size="100%">Roessler, K. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychology, University of Southern Denmark: Syddansk Universitet, Odense, Denmark.&#xD;Specialized Hospital for Polio and Accident Victims, Roedovre, Denmark.&#xD;Unit of Clinical Alcohol Research, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Values-based cognitive behavioural therapy for the prevention of chronic whiplash associated disorders: A randomized controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Pain</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1256-1268</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">20220411</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Catastrophization/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style face="normal" font="default" size="100%">*Cognitive Behavioral Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Neck Pain/etiology/prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">*Whiplash Injuries/complications/diagnosis/therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jul</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1532-2149 (Electronic)&#xD;1090-3801 (Print)&#xD;1090-3801 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35364620</style></accession-num><abstract><style face="normal" font="default" size="100%">BACKGROUND: Whiplash is a common traffic-related injury with up to 50% of those affected continuing to experience symptoms one-year post-injury. Unfortunately, treatments have not proven highly effective in preventing and treating chronic symptomatology. The overall aim of this study was to test the effectiveness of an early values-based cognitive-behavioural therapeutic intervention (V-CBT) delivered within 6 months post-injury in preventing chronic symptomatology compared to wait list controls. METHODS: The study was a two-armed randomized controlled trial. Participants (n = 91) experienced pain, disability and at least one psychological risk factor (e.g. enhanced pain-catastrophizing) after a whiplash trauma no later than 6 months prior. Participants were randomized to 10 sessions of V-CBT starting 1 week (group A) or 3 months (group B) post-randomization. The primary outcome was pain-related disability, while secondary outcomes were pain intensity, neck-pain related disability, depression, anxiety, PTSD symptoms, pain-catastrophizing and kinesiophobia. These were evaluated at baseline and at 3, 6, 9 and 12 months post-randomization. RESULTS: At 3 months, group A demonstrated clinically important effects on all outcomes that were significantly better than group B (waitlist). When group B received the intervention at 6 months, they also demonstrated clinically important effects on all outcomes. However, there was a significant difference at 12 months for the primary outcome, in which group B increased their disability levels, while group A remained stable. CONCLUSIONS: While this indicates that an intervention window for early prevention of disability after whiplash injury may exist, this needs to be tested in a truly early intervention. SIGNIFICANCE: An early Values-based Cognitive Behavioural Therapeutic intervention delivered within 6 months post-injury (mean days 117) was effective in reducing pain-related disability and psychological distress compared to the control group that received the intervention later after a three months wait-list period. The effects were sustained at 12 months follow-up. The early intervention was significantly more effective in reducing pain-related disability compared to the control group, indicating that an intervention window for early prevention of disability after whiplash injury may exist.</style></abstract><notes><style face="normal" font="default" size="100%">Andersen, Tonny Elmose&#xD;Ravn, Sophie L&#xD;Mejldal, Anna&#xD;Roessler, Kirsten Kaya&#xD;eng&#xD;Randomized Controlled Trial&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/04/02&#xD;Eur J Pain. 2022 Jul;26(6):1256-1268. doi: 10.1002/ejp.1945. Epub 2022 Apr 11.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35364620</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">None declared.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9322531</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ejp.1945</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>269</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">269</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cantio, E.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Norgaard, S. M.</style></author><author><style face="normal" font="default" size="100%">Beck, I. H.</style></author><author><style face="normal" font="default" size="100%">Moller, S.</style></author><author><style face="normal" font="default" size="100%">Cantio, C.</style></author><author><style face="normal" font="default" size="100%">Jensen, T. K.</style></author><author><style face="normal" font="default" size="100%">Mortensen, N. B.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, A.</style></author><author><style face="normal" font="default" size="100%">Christesen, H. B. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.&#xD;Hans Christian Andersen Children&apos;s Hospital, Odense University Hospital, Odense, Denmark.&#xD;Department of Child and Adolescent Psychiatry Odense, Mental Health Hospital and University Clinic, Region of Southern Denmark, Denmark.&#xD;Clinical Pharmacology, Pharmacy and Environmental Medicine, Faculty of Health Sciences, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.&#xD;Department of Psychology, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vitamin D status in pregnancy and childhood associates with intelligence quotient at age 7 years: An Odense child cohort study</style></title><secondary-title><style face="normal" font="default" size="100%">Aust N Z J Psychiatry</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">48674221116027</style></pages><edition><style face="normal" font="default" size="100%">20220815</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Vitamin D</style></keyword><keyword><style face="normal" font="default" size="100%">Wechsler Intelligence Scale for Children</style></keyword><keyword><style face="normal" font="default" size="100%">cognition</style></keyword><keyword><style face="normal" font="default" size="100%">neurodevelopment</style></keyword><keyword><style face="normal" font="default" size="100%">prenatal</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug 15</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1440-1614 (Electronic)&#xD;0004-8674 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35971641</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: Animal studies indicate a key role for vitamin D in brain development and function, but observational studies in humans only suggests a borderline positive association between prenatal vitamin D exposure and cognitive development in the offspring. Knowledge gaps include insights in exposure time window and differences by sex for the association. We aimed to investigate the association between blood concentrations of serum 25-hydroxyvitamin D measured at four different time points and intelligence quotient score at the age of 7 years, including analyses spilt by child sex. METHODS: In Odense child cohort, we included 1404 mother-child pairs with serum 25-hydroxyvitamin D data from early pregnancy to age 7 years. Full-scale intelligence quotient was assessed with Wechsler Intelligence Scale for Children - fifth edition. Associations were adjusted for maternal education, pre-pregnancy body mass index, gestational age, sex and head circumference. Subanalyses stratified by sex were performed. RESULTS: The median (interquartile range) serum 25-hydroxyvitamin D in cord was 45.88 (31.15-61.08) nmol/L; early pregnancy, 66.45 (51.29-78.74); late pregnancy, 79.13 (59.69-97.31); 7 years, 66.29 (53.45-80.23) nmol/L. The mean (standard deviation) full-scale intelligence quotient was 99.44 (11.98). In adjusted analyses, cord serum 25-hydroxyvitamin D &lt; 50 nmol/L was associated with 2.2 points lower full-scale intelligence quotient compared to the reference (50-75 nmol/L) in boys, beta = -2.2; 95% confidence interval = [-4.3, -0.1], p = 0.039. The same association with full-scale intelligence quotient was found for early pregnancy serum 25-hydroxyvitamin D, beta = -2.5 [-4.6, -0.3], p = 0.025, primarily driven by an association in boys, beta = -4.0 [-7.2, -0.8], p = 0.015; and for serum 25-hydroxyvitamin D at 7 years in girls, beta = -3.0 [-6.0, -0.1], p = 0.042. CONCLUSION: In this cohort, serum 25-hydroxyvitamin D &lt; 50 nmol/L in both early gestation and cord blood in boys and current serum 25-hydroxyvitamin D &lt; 50 nmol/L in girls were independent risk factors for two to four points lower full-scale intelligence quotient at the age of 7 years. Vulnerability to hypovitaminosis D, especially in pregnancy, may relate to child sex.</style></abstract><notes><style face="normal" font="default" size="100%">Cantio, Emily&#xD;Bilenberg, Niels&#xD;Norgaard, Signe Monrad&#xD;Beck, Iben Have&#xD;Moller, Soren&#xD;Cantio, Cathriona&#xD;Jensen, Tina Kold&#xD;Mortensen, Nicoline Bebe&#xD;Rasmussen, Asta&#xD;Christesen, Henrik Boye Thybo&#xD;eng&#xD;England&#xD;2022/08/17&#xD;Aust N Z J Psychiatry. 2022 Aug 15:48674221116027. doi: 10.1177/00048674221116027.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35971641</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/00048674221116027</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Publisher</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>215</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">215</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rybner, A.</style></author><author><style face="normal" font="default" size="100%">Jessen, E. T.</style></author><author><style face="normal" font="default" size="100%">Mortensen, M. D.</style></author><author><style face="normal" font="default" size="100%">Larsen, S. N.</style></author><author><style face="normal" font="default" size="100%">Grossman, R.</style></author><author><style face="normal" font="default" size="100%">Bilenberg, N.</style></author><author><style face="normal" font="default" size="100%">Cantio, C.</style></author><author><style face="normal" font="default" size="100%">Jepsen, J. R. M.</style></author><author><style face="normal" font="default" size="100%">Weed, E.</style></author><author><style face="normal" font="default" size="100%">Simonsen, A.</style></author><author><style face="normal" font="default" size="100%">Fusaroli, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Linguistics, Cognitive Science and Semiotics, School of Communication and Culture, Aarhus University, Aarhus, Denmark.&#xD;Communication Sciences and Disorders, Emerson College, Boston, Massachusetts, USA.&#xD;Child and Youth Psychiatry, University of Southern Denmark, Odense, Denmark.&#xD;Psychology, University of Southern Denmark, Odense, Denmark.&#xD;Child and Adolescent Mental Health Centre, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark.&#xD;Center for Neuropsychiatric Schizophrenia Research and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Mental Health Services in the Capital Region of Denmark, Copenhagen, Denmark.&#xD;Interacting Minds Center, School of Culture and Society, Aarhus University, Aarhus, Denmark.&#xD;Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark.&#xD;Linguistic Data Consortium, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vocal markers of autism: Assessing the generalizability of machine learning models</style></title><secondary-title><style face="normal" font="default" size="100%">Autism Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Autism Res</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1018-1030</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">20220406</style></edition><keywords><keyword><style face="normal" font="default" size="100%">*Autism Spectrum Disorder</style></keyword><keyword><style face="normal" font="default" size="100%">*Autistic Disorder/diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style face="normal" font="default" size="100%">Speech</style></keyword><keyword><style face="normal" font="default" size="100%">*Voice</style></keyword><keyword><style face="normal" font="default" size="100%">autism spectrum disorder</style></keyword><keyword><style face="normal" font="default" size="100%">biobehavioral markers</style></keyword><keyword><style face="normal" font="default" size="100%">generalizability</style></keyword><keyword><style face="normal" font="default" size="100%">voice</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Jun</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Wiley</style></publisher><isbn><style face="normal" font="default" size="100%">1939-3806 (Electronic)&#xD;1939-3806 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35385224</style></accession-num><abstract><style face="normal" font="default" size="100%">Machine learning (ML) approaches show increasing promise in their ability to identify vocal markers of autism. Nonetheless, it is unclear to what extent such markers generalize to new speech samples collected, for example, using a different speech task or in a different language. In this paper, we systematically assess the generalizability of ML findings across a variety of contexts. We train promising published ML models of vocal markers of autism on novel cross-linguistic datasets following a rigorous pipeline to minimize overfitting, including cross-validated training and ensemble models. We test the generalizability of the models by testing them on (i) different participants from the same study, performing the same task; (ii) the same participants, performing a different (but similar) task; (iii) a different study with participants speaking a different language, performing the same type of task. While model performance is similar to previously published findings when trained and tested on data from the same study (out-of-sample performance), there is considerable variance between studies. Crucially, the models do not generalize well to different, though similar, tasks and not at all to new languages. The ML pipeline is openly shared. Generalizability of ML models of vocal markers of autism is an issue. We outline three recommendations for strategies researchers could take to be more explicit about generalizability and improve it in future studies. LAY SUMMARY: Machine learning approaches promise to be able to identify autism from voice only. These models underestimate how diverse the contexts in which we speak are, how diverse the languages used are and how diverse autistic voices are. Machine learning approaches need to be more careful in defining their limits and generalizability.</style></abstract><notes><style face="normal" font="default" size="100%">Rybner, Astrid&#xD;Jessen, Emil Trenckner&#xD;Mortensen, Marie Damsgaard&#xD;Larsen, Stine Nyhus&#xD;Grossman, Ruth&#xD;Bilenberg, Niels&#xD;Cantio, Cathriona&#xD;Jepsen, Jens Richardt Mollegaard&#xD;Weed, Ethan&#xD;Simonsen, Arndis&#xD;Fusaroli, Riccardo&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;2022/04/07&#xD;Autism Res. 2022 Jun;15(6):1018-1030. doi: 10.1002/aur.2721. Epub 2022 Apr 6.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35385224</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/aur.2721</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>231</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">231</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hojlund, M.</style></author><author><style face="normal" font="default" size="100%">Rasmussen, L.</style></author><author><style face="normal" font="default" size="100%">Olesen, M.</style></author><author><style face="normal" font="default" size="100%">Munk-Olsen, T.</style></author><author><style face="normal" font="default" size="100%">Pottegard, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.&#xD;Department of Psychiatry Aabenraa, Mental Health Services in the Region of Southern Denmark, Aabenraa, Denmark.&#xD;Department of Clinical Research, University of Southern Denmark, Odense, Denmark.&#xD;The National Center for Register-based Research, Aarhus University, Aarhus, Denmark.&#xD;Hospital Pharmacy Funen, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Who prescribes quetiapine in Denmark?</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Br J Clin Pharmacol</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4224-4229</style></pages><volume><style face="normal" font="default" size="100%">88</style></volume><number><style face="normal" font="default" size="100%">9</style></number><edition><style face="normal" font="default" size="100%">20220519</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Antipsychotic Agents/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark</style></keyword><keyword><style face="normal" font="default" size="100%">*General Practitioners</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Practice Patterns, Physicians&apos;</style></keyword><keyword><style face="normal" font="default" size="100%">Quetiapine Fumarate/adverse effects</style></keyword><keyword><style face="normal" font="default" size="100%">antipsychotics</style></keyword><keyword><style face="normal" font="default" size="100%">off-label</style></keyword><keyword><style face="normal" font="default" size="100%">prescriber</style></keyword><keyword><style face="normal" font="default" size="100%">quetiapine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1365-2125 (Electronic)&#xD;0306-5251 (Print)&#xD;0306-5251 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35535441</style></accession-num><abstract><style face="normal" font="default" size="100%">The second-generation antipsychotic quetiapine is commonly used off-label for its anxiolytic and hypnotic properties. However, quetiapine is associated with problematic side-effects. We used Danish Medicinal Product Statistics and a 20% random sample of the Danish population&apos;s prescription fills (2001-2020) to describe the utilization of quetiapine and proportion of various prescriber types (general practitioner [GP], specialist in private practice, hospital physician and other prescribers) both in connection to first-time and subsequent prescriptions. In 2020, 92% of all quetiapine was dispensed outside hospitals and the average daily dispensed quantity of quetiapine per user corresponded to 100 mg/user/d. A GP issued 53% of first-time prescriptions and 75% of subsequent prescriptions for quetiapine in 2020. The proportion of quetiapine prescriptions issued by GPs varied by age group-from 14% among 0-17-year-olds to 93% among the &gt;/=80-year-olds. Future initiatives on the rational use of quetiapine and related drugs, especially among adults, should target GPs.</style></abstract><notes><style face="normal" font="default" size="100%">Hojlund, Mikkel&#xD;Rasmussen, Lotte&#xD;Olesen, Morten&#xD;Munk-Olsen, Trine&#xD;Pottegard, Anton&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;England&#xD;2022/05/11&#xD;Br J Clin Pharmacol. 2022 Sep;88(9):4224-4229. doi: 10.1111/bcp.15388. Epub 2022 May 19.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35535441</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Mikkel Hojlund reports personal honoraria for consultancy/lecturing from the Lundbeck Foundation and Otsuka Pharmaceutical Co., Ltd. unrelated to this work. Lotte Rasmussen reports participation in research projects funded by Novo Nordisk with no relation to the work reported in this paper. Anton Pottegard reports participation in research projects funded by Alcon, Almirall, Astellas, AstraZeneca, Boehringer-Ingelheim, Novo Nordisk, Servier and LEO Pharma, all regulator-mandated phase IV-studies, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. The remaining authors reports no conflict of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9545446</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/bcp.15388</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>226</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">226</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tarp, K.</style></author><author><style face="normal" font="default" size="100%">Sari, S.</style></author><author><style face="normal" font="default" size="100%">Nielsen, A. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Telepsychiatry, Region of Southern Denmark, Odense, Denmark; and University of Southern Denmark, Odense, Denmark. RINGGOLD: 72736. RINGGOLD: 6174&#xD;University of Southern Denmark, Odense, Denmark. RINGGOLD: 6174</style></auth-address><titles><title><style face="normal" font="default" size="100%">Why treatment is not an option: Treatment naive individuals, suffering from alcohol use disorders&apos; narratives about alcohol use and treatment seeking</style></title><secondary-title><style face="normal" font="default" size="100%">Nordisk Alkohol Nark</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nordisk Alkohol Nark</style></full-title></periodical><pages><style face="normal" font="default" size="100%">437-452</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">4</style></number><edition><style face="normal" font="default" size="100%">20220421</style></edition><keywords><keyword><style face="normal" font="default" size="100%">alcohol use</style></keyword><keyword><style face="normal" font="default" size="100%">alcohol use disorder</style></keyword><keyword><style face="normal" font="default" size="100%">patient perceptions</style></keyword><keyword><style face="normal" font="default" size="100%">treatment barriers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Aug</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1458-6126 (Electronic)&#xD;1455-0725 (Print)&#xD;1455-0725 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">36003123</style></accession-num><abstract><style face="normal" font="default" size="100%">Aims: To investigate the narratives of in- and outpatients at mental health and somatic hospitals, who suffer from alcohol use disorders (AUD) but have never sought AUD treatment. More specifically, to understand how the individuals view their alcohol use and explore their reasons for not seeking treatment. Methods: Individuals suffering from AUD were recruited at somatic and mental health hospitals. The study was qualitative, based on semi-structured individual interviews. A narrative analysis was performed. A total of six patients participated: three recruited at a mental health hospital, three from a somatic hospital. Results: The individuals described how heavy alcohol use had always characterised their lives; it was part of their surroundings and it added to their quality of life. Two narrative forms within the individuals&apos; stories were identified, in which treatment was considered either as a positive option for others but not relevant for themselves, or as representing a threat to the individuals&apos; autonomy. The participants expressed that they did not believe treatment was relevant for them, and if necessary, they preferred to deal with their heavy drinking themselves. Conclusions: Our findings indicate that a broad focus is needed if relatively more individuals suffering from AUD should seek treatment, since they - in spite of clearly suffering from AUD - nevertheless see themselves as heavy drinkers and have not even thought of seeking treatment. Thus, it is not (only) a question about the attractiveness of the treatment offer or due to lack of knowledge about treatment options that patients suffering from AUD do not seek treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Tarp, Kristine&#xD;Sari, Sengul&#xD;Nielsen, Anette Sogaard&#xD;eng&#xD;2022/08/26&#xD;Nordisk Alkohol Nark. 2022 Aug;39(4):437-452. doi: 10.1177/14550725221082512. Epub 2022 Apr 21.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/36003123</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Declaration of conflicting interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9379291</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/14550725221082512</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">PubMed-not-MEDLINE</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>216</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">216</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Conway, P. M.</style></author><author><style face="normal" font="default" size="100%">Erlangsen, A.</style></author><author><style face="normal" font="default" size="100%">Grynderup, M. B.</style></author><author><style face="normal" font="default" size="100%">Clausen, T.</style></author><author><style face="normal" font="default" size="100%">Rugulies, R.</style></author><author><style face="normal" font="default" size="100%">Bjorner, J. B.</style></author><author><style face="normal" font="default" size="100%">Burr, H.</style></author><author><style face="normal" font="default" size="100%">Francioli, L.</style></author><author><style face="normal" font="default" size="100%">Garde, A. H.</style></author><author><style face="normal" font="default" size="100%">Hansen, A. M.</style></author><author><style face="normal" font="default" size="100%">Hanson, L. M.</style></author><author><style face="normal" font="default" size="100%">Kirchheiner-Rasmussen, J.</style></author><author><style face="normal" font="default" size="100%">Kristensen, T. S.</style></author><author><style face="normal" font="default" size="100%">Mikkelsen, E. G.</style></author><author><style face="normal" font="default" size="100%">Stenager, E.</style></author><author><style face="normal" font="default" size="100%">Thorsen, S. V.</style></author><author><style face="normal" font="default" size="100%">Villadsen, E.</style></author><author><style face="normal" font="default" size="100%">Hogh, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Psychology, University of Copenhagen, Oster Farimagsgade 2A, 1353 Copenhagen, Denmark. paul.conway@psy.ku.dk.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Workplace bullying and risk of suicide and suicide attempts: A register-based prospective cohort study of 98 330 participants in Denmark</style></title><secondary-title><style face="normal" font="default" size="100%">Scand J Work Environ Health</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">425-434</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">6</style></number><edition><style face="normal" font="default" size="100%">20220601</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Adult</style></keyword><keyword><style face="normal" font="default" size="100%">*Bullying</style></keyword><keyword><style face="normal" font="default" size="100%">Denmark/epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Male</style></keyword><keyword><style face="normal" font="default" size="100%">*Occupational Stress</style></keyword><keyword><style face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style face="normal" font="default" size="100%">Suicidal Ideation</style></keyword><keyword><style face="normal" font="default" size="100%">Suicide, Attempted</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style face="normal" font="default" size="100%">Sep 1</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">Scandinavian Journal of Work, Environment and Health</style></publisher><isbn><style face="normal" font="default" size="100%">1795-990X (Electronic)&#xD;0355-3140 (Print)&#xD;0355-3140 (Linking)</style></isbn><accession-num><style face="normal" font="default" size="100%">35648097</style></accession-num><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The aim of this study was to analyze whether individuals reporting exposure to workplace bullying had a higher risk of suicidal behavior, including both suicide attempt and death by suicide, than those not reporting such exposure. METHODS: Using a prospective cohort study design, we linked data from nine Danish questionnaire-based surveys (2004-2014) to national registers up to 31 December 2016. Exposure to workplace bullying was measured by a single item. Suicide attempts were identified in hospital registers and death by suicide in the Cause of Death Register. Among participants with no previous suicide attempts, we estimated hazard ratios (HR) and 95% confidence intervals (CI), adjusting for sex, age, marital status, socioeconomic status, and history of psychiatric morbidity. RESULTS: The sample consisted of 98 330 participants (713 798 person-years), 63.6% were women, and the mean age was 44.5 years. Of these participants, 10 259 (10.4%) reported workplace bullying. During a mean follow-up of 7.3 years, we observed 184 cases of suicidal behavior, including 145 suicide attempts, 35 deaths by suicide and 4 cases that died by suicide after surviving a suicide attempt. The fully-adjusted HR for the association between workplace bullying and suicidal behavior was 1.65 (95% CI 1.06-2.58). The HR for suicide attempts and death by suicide were 1.65 (1.09-2.50) and 2.08 (0.82-5.27), respectively. Analyses stratified by sex showed a statistically significant association between workplace bullying and suicidal behavior among men but not women. CONCLUSIONS: The results suggest that exposure to workplace bullying is associated with an elevated risk of suicidal behavior among men.</style></abstract><notes><style face="normal" font="default" size="100%">Conway, Paul Maurice&#xD;Erlangsen, Annette&#xD;Grynderup, Matias Brodsgaard&#xD;Clausen, Thomas&#xD;Rugulies, Reiner&#xD;Bjorner, Jakob Bue&#xD;Burr, Hermann&#xD;Francioli, Laura&#xD;Garde, Anne Helene&#xD;Hansen, Ase Marie&#xD;Hanson, Linda Magnusson&#xD;Kirchheiner-Rasmussen, Jonas&#xD;Kristensen, Tage S&#xD;Mikkelsen, Eva Gemzoe&#xD;Stenager, Elsebeth&#xD;Thorsen, Sannie Vester&#xD;Villadsen, Ebbe&#xD;Hogh, Annie&#xD;eng&#xD;Research Support, Non-U.S. Gov&apos;t&#xD;Finland&#xD;2022/06/02&#xD;Scand J Work Environ Health. 2022 Sep 1;48(6):425-434. doi: 10.5271/sjweh.4034. Epub 2022 Jun 1.</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/35648097</style></url></related-urls></urls><custom1><style face="normal" font="default" size="100%">Authors declare no conflicts of interest.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC9888442</style></custom2><electronic-resource-num><style face="normal" font="default" size="100%">10.5271/sjweh.4034</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Medline</style></remote-database-name><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record><record><database name="2022.enl" path="C:\BIB\2021\2022.enl">2022.enl</database><source-app name="EndNote" version="20.5">EndNote</source-app><rec-number>295</rec-number><foreign-keys><key app="EN" db-id="w9w9saexaxeszmetav45w5xidt0ea9zrpd22">295</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hansen, Nina Beck</style></author><author><style face="normal" font="default" size="100%">Vang, Maria Louison</style></author><author><style face="normal" font="default" size="100%">Lichtenstein, Mia Beck</style></author><author><style face="normal" font="default" size="100%">Pihl-Thingvad, Jesper</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Workplace Sexual Harassment Increases the Risk of PTSD Symptoms with Higher Frequency and Harassment Coming from a Colleague or Leader as Risk Factors</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Work and Organizational Psychology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Work and Organizational Psychology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2022</style></year></dates><isbn><style face="normal" font="default" size="100%">2002-2867</style></isbn><urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.16993/sjwop.174</style></electronic-resource-num></record></records></xml>